dacarbazine and Melanoma

dacarbazine has been researched along with Melanoma in 1361 studies

Research

Studies (1,361)

TimeframeStudies, this research(%)All Research%
pre-1990330 (24.25)18.7374
1990's273 (20.06)18.2507
2000's353 (25.94)29.6817
2010's352 (25.86)24.3611
2020's53 (3.89)2.80

Authors

AuthorsStudies
Lin, AJ; Loo, TL1
Cosby, LA; Hrubiec, RT; Sartorelli, AC; Shyam, K1
Benvenuto, J; Farquhar, D1
Dalton, JT; Li, W; Lu, Y; Miller, DD; Wang, Z1
Chen, J; Dalton, JT; Li, W; Lu, Y; Miller, DD; Wang, Z1
Abrantes, AM; Botelho, MF; Gonçalves, AC; Laranjo, M; Rocha Gonsalves, AM; Sarmento-Ribeiro, AB; Serra, AC1
Abdullah, SE; Baurain, JF; Butler, MO; Carvajal, RD; Curti, B; Demidov, L; Dummer, R; Gastaud, L; Goodall, H; Hamid, O; Hassel, JC; Holland, C; Joshua, AM; Kirkwood, JM; Mauch, C; Milhem, M; Nathan, P; Ochsenreither, S; Orloff, M; Piperno-Neumann, S; Piulats, JM; Rutkowski, P; Sacco, JJ; Salama, AKS; Schlaak, M; Shoushtari, AN; Sullivan, RJ; Yushak, M1
Agorio, CI; Chabalgoity, JA; Chilibroste, S; Mónaco, A; Moreno, M; Plata, MC; Vola, M1
Castañeda-Cardona, C; Castrillón-Correa, J; Gil-Rojas, Y; Hernández, F; Herrera, D; Lasalvia, P; Rosselli, D1
Chen, P; Cun, B; Guo, Y; Li, X; Luo, N; Yang, C; Yang, Y1
Bordini, HP; Cecchini, AL; Fagundes, TR; Luiz, RC; Madeira, TB; Marinello, PC; Melo, GP; Nixdorf, SL1
Bagherzadeh, M; Barjasteh, M; Pooshang Bagheri, K; Vossoughi, M1
Attaran, N; Esmailzadeh, A; Hejazi, SH; Hemati, S; Shanei, A1
Googe, PB; Li, H; McKenna, EF; Moschos, SJ; Pergaris, A; Theocharis, S; Yan, Y1
Bastos, V; Oliveira, H; Salvador, D1
Chen, H; Fei, X; Huang, Q; Ji, X; Jiang, D; Meng, X; Qin, R; Sun, F; Wang, A; Wang, Z; Xie, X; Zhao, Y1
Asahina, A; Katsumata, F; Nobeyama, Y; Waki, Y1
Barbarić, M; Brala, CJ; Dabelić, N; Dabelić, S; Kugić, A1
Lan, M; Li, AA; Li, F; Xie, D; Yan, MY; Zhang, Y1
Hagelstein, V; Klee, G; Kurzhals, JK; Langan, EA; Terheyden, P; Zillikens, D1
de Oliveira Junior, RG; Ferraz, CAA; Grougnet, R; Nicolau, E; Picot, L1
Belenyuk, VD; Esimbekova, AR; Palkina, NV; Ruksha, TG; Savchenko, AA; Sergeeva, EY; Zinchenko, IS1
Feng, S; Shi, H; Wan, Y; Xu, K; Yu, X; Yue, Y; Zhang, C1
Asano, Y; Fujimura, T; Muto, Y1
Ciardulli, MC; Della Porta, G; Guadagno, L; Longo, R; Mariconda, A; Raimondo, M; Sirignano, M; Vertuccio, L1
Cui, H; Dong, Z; Guo, L; Hu, X; Ji, Y; Li, C; Liu, C; Liu, L; Liu, Y; Shi, Y; Wan, S; Wu, Z; Xu, J; Yang, Y; Zhang, X; Zhang, Y1
Deng, Y; Li, J; Lu, Q; Pei, J; Su, Z; Yang, Y; Zeng, X; Zhang, Y; Zhong, Y1
Amini, M; Baradaran, B; Firouzamandi, M; Mohammadi, A; Najafi, S1
Azambuja, JH; Braganhol, E; de Cássia Sant'ana, R; de Souza, PO; Debom, GN; Fachel, FNS; Gelsleichter, NE; Lenz, GS; Michels, LR; Roliano, GG; Teixeira, FC; Teixeira, HF; Visioli, F1
Amaral, JD; Francisco, AP; Gaspar, MM; Godinho-Santos, A; Matias, M; Mendes, E; Perry, MJ; Pinho, JO; Rodrigues, CMP1
Agrawal, AK; Dubey, PK; Kumar, DN; Mohapatra, D; Pandey, V; Sahu, AN; Shreya, S1
Palkina, N; Ruksha, T; Sergeeva, E1
Ataabadi, FV; Etebari, M; Oveissi, F; Taheri, A1
Barszczewska-Pietraszek, G; Czarny, P; Czyż, M; Drzewiecka, M; Gajos-Michniewicz, A; Hoser, G; Jaśniak, D; Piekarski, J; Radek, M; Sitarek, P; Skorski, T; Śliwiński, T1
Charpentier, C; Dreno, B; Flet, L; Fronteau, C; Guile, R; Khammari, A; Nguyen, JM; Poinas, A; Riche, VP; Thomare, P; Varey, É1
Cardoso, CO; Cunha-Filho, M; Gelfuso, GM; Gratieri, T; Uwai, TY1
Edwards, CRW; Goff, PS; Gorelkin, PV; Korchev, Y; Sviderskaya, EV; Woodcock, E; Zhang, Y1
Chen, TM; Chiu, CF; Hsu, TW; Lee, WR; Liao, PH; Su, YH; Tseng, PC; Tzeng, YS; Wang, CH; Yeh, YW1
Beberok, A; Respondek, M; Rok, J; Rzepka, Z; Wrześniok, D1
Ascierto, PA; Becker, JC; Cascinu, S; Catania, C; Danielli, R; Dummer, R; Eigentler, T; Elia, G; Garbe, C; Hauschild, A; Neri, D; Romanini, A; Trefzer, U; Weide, B1
Franken, MG; Gheorghe, M; Haanen, JBAG; Leeneman, B; Uyl-de Groot, CA; van Baal, PHM1
Sciumè, C; Sinagra, E1
Ascierto, PA; Blank, CU; Chapman, PB; D'Amelio, A; Demidov, LV; Dutriaux, C; Gasal, E; Grob, JJ; Gutzmer, R; Haas, T; Hauschild, A; Kefford, R; Kiecker, F; Lebbé, C; Millward, M; Mookerjee, B; Ribas, A; Rutkowski, P; Schadendorf, D1
Bentley, MVLB; Borgheti-Cardoso, LN; Caron, AL; Kravicz, M; Praça, FG; Silvestrini, AVP; Viegas, JSR1
Chan, K; Cope, S; Jansen, JP1
Ishimoto, K; Minami, K; Tsujiuchi, T; Ueda, N1
Haghjooy Javanmard, S; Hajimoradi Javarsiani, M; Sajedianfard, J1
Asano, T; Hata, H; Kato, T; Kitamura, S; Maeda, T; Narahira, A; Nozaki, A; Shimizu, H; Watari, H; Yanagi, T1
Hide, M; Kan, T; Kawai, M; Matsubara, D; Takahagi, S; Tanaka, A1
Alimohammadi, M; Bekeschus, S; Golpur, M; Hadavi, S; Niaki, HA; Rafiei, A; Sohbatzadeh, F; Valadan, R1
Ascierto, PA; Dréno, B; Flaherty, KT; Hauschild, A; Larkin, J; Lewis, KD; McArthur, GA; McKenna, E; Mun, Y; Ribas, A; Zhu, Q2
Barth, S; Biteghe, FAN; Chalomie, NET; Davids, LM; Ndong, JC; Padayachee, E1
Jobani, BM; Mohebi, E; Najafzadeh, N1
Costa, L; Lobo-Martins, S; Mansinho, A; Pais, HL; Soares-de-Almeida, L; Teixeira de Sousa, R1
Alencar, LMR; Alexis, F; da Silva de Barros, AO; Dahoumane, SA; de Oliveira Siqueira, LB; do Reis, SRR; Helal-Neto, E; Pinto, SR; Portilho, FL; Ricci-Junior, E; Santos-Oliveira, R1
Dong, L; Jiang, X; Meng, L; Qu, C; Wang, B; Wang, H; Wei, J; Xin, Y; Zhao, Q1
Anisimov, VN; Baldueva, IA; Berstein, LM; Latipova, DK; Novik, AV; Protsenko, SA; Semenova, AI; Semiglazova, TY; Tkachenko, EV; Zhuk, IN1
He, J; Huang, X; Sun, K; Teng, W; Tian, J; Yang, J; Zhan, X; Zhou, C; Zhou, L1
Brisigotti, V; Campagna, R; Campanati, A; Emanuelli, M; Molinelli, E; Offidani, A; Pompei, V; Pozzi, V; Salvolini, E; Salvucci, A; Sartini, D1
Beauchet, A; Blom, A; Bouchereau, S; Chapalain, M; Chaplain, L; Fort, M; Funck-Brentano, E; Gonzalez-Lara, L; Longvert, C; Saiag, P; Sidibé, T1
Alexopoulos, LG; Charles, EM; Hellwig, CT; Rehm, M; Rožanc, J; Vetma, V1
Furue, M; Hagihara, A; Ito, T; Nakahara, T; Tsuji, G; Uchi, H; Wada, M1
Chen, YN1
Beck, D; Bonin, M; Garbe, C; Kosnopfel, C; Krieg, K; Lasithiotakis, K; Meier, F; Niessner, H; Sinnberg, T; Wanke, I1
Andersson, Y; Flatmark, K; Flem-Karlsen, K; Fodstad, Ø; Nunes-Xavier, CE; Tekle, C1
Li, J; Liu, L; Liu, Q; Shen, C; Shezad, K; Tao, J; Xu, N; Zhang, L; Zhang, Y; Zhu, J1
Chang, X; Lian, S; Zhang, H; Zhu, W1
Bassett, RL; Bedikian, AY; Cain, S; Homsi, J; Hwu, P; Hwu, WJ; Kim, DW; Kim, KB; Papadopoulos, NE; Patel, SP; Washington, E1
Han, F; Huang, CY; Kang, X; Luo, JS; Qin, XM; Xie, T1
Glickson, JD; Lee, SC; Leeper, DB; Nath, K; Nelson, DS; Putt, ME; Roman, J1
Amson, R; Appel, MH; Basílio, AB; Boia-Ferreira, M; Chaim, OM; Da Costa, CRV; Hamasaki, AE; Matsubara, FH; Senff-Ribeiro, A; Telerman, A; Veiga, SS1
Hamidi, V; Klemp, M; Odgaard-Jensen, J; Pike, E; Saeterdal, I1
Aiba, S; Fujimura, T; Furudate, S; Kakizaki, A; Kambayashi, Y; Lyu, C; Sato, Y; Tanita, K1
Ascierto, PA; Caro, I; Chang, I; Chapman, PB; Coleman, S; Dummer, R; Flaherty, KT; Haanen, JB; Hamid, O; Hauschild, A; Hogg, D; Larkin, J; Lorigan, PC; McArthur, GA; Ribas, A; Robert, C; Sosman, JA; Testori, A1
Atkins, MB; Flaherty, LE; Kirkwood, JM; Moon, J; Othus, M; Ribas, A; Samlowski, WE; Sondak, VK; Witter, M1
Al-Qahtani, M; Barja-Fidalgo, TC; Bernardes, ES; de Jesus Andreoli Pinto, T; Dos Santos, SN; Ghisleni, DDM; Kozempel, J; Ricci-Junior, E; Rosa, TG; Santos-Oliveira, R1
Barone, C; Blasi, MA; Cassano, A; Dadduzio, V; Pagliara, M; Quirino, M; Rossi, E; Schinzari, G1
Chammas, R; Cirilo, PDR; Corrêa, BRS; de Sousa Andrade, LN; Furuya, TK; Penalva, LOF; Qiao, M1
Anghel, RM; Haidar, A; Popescu, A1
Hafeez, A; Kazmi, I1
Saxena, S; Singh, RK; Varney, ML; Wu, S1
Guo, Z; He, J; Huang, X; Sun, K; Wang, H; Yang, J; Zha, ZG; Zhang, H; Zhang, HT; Zhou, C1
Caruntu, C; Constantin, C; Neagu, M; Surcel, M; Zurac, S1
Ates, KE; Duzgun, O; Gokcay, S; Sarici, IS; Yılmaz, MB1
Annovazzi, L; Battaglia, L; Biasibetti, E; Boggio, E; Cangemi, L; Capucchio, MT; Clemente, N; Dianzani, C; Dianzani, U; Ferrara, B; Gigliotti, CL; Mellai, M; Miglio, G; Muntoni, E; Schiffer, D1
Cui, H; Huang, W; Li, X; Liao, X; Liu, X; Min, L; Shi, B; Sun, X; Xu, S; Yang, J; Zhang, M; Zheng, H; Zhu, Z1
Cabezas, SS; Dos Santos, SN; Helal-Neto, E; Martínez-Máñez, R; Pinto, SR; Portilho, FL; Pozzo, L; Sancenón, F; Santos-Oliveira, R1
Ellis, J; Hertel, N; Johnson, H; Lee, D; Meng, Y; Morais, E; Philips, Z; Roskell, N; Walker, A1
Barker, P; Berking, C; Carvajal, RD; Chapman, PB; Chmielowski, B; Clemett, D; Cocquyt, V; Evans, TRJ; Frank, S; Gastaud, L; Ghiorghiu, D; Joshua, AM; Kapiteijn, E; Kilgour, E; Lai, Z; Linette, G; Lovick, S; Mariani, G; Nathan, P; Piperno-Neumann, S; Piulats, JM; Rodrigues, MJ; Schachter, J; Schwartz, GK; Shoushtari, AN; Spratt, S; Wolter, P1
Caselli, A; Cirri, P; Livi, L; Lori, G; Mangoni, M; Marzocchini, R; Paoli, P; Raugei, G; Talamonti, C1
Cen, Y; Chen, J; He, M; Li, H; Wang, X; Zhang, Z1
Abramov, I; Khochenkov, D; Prokofieva, A; Ryabaya, O; Stepanova, E; Zasedatelev, A1
Ekielski, A; Iqbal, Z; Jaggi, M; Mishra, H; Mishra, PK; Talegaonkar, S1
Altomonte, M; Bova, G; Calabrò, L; Camerini, R; Cisternino, F; Danielli, R; Di Giacomo, AM; Dragonetti, R; Giannarelli, D; Maio, M; Savelli, V1
Chmielowski, B; Copley-Merriman, C; Liu, FX; Mauskopf, J; Stevinson, K; Wang, J; Zimovetz, EA1
Koskivuo, I; Lahtela, V; Mattila, K; Pyrhönen, S; Raanta, P; Vihinen, P1
Arance, A; Ascierto, PA; Atkinson, V; Brady, B; Charles, J; Chiarion-Sileni, V; Cognetti, F; Di Giacomo, AM; Dutriaux, C; Gogas, H; Hassel, JC; Hernberg, MM; Jiang, J; Kalinka-Warzocha, E; Lebbé, C; Long, GV; Mauch, C; McNeil, C; Mihalcioiu, C; Mortier, L; Ny, L; Rizzo, J; Robert, C; Rutkowski, P; Saci, A; Savage, KJ; Schadendorf, D; Svane, IM1
Hide, M; Hirakawa, K; Kawai, M; Saito, R; Takahagi, S; Tanaka, M1
Alexopoulos, LG; Charles, EM; Rehm, M; Rožanc, J; Skoko, J1
Alipour, M; Asiabi, H; Hosseinkhani, S; Shamsayei, M; Yamini, Y1
Specenier, P1
Assmann, CE; Bagatini, MD; da Cruz, IBM; de Andrade, CM; de Oliveira Alves, A; Mânica, A; Morsch, VMM; Palma, TV; Pelinson, LP; Pillat, MM; Schetinger, MRC; Stefanello, N; Ulrich, H; Weis, GCC1
Beaugeard, L; Bonnet, A; Braconnier, E; da Silva Almeida, JRG; de Oliveira Júnior, RG; Ferraz, CAA; Grougnet, R; Groult, H; Picot, L; Prunier, G1
Devji, T; Levine, O; Thabane, L; Xie, F; Zoratti, MJ1
Bell Gorrod, H; Bullement, A; Latimer, NR1
Flem-Karlsen, K; Flørenes, VA; Fodstad, Ø; Mælandsmo, GM; Nunes-Xavier, CE; Tekle, C; Øyjord, T1
Piotrowska, A; Rybarczyk, A; Slominski, AT; Tuckey, RC; Wierzbicka, J; Żmijewski, MA1
Corrêa, FM; Fernandes, RRA; Guerra, RL; Zimmerman, IR1
Corrêa, FM; Fernandes, RRA; Guerra, RL; Souza, MC; Zimmermann, IR1
Ishimoto, K; Maeda, H; Minami, K; Otagaki, S; Tsujiuchi, T; Ueda, N1
Achberger, S; Aldrich, W; Binkley, E; Rybicki, L; Singh, A; Triozzi, PL1
Aprea, P; Ascierto, PA; Botti, G; Caracò, C; Cavalcanti, E; Comella, G; Cossu, A; Daponte, A; Gallo, C; Grimaldi, AM; Lastoria, S; Maiorino, L; Massidda, B; Mozzillo, N; Palmieri, G; Petrillo, A; Signoriello, S; Simeone, E1
Harris, PJ; Ivy, SP; Luke, JJ; Rubinstein, LV; Smith, GL1
Abbattista, A; Calvert, H; Curtin, N; Dewji, R; Gallo, J; Lorigan, P; Middleton, MR; Mulligan, E; Plummer, R; Scott, L; Steven, N; Wang, D; Wilson, RH1
Carlson, GW; Crocker, IR; Delman, KA; Khan, MK; Lawson, DH; Lowe, M; Marcus, DM; Maynard, N; Melton, A; Rizzo, M; Shelton, JW1
Cheng, Q; Jiang, AJ; Jiang, G; Li, LT; Tian, H; Zheng, JN1
Cliby, WA; Janco, JM; Markovic, SN; Weaver, AL1
Cuellar, S; Culos, KA1
Chi, Z; Cui, C; Gu, K; Guo, J; Kong, Y; Li, S; Lian, B; Lin, T; Mao, L; Qin, S; Ren, X; Sheng, X; Si, L; Song, X; Tao, M1
Berge, EO; Birkeland, E; Busch, C; Geisler, J; Jönsson, G; Knappskog, S; Lillehaug, JR; Lønning, PE1
Ancarani, V; Ascierto, PA; Baravelli, S; de Rosa, F; Fiammenghi, L; Gentilcore, G; Granato, AM; Guidoboni, M; Nicoletti, SV; Pancisi, E; Petrini, M; Riccobon, A; Ridolfi, L; Ridolfi, R; Scarpi, E; Simeone, E; Valmorri, L1
Arance, A; Cantarini, M; Dummer, R; Gutzmer, R; Kim, KB; Liszkay, G; Lorigan, P; Middleton, MR; Nyakas, M; Robert, C; Schadendorf, D; Spencer, S1
Benlalam, H; Caillou, B; Carré, T; Chouaib, S; Jalil, A; Noman, Z; Robert, C; Tittarelli, A; Vielh, P1
Armstrong, AW; Ma, C1
Ejaz, S; Habra, MA; Henderson, SA; Shawa, H1
Chin, K; Kotapati, S; Sherrill, B; Wang, J1
Czyz, ME; Hartman, ML; Koprowska, K; Sztiller-Sikorska, M1
Gibney, GT; Sondak, VK1
Chi, Z; Cui, C; Guo, J; Kong, Y; Li, S; Lian, B; Mao, L; Sheng, X; Si, L; Tang, B1
Abdollahi, M; Nikfar, S; Teimouri, F1
Chong, K; Hoon, DS; Huang, SK; Marzese, DM; Ohta, K; Sato, Y; Sim, MS1
Hellwig, CT; Leverkus, M; Passante, E; Rehm, M; Würstle, ML1
Eich, M; Kaina, B; Nikolova, T; Roos, WP1
Andrés, R; Brown, E; Calvert, H; Chmielowska, E; Cullell-Young, M; de Miguel, B; Demidov, L; Extremera, S; Kahatt, C; Kudryavtseva, G; Lorigan, P; Moiseyenko, V; Plummer, R; Soriano, V; Szyldergemajn, S; Zaucha, R1
Lewis, BC; Miners, JO1
Agostinis, P; Govaere, O; Gremeaux, L; Maes, H; Roskams, T; Stas, M; Van den Broeck, A; van den Oord, JJ; Vankelecom, H; Wouters, J1
Jia, HY; Jiang, G; Lei, TC; Li, RH; Liu, YQ; Sun, C1
Anderson, JE; Davis, JE; Kim, KB; Trinh, VA1
Iversen, TZ1
Akiyama, M; Matsumoto, T; Nin-Asai, R; Saito, S; Sawada, M; Yokota, K1
Fang, Q; Hu, X; Li, Y; Ma, D; Wang, J; Yang, Y; Zhang, W1
Ascierto, PA; Dummer, R; Eggermont, AM; Flaherty, KT; Hauschild, A; Hennig, M; Kefford, R; Kirkwood, JM; Lee, SJ; Long, GV; Lorigan, P; Mackensen, A; McArthur, G; O'Day, S; Patel, PM; Robert, C; Schadendorf, D1
Bodell, MA; Kraus, ES; Lipson, EJ; Sharfman, WH1
Amonkar, MM; Casey, M; Demidov, LV; Dummer, R; Garbe, C; Grotzinger, K; Hassel, JC; Lefeuvre-Plesse, C; Milhem, M; Mohr, P; Patel, K; Robert, C; Rutkowski, P; Rutten, A; Schadendorf, D; Sherman, L; Steven, N; Trefzer, U; Ullenhag, G; Wolter, P; Wu, FS1
Bedane, C; Combemale, P; Cupissol, D; Derrey, S; Dygai-Cochet, I; Lamant, L; Leccia, MT; Lubrano, V; Mazeau-Woynar, V; Mirabel, X; Modiano, P; Mourrégot, A; Planchamp, F; Rougé Bugat, ME; Sassolas, B; Siegrist, S; Thariat, J; Tiffet, O; Truc, G; Verdoni, L1
Ascierto, PA; Caro, I; Chapman, PB; Cheng, S; Dréno, B; Dummer, R; Eggermont, AM; Flaherty, KT; Garbe, C; Haanen, JB; Hamid, O; Hauschild, A; Hogg, D; Jouary, T; Kirkwood, JM; Larkin, J; Lebbé, C; Lorigan, P; Maio, M; McArthur, GA; O'Day, SJ; Ribas, A; Robert, C; Schadendorf, D; Sosman, JA; Testori, A; Trunzer, K; Yin, M1
Huang, X; Zhang, L; Zhang, X1
Alavi, A; Goncalves, MD; Torigian, DA1
Bauer, J; Büttner, P; Eigentler, TK; Garbe, C; Keim, U; Leiter, U; Meckbach, D; Pflugfelder, A; Richter, S; Weide, B1
Koon, HB; Megahed, AI1
Chen, J; Chi, M; Ye, Y; Zhang, XD1
Kerr, J; Reyes, C; Satram-Hoang, S; Stepanski, EJ; Walker, MS1
Augustine, CK; Beasley, GM; Davies, MA; Deng, W; Dewhirst, MW; Fontanella, A; Lidsky, ME; Padussis, JC; Tokuhisa, Y; Toshimitsu, H; Turley, RS; Tyler, DS1
Bedikian, AY; Conry, R; Garbe, C; Grob, JJ; Lebbe, C1
Barrera-Baena, P; Hervás-Molina, AJ; Jurado-García, J; Ruiz-Cuesta, P; Villar-Pastor, CM1
Azimi, A; Egyházi Brage, S; Frostvik Stolt, M; Hansson, J; Hertzman Johansson, C; Lehtiö, J; Pernemalm, M1
Alrwas, A; Bassett, R; Bedikian, AY; Cain, S; Davies, MA; Deburr, TL; Hwu, P; Hwu, WJ; Kim, KB; Papadopoulos, NE; Patel, SP; Woodman, SE1
Amonkar, MM; Chiarion-Sileni, V; Demidov, LV; Goodman, V; Grob, JJ; Grotzinger, K; Haney, P; Hauschild, A; Kämpgen, E; Karaszewska, B; Martin-Algarra, S; Mauch, C; Miller, WH; Millward, M; Mirakhur, B; Rutkowski, P; Swann, S1
Hutchinson, L2
Dubóczki, Z; Liszkay, G; Lóránd, A; Mészáros, P; Plótár, V; Vörös, A; Zs Tóth, E1
Bedikian, AY; Carvajal, RD; Gordon, MS; Lewis, KD; Pavlick, AC; Rojas, PB; Schwartz, JD; Thompson, JA; Wolchok, JD; Wong, MK1
Abramson, DH; Albertini, MR; Ambrosini, G; Ancell, K; Bluth, M; Carvajal, RD; Chapman, PB; Dickson, MA; Doyle, A; Erinjeri, J; Flynn, PJ; Gajewski, TF; Hedvat, C; Joshua, AM; Kudchadkar, RR; Lao, CD; Lawson, DH; Lewis, K; Linette, GP; Lutzky, J; Marr, B; Milhem, MM; Panageas, KS; Quevedo, JF; Sato, T; Schwartz, GK; Sosman, JA; Wolchok, JD1
Arozarena, I; Erice, O; Ferguson, J; Goicoechea, I; Margison, GP; Wellbrock, C1
Arrighetti, N; Carenini, N; Ciniselli, CM; Ciusani, E; Cominetti, D; Corna, E; De Cesare, M; Gatti, L; Manenti, G; Perego, P; Rivoltini, L; Rodolfo, M; Sevko, A; Umansky, V; Verderio, P; Zaffaroni, N1
Amaravadi, RK; Chang, YC; Davis, LE; DeMichele, AM; Evans, TL; Fecher, LA; Gallagher, M; Heitjan, DF; Kaiser, J; Kramer, A; Leone, R; Nathanson, KL; O'Dwyer, PJ; Piao, S; Pontiggia, L; Rangwala, R; Rodgers, G; Schuchter, LM; Tan, KS; Troxel, AB1
Amaravadi, RK; Caro, I; Choe, CH; Kempen, JH; McArthur, GA1
Deutsch, J; Frees, M; Laux, D; Leon-Ferre, R; Milhem, M; Smith, BJ; Xia, C1
Bordeaux, JS; Koon, HB; Palathinkal, DM; Sharma, TR1
Jiang, G; Li, RH; Liu, YQ; Sun, C; Wei, ZP; Zheng, JN1
Abernethy, AP; Jiang, BS; Mosca, PJ; Speicher, PJ; Thomas, S; Tyler, DS1
Augustine, CK; Beasley, GM; Dolber, PC; Mosca, PJ; Peterson, BL; Ross, M; Royal, R; Sharma, K; Speicher, P; Tyler, DS; Zager, JS1
Apetoh, L; Bel, B; Dalac, S; Ghiringhelli, F; Hervieu, A; Jeudy, G; Mignot, G; Vabres, P1
Bouchaab, H; Bucher, M; Gaide, O; Homicsko, K; Letovanec, I; Michielin, O; Peters, S; Zimmerman, S1
Benhammane, H; Bensouda, Y; Boutayeb, S; El Khannoussi, B; Elghissassi, I; Errihani, H; Kharmoum, J; Kharmoum, S; Mohamed, M; Mrabti, H; Sbitti, Y; Setti, K; Touri, S1
Andersen, MH; Iversen, TZ; Svane, IM1
Egger, ME; Gomez-Gutierrez, JG; McMasters, KM; McNally, LR; Nitz, J1
Indurthi, VS; Koladia, M; Law, B; Leclerc, E; Meghnani, V; Vetter, SW; Wagh, A1
Atkins, MB; Flaherty, LE; Haluska, FG; Kirkwood, JM; Moon, J; Othus, M; Pappo, AS; Redman, BG; Ribas, A; Sondak, VK; Sosman, JA; Thompson, JA; Tuthill, RJ; Vetto, JT1
Atanasov, G; Bartels, M; Hau, HM; Morgül, MH; Schmelzle, M; Schoenberg, MB; Seitz, AT; Simon, JC; Tautenhahn, HM; Uhlmann, D; Wiltberger, G1
Aresu, L; Cancedda, S; Dacasto, M; Gracis, M; Leone, VF; Marconato, L; Pizzoni, S; Rohrer Bley, C1
Arance, A; Ascierto, PA; Atkinson, V; Brady, B; Charles, J; Chiarion-Sileni, V; Cognetti, F; Dutriaux, C; Gogas, H; Hassel, JC; Hernberg, MM; Horak, C; Kalinka-Warzocha, E; Lebbé, C; Long, GV; Lundgren-Eriksson, L; Maio, M; Mauch, C; McNeil, C; Mihalcioiu, C; Mortier, L; Robert, C; Rutkowski, P; Savage, KJ; Schadendorf, D; Schmidt, H; Sharkey, B; Waxman, IM1
Egyházi Brage, S; Frostvik Stolt, M; Hansson, J; Hertzman Johansson, C; Jewell, R; Johansson, H; Lindén, D; Lindholm, C; Newton-Bishop, J; Snowden, H; Stierner, U; Tuominen, R; van den Oord, JJ; Walker, C; Wolter, P1
Longo, DL; Sznol, M1
Jiang, G; Li, RH; Liu, YQ; Sun, C; Zheng, JN1
Chen, TC; Cho, HY; Hofman, FM; Jhaveri, N; Nguyen, J; Rosenstein-Sisson, R; Schönthal, AH; Wang, W1
Ahmad, MW; Alken, S; Colleran, GC; Fitzpatrick, D; Kavanagh, EC; Kelly, CM; Lyons, TG; Murray, B; O'Kane, GM1
Christmann, M; Kaina, B; Krumm, A; Loquai, C; Merz, S; Quiros, S; Roos, WP; Switzeny, OJ1
Dhermain, F; Grob, JJ; Guillot, B; Jouary, T; Le Rhun, É; Lebbe, C; Leccia, MT; Mateus, C; Mortier, L; Robert, C; Thomas, M1
Bafaloukos, D; Fountzilas, G; Gogas, H; Linardou, H; Makatsoris, T; Pectasides, D; Pentheroudakis, G; Varthalitis, I1
Armstrong, JL; Babatunde, F; Corazzari, M; Eleni Anagnostou, M; Hernandez-Tiedra, S; Hill, DS; Lopez-Valero, I; Lorente, M; Lovat, PE; McKee, CS; Redfern, CPF; Velasco, G1
Ahn, JB; Choi, HJ; Chung, HC; Heo, SJ; Jung, M; Kim, HR; Kim, HS; Lee, CK; Rha, SY; Roh, MR; Shin, SJ1
Aamdal, S; Bondarenko, I; Chen, TT; Chiarion-Sileni, V; Garbe, C; Grob, JJ; Maio, M; Robert, C; Testori, A; Thomas, L; Tschaika, M; Wolchok, JD1
Faião-Flores, F; Fruet, AC; Maria, DA; Maria-Engler, SS; Pardi, PC; Quincoces Suarez, JA1
Coco, P; Cocorocchio, E; Ferrucci, PF; Gandini, S; Minchella, I; Mosconi, M; Munzone, E; Pari, C; Passoni, C; Testori, A; Verrecchia, F1
Gupta, K; Hardy, KM; Hendrix, MJ; Margaryan, NV; Murphy, GF; Scolyer, RA; Strizzi, L1
Bilgi, O; Çelik, S; Emirzeoğlu, L; Karagöz, B; Özet, A; Özgün, A1
Acosta, JC; Arozarena, I; Barriuso, J; Erice, O; Goicoechea, I; Jones, C; Margison, GP; Smith, MP; Wellbrock, C; White, R1
Alfano, D; Caputo, E; Cavalcanti, E; Fico, A; Patriarca, EJ; Travali, S; Valentino, A; Vasta, V1
Abhyankar, S; Chang, CL; Donga, P; Munakata, J; Reyes, CM; Schabert, VF; Yim, YM1
Aricò, E; Belardelli, F; Belli, R; Buccione, C; Capone, I; Cappellini, GA; Carlei, D; Casorelli, I; Castiello, L; D'Agostino, G; Macchia, I; Marchetti, P; Monque, D; Montefiore, E; Moschella, F; Napolitano, M; Pavan, A; Proietti, E; Rizza, P; Rozera, C; Santodonato, L; Sestili, P; Urbani, F1
Atkins, MB; Gibney, GT1
Bagijn, M; Barber, B; Corrie, P; Jones, C; Saltman, D; Zhao, Z1
Abrams, KR; Amonkar, MM; Latimer, NR; Stapelkamp, C; Swann, RS1
Eastwood, A; Giannopoulou, C; McKenna, C; Moe-Byrne, T; Sideris, E; Wade, R1
Carvajal, RD; Mann, H; Nathan, PD; Schwartz, GK; Smith, I1
Chyla, B; Daud, A; Falotico, N; Friedlander, P; Giranda, VL; Hamid, O; Jiang, F; Luo, Y; McArthur, GA; McKee, M; McKeegan, E; Middleton, MR; Mostafa, NM; Plummer, R; Qian, J; Zhu, M1
Li, W; Mahato, RI; Mundra, V1
Chang, JW; Huang, WK; Wang, HM; Wu, CF1
Kubo, Y; Shibuya, J; Shida, A; Suzuki, K; Takahashi, T; Yanagihara, M1
Carlino, MS; Long, GV1
Hou, XY; Jiang, G; Li, RH; Liu, WL; Liu, YQ; Tang, JQ; Yang, CS1
Fukushima, S; Kiyohara, Y; Namikawa, K; Okuyama, R; Otsuka, Y; Shibagaki, N; Tokudome, T; Tsutsumida, A; Uchi, H; Uhara, H; Yamazaki, N1
Agarwala, SS; Bhatia, S; Brachmann, C; Brown, MP; Clawson, A; Conry, R; Del Vecchio, M; Elias, I; Ernst, S; Grob, JJ; Gutzmer, R; Hauschild, A; Haydon, A; Hersh, EM; Homsi, J; Karnoub, M; Kefford, R; Kendra, K; Li, M; Loquai, C; Renschler, MF; Robert, C; Testori, A1
Aleksic, T; Asher, R; Bridges, E; Gao, S; Kamdoum, WP; Li, JL; Macaulay, VM; Margison, GP; Middleton, MR; Pfister, SX; Ramcharan, R; Repapi, E; Tanner, J; Watson, AJ; Woodcock, M1
Andresen, C; Falchook, GS; George, GC; Hong, DS; Kim, KB; Kurzrock, R; Kwak, J; Nemunaitis, J; Nguyen, LM; O'Brien, JP; Ren, M; Xu, L1
Henderson, M; Heriot, AG; Knowles, J; Lynch, AC; Warrier, SK1
Goormaghtigh, E; Le Corre, Y; Martin, L; Mathieu, V; Wald, N1
Schuchter, LM; Wilson, MA1
Bíró, T; Buzás, K; Endrész, V; Gyukity-Sebestyén, E; Harmati, M; Katona, RL; Kemény, L; Marton, A; Nagy, K; Németh, IB; Oláh, J; Tubak, V; Vígh, L; Vizler, C; Zvara, Á1
Chen, TT1
Arnold, A; Braun, R; Dummer, R; Guckenberger, M; Hunger, RE; Lindenblatt, N; Michielin, O; Mihic-Probst, D; Najafi, Y; Siano, M; von Moos, R1
Asselain, B; Bidard, FC; Cassoux, N; Decaudin, D; Diallo, A; Etienne-Grimaldi, MC; Mariani, P; Piperno-Neumann, S; Plancher, C; Rodrigues, M; Servois, V1
Chen, YP; Feng, SX; Hou, XY; Jiang, G; Jiang, XX; Liu, YQ; Xu, XF; Yang, CS; Yang, M1
Beaumont, KA; Daignault, SM; Gabrielli, B; Haass, NK; Hill, DS; Lui, GYL; Sharp, DM; Weninger, W1
Hou, XY; Huang, Q; Jiang, G; Tang, JQ; Xin, Y; Yang, M; Zhang, LZ; Zhang, P1
Abrams, KR; Amonkar, MM; Bell, H; Casey, M; Latimer, NR1
Briggs, A; Hatswell, AJ; Hertel, N; Lee, D; Porter, J1
Ishikawa, M; Oashi, K1
Fortunato, RS; Kajitani, GS; Menck, CF; Quinet, A; Rocha, CR1
Abernethy, AP; Ascierto, PA; Atkinson, V; Coon, C; Dastani, HB; Gilloteau, I; Hassel, JC; Long, GV; Robert, C; Rutkowski, P; Savage, KJ; Taylor, F; Waxman, IM1
Ding, B; Ding, X; Gao, S; Huang, X; Huang, Y; Wang, J; Wu, X; Xie, C; Xu, N; Zhan, S; Zhang, W; Zheng, Y1
Averineni, RK; Guan, X; Sadhu, SS; Seefeldt, T; Wang, S; Yang, Y1
Amaria, RN; Bassett, RL; Bedikian, AY; Cain, S; Davies, MA; Hwu, P; Hwu, WJ; Lecagoonporn, S; McQuade, JL; Patel, SP; Posada, LP1
Blank, C; Cranmer, L; Daud, A; Dummer, R; Ebbinghaus, S; Hamid, O; Hauschild, A; Hille, D; Kang, SP; Loquai, C; Mehnert, JM; O'Day, S; Puzanov, I; Ribas, A; Robert, C; Salama, A; Schachter, J; Schadendorf, D; van den Eertwegh, A; Zhou, W1
Cheng, P; Czyż, M; Dummer, R; Gajos-Michniewicz, A; Gritsyuk, D; Hoser, G; Levesque, M; Majchrzak, K; Nieborowska-Skorska, M; Skorski, T; Sliwinski, T; Szemraj, J; Toma, M1
Musha, A; Nakano, T; Ohno, T; Saitoh, JI; Shirai, K; Yokoo, S1
Dronca, RS; Ivanov, LV; Kottschade, LA; Leontovich, AA; Markovic, SN; Nevala, WK; Thompson, MA1
Chmielowski, B; Dry, SM; Eilber, FC; Hoffman, RM; Igarashi, K; Kawaguchi, K; Kiyuna, T; Li, Y; Murakami, T; Nelson, SD; Russell, TA; Singh, A; Unno, M; Zhang, Y; Zhao, M1
Ling, B; Michel, D; Sakharkar, MK; Yang, J1
Biteghe, FN; Davids, LM1
Chatard, M; Felder-Flesch, D; Perek, N; Prevot, N; Puech, C1
Cao, H; Ding, M; Liu, N; Mao, LJ; Xu, K; Yang, C1
Egorova, AV; Emelyanova, MA; Inshakov, AN; Khochenkov, DA; Nasedkina, TV; Ryabaya, OO; Stepanova, EV; Zasedatelev, AS1
Barber, B; Kudlac, A; Ma, Q; Palmer, S; Quinn, C; Zhao, Z1
Guo, W; Hou, X; Jiang, G; Li, R; Liu, Y; Ma, Y; Tang, J; Xin, Y; Yang, C1
Kerger, J; Kourie, HR; Simon, A1
Barber, BL; Batty, N; Chen, YJ; Hines, DM; Ma, Q; Munakata, J; Zhao, Z1
Chibbaro, S; Clavier, JB; Goichot, B; Lhermitte, B; Proust, F; Todeschi, J1
Chen, Q; Flowers, CR; Goldstein, DA; Kohn, CG; Montero, AJ; Zeichner, SB1
Arance, A; Ascierto, PA; Bozón, V; Del Vecchio, M; Demidov, L; Di Giacomo, AM; Dummer, R; Dutriaux, C; Flaherty, K; Ford, J; Garbe, C; Gutzmer, R; Hogg, D; Jehl, V; Liszkay, G; Long, GV; Mandala, M; Queirolo, P; Rutkowski, P; Schadendorf, D; Sirulnik, LA; Thomas, L; Wasserman, E; Weill, M1
Hata, H; Homma, S; Ichikawa, N; Imafuku, K; Kawamura, H; Kitamura, S; Miyazawa, H; Ohno, Y; Shimizu, H; Taketomi, A; Uehara, J; Yamaguchi, Y; Yanagi, T; Yoshida, T1
Kudriavtsev, DV; Kudriavtseva, GT; Mardynskiĭ, IuS1
Bedikian, AY; Hwu, P; Hwu, WJ; Johnson, MM; Kim, K; McIntyre, S; Papadopoulos, N; Warneke, CL1
Adamina, M; Guller, U; Heberer, M; Rosenthal, R; Spagnoli, GC; Viehl, CT; Weber, WP; Zuber, M1
Ugurel, S1
Both-Skalsky, J; Dummer, R; Egberts, F; Fink, W; Hauschild, A; Kaehler, KC; Laetsch, B; Schadendorf, D; Ugurel, S1
Chi, ZH; Cui, CL; Guo, J; Lian, HY; Si, L; Yuan, XQ1
Bar-Eli, M; Lev, DC; Melnikova, VO; Villares, GJ; Zigler, M1
Agarwala, SS; Gooding, WE; Kirkwood, JM; Moschos, S; Tarhini, AA1
Artamonova, EV; Demidov, LV; Kharkevitch, GY; Manziuk, LV; Pirogova, NA1
Agarwala, S; Atkins, MB; Clark, JI; Curti, B; Dutcher, JP; Ernstoff, MS; Lawson, D; Logan, T; Margolin, KA; Sosman, JA; Weiss, G1
Ballo, MT; Bartell, HL; Bedikian, AY; Dett, TK; Hwu, P; Kim, KB; Myers, JN; Papadopoulos, NE1
Jones, C; Plummer, ER1
Clynes, M; Crown, J; Eustace, AJ; O'Donovan, N1
Hwu, P; Kim, K; Lazar, AJ; Quintás-Cardama, A; Ross, M; Woodman, SE1
Kitai, R; Kodera, T; Kubota, T; Sato, K; Takeuchi, H; Yoshida, K1
Aldrich, W; Dombos, C; Triozzi, PL1
Kawano, N; Kihara, Y; Kume, K; Otsuki, M; Syukuwa, K; Taguchi, M; Tashiro, M; Yamasaki, M; Yoshikawa, I1
Atkins, MB; Cohen, GI; Flaherty, LE; Hsu, J; Kirkwood, JM; Lee, S; Sondak, VK; Sosman, JA1
Bedikian, AY; Camacho, LH; Frost, AM; Hernandez, IM; Hwu, P; Hwu, WJ; Jack, MA; Kim, KB; Ng, C; Papadopoulos, NE1
Bar, J; Catane, R; Gutman, H; Kutchuk, I; Schachter, J; Shapira-Frummer, R; Sulkes, A; Yerushalmi, R1
Mori, K; Nakao, Y; Wada, R; Watanabe, M; Yamamoto, T1
Al-Jamal, RT; Eskelin, S; Kivelä, T; Pyrhönen, S1
Cowan, DH; Gardere, S; Hussain, S1
Ahmann, DL; Bisel, HF; Hahn, RG1
Bocangel, D; Chada, S; Ekmekcioglu, S; Grimm, EA; Poindexter, N; Ramesh, R; Zheng, M1
Campos, M; Flaherty, KT; Garbe, C; Gogel, J; Kulms, D; Lasithiotakis, K; Maczey, E; Meier, F; Niessner, H; Schittek, B; Sinnberg, T1
Egberts, F; Hauschild, A; Hitschler, WN; Weichenthal, M1
Belohlavek, C; Christmann, M; Jöst, E; Kaina, B; Lennerz, V; Naumann, SC; Roos, WP; Schmidt, CW1
Ballarini, M; Contegno, F; Croci, D; Goldhirsch, A; Minucci, S; Munzone, E; Nolè, F; Pelicci, PG; Rocca, A; Salmaggi, A; Testori, A; Tosti, G1
Ali-Osman, F; Augustine, CK; Friedman, HS; Nevins, JR; Potti, A; Tyler, DS; Yoo, JS; Yoshimoto, Y; Zipfel, PA1
Dohmen-Scheufler, H; Guzel, A; Maciaczyk, J; Nikkhah, G; Ostertag, CB; Senturk, S; Volk, B1
Becker, MR; Gaiser, T1
Boeckmann, L; Emmert, S; Gutzmer, R; Has, C; Kunz, M; Kuschal, C; Laspe, P; Struever, D; Thoms, KM1
Baloglu, A; Bezircioglu, I; Cetinkaya, B; Yavuzcan, A1
Berger, W; Dehoux, M; DeNeve, N; Gaussin, JF; Kiss, R; Lefranc, F; Martin de Lassalle, E; Mathieu, V; Mijatovic, T; Pirker, C; Vernier, M1
Heppner, FL; Ingold, B; Moch, H; Schraml, P1
Lee, F; Richmond, A; Smykla, R; Thu, YM; Yang, J; Zaja-Milatovic, S1
Casadevall, A; Dadachova, E; Guimaraes, AJ; Howell, RC; Jongco, AM; Koba, W; Nosanchuk, JD; Revskaya, E; Sellers, RS1
Cuttone, G; Iannolo, G; Korićanac, LB; Petrović, IM; Privitera, G; Ristić-Fira, AM; Valastro, LM; Zakula, JJ1
Abdi, E; Beith, J; Corrie, PG; Kefford, RF; Kotasek, D; Margison, GP; Middleton, MR; Mortimer, P; Palmer, C; Ranson, M; Thomas, NP; Watson, AJ1
Beith, J; Davis, ID; Haydon, A; Hayward, O; Hersey, P; Kefford, R; Lorigan, P; Margison, GP; McArthur, G; McGown, G; Middleton, MR; Mortimer, P; Ranson, M; Sabharwal, A; Thomson, D; Thorncroft, M; Watson, AJ1
Chang, PN; Lee, DT; Ling, MT; Wong, YC; Yap, WN; Yap, YL1
Jin, S; Kang, X; Sun, W; Wang, J; Zhang, Q1
Agarwala, SS; Bedikian, AY; Eggermont, AM; Gilles, E; Itri, LM; Kay, R; Keilholz, U; Stein, CA; Suciu, S; Wu, J1
Alvarado, G; Anderson, CM; Bedikian, AY; Benjamin, RS; Buzaid, AC; Eton, O; Frost, AM; Gershenwald, JE; Gonzalez, R; Hwu, P; Hwu, WJ; Johnson, MM; Kim, KB; Lee, JE; Legha, SS; Liu, P; Mansfield, PF; Papadopoulos, NE; Plager, C; Prieto, VG; Ross, MI1
Cubitt, CL; Daud, AI; Homsi, J; Jove, R; Messina, JL; Munster, PN; Sullivan, DM; Yu, H; Zhang, S1
Chen, M; Orlow, SJ; Osman, I1
Bedikian, AY; Cain, S; Glass, MR; Homsi, J; Hwu, P; Hwu, WJ; Kim, KB; Papadopoulos, NE; Rudewicz, P; Vernillet, L1
Chang, JL; Farrell, K; Jones, A; Muggia, F; Oratz, R; Ott, PA; Pavlick, AC1
Bedikian, A; Gerber, DL; Homsi, J; Hwu, P; Hwu, WJ; Kim, KB; Papadopoulos, NE; Ring, S1
Castellón Rubio, V; Delgado Pérez, JR; González Astorga, B; González Flores, E; Jiménez Rubiano, B; Luque Caro, R; Sánchez Toro, C; Valdivia Bautista, J1
Marshall, E; O'Day, S; Redman, B; Trefzer, U; van den Eertwegh, AJ; Wagner, S; Weber, JS; Zarour, H1
Guenova, E; Hoetzenecker, W; Lichte, V; Moehrle, M; Roecken, M; Schaller, M; Woelbing, F1
Cruz-Munoz, W; Kerbel, RS; Man, S1
Subbiah, V; Wolff, JE1
Collins, CM; Morgan, DS; Mosse, C; Sosman, J1
Boeckmann, L; Brockmoeller, J; Emmert, S; Gutzmer, R; Has, C; Kunz, M; Kuschal, C; Laspe, P; Rosenberger, A; Schirmer, M; Schoen, MP; Struever, D; Thoms, KM1
Bajetta, E; Cascinu, S; Crinò, L; Danova, M; Del Prete, S; Salvagni, S; Schiavetto, I; Siena, S; Vitali, M1
Amatruda, T; Anderson, CM; Atkins, MB; Boasberg, P; Gonzalez, R; Hersh, EM; Lutzky, J; O'Day, SJ; Thompson, JA; Wang, HJ; Weber, JS1
Clark, JI; Da Silva, DM; Flaherty, LE; Hutchins, LF; Kast, WM; Liu, PY; Moon, J; Sondak, VK; Sosman, JA; Thompson, JA1
Chen, M; Doudican, N; Orlow, SJ; Osman, I; Rose, AE1
Bracher, A; Loewe, R; Neumüller, K; Niederleithner, H; Pehamberger, H; Petzelbauer, P; Steele, S; Valero, T1
Alvarado, GC; Bedikian, AY; Camacho, LH; Hwu, P; Kim, KB; McIntyre, S; Papadopoulos, NE; Yoon, C1
Komori, T; Oguni, A; Shigeta, T; Takahashi, H; Umeda, M1
Fuse, H; Imamura, Y; Nohara, T; Sakai, A1
Alvino, E; Bonmassar, E; Brasca, MG; Caporali, S; Castiglia, D; Ciomei, M; Covaciu, C; D'Atri, S; Garbin, A; Levati, L; Starace, G1
Amiri, KI; Ayers, GD; Horton, LW; Kelley, MC; Koehler, E; Puzanov, I; Richmond, A; Sosman, JA; Su, Y; Yu, Y1
Bearden, JD; Behl, D; Brown, PD; Deming, RL; Markovic, SN; Rowland, KM; Sande, JR; Schild, SE1
Bedane, C; Guillet, G; Guillot, B; Mourey, L; Sassolas, B; Tourani, JM; Wierzbicka-Hainaut, E1
Brady, MS; Carvajal, RD; Chapman, PB; Coit, DG; Gold, JS; Panageas, KS; Shah, GD; Socci, ND; Viale, A; Wolchok, JD1
Cranmer, LD; Hersh, EM; Khan, KD; Nichol, GM; O'Day, SJ; Pavlick, AC; Powderly, J; Samlowski, WE; Weber, JS; Yellin, MJ1
Gundersen, S; Hager, B; Jacobsen, KD; Tausjø, J1
Blaskovits, FM; Carson, WE; Chan, AN; Grignol, VP; Guenterberg, KD; Lesinski, GB; Mundy, BL; Nuovo, GJ; Raig, ET; Young, GS; Zimmerer, JM1
Bedikian, A; Buzoianu, M; Gonzalez, R; Hammershaimb, L; Hersey, P; Kirkwood, JM; Logan, T; O'Day, S; Richards, J; Sharfman, W; Sosman, J; Weber, R1
Bae, SY; Baek, HJ; Han, DK; Hwang, TJ; Kook, H; Lee, JB; Lee, JK; Lee, MC; Lee, SY; Yun, SJ1
Ali-Osman, F; Angelica Selim, M; Augustine, CK; Friedman, HS; Padussis, JC; Pruitt, SK; Toshimitsu, H; Tyler, DS; Yoo, JS; Yoshimoto, Y1
Jiang, G; Liu, YQ; Mao, LJ; Pei, DS; Wei, ZP; Zheng, JN1
Camerini, R; Cognetti, F; Ferraresi, V; Garbe, C; Gascon, P; Gilde, K; Guillot, B; Jassem, J; Lesimple, T; Mackiewicz, A; Maio, M; Testori, A; Trefzer, U1
Ballmer, A; Brady, B; Clingan, PR; Hersey, P; Kefford, RF; Morganti, A1
Asselain, B; Barillot, E; Bessard, MA; Couturier, J; Dahmani, A; Decaudin, D; Desjardins, L; Donnadieu, MH; Gentien, D; Lantz, O; Laurent, C; Mariani, P; Némati, F; Péguillet, I; Piperno-Neumann, S; Plancher, C; Reyes, C; Robert, D; Roman-Roman, S; Sastre-Garau, X; Saule, S1
Ali-Osman, F; Augustine, CK; Friedman, HS; Jung, SH; Olson, JA; Sohn, I; Tyler, DS; Yoo, JS; Yoshimoto, Y1
Hernberg, M; Ivaska, J; Laukka, M; Lundin, J; Pyrhönen, S; Tyynelä, K; Vihinen, PP; Vuoristo, MS1
Andersson, Y; Fodstad, O; Risberg, K1
de Juan, M; Díaz, R; Fonfría, M; Mancheño, N; Moral, P; Tormo, A1
Acland, K; Calonje, E; Harries, M; O'Doherty, M; Perez, A; Szyszko, T; Turajlic, S1
Busch, C; Geisler, J; Knappskog, S; Lillehaug, JR; Lønning, PE1
Kim, C; Klasa, R; Kovacic, L; Lee, CW; Savage, KJ; Shah, A1
Burd, R; Limesand, KH; Mendoza, EE; Mitchell, GC; Radhakrishnan, VM; Sittadjody, S; Thangasamy, T1
Busch, C; Geisler, J; Lillehaug, JR; Lønning, PE1
Dorr, R; Gonzalez, R; Grenier, K; Hersh, E; O'Day, S; Ribas, A; Samlowski, WE; Sato, T; Stephenson, J; Weber, JS1
Hwu, WJ; Neyns, B; Reardon, DA; Tosoni, A1
Ali-Osman, F; Augustine, CK; Beasley, GM; Burchette, J; Jung, SH; McMahon, N; Padussis, J; Pruitt, SK; Selim, MA; Toshimitsu, H; Tyler, DS; Yoo, JS; Yoshimoto, Y; Zipfel, PA1
Bito, T; Ikeda, T; Nishigori, C; Nishitani, N; Tokura, Y1
Lee, N; Setton, J1
Dianov, GL; Digweed, M; Eich, M; Kaina, B; Roos, WP1
Dummer, R; Edler, L; Hassel, JC; Kurzen, H; Mauch, C; Moll, I; Rass, K; Schadendorf, D; Spieth, K; Stresemann, C; Sucker, A1
Belardelli, F; Catricalà, C; Del Bello, D; Ferraresi, V; Ghidini, C; Gualtieri, N; Imberti, L; Natali, PG; Nisticò, P; Palermo, B; Proietti, E; Serana, F; Sottini, A1
Augustine, CK; Osmond, GW; Padussis, J; Tyler, DS; Zipfel, PA1
Agarwala, S; Bedikian, AY; Conry, R; DeConti, RC; Ernstoff, M; Kim, KB; Papadopoulos, N1
Bassett, R; Bedikian, A; Hwu, P; Hwu, WJ; Kim, KB; Knight, RD; Papadopoulos, NE; Patnana, M1
Davis, MD; Harlan, E; Pittelkow, MR1
Doi, H; Iizuka, H; Ishida-Yamamto, A; Ito, Y; Tsuji, H1
Drabick, JJ; Fateh, S; Gingrich, R; Neves, RI; Schell, TD1
Davis, ME; Hsueh, T; Koya, RC; Ribas, A; Zuckerman, JE1
Hatanaka, K; Hidemura, A; Ishimaru, M; Kojima, T; Sasaki, S; Uekusa, T1
Fu, JH; Huang, XY; Li, Y; Wang, X; Xie, X; Yu, H; Zhang, LJ; Zhou, JL1
Jiang, G; Liu, YQ; Zheng, JN1
Fujimoto, M; Hayashida, N; Muto, M; Nakai, A; Nakamura, Y; Takii, R1
Colucci, G; Cramarossa, A; Fistola, E; Giudice, G; Guida, M; Lubello, K; Porcelli, M1
Guo, W; Hu, YJ; Li, J; Ren, GX; Yang, WJ; Yang, X; Zhang, CP; Zhong, LP; Zhou, GY1
Boasberg, P; Hamid, O; O'Day, S1
Di Giacomo, AM; Maio, M; Margolin, KA1
Bedikian, AY; Homsi, J; Hwu, P; Hwu, WJ; Johnson, MM; Kim, KB; McIntyre, S; Papadopoulos, NE; Rohlfs, M; Warneke, CL1
D'Atri, S; Graziani, G; Lacal, PM; Levati, L; Muzi, A; Ruffini, F; Umezawa, K1
Bei, D; Meng, J; Youan, BB1
Alamanda, V; Chellappan, S; Davis, R; Lawrence, N; Pernazza, D; Pireddu, R; Sebti, S; Singh, S1
Lee, FC; Mangalik, A; Movva, S; Parks, V; Rabinowitz, I; Verschraegen, CF1
Di, Y; Gong, J; Guo, JL; He, L; Jin, JL; Lu, YJ; Noteborn, MH; Qu, S; Sun, J; Xia, JJ; Xie, YY; Yin, TJ1
Hackel, RE; He, SX; Heckenlively, JR; Johnson, MW; Khan, NW; Koreen, L1
Dalle, S; Dumontet, C; Julia, F; Thomas, L1
Ikeya, T; Nitta, Y; Sakakibara, A; Tomita, Y1
Caccuri, AM; Cuzzocrea, S; Dorio, AS; Federici, G; Graziani, G; Mazzon, E; Muzi, A; Sau, A; Tentori, L; Vernole, P1
Joffe, S; Miller, FG1
Amaravadi, RK; Li, LZ; Lum, JJ; Ma, XH; McAfee, QW; Nathanson, KL; Piao, S; Wang, D1
Burke, W; Califano, R; Carmichael, J; Gore, M; Greystoke, A; Khan, OA; Larkin, J; Lorigan, P; Margison, GP; McGown, G; Middleton, MR; Stone, J; Thorncroft, M; Watson, AJ; Wellman, S1
Jiang, G; Liu, YQ; Pei, DS; Wei, ZP; Xin, Y; Zheng, JN1
Boeckmann, L; Emmert, S; Kuschal, C; Nickel, AC; Schaefer, A; Schön, MP; Thomale, J; Thoms, KM1
Kim, JH; Lee, HR; Lee, J; Lee, SI; Lim, DH; Park, KW; Yi, JH; Yi, SY1
Abramov, ME; Artamonov, DN; Gorbacheva, LB; Tronov, VA1
Belohlavek, C; Fritz, G; Jöst, E; Kaina, B; Nagel, G; Roos, WP1
Engebråten, O; Engesæter, BO; Flørenes, VA; Hellenes, T; Holm, R; Mælandsmo, GM; Sathermugathevan, M1
Cathomas, R; Dummer, R; Gillessen, S; Goldinger, SM; Mamot, C; Michielin, O; Mjhic-Probst, D; Moch, H; Ochsenbein, A; Schläppi, M; Schönewolf, N; Schraml, PH; Seifert, B; Simcock, M; von Moos, R1
Algazi, AP; Cha, EN; Daud, AI; Soon, CW; Webb, EM1
Aamdal, S; Dueland, S; Gaudernack, G; Julsrud, L; Kyte, JA; Trachsel, S1
Agarwala, SS; Becker, J; Conry, R; Davidson, N; Dummer, R; Eggermont, AM; Engelen, K; Hwu, WJ; Keilholz, U; Kruit, WH; Mortier, L; Patel, PM; Punt, CJ; Robert, C; Schadendorf, D; Spatz, A; Suciu, S; Thompson, JA; Trefzer, U1
Brugnara, S; Chiarion-Sileni, V; Colucci, G; De Salvo, GL; Del Bianco, P; Guida, M; Pigozzo, J; Ridolfi, L; Ridolfi, R; Romanini, A1
Ascierto, P; Chapman, PB; Dreno, B; Dummer, R; Eggermont, AM; Flaherty, KT; Garbe, C; Haanen, JB; Hauschild, A; Hogg, D; Hou, J; Jouary, T; Kirkwood, JM; Larkin, J; Lebbe, C; Lee, RJ; Li, J; Lorigan, P; Maio, M; McArthur, GA; Nelson, B; Nolop, K; O'Day, SJ; Ribas, A; Robert, C; Schadendorf, D; Sosman, JA; Testori, A1
Baurain, JF; Bondarenko, I; Chen, TT; Davidson, N; Francis, S; Garbe, C; Gascon, P; Grob, JJ; Harmankaya, K; Hauschild, A; Hoos, A; Humphrey, R; Ibrahim, R; Lebbe, C; Lotem, M; Maio, M; Miller, WH; O'Day, S; Richards, J; Robert, C; Testori, A; Thomas, L; Weber, J; Wolchok, JD1
Abastado, JP; Audebourg, A; Avril, MF; Caignard, A; Garcette, M; Molina, TJ; Nardin, A; Prévost-Blondel, A; Tissier, F; Tow, C; Wong, WC1
Caminal, JM; Fabra, A; Ferreres, JR; Marcoval, J; Penín, RM; Piulats, JM1
Handler, MZ; Mruthyunjaya, P; Nelson, K1
Tuma, RS1
Andrieu-Abadie, N; Bedia, C; Casas, J; Fabriàs, G; Levade, T1
Boulinguez, S1
Blasius, E; Glas, M; Herrlinger, U; Moehlenbruch, M; Rasch, K; Schaefer, N; Scheffler, B; Stuplich, M; Urbach, H1
Affolter, A; Ahmad, T; Chao, D; Chevreau, C; Corrie, P; Eisen, T; Gibbens, I; Gore, ME; Harries, M; James, MG; Jouary, T; Lorigan, P; Marais, R; Montegriffo, E; Nathan, PD; Negrier, S; Ottensmeier, C; Prendergast, S; Robert, C; Strauss, UP1
Chao, D; de Boer, CJ; Gonzalez, R; Gore, ME; Gutzmer, R; Hait, W; Ho, P; Lang, Z; Lawson, D; Loquai, C; Marshall, D; Mohr, P; O'Day, S; Ottensmeier, C; Pavlick, A; Richards, J; Schadendorf, D; Thompson, JA; Trefzer, U; Uhlar, C; Zhong, B1
Bedeir, A; Berger, W; Ghassemi, S; Grasl-Kraupp, B; Grusch, M; Heffeter, P; Heinzle, C; Held, G; Holzmann, K; Marian, B; Metzner, T; Micksche, M; Peter-Vörösmarty, B; Pirker, C; Spiegl-Kreinecker, S1
Abramov, ME; Artamonov, DN; Gorbacheva, LB; Lichinitser, MR; Tronov, VA1
Kirkwood, JM; Moschos, S; Radkowski, R; Shipe-Spotloe, J; Sulecki, M; Tarhini, A; Tawbi, HA; Villaruz, L; Viverette, F1
Chow, HH; Dorr, RT; Samulitis, BK1
Cooper, DA; Fujita, M; Goldstein, NB; Norris, DA; Partyka, KA; Reuland, SN; Shellman, YG1
Berking, C; Flaig, MJ; Kunte, C; Roider, E; Ruzicka, T; Schneider, J1
Abastado, JP; Avril, MF; Hong, M; Huang, C; Kato, M; Loumagne, L; Mackay, C; Nardin, A; Prévost-Blondel, A; Puaux, AL; Tow, C1
Ding, B; Ding, X; Fan, W; Gao, J; Gao, S; Liu, J; Ma, L; Wu, X; Wu, Z; Xiang, W; Zhang, W; Zhu, Q1
Craig, EA; Spiegelman, VS1
Wilson, KS1
Copur, MS; Obermiller, A1
Kaplan, MG1
Morita, H; Nagai, R1
Dalle, S; Poulalhon, N; Thomas, L1
Lott, JP1
Mateus, C; Robert, C1
Cella, D; Cormier, JN; Revicki, DA; Robinson, DW; Uhlar, CM; Zhao, N1
de Braud, F; Eigentler, TK; Garbe, C; Giovannoni, L; González-Iglesias, R; Kaspar, M; Lovato, V; Menssen, HD; Neri, D; Pflugfelder, A; Romanini, A; Schwager, K; Spitaleri, G; Tasciotti, A; Trachsel, E; Weide, B1
Larkin, J; Minchom, A; Young, K1
Bastholt, L; Cantarini, M; Dummer, R; Hersey, P; Kemsley, K; Kirkwood, JM; Larkin, J; Middleton, M; Robert, C; Sosman, J; Zazulina, V1
Drecoll, U; Garbe, C; Hauschild, A; Hofmann, MA; Kaatz, M; Mohr, P; Schadendorf, D; Tilgen, W; Trefzer, U; Ulrich, J; Weichenthal, M1
Conte, H; Darrigade, AS; Ip Kan Fong, H; Jouary, T; Taïeb, A1
Allegra, M; Bahadoran, P; Ballotti, R; Bertolotto, C; Deville, A; Giacchero, D; Lacour, JP; Ortonne, JP; Passeron, T; Ségalen, C; Thyss, A1
Bhattacharya, A; Khaliq, A; Kochhar, R; Siddappa, PK; Singh, K; Thandassery, RB; Vaiphei, K1
Algazi, AP; Andrews, SC; Daud, AI; DeConti, RC; Hwang, J; McCalmont, T; Messina, JL; Munster, PN; Sondak, VK; Urbas, P; Weber, JS1
Czyż, M; Koprowska, K1
Dzhabarov, FR; Nepomniashchaia, EM; Pozdniakova, VV; Rozenko, LIa1
Aoude, LG; Bonazzi, VF; Brooks, BR; Brown, KM; Chow, D; Dutton-Regester, K; Ellis, JJ; Gartside, MG; Gibbs, R; Hayward, NK; Kobe, B; Lanagan, C; MacKeigan, JP; Muzny, D; Newsham, I; Niemi, NM; Palmer, JM; Pollak, T; Reid, J; Schmidt, CW; Sereduk, C; Stark, MS; Tang, N; Trent, J; Tyagi, S; Woods, SL; Wu, Y; Yin, H; Youngkin, D; Zismann, V1
Chen, R; Devito, N; Pan, E; Yu, M1
Borden, EC; Budd, TG; Elson, P; Hollovary, E; Jacobs, B; Mitsuhashi, M; Spiro, T; Triozzi, P; Yi, T1
Bennett, DC; Chang, PJ; Chinen, M; Cleaver, JE; Demetriou, S; Huang, ZM; Millhauser, GL; Oh, DH; Patel, MP; Scherzer, R; Sviderskaya, EV; Wei, ML; Xie, T; Zhong, L1
Arai, M; Hirano, T; Ishibashi, M; Onda, K; Tanaka, S1
Abken, H; Bangard, C; Kurschat, P; Mauch, C; Schlaak, M; Schmidt, P1
Cun, B; Fan, X; Ge, S; Jia, R; Song, X; Wang, H; Zhao, X1
Queirolo, P; Spagnolo, F1
Hartmann, G; Katoh, N; Kishimoto, S; Nakai, N; Nomiyama, T; Ozawa, A; Takenaka, H1
Amin, S; Cheng, Y; Huber-Keener, KJ; Liao, J; Ren, X; Sharma, AK; Sk, UH; Sun, YW; Yang, JM; Zhang, L; Zhang, Y1
Balañá, C; Bruna, J; Chacón, I; Gil, M; Langa, JM; Martín, M; Segura, PP1
Dummer, R; Michielin, O; Mihic-Probst, D; Moch, H; Ochsenbein, A; Schläppi, M; Schraml, P; Seifert, B; Simcock, M; von Moos, R; von Teichman, A1
Ahn, NG; Dallaglio, K; Ellis, LZ; Fujita, M; Gonzalez, R; Lewis, KD; Liu, W; Luo, Y; McCarter, MD; Norris, DA; Robinson, SE; Robinson, WA; Roop, DR; Spritz, RA; Takeda, M1
Annereau, JP; Chartrain, M; Gairin, JE; Gomes, B; Guilbaud, N; Lamant, L; Meyer, N; Riond, J; Stennevin, A; Vandenberghe, I1
Margolin, K1
Blank, CU; Chapman, PB; Chiarion-Sileni, V; Demidov, LV; Goodman, V; Grob, JJ; Guckert, ME; Gutzmer, R; Haney, P; Hauschild, A; Jouary, T; Kaempgen, E; Karaszewska, B; Martin, AM; Martín-Algarra, S; Mauch, C; Miller, WH; Millward, M; Mirakhur, B; Rutkowski, P; Swann, S1
Abe, N; Irisawa, R; Kurashige, Y; Saito, M; Tsuboi, R1
Doñate, F; Fruehauf, JP; Lee, K; Mazar, AP; Trapp, V1
Abrial, C; Durando, X; Gadea, E; Gimbergues, P; Planchat, E; Tatar, Z; Thivat, E1
Becker, M; Gao, D; Gonzalez, R; Kounalakis, N; Lewis, K; McCarter, M; Pearlman, N; Poust, J; Robinson, W1
Chen, Y; Dallaglio, K; Fujita, M; Gonzalez, R; Luo, Y; McCarter, MD; Norris, DA; Robinson, SE; Robinson, WA; Roop, DR; Thompson, DC; Vasiliou, V; Wang, J1
Brocard, L; Daste, A; Durando, X; Gimbergues, P; Magné, N; Mansard, S; Thivat, E1
Akiyama, S; Fukushige, T; Gunshin, K; Ikeda, R; Kanekura, T; Kawai, K; Matsushita, S; Okumura, H; Tajitsu, Y; Takeda, Y; Ushiyama, M; Yamada, K1
Amatruda, TT; Cohen, PA; Geoffroy, FJ; Gross, HM; Jaslowski, AJ; Kaur, JS; Kosel, ML; Kottschade, LA; Markovic, SN; McWilliams, RR; Perez, DG; Suman, VJ1
Koekkoek, JA; Oosterkamp, HM; Oosterkamp, RM; Taphoorn, MJ; Wiggenraad, RG; Zwinkels, H1
Abasq, C; Charles-Pétillon, F; Coat, C; De Braekeleer, M; Marcorelles, P; Quintin-Roué, I; Talagas, M; Uguen, A1
Engebraaten, O; Engesæter, B; Flørenes, VA; Mælandsmo, GM1
Calabrò, L; Danielli, R; Di Giacomo, AM; Fonsatti, E; Maio, M1
Byron, SA; Doudican, NA; Orlow, SJ; Pollock, PM1
Chang, J; Cheng, X; Escano, C; Gandhi, A; Kannan, R; Liebes, L; Madden, K; Mendoza, S; Muren, C; Ott, PA; Pavlick, AC; Shao, Y1
Ahmed, AS; Dellinger, RW; Duong, PH; Matundan, HH; Meyskens, FL1
Ding, W; Jiang, H; Li, WP; Qian, C; Wu, BJ; Zhou, ZW1
Beumer, JH; Buch, SC; Christner, S; Egorin, MJ; Kirkwood, JM; Lin, Y; Moschos, S; Tarhini, AA; Tawbi, HA1
Achberger, S; Aldrich, W; Borden, EC; Grane, R; Singh, AD; Triozzi, PL1
Bichakjian, CK; Fox, MC; Frohm, ML; Johnson, TM; Lao, CD; Schwartz, JL1
Birdsell, CA; Crosby, NA; Ernstoff, MS; Poklepovic, A; Ramakrishnan, V; Roberts, JD; Winning, M; Youseffian, L; Youssefian, LE1
Frank, S; Lotem, M; Merims, S; Ospovat, I; Peretz, T1
Allred, JB; Creagan, ET; Dronca, RS; Kaur, JS; Lieser, EA; Maples, WJ; Marchello, BT; Markovic, SN; Moore, TD; Nevala, WK; Perez, DG; Pockaj, BA; Thompson, M1
Faião-Flores, F; Maria, DA; Maria-Engler, SS; Pérez-Tomás, R; Soto-Cerrato, V; Suarez, JA1
Danson, SJ; Middleton, MR1
Donnelly, DJ; Margison, GP; McElhinney, RS; McMurry, TB; Middleton, MR; Thatcher, N1
Egyházi, S; Hansson, J; Ma, S; Martenhed, G; Ringborg, U1
Chapman, PB; Hwu, WJ; Livingston, PO; Panageas, KS; Quinn, C; Williams, L; Wolchok, JD1
Fierlbeck, G; Metzger, S; Ulmer, A1
Baumann, MA; Koduri, J1
Becker, JC; Bröcker, EB; Fischer, WH; Kirst, A; Lutz, WK; Wack, C1
Cappugi, P; Coronnello, M; Giannotti, B; Mini, E; Pimpinelli, N; Prignano, F1
Emmert, S; Helmbold, P; Kretschmer, L; Marsch, WC1
Ames, P; Boasberg, PD; Deck, R; Fournier, P; Gammon, G; Kim, H; Kristedja, TS; Martin, M; O'Day, SJ; Piro, L; Shinn, K; Wang, HJ1
Christophers, E; Frick, S; Haacke, TC; Hauschild, A; Lischner, S; Rosien, F; Schäfer, F1
Bernsen, MR; Gustafsson, B; Håkansson, A; Håkansson, L; Krysander, L; Rettrup, B; Ruiter, D2
Atkins, MB; Gollob, JA; McDermott, DF; Mier, JW; Parker, RA; Sorokin, P; Sosman, JA; Tutin, L1
Bernstein, Z; Drumea, K; Haim, N; Sklar, Z; Stein, ME; Steiner, M; Tsalic, M1
Li, Y; McClay, EF1
Aglione, S; Bajetta, E; Bernard-Marty, C; Buzzoni, R; Del Vecchio, M; Khayat, D; Nova, P; Rixe, O; Taillibert, S; Vitali, M1
Aravantinos, G; Bafaloukos, D; Briasoulis, E; Fountzilas, G; Gogas, H; Kosmidis, P; Mylonakis, N; Samonis, G; Skarlos, DV; Stathopoulos, G1
Eskelin, S; Hahka-Kemppinen, M; Kivelä, T; Muhonen, T; Nikkanen, V; Pyrhönen, S; Summanen, P; Tarkkanen, A1
Bloem, A; De Gast, GC; Groenewegen, G1
Camp, R; Hemming, AW; Lind, DS1
Castel, T; Conill, C; Puig, S; Toscas, I1
Balduzzi, A; Barbarino, M; Biroccio, A; Gold, B; Graziani, G; Levati, L; Lombardi, ML; Portarena, I; Tentori, L; Vergati, M1
Agarwala, SS; Kirkwood, JM2
Boiardi, A; Eoli, M; Lamperti, E; Salmaggi, A; Silvani, A1
Bonmassar, E; D'Atri, S; Falcinelli, S; Fuggetta, MP; Jiricny, J; Marra, G; Pagani, E; Pepponi, R1
Acito, L; Bacchi, M; Beretta, M; Carlini, P; Cocconi, G; Di Sarra, S; Foladore, S; Gebbia, V; Maiello, E; Marchi, M; Passalacqua, R1
Ake Hofer, P; Andersson, R; Henriksson, R; Riklund-Ahlström, K1
Dmitruk, A; Kozlowski, L; Ostrowska, K; Wojtukiewicz, MZ; Zacharski, LR1
Dréno, B; Wallon-Dumont, G1
Batchelor, D; Boogerd, W; de Gast, GC; de Waal, MA; Kersten, MJ; Nieweg, OE; Nooijen, WJ; Sein, J; van de Kasteele, WF; Vyth-Dreese, FA1
Binder, B; Cerroni, L; Kerl, H; Richtig, E; Smolle, J; Wolf, IH1
Neville, F; Nystrom, ML; Oliver, RT; Shamash, J; Steele, JP1
Gore, M; Hahka-Kemppinen, M; Hansson, J; Humblet, Y; Kivelä, T; Kloke, O; Kruit, WH; Kumpulainen, E; Parvinen, LM; Pyrhönen, S; Suciu, S; Vuoristo, MS1
Ames, P; Boasberg, PD; Deck, R; Kristedja, TS; Martin, M; O'Day, SJ; Petrovich, Z; Shinn, K; Tamar, B; Wang, H1
De Salvo, GL; Foletto, M; Lejeune, FJ; Lise, M; Lopes, M; Mocellin, S; Pilati, PL; Pontes, L; Ribeiro, M; Rossi, CR1
Bedikian, AY; Eton, O; Papadopoulos, N; Plager, C; Ring, S1
Günsberg, P; Jansen, B; Maierhofer, H; Monia, BP; Pehamberger, H; Polterauer, P; Selzer, E; Thallinger, C; Wacheck, V; Wolff, K; Wolschek, MF1
Ide, H; Nakamura, T1
Alvino, E; Bonmassar, L; D'Atri, S; Falcinelli, S; Fuggetta, MP; Guadagni, F; Lacal, PM; Pagani, E; Passarelli, F; Pepponi, R; Prete, SP; Turriziani, M1
Arance, A; Ashcroft, L; Clamp, A; Danson, S; Hodgetts, J; Lomax, L; Lorigan, P; Middleton, MR; Ranson, M; Thatcher, N1
Chiarion-Sileni, V; Corgna, E; Dalla Palma, M; De Salvo, GL; Del Bianco, P; Labianca, R; Lo Presti, G; Lo Re, G; Nortilli, R; Ridolfi, R; Romanini, A1
Hakozaki, H; Iijima, S; Kawano, H; Kawasaki, T; Mori, N; Nihei, T; Oka, K; Saito, H; Sandoh, N; Sasaki, M; Tateishi, Y1
Akimov, MA; Barchuk, AS; Gel'fond, ML; Gershanovich, ML1
Bar-Eli, M; Lev, DC; McGary, EC; Mills, L; Price, JE; Ruiz, M1
Chapman, PB; Foster, T; Houghton, AN; Hwu, WJ; Krown, SE; Lamb, LA; Livingston, PO; Menell, JH; Merrell, J; Panageas, KS; Quinn, CJ; Williams, LJ; Wolchok, JD1
Isobe, T; Kato, Y; Koga, M; Mizuguchi, J; Saito, M; Shibuya, H; Toyota, H; Tsuboi, R1
Komorowski, AL; Mituś, J; Wysocki, WM1
Egyházi, S; Hansson, J; Kreklau, EL; Lindholm, C; Ma, S; Ringborg, U; Stierner, U; Ueno, T1
Apostolidis, C; Rapidis, AD; Valsamis, S; Vilos, G1
Boxall, J; Marples, M; Meyer, T; Napier, MP; Rustin, GJ; Strauss, SJ1
Eisen, TG; Lens, MB1
Jelić, S; Jović, V; Jurisić, V; Konjević, G; Radulović, S; Spuzić, I1
Gajewski, TF1
Chapman, PB; Foster, T; Krown, SE; Livingston, PO; Quinn, C; Sepkowitz, KA; Sohn, S; Su, YB; Williams, L; Wolchok, JD1
Jonas, DL; Kiebert, GM; Middleton, MR1
Oubre, DN1
Zelger, B; Zelger, BG1
Busam, KJ; Chapman, P; Jungbluth, AA; Wolchok, J1
Harkness, KA; Manford, MR1
Aamdal, S; Avril, MF; Bieber, T; Bonerandi, JJ; Bonneterre, J; Fra, J; Gilde, K; Gonzalez Larriba, JL; Grob, JJ; Guillem Porta, V; Hauschild, A; Kamanabrou, D; Menu, Y; Mohr, P; Neuber, K; Pehamberger, H; Saïag, P; Scherrer, A; Sufliarsky, J; Weichenthal, M1
Graziani, G; Tentori, L1
Haluska, FG; Yang, S1
Eigentler, TK; Garbe, C1
Castel, T; Conill, C; Fernández-Ibiza, J; Malvehy, J; Puig, S; Sánchez, M1
Agarwala, SS; Kirkwood, JM; Neuberg, D; Park, Y1
Agarwala, SS; Tarhini, AA1
Castel, T; Conill, C; González-Cao, M; Jorcano, S; Malvehy, J; Martí, R; Puig, S1
Geilen, CC; Georgieva, J; Orfanos, CE; Treudler, R1
Mitchell, MS1
Ananthaswamy, HN; Bar-Eli, M; Lev, DC; McGary, EC; Melinkova, VO; Miller, C; Onn, A; Price, JE; Ruiz, M; Stone, V1
Dvorak, J; Hadzi-Nikolov, D; Melichar, B; Petera, J; Zizka, J1
Agarwala, SS; Atkins, M; Buzaid, A; Czarnetski, B; Dreno, B; Gore, M; Kirkwood, JM; Rankin, EM; Skarlos, D; Thatcher, N1
Akimov, MA; Gershanovich, ML1
Cannavò, E; D'Atri, S; Falchetti, R; Fuggetta, MP; Lanzilli, G; Ravagnan, G; Tricarico, M; Zambruno, G1
Amiri, KI; Horton, LW; LaFleur, BJ; Richmond, A; Sosman, JA1
Fialla, R; Forstinger, Ch; Fritsch, P; Hofmann-Wellenhof, R; Kehrer, H; Kerl, H; Kindermann-Glebowski, E; Klein, G; Koller, J; Konrad, K; Kos, C; Lang, A; Mischer, P; Pachinger, W; Pehamberger, H; Raml, J; Ratzinger, G; Richtig, E; Seeber, A; Smolle, J; Steiner, A; Ulmer, H; Wolff, K; Zelger, B1
Eggermont, AM; Kirkwood, JM1
Bafaloukos, D; Briassoulis, E; Christodoulou, C; Fountzilas, G; Gogas, H; Hatzichristou, H; Kalofonos, HP; Linardou, H; Panagiotou, P; Tsoutsos, D1
Amaducci, L; Biasco, G; Guida, M; Leoni, M; Michiara, M; Poletti, P; Ravaioli, A; Ridolfi, R; Romanini, A; Sileni, VC1
Cansiz, H; Güzel, MZ; Karakullukçu, B; Ozek, H; Oztürk, O1
Bafaloukos, D; Bedikian, AY; Gogas, H1
Négrier, S; Neidhardt-Bérard, EM1
Bonenkamp, JJ; de Faria Lima, R; de Wilt, JH; Doubrovsky, A; Kam, PC; Thompson, JF1
Friedman, HS; Grubbs, E; Ko, SH; Pruitt, SK; Tyler, DS; Ueno, T1
Ballardini, B; Bassi, F; De Pas, T; Gatti, G; Luini, A; Mauri, E1
Hahka-Kemppinen, MH; Hernberg, MM; Pyrhönen, SO1
Harting, MS; Kim, KB1
Argon, A; Camlica, H; Duranyildiz, D; Oguz, H; Tas, F; Topuz, E; Yasasever, V1
Agarwala, SS1
Kefford, R; Lim, I; Manolios, N1
Buzaid, AC1
Bessho, A; Mogami, H; Nakata, M; Okita, R; Teramoto, N; Yamashita, M1
Grange, JD; Kodjikian, L; Rivoire, M1
Piro, LD1
Boasberg, P; Groshen, S; Kristedja, T; Liu, D; Milford, R; O'Day, SJ; Weber, J; Yang, D1
Aravantinos, G; Bafaloukos, D; Bamias, A; Carina, M; Christodoulou, C; Klouvas, G; Linardou, H; Skarlos, D1
Azzabi, A; Boddy, AV; Calvert, AH; Calvert, PM; Fishwick, K; Griffin, MJ; Hughes, AN; Kelly, C; Lind, MJ; Maraveyas, A; Plummer, ER; Todd, R1
Feun, L; Hurley, J; Marini, A; Mazumder, A; Moffat, F; Savaraj, N1
Bafaloukos, DI; Brountzos, EN; Kelekis, DA; Panagiotou, IE; Papathanasiou, MA1
Kharoubi, S1
Bafaloukos, D; Briassoulis, E; Chalkidou, S; Christodoulou, C; Efstathiou, E; Fountzilas, G; Gogas, H; Iconomou, T; Kalofonos, H; Kouroussis, C; Linardou, E; Panagiotou, P; Polyzos, A; Tsoutsos, D1
Chapman, PB; Houghton, AN; Hwu, WJ; Krown, SE; Lamb, LA; Lis, E; Livingston, PO; Menell, JH; Merrell, J; Panageas, KS; Williams, LJ; Wolchok, JD1
Boddy, AV; Calvert, AH; Curtin, NJ; Harris, AL; Hickson, I; Jones, C; Margison, GP; McGown, G; McHugh, P; Middleton, MR; Newell, DR; Olsen, A; Plummer, ER; Thorncroft, M; Watson, AJ1
Di Lauro, V; Freschi, A; La Mura, N; Nigri, P; Scalone, S; Veronesi, A; Zanetti, M1
Fink, D; Gleave, ME; Hoeller, C; Jansen, B; Kovacic, B; Pehamberger, H; Pratscher, B; Sexl, V; Thallinger, C; Wacheck, V; Winter, D1
Aoyama, N; Minamide, J; Ogata, T; Suzuki, Y; Takata, K1
Hahka-Kemppinen, M; Kellokumpu-Lehtinen, P; Korpela, M; Parvinen, LM; Pyrhönen, S; Seppä, H; Vuoristo, MS1
Benedetti, G; Biasco, G; Pantaleo, MA; Poggi, R1
Cupissol, D; Cuq, P; Depeille, P; Evrard, A; Passagne, I; Vian, L1
Jović, V; Konjević, G; Radomirović, V; Spuzić, I1
Birner, P; Boehm, J; Heere-Ress, E; Hoeller, C; Jansen, B; Pehamberger, H; Thallinger, C; Wacheck, V; Wolff, K1
Anderson, C; Baron, A; Gibbs, P; Gonzalez, R; Lewis, KD; O'Day, S; Richards, J; Russ, P; Weber, J; Zeng, C1
Bonaccorsi, P; Borroni, RG; Bottoni, U; Calvieri, S; Clerico, R; Devirgiliis, V; Panasiti, V; Trasimeni, G1
Castel, T; Conill, C; Gascón, P; González Cao, M; Herrero, JE; Malvehy, J; Martí, RM; Mellado, B; Puig, S; Sánchez, M1
Budach, V; Hofmann, M; Kiecker, F; Schlenger, L; Sterry, W; Trefzer, U; Wurm, R1
Bogdahn, U; Koch, HJ; Kuchelmeister, K; Roeber, S; Schachenmayr, W; Schäfer, C; Steinbrecher, A; Villarrubia, V; Zimmermann, UW1
Eggermont, AM; Gore, M; Keilholz, U; Kleeberg, U; Kruit, W; Lehman, F; Lienard, D; Negrier, S; Patel, P; Proebstle, TM; Punt, CJ; Schadendorf, D; Schmittel, A; Suciu, S; Thomas, J; Velu, T1
Aronson, F; Kennedy, T; Ready, N; Wanebo, H1
Narita, Y1
Benimetskaya, L; Miller, P; Stein, CA1
Kiss, R; Mathieu, V; Mijatovic, T; van Damme, M1
Denny, SR; Harvey, WB; Kashani-Sabet, M; Madland, MT; Minor, DR1
Amatruda, TT; Elashoff, RM; Gonzalez, R; Hoon, DS; Koyanagi, K; Lewis, K; O'Day, SJ; Robinson, WA; Takeuchi, H; Umetani, N; Wang, HJ1
Allen, R; Ames, P; Cook, M; Cruickshank, S; Deck, R; Gonzalez, R; Good, J; Meyer, J; O'Day, S; Rose, M; Spitler, LE; Timmerman, M; Trautvetter, S; Weber, RW1
Becker, JC; Dummer, R; Garbe, C; Kaufmann, R; Krengel, S; Kretschmer, L; Leiter, U; Linse, R; Mauch, C; Schadendorf, D; Sebastian, G; Spieth, K; Tilgen, W; Vogt, T; von den Driesch, P1
Baur, A; Berger, TG; Dieckmann, D; Efferth, T; Funk, JO; Schuler, G; Schultz, ES1
Sterry, W; Trefzer, U1
Forini, O; Gold, B; Graziani, G; Lacal, PM; Leonetti, C; Li, W; Muzi, A; Ruffini, F; Scarsella, M; Tentori, L; Vergati, M; Zhang, J1
Brennecke, S; Deichmann, M; Kurzen, H; Naeher, H1
Argon, A; Camlica, H; Tas, F; Topuz, E1
Hoon, DS; Kitago, M; Koyanagi, K; Kuo, C; Martinez, SR; Milford, R; Mori, T; Nguyen, SL; O'Day, SJ; Takeshima, TL; Umetani, N; Vu, VD; Wang, HJ1
Conway, BR; Suppasansatorn, P; Wang, G; Wang, W; Wang, Y1
Becker, JC; Berger, T; Bröcker, EB; Burg, G; Edler, L; Enk, A; Grabbe, S; Jonuleit, H; Kamarashev, J; Kämpgen, E; Keikavoussi, P; Nestle, FO; Rittgen, W; Schadendorf, D; Schuler, G; Schuler-Thurner, B; Sucker, A; Tüttenberg, A; Ugurel, S; Zimpfer-Rechner, C1
Bai, CM; Lang, JH; Ma, SQ; Yu, XH; Zhong, S1
Carrera, C; Castel, T; Conill, C; Gascón, P; González Cao, M; Herrero, J; Malvehy, J; Martí, R; Martín, M; Mellado, B; Puig, S; Sánchez, M1
Asna, N; Inbar, MJ; Metser, U; Ron, IG; Ryvo, L; Safra, T; Sapir, EE; Sarid, D; Schneebaum, S1
Bajetta, E; Bernengo, MG; Cascinelli, N; Daponte, A; Del Vecchio, M; Formisano, B; Fusi, A; Legha, SS; Nova, P; Queirolo, P; Sertoli, MR; Taveggia, P1
Archimbaud, A; Basset-Seguin, N; Dubertret, L; Guitera, P; Kerob, D; Levy, A; Ollivaud, L1
Chan, V; Chaudhry, AA; Clark, CT; Daw, HA; Kundranda, MN1
Abdel-Wahab, OI; Abdel-Wahab, Z; Augustine, C; Cheng, TY; Friedman, HS; Grubbs, E; Ko, SH; Pruitt, SK; Tyler, DS; Ueno, T; Yoshimoto, Y1
Fukunaga, T; Kageshita, T; Kojima, S; Ogawa, H; Ono, T; Sakamoto, T; Soejima, H; Sugamura, K; Sugiyama, S; Tanoue, T; Yoshimura, M1
Aird, S; Chapman, PB; Houghton, AN; Hwu, WJ; Krown, SE; Lamb, LA; Livingston, PO; Menell, JH; Panageas, KS; Williams, LJ; Wolchok, JD1
Castel, T; Conill, C; Domingo-Doménech, J; Gallego, R; Jorcano, S; Malvehy, J; Puig, S; Sánchez, M; Vilella, R1
Butt, M; Eswar, CV; Gillis, P; Marshall, E; O'Neill, PA1
Berger, Y; Bernasconi, CC; Juillerat-Jeanneret, L1
Arce-Lara, C; Kloecker, GH; Laber, DA; McMasters, KM; Miller, DM; Okeke, RI; Schonard, CL; Taft, BS1
Hansson, J1
Bieber, T; Gollnick, H; Köhler, U; Linse, R; Luger, T; Schroth, K; Schubert, R; Stadler, R; Strannegård, O; Technau, K; Thoren, F; Vakilzadeh, F; Volkenandt, M; Von Eick, H1
Barbaud, A; Schmutz, JL; Trechot, P1
Amatruda, TT; Anderson, C; Baron, A; Becker, M; Dollarhide, S; Gonzalez, R; Lewis, KD; Matijevich, K; McCarter, M; O'Day, SJ; Pearlman, N; Robinson, WA; Zeng, C1
Ekmekcioglu, S; Fok, JY; Mehta, K1
Biasco, G; Casamassima, A; Chiarion-Sileni, V; Freschi, A; Galligioni, E; Guida, M; Nanni, O; Nortilli, R; Palma, MD; Picozzo, J; Ravaioli, A; Riccobon, A; Ridolfi, R; Romanini, A1
Hansson, J; Månsson-Brahme, E; Masucci, GV; Nilsson, B; Ragnarsson-Olding, B; Wagenius, G1
Crespo, C; del Muro, XG; Filipovich, E; García, M; Germà-Lluch, JR; López, JJ; Pérez, X; Rifà, J; Tres, A; Valladares, M1
Dadban, A; Daneshpazhooh, M; Raafat, J; Shokoohi, A1
Geng, B; Liu, YS; Sun, YF; Yang, CH; Zhang, WD1
Andrews, S; Brem, S; Daud, AI; Ismail-Khan, R; Khan, MA; King, J; Munster, PN; Reintgen, DS; Sondak, VK1
Alvino, E; Bonmassar, E; Caporali, S; Caporaso, P; Castiglia, D; D'Atri, S; Fischer, F; Jiricny, J; Lacal, PM; Marra, G; Pepponi, R; Zambruno, G1
Bedikian, AY; Conry, R; DeConti, R; Gore, M; Haluska, FG; Hersey, P; Hersh, EM; Kirkwood, JM; Millward, M; Pavlick, AC; Pehamberger, H; Trefzer, U1
Fountzilas, G; Frangia, K; Gogas, H; Mantzourani, M; Markopoulos, C; Middleton, M; Panagiotou, P; Papadopoulos, O; Pectasides, D; Polyzos, A; Stavrinidis, I; Tsoutsos, D; Vaiopoulos, G1
Haluska, FG; Hodgson, L; Houghton, AN; Hwu, WJ; Krown, SE; Niedzwiecki, D1
Egberts, F; Garbe, C; Hauschild, A; Kreissig, M; Linse, R; Mohr, P; Schadendorf, D; Thoelke, A; Tilgen, W; Trefzer, U; Ugurel, S; Vogt, T1
Eggermont, AM; Gore, MA; Keilholz, U; Koller, J; Kruit, WH; Lienard, D; Patel, P; Punt, CJ; Suciu, S; Thomas, J1
Cerny, T; Gillessen, S; Korte, W; Schlaeppi, MR; von Moos, R1
Delaunay, M; Jouary, T; Taieb, A1
Bate, SC; Beirne, DA; Eisen, TG; Gibbens, IM; Gore, ME; Hughes, SA; Larkin, JM; Patel, PM; Thomas, K1
Boogerd, W; Dalesio, O; de Gast, GC1
Bonmassar, E; Caporali, S; Caporaso, P; D'Atri, S; Falcinelli, S; Pagani, E; Pepponi, R; Turriziani, M1
Becker, JC; Beiteke, U; Bröcker, EB; Durani, B; Jünger, M; Junghans, V; Kortüm, AK; Mauch, C; Remling, R; Schadendorf, D; Schulze, HJ; Terheyden, P1
Cuttone, G; Korićanac, LB; Petrović, IM; Privitera, G; Ristić-Fira, AM; Todorović, DV; Valastro, LM1
Engebraaten, O; Engesaeter, BO; Fodstad, O; Lillehammer, T; Maelandsmo, GM; Prasmickaite, L1
Hofmann, MA; Sterry, W; Trefzer, U1
Ali-Osman, F; Augustine, CK; Friedman, HS; Pruitt, SK; Selim, MA; Tyler, DS; Yoo, JS; Yoshimoto, Y; Zipfel, PA1
De Neve, N; Gras, T; Kiss, R; Le Mercier, M; Lefranc, F; Mathieu, V; Roland, I; Sauvage, S1
Joukhadar, C; Kovar, FM; Poeppl, W; Pratscher, B; Quehenberger, P; Thallinger, C; Valent, P; Werzowa, J1
Ascierto, PA; Casula, M; Cossu, A; Palmieri, G; Tanda, F1
Baka, S; Beith, J; Davis, ID; Harris, PA; Haydon, A; Hersey, P; Kefford, RF; Margison, GP; McArthur, GA; Middleton, MR; Mortimer, P; Ranson, M; Sabharwal, A; Seebaran, A; Thompson, D; Watson, AJ1
Weller, M1
Balafouta, MJ; Kolokouris, D; Kouloulias, VE; Kouvaris, JR; Miliadou, A; Papacharalampous, XN; Vlahos, LJ1
Boucher, KM; Jensen, RL; Leachman, SA; Majer, M; Samlowski, WE; Shrieve, DC; Wang, M; Watson, GA1
Conway, BR; Du, L; Nimmannit, U; Suppasansatorn, P; Wang, Y1
Iwai, T; Kawada, K; Kawano, T; Nagai, K; Nakajima, Y; Nishikage, T; Ogiya, K; Tanaka, K; Tokairin, Y1
Ahmadloo, N; Mohammadianpanah, M; Mosalaei, A; Omidvari, S; Shirazi, M1
Lau, TK; Li, RH; Mok, TS; Ng, PC; Tam, B; Tam, WH1
Anderson, R; Burdette-Radoux, S; Gehlsen, K; Hauschild, A; Hellstrand, K; Middleton, M; Naredi, P; Thomson, D1
Hesse, A; Mainka, A; Nettelbeck, DM; Quirin, C1
Agarwala, SS; Cai, C; Gooding, WE; Kirkwood, JM; Tarhini, AA1
Cloud, GA; Fiveash, JB; Guthrie, BL; Markert, JM; Meredith, RF; Nordal, RA; Sawrie, SM; Spencer, SA1
Camlica, H; Tas, F; Topuz, E1
Bak, K; Charette, M; Petrella, T; Quirt, I; Verma, S1
Cashin, R; Corey-Lisle, PK; Einarson, TR; Hemels, M; Lui, P; Machado, M1
Adema, AD; Bhakat, KK; Boven, E; Fontijn, D; Peters, GJ; Pinedo, HM1
Hayashi, K; Inaba, Y; Isobe, H; Miura, T; Moriya, T; Takiguchi, M; Tezuka, K; Watabe, S; Yanagawa, N1
Stein, CA1
Enk, A; Grabbe, S; Müller, ML; Nashan, D; Wustlich, S1
Bayer, W; Heim, A; Hoffmann, D; Nettelbeck, DM; Potthoff, A; Wildner, O1
Allen, J; Avery-Kiejda, KA; Hersey, P; Mhaidat, NM; Scott, RJ; Zhang, XD1
Jelić, S; Jović, V; Konjević, G; Radulović, S; Spuzić, I; Vuletić, A1
Bajetta, E1
Brocard, A; Dréno, B; Quéreux, G1
Bratta, M; Candeloro, G; Fumagalli, L; Necozione, S; Rea, S; Recchia, F1
Becker, JC; Beyeler, M; Bröcker, EB; Dummer, R; Garbe, C; Gille, J; Hauschild, A; Kaehler, KC; Kaufmann, R; Leiter, U; Pföhler, C; Schadendorf, D; Spieth, K; Tilgen, W; Ugurel, S1
Dummer, R; Eigentler, T; Ellwanger, U; Garbe, C; Gutzmer, R; Hauschild, A; Linse, R; Radny, P; Stadler, R; Ulrich, J; Weichenthal, M1
Camacho, L; Gupta, R; Hoos, A; Kirkwood, JM; Lutzky, J; Mann, GB; Parmiani, G; Richards, J; Srivastava, PK; Testori, A; Tosti, G; Whitman, E; Yuh, L1
Neff, WJ; Nystrom, KK; Pick, AM1
Dimov, A; Gadjeva, V; Georgieva, N1
Herrmann, R; Hess, V; Schwabe, M; Veelken, H1
Bedane, C; Cupissol, D; Delaunay, M; Dereure, O; Dreno, B; Guillot, B; Khamari, A; Picot, MC1
Bael, TE; Gollob, JA; Peterson, BL1
Dorio, AS; Graziani, G; Lacal, PM; Muzi, A; Navarra, P; Ruffini, F; Tentori, L1
Dutz, JP; Najar, HM1
Schuh, T; Siedek, V; Wollenberg, A1
Acres, B; Bleuzen, P; Dummer, R; Lacoste, G; Limacher, JM; Rochlitz, C; Romero, P; Slos, P; Urosevic, M; Velu, T1
Kirkwood, JM; Lotze, MT; Mandic, M; Moschos, SJ; Storkus, WJ1
Brell, J; Dehart, WK; Gilliam, AC; Lu, KQ1
Agarwala, S; Beeram, M; Cranmer, L; Frenette, G; Gonzalez, R; Hersh, E; Hodi, FS; Jakub, JW; Kirkwood, J; Lewis, K; Linette, GP; McDermott, DF; Patel, K; Puzanov, I; Richards, J; Sosman, JA; Tarantolo, S; White, JM; Xia, C1
Busam, K; Chapman, PB; Gerst, S; Jungbluth, AA; Krown, S; Orlow, I; Panageas, K; Rietschel, P; Smith, K; Wolchok, JD1
Augustine, CK; Febbo, P; Gupta, M; Pendergast, AM; Peters, WP; Selim, MA; Tyler, DS; Yoshimoto, Y; Zipfel, PA1
Komatsubara, H; Komori, T; Minamikawa, T; Ojima, Y; Shibuya, Y; Shigeta, T; Umeda, M; Yokoo, S1
Hagen, S; Klepp, O; Stridsklev, IC1
Czarnetzki, BM; Macher, E1
Agrup, G; Arnbjörnsson, E; Hafström, L; Jönsson, PE; Rorsman, H1
Fiedler, H; Wohlrab, W; Wozniak, KD; Zaumseil, RP1
Thiers, BH1
Baki, AV; Vaughan, K1
Cheung, T; Cohen, SM; Holland, JF; Ohnuma, T1
Khan, MS; Ross, WM1
Kennealey, GT; Kirkwood, JM; Luikart, SD1
Balch, CM; Hersey, P1
Allegra, JC; Blumenreich, MS; Gentile, PS; Kubota, TT; Richman, SP; Woodcock, TM1
Bychkov, MB; Perevodchikova, NI1
Armand, JP; Bui, NB; Cappelaere, P; Chauvergne, J; Durand, M; Gary-Bobo, J; Guerrin, J1
Bernengo, MG; Doveil, GC; Lisa, F; Meregalli, M1
Kemeny, N1
Al-Sarraf, M; Balcerzak, SP; Costanzi, JJ; Eyre, HJ; Fletcher, WS; Frank, J; O'Bryan, RM; Taylor, S1
Hill, GJ; Hill, HZ; Krementz, ET1
Balch, CM; Bartolucci, AA; Murray, D; Presant, C1
Kendall, AR; Stein, BS1
Barduagni, A; Di Lauro, L; Ganzina, F; Lopez, M; Papaldo, P; Perno, CF1
Aigner, KR; Börger, G; Illig, L; Jungbluth, A; Link, KH; Müller, H; Ringenberg, T; Ruppel, R; Schwemmle, K; Walther, H1
Ichihashi, M; Inoi, T; Mishima, Y; Mojamdar, M2
Angelini, G; Bonifazi, E; Meneghini, CL1
Baker, LH; Bhathena, DB; Cummings, G; McDonald, B; Samson, MK; Talley, RW1
Jimbow, K; Kawamura, M; Maeda, K; Miura, S1
Erichsen, C; Jönsson, PE1
Hayward, IP; Parsons, PG1
Osieka, R1
Del Prete, SA; Forcier, RJ; LeMarbre, P; Maurer, LH; O'Donnell, J1
Lüchtrath, H; Schmich, HR1
Aubert, C; Rouge, F1
Harada, M; Komi, N; Makinoya, T; Miyamoto, H; Miyoshi, Y; Tamura, T; Yamamoto, M1
Bernengo, MG; Fra, P; Lisa, F; Meregalli, M; Zina, G1
Bertelsen, CA; Kaiser, LR; Kern, DH; Korn, EL; Mann, BD; Morton, DL; Storm, FK1
Dor, P; Jortay, AM; Lejeune, FJ1
Ingvar, C; Jönsson, PE; Stridbeck, H1
Metelmann, HR; Von Hoff, DD1
Calbo, L; Gorgone, S; Melita, P; Palmeri, R; Salibra, M1
Aigner, K; Schwemmle, K1
Aigner, K; Henneking, K; Hild, P; Hundeiker, M; Paul, E1
Giraldi, T; Lassiani, L; Nisi, C; Sava, G1
Ariyan, S; Kirkwood, JM; Mitchell, MS1
Hayasaka, K; Ikeda, S; Ishihara, K; Jimbow, K; Kukita, A; Seki, Y; Suzuki, M; Terakado, T1
Hill, GJ; Hill, HZ; Raina, S; Rush, BF1
Klemm-Mayer, H; Rasokat, H; Wagner, G1
Kohlsmith, DJ; Luner, SJ; Vaughan, K1
Hori, Y; Kawashima, M; Kukita, A; Mizoguchi, M; Shimada, S; Watanabe, S; Yamada, K2
Balda, BR; Bassermann, R1
Campbell, ED; Carter, WH; Stablein, DM; Wampler, GL1
Féaux de Lacroix, W; Pullmann, H; Runne, U1
Kirkwood, JM; Marsh, JC1
Doepfmer, K; Féaux de Lacroix, W; Groth, W; Hauk, H; Runne, U; Wacker, D1
Aigner, K; Hild, P; Hundeiker, M1
Atassi, G; Dumont, P; Tagnon, HJ1
Ding, YA; Hwang, WS; Lee, WC; Leu, FJ1
Byrne, MJ; Reynolds, PM1
Haruyama, H; Ijichi, H; Isemura, T; Nakagawa, M; Nakanishi, S; Okano, R; Sawada, S; Shimazaki, C; Tsuji, H; Ueda, K1
Aiba, K; Domyo, M; Ezaki, K; Horikoshi, N; Inagaki, J; Inoue, K; Miyamoto, H; Nagata, T; Ogawa, M1
Antz, H; Doepfmer, K; FEAUX DE Lacroix, W; Groth, W; Runne, U1
Bolton, PM; Clunie, GJ; Dury, M; Furnival, CM; Gough, IR1
Borisov, AI; Kogoniia, LM; Moroz, LV; Perevodchikova, NI; Platinskiĭ, LV1
Fletcher, WS; Golomb, FM; Grage, TB; Hill, GJ; Krementz, ET; Minton, JP; Moss, SE1
Jimbow, K; Nishio, C; Yanbe, H1
Beretta, G1
Banzet, P; Jacquillat, C; Maral, J1
Behrendt, H; Czarnetzki, BM; Lejeune, F; Macher, E1
Balch, C; Bartolucci, AA; Presant, CA; Troner, M1
Greco, FA; Knost, JA; Oldham, RK; Reynolds, V1
Bodey, GP; Gutterman, JU; Hersh, EM; Robidoux, A1
Al-Sarraf, M; Bottomley, R; Costanzi, JJ; Dixon, D; Fabian, C; Groppe, C; Neidhart, J1
Chiba, M; Homma, K; Jimbow, K; Kizukuri, K1
Adamus, J; Aubert, C; Bajetta, E; Beretta, G; Bonadonna, G; Bufalino, R; Cascinelli, N; Cocconi, G; De Marsillac, J; Durand, J; Ikonopisov, RL; Kiss, B; Lejeune, F; MacKie, R; Madej, G; Mechl, Z; Milton, GW; Morabito, A; Mulder, H; Paul, E; Peter, H; Priario, J; Rumke, P; Sertoli, R; Tomin, R; Veronesi, U1
Elliott, RS; Gomes, AS; Goodnight, JE; Harrison, WH; Kaiser, LR; Morton, DL; Storm, FK1
Arlen, M; Cohen, M; Hollinshead, A; Kundin, WD; Scherrer, J; Tanner, K; Yonemoto, R1
Hill, GJ; Hill, HZ1
Hayward, IP; Morrison, LE; Parsons, PG; Smellie, SG1
Cascinelli, N; Marolda, R; Orefice, S; Rovini, D; Vaglini, M; Veronesi, U1
Muth, M; Pullmann, H1
Swensson-Beck, H; Trettel, WH1
Altenähr, E; Doering, C; Orfanos, CE; Pickartz, H1
Boeva, M; Hadjikirova, M; Ikonopisov, R1
Hayasaka, K; Ikeda, S; Ishihara, K; Jimbow, K; Kukita, A; Seki, Y; Takahashi, H; Terakado, T1
Becher, R; Schmidt, CG; Seeber, S1
Bowers, T; Charnsangavej, C; Chuang, VP; Soo, CS; Wallace, S1
Koriech, OM; Shükla, VS1
Fodstad, O; Olsnes, S; Pihl, A; Tveit, KM1
Caselitz, J; Jänner, M; Voigt, H1
Bettendorf, U; Frank, K; Reinhardt, P1
Crone-Münzebrock, W; Kröger, E; Stritzke, P; Voigt, H1
Lorincz, AL; Winston, EM; Yung, CW1
Crone-Münzebrock, W; Denkhaus, H; Voigt, H1
Adamczyk, B; Pawlicki, M; Zuchowska-Vogelgesang, B1
Endresen, L; Fodstad, O; Pihl, A; Rugstad, HE; Tveit, KM1
Blackledge, G; Crowther, D; Palmer, MK; Thatcher, N1
Fodstad, O; Pihl, A; Tveit, KM1
Gordy, DD; Murray, JL; Robertson, DM; Wilkinson, CP1
Aass, N; Fodstad, O; Pihl, A2
Bodey, GP; Burgess, MA; Gutterman, JU; Heilbrun, LK; Hersh, EM; Murphy, WK; Schwarz, MA; Stone, E; Turner-Chism, V1
Arseneau, JC; Asbury, RF; Descalzi, ME; Ratcliffe, RL; Rosenthal, SN1
Kollakowski, M; Kunze, J; Roeber, H1
Duchková, H; Král, V; Kubíková, M; Ragan, J1
Duchková, H; Hrivnáková, J; Kubíková, M; Kvasnicka, J; Peska, J; Ragan, J; Richter, J; Vohryzková, E1
Nifontova, TP1
Barber, NA; Didolkar, MS; Elias, EG; Moore, RH1
Bolling, R; Meyer-Hamme, S; Schauder, S1
Dufour, FD; Mah, SG; Morton, DL; Okada, GT1
Hafström, L; Jönsson, PE1
Dubois, JB; el Amrani, N; Mathieu-Daude, H; Melhouf, MM1
Feun, LG; Hurley, J; Liebmann, A; Moffat, F; Raub, WA; Richman, SP; Robinson, D; Savaraj, N1
Betticher, DC; Clemons, M; Lee, SM; Morris, C; Thatcher, N1
Brossart, P; Geueke, AM; Hunstein, W; Jochim, A; Keilholz, U; Maclachlan, D; Möhler, T; Scheibenbogen, C1
Algermissen, B; Czarnetzki, BM; Kohlmus, CM; Schadendorf, D; Worm, M1
Dvorák, E; Haas, RE; Liebner, EJ1
Hahka-Kemppinen, M; Muhonen, T; Pakkala, S; Pyrhönen, S1
Gröhn, P; Korpela, M; Kumpulainen, E; Vuoristo, M1
de Vries, EG; Koops, HS; Mulder, NH; Sleijfer, DT; van der Graaf, WT; Willemse, PH1
Ishihara, K3
Gröhn, P; Joensuu, H; Kellokumpu-Lehtinen, P; Korpela, M; Kumpulainen, E; Nevantaus, A; Tiusanen, K; Turunen, M; Vuoristo, MS1
Asko-Seljavaara, S; Hahka-Kemppinen, M; Jekunen, A; Muhonen, T; Pyrhönen, S; Virolainen, M1
Kishimoto, S; Ueda, E; Yasuno, H1
Gillen, P; Keane, FB; Kerin, MJ; Monson, JR; Tanner, WA; Wilkie, J1
Brossart, P; Hunstein, W; Keilholz, U; Möhler, T; Scheibenbogen, C; Tilgen, W1
Dreno, B; Mansat-Krzyzanowska, E1
Chmielowska, E; Pluzańska, A; Potemski, P1
Atzpodien, J; Chaitchik, S; Duensing, S; Franzke, A; Kirchner, H; Körfer, A; Lopez Hänninen, E; Poliwoda, H; Schomburg, A; Volkenandt, M1
Belliveau, JF; Darnowski, JW; Leenen, L; Turk, PS; Wanebo, HJ; Weinberg, MC1
Asano, K; Ishihara, K; Yamazaki, N1
Bleehen, NM; Brampton, M; Calvert, AH; Lee, SM; Newlands, ES; Rustin, GJ; Selby, P; Stevens, MF; Thatcher, N1
Ameglio, F; Carpano, S; Cavaliere, R; Di Lauro, L; Frasca, AM; Lopez, M; Pignatti, F; Rosselli, M; Vici, P; Vitelli, G1
Becker, JC; Burg, G; Dieleman, JP; Dummer, R; Gore, ME; Grobben, HC; Guillou, PJ; Hancock, BW; Oskam, R1
Keilholz, U1
A'Hern, R; Atkinson, H; Chang, J; Gore, ME; Lorentzos, A1
Ali-Osman, F; Bedikian, A; Benjamin, R; Buzaid, AC; Eton, O; Grimm, EA; Legha, SS; Papadopoulos, NE; Plager, C; Ring, S1
Borus, T; Edwards-Prasad, J; Hernandez, C; Nelson, J; Prasad, KN; Robinson, WA1
Berd, D; Mastrangelo, MJ1
Balch, CM; Benjamin, RS; Buzaid, A; el-Naggar, AK; Legha, SS; Papadopoulos, NE; Plager, C; Ring, S; Ross, M1
Korovin, SI; Tolstopiatov, BA2
Carmichael, J; Ganesan, TA; Harris, AL; Philip, PA; Tonkin, K1
Buzaid, AC; Legha, SS2
Asko-Seljavaara, S; Franssila, K; Kangas, L; Laasonen, A; Muhonen, T; Pyrhönen, S; Wasenius, VM1
Atkins, MB; Ernest, ML; Fisher, RI; Kappler, K; Margolin, KA; Mier, JW; O'Boyle, KR; Sosman, JA; Sparano, JA; Weiss, GR1
Bootz, F; Breuninger, H; Lindstedt-Hilden, M1
Bos, G; Brown, D; Fletcher, WS; Lebredo, L; Moseley, HS; Small, K; Woltering, EA1
Ferrone, S; Imai, K; Kageshita, T; Kimura, T; Kuriya, N; Ono, T; Tsujisaki, M; Yoshii, A1
McClay, EF; McClay, ME1
Crowther, D; Lee, SM; Margison, GP; Thatcher, N2
Bajetta, E; Barduagni, M; Bernengo, MG; Comella, G; Di Leo, A; Giannotti, B; Queirolo, P; Sertoli, MR; Tribbia, G; Zampino, MG1
Becker, JC; Bröcker, EB; Klingert, S; Winkler, B1
Coates, AS; Segelov, E1
Chaitchik, S; Eisenthal, A; Inbar, MJ; Mordish, Y; Ron, IG; Skornick, Y1
Chaitchik, S; Eisenthal, A; Ron, I; Skornick, Y; Zakuth, V1
Losada, R; Meelu, MA; Nathanson, L1
Bureau, B; Célérier, P; Dreno, B; Litoux, P1
Alevizakos, N; Asimakopoulos, G; Athanassiou, A; Bafaloukos, D; Dimitriadis, M; Pectasides, D; Tzonou, A; Varthalitis, I1
Crowell, EB; Higa, GM1
Dana, B; Daniels, DS; Fletcher, WS; Hutchins, LF; Hynes, HE; Pancoast, JR; Sondak, VK; Townsend, R1
Beadle, G; Coates, A; Gill, PG; Hersey, P; Kefford, R; Lowenthal, RM; McLeod, GR; Olver, IN; Thomson, D; Walpole, E1
Chaitchik, S; Merimsky, O2
Czarnetzki, BM; Schadendorf, D; Worm, M1
Gore, ME; Lorentzos, A; McKeage, MJ1
Aliaga, A; Bizzari, JP; Cour, V; Lopez Lopez, JJ; Oliver, V; Perez, E; Ponchon, A1
Dougal, M; Lee, SM; Margison, GP; Thatcher, N1
Calvert, AH; Carmichael, J; Foster, BJ; Goodard, PM; Gumbrell, LA; Harris, AL; Jones, M; Newell, DR1
Christophers, E; Clausen, M; Hauschild, A; Osterkamp, G1
Burgess, MA; Hersh, EM; Legha, SS; Papadopoulos, N; Plager, C; Verschraegen, CF1
Aamdal, S; Bizzari, JP; D'Incalci, M; Gerard, B; Lee, SM; Leyvraz, S; Lucas, C1
Hoffman, KD1
Flaherty, LE; Gonzalez, R; Kraut, M; Martino, S; Redman, BG; Robinson, W; Rudolph, AR; Valdivieso, M1
Newlands, ES; Stevens, MF1
Lee, SM; Margison, GP; Thatcher, N; Woodcock, AA1
Chaitchik, S; Gutman, M; Inbar, MJ; Merimsky, O; Ron, IG1
Appino, A; Bernengo, MG; Bertero, M; Colonna, S; Doveil, GC; Fierro, MT; Novelli, M1
Adena, M; Beadle, GF; Coates, AS; Gill, PG; Hersey, P; Kefford, RF; Lowenthal, RM; McLeod, GR; Olver, IN; Thomson, DB1
Borović, S; Hartleb, M; Ilić, Z; Jurin, M; Zarković, N1
Clendeninn, NJ; Feun, LG; Gonzalez, R; Liebmann, A; Offenhauser, K; Robinson, WA; Savaraj, N1
Chertoff, J; DelPrete, SA; Ernstoff, MS; Forcier, RJ; Lattanzi, SC; LeMarbre, PJ; Maurer, LH; Mott, L; O'Donnell, J; Tosteson, T1
Falkson, CI1
Aamdal, S; Boeryd, B; Carstensen, J; Jungnelius, U; Kågedal, B; Karlsson, M; Westberg, R; Wingren, S1
Antoine, E; Auclerc, G; Benhammouda, A; Bizzari, JP; Borel, C; Paraiso, D; Petit, T; Rixe, O; Soubrane, C; Weil, M1
Flaherty, LE; Fletcher, WS; Goodwin, JW; Liu, PY; Mitchell, MS; Sondak, VK; Stephens, RL; Walker, MJ1
Alas, LG; Belanich, M; Citron, ML; Dolan, ME; Gander, M; Kibitel, JT; Lejeune, FJ; Li, BF; Pastor, MA; Randall, T; Schold, SC; Wasserman, P; White, AB; Yarosh, DB1
Hahka-Kemppinen, M; Hernberg, M; Muhonen, T; Pyrhönen, S; Turunen, JP1
Baba, N; Ichiyama, S; Matsuzaki, T; Miyagawa, K; Miyazawa, M; Nagatani, T; Nakajima, H; Onuma, R; Uchiyama, M1
Guichard, M; Lartigau, E1
Armitage, GR; Bennett, K; Bodurtha, AJ; Burdette-Radoux, S; Iscoe, NA; James, KW; Jensen, J; Lohmann, RC; McCulloch, PB; Quirt, IC; Rusthoven, JJ; Silver, HK; Verma, S; Zee, B1
Benoit, F; Bertheas, MF; Cambazard, F; Graille, MC; Guy, C; Lanthier, K; Perrot, JL1
Atzpodien, J; Kirchner, HH; Poliwoda, H1
Bruske, T; Kreysel, HW; Reinhold, U1
De Lena, M; Guida, M; Latorre, A; Mastria, A1
Anderson, CM; Buzaid, AC; Legha, SS1
Cavillon, C; Claude, R; Desplechain, C; Egloff, H; Franck, F; Goujon, N; Lautier, A; Plagne, R; Rigondet, G; Sale, JM1
Ogasawara, H; Sakagami, M; Seo, W1
Hahka-Kemppinen, M; Kangas, L; Muhonen, T; Pyrhönen, S1
Hauschild, A1
Rudolf, Z; Strojan, P2
Vuoristo, MS1
Lyng, H; Rofstad, EK1
Benedicic, D; Stabuc, B1
Keilholz, U; Proebstle, TM; Scheibenbogen, C; Sterry, W1
Bedikian, A; Buzaid, AC; Eton, O; Legha, SS; Papadopoulos, N; Plager, C; Ring, S2
Ang, PT; Tan, EH1
Buda, BS; Didolkar, MS; Fitzpatrick, JL; Jackson, AJ; Johnston, GS; Lesko, LJ; Zech, LA1
Chapman, PB; Houghton, AN; Meyers, ML1
Saida, T1
Egyházi, S; Hansson, J; Margison, GP; Ringborg, U1
Ariyan, S; Bolognia, J; Poo, WJ1
Drechsler, S; Faerber, L; Fiedler, H; Garbe, C; Kuehne, KH; Landthaler, M; Schroeder, K; Tilgen, W1
Legha, SS1
Fefer, A; Gold, PJ; Thompson, JA1
Buzaid, AC; Poo, WJ; Schultz, MZ1
Tachihara, R1
de Mulder, PH; Jansen, RL; Muller, EW; Punt, CJ; van Herpen, CM; Vreugdenhil, G1
Berd, D; De Potter, P; Mastrangelo, MJ; Nathan, FE; Sato, T; Shield, JA; Shields, CL1
Hahka-Kemppinen, M; Muhonen, T; Nordling, S; Pyrhönen, S1
Caponigro, F; Casaretti, R; Comella, G; Comella, P; Daponte, A; Fiore, F; Frasci, G; Gravina, A; Ionna, F; Mozzillo, N; Parziale, AP; Presutti, F1
Driscoll, DL; Karakousis, CP; Kontzoglou, K1
Burg, G; Dummer, R; Flace, A; Meyer, JC; Seifert, B; Wimmer, I1
Dekio, S; Hayashi, S; Ohno, T; Takata, Y1
Bouche, O; Cartier, H; Egreteau, JP; Lambolais, C; Quinio, P; Savry, C1
Azevedo, MC; Lopes, M; Pontes, L; Ribeiro, M; Santos, JG1
Bedikian, A; Eton, O; Legha, SS; Papadopoulos, N; Plager, C; Ring, S1
Eggermont, AM; Keilholz, U; Lejeune, F; Punt, CJ; Scheibenbogen, C; Stoter, G1
Byrd, DR; Fefer, A; Gold, PJ; Lindgren, CG; Markowitz, DR; Thompson, JA1
Brown, BD; Bryan, RN; Eichler, HG; Jansen, B; Müller, M; Pehamberger, H; Schlagbauer-Wadl, H; van Elsas, A; Wolff, K1
Hart, AA; Israels, SP; Kroon, BB; Nieweg, OE; Rümke, P; Strobbe, LJ1
Flaherty, LE; Fletcher, WS; Liu, PY; Margolin, KA; Smith, JW; Sondak, VK; Sosman, JA; Unger, JM; Walker, MJ; Weiss, GR1
Enk, AH; Knop, J; Nashan, D1
Becker, JC; Bröcker, EB; Kämpgen, E; Schwaaf, A; Trcka, J1
Ariyan, S; Poo, WJ1
Broadley, K; Fisher, C; Gore, ME; Henk, M; Henson, G; Johnston, SR1
Barth, NM; Dillman, RO; Honeycutt, PJ; Schulof, R; Soori, G; Stark, JJ; Wiemann, MC1
A'Hern, RP; Atkinson, H; Constenla, DO; Dadian, G; Gore, ME; Johnston, SR; Moore, J; Riches, PG1
Atkins, MB; Blum, RH; Coates, AS; Falkson, CI; Ibrahim, J; Kirkwood, JM1
Punt, CJ1
Akande, N; Ali-Osman, F; Bedikian, A; Benjamin, RS; Buzaid, AC; Eton, O; Grimm, EA; Lee, JJ; Legha, SS; Papadopoulos, N; Plager, C1
Ali-Osman, F; Anderson, CM; Bedikian, A; Braunschweiger, PG; Buzaid, AC; Eton, O; Grimm, EA; Lee, JJ; Legha, SS; Papadopoulos, N; Plager, C; Sussman, J1
Bassères, N; Bizzari, JP; Bonerandi, JJ; Gérard, B; Grob, JJ; Richard, MA; Zarrour, H1
Casella, G; di Bonito, M; Fortuna, G; Iodice, F; Stellato, G; Tramontana, R; Tramontana, S1
Dreno, B; Legoux, B; Litoux, P; Mansat, E; Tessier, MH1
Cohen, GL; Falkson, CI1
Egorova, NI; Garin, AM; Gorozhanskaia, EG; Koroleva, EIu; Kushlinskiĭ, NE; Larionova, VB1
Berd, D; Mastrangelo, MJ; McClay, EF1
Bénard, J1
Bisighini, G; Di Lernia, V; Lo Scocco, G1
Bauer, J; Biollaz, J; Buclin, T; Decosterd, LA; Gander, M; Lejeune, F; Leyvraz, S; Marzolini, C; Shen, F1
Atzpodien, J; Buer, J; Franzke, A; Ganser, A; Hoffmann, R; Kirchner, H; Lassmann, S; Müller, I; Neuber, K; Oevermann, K; Probst, M1
Aoki, K; Hayashi, O; Nishioka, K; Ohara, H; Tanaka, K; Umeda, T; Yokoyama, A1
Ganesan, TS; Harris, AL; Kyrtopoulos, SA; Mitchell, K; Philip, PA; Salisbury, A; Souliotis, VL; Tates, AD; van Delft, JH1
Day, R; Donnelly, S; Gerson, SL; Kirkwood, JM; Liu, L; Smith, DC; Trump, DL1
Bleehen, NM; Brampton, MH; Calvert, AH; Lee, SM; Lind, MJ; Lunn, JM; Margison, GP; Middleton, MR; Morris, C; Newell, DR; Newlands, ES; Rustin, G; Thatcher, N; Wedge, SR1
Aamdal, S; Andersson, R; Bjelkengren, G; Ingvar, C; Jungnelius, U; Karlsson, M; Malmström, P; Mattsson, J; Ringborg, U; Stierner, U; Westberg, R; Willman, K; Wist, E1
Albert, DM; Chappell, R; Darjatmoko, SR; Howes, KA; Koop, BA; Lokken, JM; Mangold, G; Steeves, RA; Syed, NA; Wallow, IH; Windle, JJ1
Arista, MC; Carpano, S; Conti, L; De Franceschi, L; Francavilla, V; Lopez, M; Valente, F; Vercillo, M1
Haisa, M; Hara, K; Kamikawa, Y; Kenzo, A; Naomoto, Y; Perdomo, JA; Taguchi, K; Tanaka, N; Yamatsuji, T1
Bedikian, A; Benjamin, R; Buzaid, AC; Colome, M; Eton, O; Lee, JE; Lee, JJ; Legha, SS; Mansfield, P; Papadopoulos, N; Plager, C; Rice, J; Ring, S; Ross, M; Strom, E1
Fuchs, T; Keilholz, U; Proebstle, TM; Scheibenbogen, C; Sterry, W1
Keilholz, U; Max, R; Scheibenbogen, C; Schmittel, A; Thiel, E1
Bernstein, Z; Drumea, K; Haim, N; Shklar, Z; Stein, ME; Steiner, M; Zalik, M1
Binder, M; Pehamberger, H; Seeber, A; Steiner, A; Wolff, K1
Einhorn, JH; Hwu, P; Marincola, FM; Rosenberg, SA; Schwartzentruber, DJ; Seipp, CA; Steinberg, SM; Topalian, SL; White, DE; Yang, JC1
Gale, D; Lestingi, T; Mehta, N; Richards, JM1
Castro, MP; Legha, S; Spencer-Cisek, P; Sponzo, RW; VanAuken, J1
Agarwala, SS; Ferri, W; Gooding, W; Kirkwood, JM1
Jedrzejczak, WW1
Flaherty, LE; Fletcher, WS; Hersh, EM; Hutchins, LE; Liu, PY; Margolin, KA; Smith, JW; Sondak, VK; Sosman, JA; Unger, JM; Urba, WJ; Weiss, GR1
Belanich, M; Biollaz, J; Bonfanti, M; Colella, G; D'Incalci, M; Decosterd, L; Gander, M; Lejeune, F; Leyvraz, S; Liénard, D; Marzolini, C; Perey, L; Shen, F; Yarosh, D1
Ishikawa, M; Wada, T; Yamamoto, A; Yamazaki, N1
Comella, P; Daponte, A1
Gademann, G; Gollnick, H; Ulrich, J1
Creagan, ET; Dalton, RJ; Krook, JE; Long, HJ; Michalak, JC; Pitot, HC; Rowland, KM; Suman, VJ; Veeder, MH; Vukov, AM1
Agarwala, SS; Begg, CB; Chapman, PB; Destro, AN; Einhorn, LH; Ernstoff, MS; Houghton, AN; Kirkwood, JM; Meyers, ML; Panageas, KS; Saxman, S; Schuchter, LM1
Boasberg, PD; Cannon, M; Edwards, S; Essner, R; Fawzy, NW; Foshag, LJ; Fournier, P; Gammon, G; Guo, M; Johnson, TD; Kristedja, TS; Martin, MA; Morton, DL; O'Day, SJ; Stern, S; Weisberg, M1
Batra, V; Beale, P; Brada, M; Cutler, D; Dugan, M; Judson, I; Moore, S; Reidenberg, P; Statkevich, P1
Bedikian, A; Benjamin, RS; Buzaid, AC; Carrasco, CH; East, M; Eton, O; Gianan, M; Hodges, C; Legha, SS; Papadopoulos, N1
Bajetta, E; Barduagni, L; Bernengo, MG; Bufalino, R; Cascinelli, N; Comella, G; Criscuolo, D; Del Vecchio, M; DelVecchio, M; Morabito, A; Queirolo, P; Sertoli, MR; Vecchio, S1
Aamdal, S; Aaronson, N; Cebon, J; Coates, A; Dreno, B; Fierlbeck, G; Fraass, U; Gore, M; Grob, JJ; Henz, M; Kapp, A; Middleton, MR; Muller, M; Schadendorf, D; Seiter, S; Statkevich, P; Thatcher, N; Tilgen, W; Weiss, J1
Donnelly, DJ; Kelly, J; Margison, GP; McCormick, JE; McElhinney, RS; McMurry, TB; Middleton, MR; Thatcher, N1
Boeynaems, JM; Duhant, X; Ghanem, G; Jacquemotte, F; Kinnaert, E; Morandini, R1
de Gast, GC; Groenewegen, G1
Popova, L; Rohrbach, J; Sivkova, N; Steuhl, KP1
Chollet, P; Cure, H; D'incan, M; Fargeot, P; Fumoleau, P; Hanauske, A; Lentz, MA; Ouabdesselam, R; Ravaud, A; Roche, H; Souteyrand, P; Viens, P1
Braybrooke, JP; Crawley, JE; Harris, AL; Houlbrook, S; O'Byrne, KJ; Propper, DJ; Shuker, DE; Stratford, IJ; Talbot, DC1
Flaherty, LE1
Eggermont, AM; Keilholz, U1
Ashcroft, L; Harper, P; Lee, SM; Lorigan, P; Middleton, MR; Owen, J; Thatcher, N1
Agarwala, S; Hillner, BE; Middleton, MR1
Kageshita, T; Kuribayashi, N; Ono, T1
Allen, J; Becker, M; Gibbs, P; Gonzalez, R; Iannucci, A; McDowell, K; Murphy, J; O'Driscoll, M; Rosse, P; Williams, P1
Garaci, E; Izzo, F; Pierimarchi, P; Ranuzzi, M; Rasi, G; Sinibaldi-Vallebona, P; Terzoli, E; Tuthill, C1
Cohen, MH; Johnson, JR; Middleton, MR1
Enk, AH; Knop, J; Nashan, D; Rübben, A1
Braybrooke, JP; Christodoulos, K; Ganesan, TS; Han, C; Harris, AL; Levitt, NC; O'Byrne, K; Propper, DJ; Talbot, DC1
Cognetti, F; Sega, FM; Serrone, L; Zeuli, M1
Adler, A; Rakowsky, E; Schachter, J; Sulkes, A1
Hahka-Kemppinen, M; Hemminki, K; Jansèn, CT; Kumar, R; Punnonen, K; Pyrhönen, S; Sauroja, I; Smeds, J; Talve, L; Vlaykova, T1
Atkins, MB; Clancy, MA; Lawrence, DP; McDermott, DF; Mier, JW; Rubin, KM; van den Brink, MR1
Eggermont, AM; Keilholz, U; Suciu, S1
Calvert, H; Friedman, HS; Kerby, T1
Egorov, GN; Gorbonova, VA; Orel, NF; Perevodchikova, NI1
Chapman, PB; Houghton, AN; Hwu, WJ; Klimek, VM; Wolchok, JD1
Deraemaecker, R; Sales, F; Vandeweyer, E1
Christophers, E; Hauschild, A; Lischner, S1
Buzaid, AC; Eton, O; Grimm, EA; Lee, JJ; Smid, CM; Tseng, CH1
Arance, A; Lee, SM; Margison, GP; Middleton, MR; Thatcher, N; Wood, M1
A'Hern, RP; Ayliffe, MJ; Eisen, T; Gore, ME; Hill, ME; Johnston, SR; Moore, J; Riches, PG; Thomas, JM; Vaughan, MM1
Goos, M; Hillen, U; Willers, C1
Kroon, BB; Nieweg, OE1
Heere-Ress, E; Hoeller, C; Hoermann, M; Hollenstein, U; Jansen, B; Lucas, T; Pehamberger, H; Schlagbauer-Wadl, H; Wacheck, V; Wolff, K1
Kretschmer, L; Marsch, WC; Neumann, C; Preusser, KP1
Flaherty, LE; Philip, PA1
Ascierto, PA; Cellerino, R; Comella, G; Comella, P; Daponte, A; DeLena, M; Gravina, A; Marini, G; Melucci, MT; Palmieri, G1
Church, C; DePriest, CB; Dillman, RO; Dobbs, TW; Ruben, RH; Schulof, R; Soori, G; Wiemann, MC1
Christophers, E; Hauschild, A; Lischner, S; Möller, M1
Hwu, WJ1
Caubet, JF; Huncharek, M; McGarry, R1
Franke, W; Neumann, NJ; Ruzicka, T; Schulte, KW1
Kamanabrou, D1
Burg, G; Dummer, R1
Achtelik, W; Dummer, R; Ellwanger, U; Fey, M; Garbe, C; Hauschild, A; Kaufmann, R; Linse, R; Mohr, P; Nashan, D; Sebastian, G; Seiter, S; Stolz, W; Tilgen, W; Ugurel, S; Ulrich, J1
D'incan, M; Souteyrand, P1
Appel, C; Atkins, M; Clark, JI; Du, W; Dutcher, J; Fisher, RI; Flaherty, LE; Gordon, MS; Lotze, M; Margolin, K; Mier, J; Sorokin, P; Sosman, J; Weiss, G1
Retsas, S2
Güven, K; Kittler, H; Pehamberger, H; Wolff, K1
Gore, M; Stebbing, J; Thomas, M1
Biasco, G; Casadei, S; Pantaleo, MA1
Chan, C; O'Day, J1
Dzodić, R; Jelić, S; Jović, V; Konjević, G; Radulović, S; Spuzić, I1
Heere-Ress, E; Jansen, B; Joukhadar, C; Klein, N; Mader, RM; Müller, M; Pehamberger, H; Rizovski, B; Schrolnberger, C; Strauchmann, N1
Bret-Dibat, C; Chevreau, C; Coulon, V; Courbon, F; Debled, M; Delaunay, M; Gualde, N; Nguyen Bui, B; Ravaud, A1
Cansiz, H; Karakullukçu, B; Ozek, H; Oztürk, O1
Bafaloukos, D; Briassoulis, E; Fountzilas, G; Georgoulias, V; Gogas, H; Kalofonos, Ch; Karabelis, A; Kosmidis, P; Samantas, E; Skarlos, D1
Hahka-Kemppinen, M; Kähäri, VM; Nikkola, J; Pyrhönen, S; Vihinen, P; Vlaykova, T1
Kennedy, RD; McAleer, JJ1
Burton, A; Dunn, JA; Goodman, A; Marsden, J; Young, AM1
Babovic, N; Jelić, S; Kovcin, V; Milanovic, N; Milicevic, N; Popov, I; Radosavljevic, D1
Akiya, Y; Hagiwara, N; Matsutani, T; Miyashita, M; Onda, M; Sasajima, K; Takubo, K; Yamashita, K1
Amicucci, G; Deraco, M; Fiorentini, G; Guadagni, S; Miotto, D; Palumbo, G; Pilati, PL; Rossi, CR; Russo, F; Santinami, M; Valenti, M1
Atzpodien, J; Bröcker, EB; Fluck, M; Kamanabrou, D; Müller, I; Neuber, K; Neumann, C; Patzelt, T; Paul, E; Reitz, M; Rünger, TM; Schuler, G; von den Driesch, P1
Brugnara, S; Chiarion-Sileni, V; Freschi, A; Guida, M; Labianca, R; Lo Re, G; Nanni, O; Nortilli, R; Ridolfi, R; Romanini, A; Vitali, P1
Anderson, C; Becker, M; Gatlin, K; Gibbs, P; Gonzalez, R; LaClaire, S; O'Driscoll, M; Pearlman, N; Stephens, J1
Herishanu, Y; Kitay-Cohen, Y; Lishner, M1
Hwu, WJ; Lis, E; Panageas, KS; Raizer, J1
Babović, N; Jelić, S; Kreacić, M; Matković, S; Popov, I; Stamatović, L1
Schadendorf, D1
Brampton, MH; Calvert, AH; Middleton, MR; Paul, MJ; Rustin, G; Summers, Y; Thatcher, N1
Atkins, B; Clark, I; Dutcher, P; Ernstoff, S; Flaherty, L; Gollob, J; II Smith, W; Johnson, D; Longmate, J; Margolin, K; Sosman, J; Thompson, A; Weber, J; Weiss, G1
Dedkov, AG; Korovin, SI; Medinets, IuR; Palivets, AIu; Protsenko, VV; Smakova, MS; Tolstopiatov, BA1
Bedikian, AY; Benjamin, RS; Buzaid, AC; East, MJ; Eton, O; Hodges, C; Lee, JJ; Legha, SS; Papadopoulos, NE; Plager, C; Ring, SE; Zhan, F1
Bernard-Marty, C; Khayat, D; Meric, JB; Rixe, O1
Feun, LG; Hurley, J; Marini, A; Savaraj, N1
Chapman, PB; Houghton, AN; Hwu, WJ; Krown, SE; Livingston, PO; Menell, JH; Panageas, KS; Quinn, CJ; Williams, LJ1
Baker, LH; Izbicki, RM; Ratanatharathorn, V; Samson, MK1
Bellet, RE; Berd, D; Catalano, RB; Mastrangelo, MJ2
Diem, E; Kokoschka, EM; Kühböck, J; Mach, K; Pehamberger, H; Pötzi, P1
Dowd, PM; Everall, JD1
Boccardo, F; Musso, M; Porcile, G; Rosso, R; Santi, L1
Bellet, RE; Berd, D; Danna, V; Mastrangelo, MJ1
Zaumseil, RP1
Banzet, P; Belaich, S; Chastang, C; Civatte, J; Cottenot, F; Israel, L; Jacquillat, C; Maral, J; Puissant, A1
Jawalekar, K; Tretter, P1
Rosenberg, SA1
Westbury, G1
Bolton, PM; Burnett, W; Clunie, GJ; Gough, IR1
Buckley, JC; Coates, AS; Green, MD; MacKay, IR1
Goldman, SL; Pollak, EW; Wolfman, EF1
Klein, R; Krüger, GR; Sesterhenn, K1
Einhorn, LH; Furnas, B1
Colsky, J; Costanza, ME; Cunningham, T; Nathanson, L; Regelson, W; Schoenfeld, D; Sedransk, N; Wolter, J1
Golbey, RB; Wittes, JT; Wittes, RE1
McPherson, TA; Paterson, AH; Willans, DJ1
Cooper, MR; Muss, HB; Ramseur, WL; Rhyne, L; Richards, F; Spurr, CL; Stuart, JJ; White, DR1
Baker, LH; Fraile, RJ; McDonald, B; Samson, MK; Talley, RW1
Chauvergne, J; Clavel, B; Klein, T; Pommatau, E1
Lewis, MG1
Agrup, G; Hafström, L; Jönsson, PE; Rorsman, H1
Gallmeier, WM1
Karrer, K1
Grünewald, K; Huber, H1
Kokoschka, EM1
Blume, MR; Chan, EY; Cohen, RJ; Friedman, MA; Gershow, J; Glassberg, AB; Kaufman, DA; Resser, KJ; Rosenbaum, EH; Williams, JE1
Goodnight, JE; Morton, DL1
Benjamin, RS1
Gutterman, JU; Hersh, EM; McBride, CM1
Bartolucci, AA; Presant, CA; Smalley, RV; Vogler, WR1
Wilczek, ZM1
Hill, GJ; Hill, HZ; Szramowski, J1
Galin, M; Hill, GJ; Hill, HZ; Miller, CL; Pfaller, M; Weiss, K1
Berger, JL; Friedman, M; Holyoke, ED; Karakousis, CP; Lopez, R; Takita, H1
Jassem, J; Kopacz, A; Wojszwiłło-Geppert, E1
Aranha, GV; Grage, TB; Gunnarsson, A; McKhann, CF; Simmons, RL1
Block, JB; Dietrich, M; Isacoff, W1
Becker, B; Krupin, T; Singer, PR; Smith, ME1
Kolarić, K; Malenica, B; Roth, A1
Hagedorn, M; Meuret, G; Schmitt, E; Waldermann, F1
Brown, SG; Parsons, PG1
Legha, S; McCredie, KB; Spitzer, G; Verma, DS1
Czarnetzki, BM; Frosch, PJ; Gottschalk, I; Grundmann, E; Macher, E1
Braun-Falco, O; Landthaler, M; Ryckmanns, F1
Fiedler, H; Lübbe, D; Zaumseil, RP1
Crowther, D; Gasiunas, N; Palmer, MK; Thatcher, N1
Baffi, RR; Catane, R; Didolkar, MS; Holyoke, ED; Kaufman, J1
Crispen, R; Das Gupta, TK; El-Domeiri, AA; Sabet, TY; Simo, C; Trippon, M1
Ahmann, DL; Bisel, HF; Edmonson, JH; Frytak, S; Kvols, LK; Rubin, J1
Carey, RW; Cosimi, AB; Kaufman, SD; Wood, WC2
Currie, GA; Hedley, DW; McElwain, TJ2
Bellet, RE; Berkelhammer, J; Mastrangelo, MJ; Prehn, RT; Thibault, LH1
Nagel, GA; Rufli, T1
Chauvergne, J; Clavel, B; Klein, T; Pammatau, E1
Kokron, O; Pridun, N; Zischinsky, W1
Banzet, P; Chastang, C; Civatte, J; Cottenot, F; Israel, L; Jacquillat, C; Maral, J; Puissant, A1
Luce, JK2
Bartold, SL; Burgess, MA; Gehan, EA; Gutterman, JU; Hersh, EM; Kennedy, A; Mavligit, G; McBride, CM; Richman, SP1
Domas, J; Gauci, L; Pujol, H; Serrou, B1
Deicher, H; Deinhardt, J; Deutschmann, KE; Peter, HH1
Beretta, G; Veronesi, U1
Block, JB; Drakes, TP; Isacoff, W; Tabbarah, H1
Brunk, SF; Colsky, J; Costanza, ME; Costello, WG; Hall, T; Nathanson, L; Oberfield, RA; Regelson, W; Wolter, J1
Comis, RL1
Burgess, MA; Gottlieb, J; Gutterman, JU; Hersh, EM; Mavligit, GM; Reed, R1
Hill, G; Johnson, RO; Krementz, E; Metter, G; Wilson, W1
Costanzi, JJ1
Carbone, PP; Costello, W1
Azzarelli, A; Bajetta, E; Beretta, G; Bonadonna, G; De Lena, M; Tancini, G; Veronesi, U1
Ahmann, DL; Bisel, HF; Eagan, RT; Edmonson, JH; Frytak, S; Hahn, RG; O'Connell, MJ1
Kleeberg, UR1
Byrne, MJ1
Bellett, RE; Bodurtha, AJ; Laucius, JF; Mastrangelo, MJ1
Cruz, AB; Davis, HL; Fletcher, WS; Golomb, FM; Grage, T; Hill, GJ; Johnson, RO; Metter, G; Wilson, WL1
Hersh, EM; Hewlett, JS; Luce, JK; McKelvey, EM; Moon, TE; Talley, RW1
Cohen, SM; Greenspan, EM; Ratner, LH; Weiner, MJ1
Bodey, GP; Lane, M; Luce, JK; McKelvey, EM; Moon, TE; Talley, RW; Vaitkevicius, VK1
Bodurtha, A; Ghose, T; Guclu, A; MacDonald, AS; Norvell, ST; Tai, J1
Brustad, T; Johannessen, JV; Mossige, J; Rofstad, EK1
Davis, JM; Mitchell, MS; Mokyr, MB1
Aranha, GV; Grage, TB1
Elliott, P; Madden, FJ; Mould, RF; Newlands, ES; Newton, KA; Oon, CJ; Roberts, JT; Topham, C; Westbury, G1
Carter, RD; Fletcher, WS; Golomb, FM; Grage, TB; Hill, GJ; Krementz, ET; Metter, GE; Minton, JP; Sparks, FC1
Beretta, G; Bonadonna, G; Cascinelli, N; Morabito, A; Veronesi, U1
Duchková, H; Kubíková, M; Richter, J; Rus, J1
Biran, S; Brufman, G; Ratzkowski, E1
Carmo-Pereira, J; Oliveira Costa, F; Pimentel, P1
Gutterman, JU; Hersh, EM; Mavligit, GM1
Blumenshein, G; Burgess, MA; Gutterman, JU; Hersh, EM; Mavligit, GM; McBride, CM1
Dickey, C; Gerner, RE; Moore, GE1
Jacobsen, GK; Povlsen, CO1
Eidemiller, LR; Fletcher, WS; Yeager, RA1
Currie, GA; McElwain, TJ1
Klepp, O1
Banzet, P; Dufourmentel, C; Jacquillat, C; Ricbourg, B1
Falkson, G; Van Dyk, JJ1
Calabresi, P; Cummings, FJ; Heppner, GH1
Andersson, T1
Barto, DA; Hendrickson, C; Sams, BJ; Susens, GP1
Kleeberg, UR; Schreml, W1
Hahka-Kemppinen, M; Muhonen, T; Pyrhönen, S1
Doherty, VR; MacKie, RM; Stables, GI1
Chaitchik, S; Inbar, M; Kovner, F; Merimsky, O; Reider-Groswasser, I1
Chaitchik, S; Gerard, B; Inbar, M; Merimsky, O1
Brunet, A1
Boaziz, C1
Garbe, C; Kreuser, ED; Orfanos, CE; Stadler, R; Zouboulis, CC1
Chosidow, O; Guillaume, JC1
Hodges, C; Legha, SS; Ring, S1
Ichiyama, S; Miyakawa, K; Nagatani, T; Uchiyama, M1
Avril, MF; Bonneterre, J; Cupissol, D; Fargeot, P; Fumoleau, P; Grob, JJ; Israel, L; Kalis, B; Kerbrat, P; Lambert, D1
Binder, M; Dorffner, R; Glebowski, E; Pehamberger, H; Winkler, A; Wolff, K1
Grabowski, T; Jez, W; Rzempołuch, J1
Kubota, K; Kubota, R; Yamada, S1
Barak, V; Ben-Bassat, H; Biran, S; Franks, CR; Gazit, Z; Isacson, R; Kalichman, I; Kedar, E; Schlesinger, M; Yurim, O1
Kan, S; Miyasaka, Y; Murata, K; Ohbu, M; Saito, M; Takagi, H; Takano, S; Yada, K1
Avril, MF; Bertrand, P; Bizzari, JP; Cour, V; Gerard, B; Khayat, D1
Albright, KD; Christen, R; Eastman, A; Howell, SB; Jones, JA; McClay, EF1
Maclennan, KA; Okon, E; Polliack, A; Shiloni, E1
Chaitchik, S; Inbar, M; Merimsky, O2
Basurto, C; Boschetti, E; Bracarda, S; Del Favero, A; Lupattelli, M; Picciafuoco, M; Roila, F; Sassi, M; Tonato, M1
Guillou, PJ; Reynolds, JV; Somers, SS1
Esteguy, M; Leiguarda, R; Merello, M; Perazzo, F1
Gröhn, P; Hakala, T; Heikkinen, M; Jakobsson, M; Korpela, M; Kumpulainen, E; Numminen, S; Nuortio, L; Salmi, R; Vuoristo, MS1
De Mulder, PH; Fiedler, W; Franks, CR; Hossfeld, DK; Jasmin, C; Oskam, R; Palmer, PA; Pyrhönen, S1
Aamdal, S; Bohman, T; D'Incalci, M; Gerard, B1
Buzaid, AC; Murren, J1
Balcerzak, SP; Daniels, D; Flaherty, LE; Fletcher, WS; Goodwin, JW; Liu, PY; Sondak, VK; Stephens, RL1
Gazit, Z; Kedar, E; Notter, M; Schirrmacher, V; Shouval, D; Walter, J; Weiss, DW; Yechezkeli, M1
Mehta, N; Ramming, K; Richards, JM; Skosey, P1
Champagne, MA; Silver, HK1
Bella, M; Boni, C; Buzzi, F; Calabresi, F; Canaletti, R; Ceci, G; Cocconi, G; Corgna, E; Costa, P; Tonato, M1
Guerry, D; Schuchter, LM1
Baan, RA; Keizer, HJ; Ouwerkerk, J; van Delft, JH; van den Ende, AM1
Cruse, CW; Klein, CJ; Reintgen, DS; Saba, HI; Wells, KE2
Cocconi, G1
Bliss, JM; Gore, ME; Lakhani, S; McElwain, TJ; Perren, TJ; Selby, P1
Fiedler, H; Hetschko, I; Lübbe, D; Taube, KM; Wohlrab, W; Wozniak, KD1
Agnifili, A; Carboni, M; D'Amore, L; Gianfelice, F; Giuliani, M; Gossetti, F; Negro, P1
Ernstoff, MS; Kirkwood, JM1
Hersey, P; McLeod, GR; Thomson, DB3
Glover, DJ1
Basile, M; Bennett, JM; Blumberg, N; Harris, J; Moskowitz, B1
Doane, LL; Gilewski, TA; Mitchel, B; Ramming, K; Richards, JM; Vogelzang, NJ1
Breistøl, K; Fodstad, O; Kjønniksen, I1
Blackledge, GR; Brampton, MH; Hoffman, R; Newlands, ES; Quarterman, CP; Rustin, GJ; Slack, JA; Smith, DB; Stevens, MF; Stuart, NS1
de Vries, EG; Mulder, NH; Schraffordt Koops, H; Sleijfer, DT; Willemse, PH3
Burg, G; Dummer, R; Eilles, C; Miller, K1
Baryshnikov, AIu; Cheremushkin, EA; Iavorskiĭ, VV; Kadagidze, ZG; Korotkova, OV; Savel'eva, EV; Solov'eva, EA1
Castel, T; Castro, J; Daniels, M; Estapé, J; Gratacós, R; Grau, JJ; Mascaró, JM; Palou, J; Vilalta, A; Viñolas, N1
Lee, SM; Margison, GP; Thatcher, N1
Flokkmann, A; Gundersen, S1
Bruce, L; Chapman, K; Dorreen, MS; Hancock, BW; Hayat, K; Reeder, S; Rees, RC; Rodgers, S; Sheridan, E; Sreenivasan, T1
Chaitchik, S; Inbar, M; Merimsky, O; Reider-Groswasser, I1
Boaziz, C; Breau, JL; Israël, L; Morere, JF1
Baker, AR; Barth, RJ; Venzon, DJ1
Bajorin, DF; Chapman, PB; Cody-Johnson, BV; Heelan, RT; Lovett, DR; Oettgen, HF; Portlock, CS; Steffens, TA; Templeton, MA; Wong, GY1
Buzaid, AC; Durivage, HJ; Murren, JR1
Aamdal, S; Cleton, FJ; Franks, CR; Iacobelli, S; Oskam, R; Rodenhuis, S; Shiloni, E; Stoter, G1
Demirkazik, A; Dincol, D; Gunel, N; Icli, F; Karaoguz, H1
Richards, JM1
Joensuu, H1
Davis, C; DeRosa, W; Durivage, HJ; Makuch, R; Murren, JR; Portlock, CS1
Abbott, BJ; Boyd, MR; Dykes, DJ; Fodstad, O; Griswold, DP; Harrison, SD; Mayo, JG; Plowman, J; Shoemaker, RH1
Chou, TH; Flaherty, L; Kaplan, J; Nakeff, A; Pillote, K; Redman, BG1
Falkson, CI; Falkson, G; Falkson, HC1
Avril, MF; Beerblock, K; Bonerandi, JJ; Chevrant-Breton, J; Delaunay, M; Dreno, B; Guillaume, JC; Kalis, B; Souteyrand, P; Verret, J1
Chakalova, G; Karag'ozov, A; Kŭrlov, T1
Bolhuis, RL; Braakman, E; Eggermont, AM; Goey, SH; Lamers, C; Slingerland, R; Stoter, G1
Ho, VC; Sober, AJ1
Costanzi, J; Ernstoff, MS; Gams, R; Giuliano, A; Grimm, M; Kirkwood, JM; Pouillart, P; Robinson, WA; Speyer, J; Spiegel, R1
Arnold, J; Barth, NM; Birch, R; Dillman, RO; Oldham, RK; West, WH1
Bajetta, E; Bernengo, MG; Brogelli, L; Brunetti, I; Giannotti, B; Maifredi, G; Negretti, E; Sertoli, MR; Sofra, MC; Zumiani, G1
Daly, A; Drumm, JE; Harkin, KP; O'Brien, P1
Baker, LH; Chabot, GG; Flaherty, LE; Valdivieso, M1
Avril, MF; Bonneterre, J; Bugat, R; Cupissol, D; Delaunay, M; Fumoleua, P; Grosshans, E; Israel, L; Kerbrat, P; Namer, M1
Ernstoff, MS; Kirkwood, JM; Luger, SM; Vlock, DR1
Barth, V; Schönfelder, M1
Colombel, F; Le Franc, P; Leroy, B; Scherpereel, P; Thomas, P1
Chaitchik, S; Inbar, M; Merimsky, O; Ron, I; Shiloni, E1
Fodstad, O; Kjønniksen, I; Nesland, JM; Pihl, A1
Bizzari, JP; Deloffre, P; Etienne, MC; Fischel, JL; Formento, P; Frenay, M; Gioanni, J; Milano, G1
Calabro, A; Carrasco, CH; Legha, SS; Singletary, SE1
Bradley, EC; Chabot, GG; Flaherty, LE; Gualdoni, SM; Heilbrun, LK; Martino, S; Redman, BG; Valdivieso, M1
Corstens, FH; De Mulder, PH; Franks, CR; Mattijssen, VJ; Van Liessum, PA; Wagener, DJ1
Hansson, J; Jungnelius, U; Ringborg, U; Strander, H1
Flaherty, LE; Redman, BG; Schwert, R1
Ikegawa, S; Ishihara, K1
Ikeda, S; Ikekawa, S; Ishihara, K; Tanaka, S1
Balch, CM2
Kato, T; Takematsu, H; Tomita, Y1
Anderson, JR; Carey, RW; Ellison, RR; Green, M; Kennedy, BJ; Nathanson, L1
Kopecný, J; Mechl, Z1
De Vries, EG; Koops, HS; Mulder, NH; Sleijfer, DT; Smit, JM; Willemse, PH1
Barnekow, A; Paul, E; Schartl, M1
Kajikawa, H; Sakaguchi, H; Seguchi, T; Takada, M1
Ballin, R; Klöppel, R; Lommatzsch, PK1
Foltz, AT; York, RM1
Epremian, BE; Gentile, PS; Hamm, JT; Seeger, J; Sheth, SP1
Avril, MF1
de Vries, EG; Mulder, NH; Samson, MJ; Schraffordt Koops, H; Sleijfer, DT; Willemse, PH1
Atkinson, WE; Bucolo, AP; Farley, H; Guin, JD; Langston, HD; Prather, JL1
Cartei, G; Ceschia, T; Clocchiatti, L; Fasola, G; Galletti, D; Marsilio, P; Morandini, G; Sibau, A1
Cerny, T; Margison, GP; Maynard, K; Parsons, PG1
English, JS; Lever, RS; MacKie, RM; Young, DW1
Bijzet, J; Bouman, J; Jurjens, H; Mulder, NH; Sleijfer, DT; Smit, JM; Woldring, MG1
Carr, T; Chadwick, G; Craig, P; Jones, R; Lind, M; Morgenstern, G; Thatcher, D1
Hafström, L; Hansson, J; Ringborg, U; Rudenstam, CM; Stenstam, B; Strander, H1
Aamdal, S; Bijman, JT; Cleton, FJ; Franks, CR; Iacobelli, S; Palmer, P; Rodenhuis, S; Shiloni, E; Stoter, G1
Di Peri, T; Franks, CR; Janssens, J; Palmer, PA; Pouillart, P; Roest, GJ; Shiloni, E; Splinter, T; Symann, M1
Bufalino, R; Cascinelli, N; MacKie, R; Morabito, A; Rümke, P1
Marsh, JC1
Eksborg, S; Ingvar, C; Jönsson, PE; Stigsson, L1
Ames, FC; Boddie, AW; Edwards, MJ; McBride, CM1
Lönn, S; Lönn, U; Nylen, U; Winblad, G1
Bijman, JT; Cleton, FJ; Franks, CR; Gundersen, S; Iacobelli, S; Palmer, P; Rodenhuis, S; Shiloni, E; Stoter, G1
Alevizakos, N; Athanassiou, A; Bafaloukos, D; Barbounis, V; Dimitriadis, M; Pectasides, D; Varthalitis, J; Yianniotis, H1
Benjamin, R; Chawla, S; Legha, SS; Papadopoulos, N; Plager, C; Ring, S1
Belli, F; Cascinelli, N; Rovini, D; Santinami, M; Vaglini, M1
Engelhardt, R1
Bellet, RE; Berd, D; Mastrangelo, MJ; McClay, EF; Sprandio, JD1
Ambrosini, G; Amichetti, M; Piazza, M; Piffer, S; Valdagni, R1
Klimek, M; Pawlicki, M1
Lönn, S; Lönn, U2
Gamel, JW; Niederkorn, JY; Sanborn, GE1
Voigt, H1
McLeod, GR1
Milbradt, R; Neubert, J; Schneider, E1
Dana, B; Fletcher, JR; Fletcher, WS; Green, S; Jewell, W; Townsend, RA1
Gundersen, S; Høie, J; Pihl, A; Tveit, KM1
Pályi, I1
Martz, G; Stahel, RA1
Abe, H; Doi, S; Murai, H; Sawamura, Y; Tashiro, K1
Böckers, M; Bork, K; Keller, E1
Bella, M; Bocchi, P; Ceci, G; Cocconi, G; Gabrielli, M; Melissari, M1
Konz, B; Korting, HC; Strasser, S1
de Garis, ST; Dische, S; Nelstrop, A; Rustin, GJ1
Garbe, C; Guenther-Eymann, K; Orfanos, CE; Stadler, R1
Czarnetzki, B; Kleeberg, UR; Mulder, J; Rozencweig, M; Rumke, P; Suciu, S; Thomas, D; Truchetet, F; Verschraegen, CF1
Benjamin, RS; Bodey, GP; Burgess, AM; Legha, SS; Polyzos, A1
Fujisaki, S; Inoue, S; Maeyama, M; Munemura, M; Shibata, S; Tohya, T1
Allegra, JC; Richman, SP; Seeger, J1
Banerjee, SS; Craig, P; Gleave, N; Mene, A; Orton, C; Thatcher, N1
Little, JH; Maynard, KR; McLeod, GR; Parsons, PG1
Kogonia, LM; Moros, LW; Perevodchikova, NJ1
Biltz, H; Budde, U; Fiedler, U; Harbrecht, U; Kreysel, HW1
Belli, F; Cascinelli, N; Marolda, R; Prada, A; Santinami, M; Vaglini, M1
Kogoniia, LM; Manziuk, LV; Marenich, AF; Osmanov, DSh; Roshchin, EM1
Abdi, EA; Hanson, J; McPherson, TA1
Bellet, RE; Berd, D; Mastrangelo, MJ; McClay, EF1
Carey, RW; Kunz, VS1
Balcerzak, SP; Costanzi, JH; Dixon, D; Fabian, CJ; Maloney, T; Neidhart, J; Neilan, B; O'Bryan, RM; Quagliana, J; Tranum, BL1
Carmo-Pereira, J; Costa, FO; Henriques, E1
Dobrek, Z1
Blum, R; Green, M; Muggia, FM; Oratz, R; Speyer, JL; Wernz, JC1
Boddie, AW; Cangir, A1
Gundersen, S1
Emrich, LJ; Karakousis, CP1
Anderson, H; Craig, P; Davenport, P; James, R; Thatcher, N1
Aragon, V; Bröcker, EB; Bünte, H; Czarnetzki, BM; Krieg, V; Macher, E1
Castello, G; Cerra, R; Comella, G; Comella, P; De Simone, G; Mastro, AA; Zarrilli, D1
Creagan, ET; Green, SJ; Long, HJ; Schutt, AJ1
Falkson, G; Sarli, R; Vorobiof, DA1
Gundersen, S; Hager, B; Tausjø, J2
Garbe, C; Orfanos, CE; Stadler, R1
Harrison, BR; Hoelzer, KL; Luedke, DW; Mahanta, B1
Craig, P; Mene, A; Orton, C; Smith, D; Thatcher, N; Wagstaff, J1
Abdi, EA; McPherson, TA; Tan, YH1
Braun-Falco, O; Hölzel, D; Konz, B; Landthaler, M; Schmoeckel, C1
Karakousis, CP1
Lusch, CJ; Mastrangelo, MJ; McClay, E1
Nosek, H; Pawlicki, M; Skołyszewski, J; Stryjewska, B1
Chessa, A; Desogus, A; Floris, C; Muggiano, A; Sulis, E; Tedde, A; Turno, R1
Baker, LH; Cummings, G; Haas, CD; Samson, MK1
Koh, H1
Aron-Rosa, D; Auclerc, G; Dhermy, P; Jacquillat, C; Maral, J; Sellami, M; Weil, M1
Clark, WH; Elder, D; Goldman, LI; Mastrangelo, MJ; Stennett, J1
Didolkar, MS; Fitzpatrick, JL; Jackson, AJ; Johnston, GS1
Case, LD; Cooper, MR; Jackson, DV; Muss, HB; Richards, F; Spurr, CL; Sterchi, JM; Stuart, JJ; Wells, HB; White, DR1
Dunleavy, S; Golomb, F; Harris, M; Hochster, H; Levin, M; Muggia, F; Roses, D; Speyer, J1
Hansson, J; Lagerlöf, B; Ringborg, U; Strander, H1
Hypa, F; Leyh, F; Weber, M; Winzer, M1
Dandu, VR; Didolkar, MS; Fiore, D; Jackson, AJ1
Chuang, VP; Frost, DB; Mavligit, G; Patt, YZ; Wallace, S1

Reviews

132 review(s) available for dacarbazine and Melanoma

ArticleYear
Carotenoids from Marine Microalgae as Antimelanoma Agents.
    Marine drugs, 2022, Sep-29, Volume: 20, Issue:10

    Topics: Antineoplastic Agents; Carotenoids; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Humans; Melanoma; Microalgae; Mutation; NF-kappa B; Proto-Oncogene Proteins B-raf; Vemurafenib; Zeaxanthins

2022
Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma.
    International journal of molecular sciences, 2022, Dec-11, Volume: 23, Issue:24

    Topics: CTLA-4 Antigen; Dacarbazine; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Ipilimumab; Melanoma

2022
A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.
    European journal of cancer (Oxford, England : 1990), 2019, Volume: 123

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Benzimidazoles; Cancer Vaccines; Carboplatin; Dacarbazine; gp100 Melanoma Antigen; Humans; Hydrazines; Imidazoles; Interleukin-2; Ipilimumab; Lenalidomide; Melanoma; Network Meta-Analysis; Nitrosourea Compounds; Nivolumab; Organophosphorus Compounds; Oximes; Paclitaxel; Piperidines; Progression-Free Survival; Proportional Hazards Models; Pyridones; Pyrimidinones; Skin Neoplasms; Sorafenib; Survival Rate; Temozolomide; Treatment Outcome; Vemurafenib

2019
Ileal Melanoma, A Rare Cause of Small Bowel Obstruction: Report of a Case, and Short Literature Review.
    Current radiopharmaceuticals, 2020, Volume: 13, Issue:1

    Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Ileal Neoplasms; Ileum; Intestinal Obstruction; Male; Melanoma; Middle Aged; Positron-Emission Tomography

2020
Nanotechnology approaches in the current therapy of skin cancer.
    Advanced drug delivery reviews, 2020, 01-01, Volume: 153

    Topics: Administration, Cutaneous; Antineoplastic Agents; Dacarbazine; Drug Carriers; Drug Resistance, Neoplasm; Fluorouracil; Gold; Humans; Melanoma; Metal Nanoparticles; Nanoparticles; Nanotechnology; Particle Size; Skin Absorption; Skin Neoplasms; Skin Physiological Phenomena; Surface Properties

2020
Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials.
    Journal of translational medicine, 2020, 08-03, Volume: 18, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Azetidines; Dacarbazine; Humans; Melanoma; Mutation; Piperidines; Prognosis; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Vemurafenib

2020
Prolonged survival following everolimus combined with temozolomide for metastatic malignant melanoma with FBXW7 mutation: a case report and literature review.
    Annals of palliative medicine, 2021, Volume: 10, Issue:7

    Topics: Adult; Brain Neoplasms; Dacarbazine; Everolimus; F-Box-WD Repeat-Containing Protein 7; Humans; Male; Melanoma; Mutation; Temozolomide

2021
Multiple treatment comparison of seven new drugs for patients with advanced malignant melanoma: a systematic review and health economic decision model in a Norwegian setting.
    BMJ open, 2017, Aug-21, Volume: 7, Issue:8

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Cost-Benefit Analysis; Dacarbazine; Drug Costs; Drug Therapy, Combination; Humans; Ipilimumab; Melanoma; Models, Economic; Network Meta-Analysis; Nivolumab; Norway; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Survival Analysis

2017
Treating malignant melanoma when a rare BRAF V600M mutation is present: case report and literature review.
    Romanian journal of internal medicine = Revue roumaine de medecine interne, 2018, Jun-01, Volume: 56, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Fatal Outcome; Humans; Interferons; Male; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; Neoplasm Metastasis; Point Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Vemurafenib

2018
Direct costs associated with adverse events of systemic therapies for advanced melanoma: Systematic literature review.
    Medicine, 2018, Volume: 97, Issue:31

    Topics: Antineoplastic Agents; Dacarbazine; Health Expenditures; Health Resources; Humans; Indoles; Ipilimumab; Melanoma; Paclitaxel; Sulfonamides; Temozolomide; Vemurafenib

2018
Efficacy of nab-paclitaxel in treating metastatic melanoma.
    Expert opinion on pharmacotherapy, 2019, Volume: 20, Issue:5

    Topics: Albumins; Animals; Antineoplastic Agents, Phytogenic; Dacarbazine; Humans; Melanoma; Paclitaxel; Temozolomide

2019
Network meta-analysis of therapies for previously untreated advanced BRAF-mutated melanoma.
    Cancer treatment reviews, 2019, Volume: 74

    Topics: Antineoplastic Combined Chemotherapy Protocols; Azetidines; Dacarbazine; Humans; Imidazoles; Melanoma; Molecular Targeted Therapy; Mutation; Oximes; Piperidines; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Randomized Controlled Trials as Topic; Vemurafenib

2019
Novel targets in the treatment of advanced melanoma: new first-line treatment options.
    The Annals of pharmacotherapy, 2013, Volume: 47, Issue:4

    Topics: Antibodies, Monoclonal; Cancer Vaccines; Clinical Trials as Topic; Dacarbazine; Drugs, Investigational; Humans; Indoles; Ipilimumab; Melanoma; Molecular Targeted Therapy; Randomized Controlled Trials as Topic; Sulfonamides; Vemurafenib

2013
Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2.
    The Journal of dermatological treatment, 2014, Volume: 25, Issue:5

    Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Dacarbazine; Female; Humans; Indoles; Interferon alpha-2; Interferon-alpha; Interleukin-2; Ipilimumab; Male; Melanoma; Middle Aged; Recombinant Proteins; Skin Neoplasms; Sulfonamides; Vemurafenib

2014
Efficacy and side effects of dacarbazine in comparison with temozolomide in the treatment of malignant melanoma: a meta-analysis consisting of 1314 patients.
    Melanoma research, 2013, Volume: 23, Issue:5

    Topics: Administration, Intravenous; Administration, Oral; Antineoplastic Agents, Alkylating; Dacarbazine; Disease Progression; Humans; Melanoma; Odds Ratio; Randomized Controlled Trials as Topic; Remission Induction; Risk Factors; Skin Neoplasms; Temozolomide; Time Factors; Treatment Outcome

2013
Generation, validation, and application of a P450 homology model.
    Current topics in medicinal chemistry, 2013, Volume: 13, Issue:18

    Topics: Antineoplastic Agents; Biocatalysis; Cytochrome P-450 CYP1A1; Dacarbazine; Humans; Kinetics; Melanoma; Methylation; Models, Molecular; Mutation; Prodrugs; Reproducibility of Results; Structure-Activity Relationship

2013
Efficacy and safety between temozolomide alone and temozolomide-based double therapy for malignant melanoma: a meta-analysis.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014, Volume: 35, Issue:1

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Melanoma; Randomized Controlled Trials as Topic; Temozolomide; Treatment Outcome

2014
Dabrafenib therapy for advanced melanoma.
    The Annals of pharmacotherapy, 2014, Volume: 48, Issue:4

    Topics: Antineoplastic Agents; Clinical Trials as Topic; Dacarbazine; Drug Resistance, Neoplasm; Humans; Imidazoles; Indoles; Melanoma; Mutation; Oximes; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Vemurafenib

2014
Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
    Danish medical journal, 2013, Volume: 60, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Carcinoma, Non-Small-Cell Lung; Dacarbazine; Epitopes; Humans; Immunotherapy; Indoleamine-Pyrrole 2,3,-Dioxygenase; Inhibitor of Apoptosis Proteins; Interferon alpha-2; Interferon-alpha; Interleukin-2; Lung Neoplasms; Lymphocyte Count; Lymphocytosis; Melanoma; Recombinant Proteins; Survivin; T-Lymphocytes; Temozolomide

2013
Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials.
    The Lancet. Oncology, 2014, Volume: 15, Issue:3

    Topics: Antineoplastic Agents, Alkylating; Biomarkers; Dacarbazine; Disease-Free Survival; Humans; Melanoma; Randomized Controlled Trials as Topic

2014
What is the role of chemotherapy in the treatment of melanoma?
    Current treatment options in oncology, 2014, Volume: 15, Issue:2

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Carboplatin; Cisplatin; Clinical Trials as Topic; Dacarbazine; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Immunosuppression Therapy; Immunotherapy; Ipilimumab; Melanoma; Paclitaxel; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Temozolomide; Treatment Outcome

2014
Current systemic therapies for melanoma.
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2014, Volume: 40, Issue:9

    Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Bridged-Ring Compounds; Dacarbazine; Humans; Imidazoles; Indoles; Interferon-alpha; Interleukin-2; Ipilimumab; Melanoma; Oximes; Platinum Compounds; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Skin Neoplasms; Sulfonamides; Taxoids; Temozolomide; Vemurafenib

2014
The targeting of indoleamine 2,3 dioxygenase -mediated immune escape in cancer.
    Basic & clinical pharmacology & toxicology, 2015, Volume: 116, Issue:1

    Topics: Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; Dacarbazine; Humans; Immunologic Factors; Immunotherapy; Indoleamine-Pyrrole 2,3,-Dioxygenase; Interferon alpha-2; Interferon-alpha; Interleukin-2; Ipilimumab; Lung Neoplasms; Male; Melanoma; Prostatic Neoplasms; Recombinant Proteins; Temozolomide; Tissue Extracts

2015
Dacarbazine combined targeted therapy versus dacarbazine alone in patients with malignant melanoma: a meta-analysis.
    PloS one, 2014, Volume: 9, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Melanoma; Molecular Targeted Therapy; Safety

2014
[Systemic treatment of melanoma brain metastases].
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2015, Volume: 19, Issue:1

    Topics: Abatacept; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Clinical Trials, Phase II as Topic; CTLA-4 Antigen; Dacarbazine; Humans; Imidazoles; Immunoconjugates; Immunotherapy; Indoles; Interleukin-2; Ipilimumab; Melanoma; Molecular Targeted Therapy; Neoplasm Proteins; Oximes; Point Mutation; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins B-raf; Sulfonamides; Vemurafenib

2015
Ipilimumab for Previously Untreated Unresectable Malignant Melanoma: A Critique of the Evidence.
    PharmacoEconomics, 2015, Volume: 33, Issue:12

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Dacarbazine; Drug Costs; Humans; Ipilimumab; Melanoma; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Survival Analysis; Technology Assessment, Biomedical

2015
Nanoparticle-mediated drug delivery for treating melanoma.
    Nanomedicine (London, England), 2015, Volume: 10, Issue:16

    Topics: Antineoplastic Agents; Dacarbazine; Drug Delivery Systems; Humans; Melanoma; Nanoparticles; Skin Neoplasms

2015
Temozolomide for Treating Malignant Melanoma.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2015, Volume: 25, Issue:9

    Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Melanoma; Melanoma, Cutaneous Malignant; Quality of Life; Skin Neoplasms; Temozolomide; Treatment Outcome

2015
Chemotherapy for Melanoma.
    Cancer treatment and research, 2016, Volume: 167

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dacarbazine; Humans; Melanoma; Neoplasm Staging; Palliative Care; Taxoids; Temozolomide

2016
The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma.
    Swiss medical weekly, 2016, Volume: 146

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Chemotherapy, Adjuvant; Dacarbazine; Dermatologic Surgical Procedures; Humans; Imidazoles; Indoles; Ipilimumab; Lymph Node Excision; Melanoma; Neoplasm Staging; Nivolumab; Oximes; Practice Guidelines as Topic; Radiotherapy, Adjuvant; Sentinel Lymph Node Biopsy; Skin Neoplasms; Sulfonamides; Switzerland; Temozolomide; Vemurafenib

2016
Meta-Analysis of the Safety and Efficacy of Interferon Combined With Dacarbazine Versus Dacarbazine Alone in Cutaneous Malignant Melanoma.
    Medicine, 2016, Volume: 95, Issue:16

    Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Immunologic Factors; Interferon-alpha; Melanoma; Melanoma, Cutaneous Malignant; Remission Induction; Skin Neoplasms; Treatment Outcome

2016
Modelling Comparative Efficacy of Drugs with Different Survival Profiles: Ipilimumab, Vemurafenib and Dacarbazine in Advanced Melanoma.
    BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2016, Volume: 30, Issue:4

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Clinical Trials as Topic; Cost-Benefit Analysis; Dacarbazine; Female; Humans; Indoles; Ipilimumab; Male; Melanoma; Middle Aged; Models, Statistical; Sulfonamides; Survival Analysis; Treatment Outcome; Vemurafenib

2016
Relative Efficacy of Granulocyte-Macrophage Colony-Stimulating Factor, Dacarbazine, and Glycoprotein 100 in Metastatic Melanoma: An Indirect Treatment Comparison.
    Advances in therapy, 2017, Volume: 34, Issue:2

    Topics: Antineoplastic Agents; Cancer Vaccines; Dacarbazine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Melanoma; Neoplasm Metastasis; Treatment Outcome

2017
Is there still a role for cytotoxic chemotherapy after targeted therapy and immunotherapy in metastatic melanoma? A case report and literature review.
    Chinese journal of cancer, 2017, Jan-13, Volume: 36, Issue:1

    Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Immunotherapy; Male; Melanoma; Middle Aged; Molecular Targeted Therapy; Mutation; Neoplasm Metastasis; Proto-Oncogene Mas; Proto-Oncogene Proteins B-raf; Treatment Outcome

2017
Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival.
    Journal of immunotoxicology, 2008, Volume: 5, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Databases, Factual; Disease-Free Survival; Female; Humans; Interferon-alpha; Interleukin-2; Male; Melanoma; Neoplasm Metastasis; Retrospective Studies; Skin Neoplasms; Survival Rate; Uveal Neoplasms; Vinblastine

2008
Active specific immunotherapy phase III trials for malignant melanoma: systematic analysis and critical appraisal.
    Journal of the American College of Surgeons, 2008, Volume: 207, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cancer Vaccines; Clinical Trials, Phase III as Topic; Dacarbazine; Dendritic Cells; Epitopes; Gangliosides; Immunotherapy, Active; Interferons; Melanoma; Vaccinia virus

2008
Tumor immunotherapy in melanoma: strategies for overcoming mechanisms of resistance and escape.
    American journal of clinical dermatology, 2008, Volume: 9, Issue:5

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; CD146 Antigen; Dacarbazine; Disease Progression; Drug Resistance, Neoplasm; Humans; Immunotherapy; Interleukin-8; Melanoma; Neoplasm Metastasis; Skin Neoplasms

2008
Multiple intracranial melanoma metastases: case report and review of the literature.
    Journal of neuro-oncology, 2009, Volume: 93, Issue:3

    Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Fatal Outcome; Female; Humans; Magnetic Resonance Imaging; Melanoma; Middle Aged; Skin Neoplasms; Temozolomide

2009
Biochemotherapy in the treatment of metastatic melanoma in selected patients.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2009, Volume: 11, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase III as Topic; Dacarbazine; Disease-Free Survival; Drug Evaluation; Female; Humans; Immunologic Factors; Immunotherapy; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Lung Neoplasms; Male; Melanoma; Meta-Analysis as Topic; Middle Aged; Multicenter Studies as Topic; Patient Selection; Randomized Controlled Trials as Topic; Recombinant Proteins; Remission Induction; Retrospective Studies; Soft Tissue Neoplasms; Vinblastine

2009
[Metastatic malignant melanoma of the urinary bladder: a case report].
    Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 2009, Volume: 100, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Interferon-beta; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Nimustine; Skin Neoplasms; Urinary Bladder Neoplasms; Vincristine

2009
Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects.
    Cancer, 2010, Jun-15, Volume: 116, Issue:12

    Topics: Antineoplastic Agents, Alkylating; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Glioma; Humans; Immunologic Factors; Lymphopenia; Melanoma; Temozolomide; Treatment Outcome

2010
Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade.
    Seminars in oncology, 2010, Volume: 37, Issue:5

    Topics: Antibodies, Monoclonal; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CTLA-4 Antigen; Dacarbazine; Drug-Related Side Effects and Adverse Reactions; Humans; Ipilimumab; Melanoma; Skin Neoplasms

2010
Brain metastasis in melanoma: clinical activity of CTLA-4 antibody therapy.
    Seminars in oncology, 2010, Volume: 37, Issue:5

    Topics: Antibodies, Monoclonal; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; CTLA-4 Antigen; Dacarbazine; Humans; Ipilimumab; Italy; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Survival Analysis; Temozolomide; United States

2010
Does complete response to systemic therapy in patients with stage IV melanoma translate into long-term survival?
    Melanoma research, 2011, Volume: 21, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dacarbazine; Female; Humans; Interferon-alpha; Interleukin-2; Logistic Models; Male; Melanoma; Neoplasm Metastasis; Paclitaxel; Proportional Hazards Models; Remission Induction; Sex Factors; Skin Neoplasms; Treatment Outcome; Vinblastine

2011
Engineering nanomedicines for improved melanoma therapy: progress and promises.
    Nanomedicine (London, England), 2010, Volume: 5, Issue:9

    Topics: Antineoplastic Agents; Carmustine; Cisplatin; Dacarbazine; Drug Delivery Systems; Humans; Melanoma; Nanomedicine; Tamoxifen

2010
Targeted therapies in metastatic melanoma: toward a clinical breakthrough?
    Anti-cancer agents in medicinal chemistry, 2010, Nov-01, Volume: 10, Issue:9

    Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Dacarbazine; Humans; Ipilimumab; Melanoma

2010
A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy.
    Biochemical and biophysical research communications, 2011, Mar-18, Volume: 406, Issue:3

    Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Silencing; Genetic Therapy; Glioma; Humans; Melanoma; Skin Neoplasms; Temozolomide; Tumor Suppressor Proteins

2011
[Anti-CTLA-4 monoclonal antibody: a major step in the treatment of metastatic melanoma].
    Medecine sciences : M/S, 2011, Volume: 27, Issue:10

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Antineoplastic Agents, Alkylating; Autoimmune Diseases; Cancer Vaccines; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; CTLA-4 Antigen; Dacarbazine; Digestive System Diseases; Drug Screening Assays, Antitumor; Humans; Immunotherapy; Immunotherapy, Active; Ipilimumab; Melanoma; Melanoma, Experimental; Mice; Monitoring, Immunologic; Nervous System Diseases; Vaccines, Subunit

2011
Ipilimumab: showing survival benefit in metastatic melanoma.
    Future oncology (London, England), 2011, Volume: 7, Issue:11

    Topics: Antibodies, Monoclonal; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; CTLA-4 Antigen; Dacarbazine; Humans; Ipilimumab; Male; Melanoma; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome

2011
[Dacarbazine, a chemotherapeutic against metastatic melanoma and a reference drug for new treatment modalities].
    Postepy higieny i medycyny doswiadczalnej (Online), 2011, Nov-23, Volume: 65

    Topics: Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Dacarbazine; DNA Damage; Humans; Immunotherapy; Indoles; Ipilimumab; Melanoma; Randomized Controlled Trials as Topic; Sulfonamides; Temozolomide; Vemurafenib

2011
Upcoming strategies for the treatment of metastatic melanoma.
    Archives of dermatological research, 2012, Volume: 304, Issue:3

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dacarbazine; Humans; Indoles; Ipilimumab; MAP Kinase Kinase Kinases; Melanoma; Neoplasm Metastasis; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-kit; Skin Neoplasms; Sulfonamides; Vemurafenib

2012
Temozolomide and unusual indications: review of literature.
    Cancer treatment reviews, 2013, Volume: 39, Issue:2

    Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Lung Neoplasms; Melanoma; Neoplasms; Neuroendocrine Tumors; Pituitary Neoplasms; Temozolomide

2013
[Therapeutic strategies and systemic treatment of brain melanoma metastases].
    Bulletin du cancer, 2013, Jan-01, Volume: 100, Issue:1

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Humans; Immunotherapy; Indoles; Ipilimumab; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Palliative Care; Radiosurgery; Radiotherapy; Skin Neoplasms; Sulfonamides; Temozolomide; Vemurafenib

2013
Thymosin α1 in melanoma: from the clinical trial setting to the daily practice and beyond.
    Annals of the New York Academy of Sciences, 2012, Volume: 1270

    Topics: Antineoplastic Agents, Alkylating; Clinical Trials, Phase II as Topic; Dacarbazine; Humans; Immunologic Factors; Immunotherapy; Melanoma; Randomized Controlled Trials as Topic; Thymosin

2012
[Ctla-4 blockade: a new hope for the immunotherapy of malignant melanoma].
    Harefuah, 2012, Volume: 151, Issue:10

    Topics: Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Autoimmunity; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; CTLA-4 Antigen; Dacarbazine; Drug Approval; Drug Monitoring; Humans; Immunotherapy; Ipilimumab; Melanoma; Pharmacovigilance; Proportional Hazards Models; Skin Neoplasms; T-Lymphocytes, Cytotoxic; Treatment Outcome

2012
Temozolomide: a novel oral alkylating agent.
    Expert review of anticancer therapy, 2001, Volume: 1, Issue:1

    Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administration Schedule; Glioma; Melanoma; Temozolomide

2001
Systemic chemotherapy for the treatment of metastatic melanoma.
    Seminars in oncology, 2002, Volume: 29, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carmustine; Cisplatin; Clinical Trials as Topic; Dacarbazine; Humans; Melanoma; Nitrosourea Compounds; Paclitaxel; Tamoxifen; Taxoids; Temozolomide

2002
Metastatic melanoma: chemotherapy.
    Seminars in oncology, 2002, Volume: 29, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Cisplatin; Clinical Trials as Topic; Cytokines; Dacarbazine; Genetic Therapy; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Paclitaxel; Tamoxifen; Taxoids; Thalidomide

2002
[Treatment of melanoma].
    Presse medicale (Paris, France : 1983), 2003, Jan-11, Volume: 32, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cell- and Tissue-Based Therapy; Cells, Cultured; Chemotherapy, Adjuvant; Clinical Trials as Topic; Dacarbazine; Drug Therapy, Combination; Forecasting; Humans; Immunization, Passive; Immunotherapy; Immunotherapy, Active; Interferon-alpha; Interleukin-2; Lymph Node Excision; Lymphatic Metastasis; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; T-Lymphocytes, Cytotoxic; Temozolomide; Time Factors

2003
[Malignant melanoma of the alimentary tract].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Diagnosis, Differential; Esophageal Neoplasms; Female; Humans; Male; Melanoma; Nimustine; Rectal Neoplasms; Vincristine

2003
Systemic chemotherapy in the treatment of malignant melanoma.
    Expert opinion on pharmacotherapy, 2003, Volume: 4, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Dacarbazine; Humans; Lomustine; Melanoma; Neoplasm Metastasis; Skin Neoplasms; Tamoxifen; Treatment Outcome; Vincristine

2003
[Therapy of malignant melanoma at the stage of distant metastasis].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2004, Volume: 55, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dacarbazine; Disease Progression; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Melanoma; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Palliative Care; Prognosis; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Skin Neoplasms; Temozolomide; Time Factors; Tomography, X-Ray Computed; Vindesine

2004
Management of brain metastases in patients with melanoma.
    Current opinion in oncology, 2004, Volume: 16, Issue:2

    Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System; Chemotherapy, Adjuvant; Dacarbazine; Humans; Immunotherapy; Melanoma; Radiosurgery; Radiotherapy, Adjuvant; Radiotherapy, Computer-Assisted; Survival Rate; Temozolomide

2004
Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?
    European journal of cancer (Oxford, England : 1990), 2004, Volume: 40, Issue:12

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Evaluation; Hematologic Diseases; Humans; Melanoma

2004
The role of taxanes in the treatment of metastatic melanoma.
    Melanoma research, 2004, Volume: 14, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Dacarbazine; Humans; Melanoma; Skin Neoplasms; Tamoxifen; Taxoids; Temozolomide; Treatment Outcome

2004
[Disseminated melanoma treatment].
    La Revue du praticien, 2004, Jun-15, Volume: 54, Issue:11

    Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Lymph Nodes; Lymphatic Metastasis; Melanoma; Prognosis; Skin Neoplasms

2004
Management of metastatic cutaneous melanoma.
    Oncology (Williston Park, N.Y.), 2004, Volume: 18, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Dacarbazine; Humans; Immunotherapy; Interleukin-2; Melanoma; Multicenter Studies as Topic; Neoplasm Staging; Prognosis; Randomized Controlled Trials as Topic; Skin Neoplasms; Survival Analysis; Temozolomide; Thionucleotides; Treatment Outcome

2004
Apoptosis, Bcl-2 antisense, and cancer therapy.
    Oncology (Williston Park, N.Y.), 2004, Volume: 18, Issue:13 Suppl 1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dacarbazine; Genes, bcl-2; Humans; Melanoma; Neoplasms; Oligonucleotides, Antisense; Proto-Oncogene Mas; Proto-Oncogene Proteins c-bcl-2; Randomized Controlled Trials as Topic; Thionucleotides; Transplantation, Heterologous

2004
[Chemotherapy for brain metastases].
    Nihon rinsho. Japanese journal of clinical medicine, 2005, Volume: 63 Suppl 9

    Topics: Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Dacarbazine; Dementia, Vascular; Humans; Lung Neoplasms; Melanoma; Metalloporphyrins; Prednisolone; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Temozolomide

2005
Temozolomide in advanced malignant melanoma with small brain metastases: can we withhold cranial irradiation?
    Cancer, 2007, Jan-15, Volume: 109, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cranial Irradiation; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Randomized Controlled Trials as Topic; Survival Analysis; Temozolomide; Treatment Outcome

2007
Temozolomide for the treatment of metastatic melanoma: a systematic review.
    The oncologist, 2007, Volume: 12, Issue:9

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dacarbazine; Humans; Melanoma; Quality of Life; Randomized Controlled Trials as Topic; Survival Rate; Temozolomide; Treatment Outcome

2007
Treatments for metastatic melanoma: synthesis of evidence from randomized trials.
    Cancer treatment reviews, 2007, Volume: 33, Issue:8

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Melanoma; Randomized Controlled Trials as Topic; Skin Neoplasms

2007
Systemic therapy of disseminated malignant melanoma: an evidence-based overview of the state-of-the-art in daily routine.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2007, Volume: 21, Issue:10

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Dacarbazine; Evidence-Based Medicine; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Melanoma; Neoplasm Metastasis; Prognosis

2007
Focus on FOCIS: interleukin 2 treatment associated autoimmunity.
    Clinical immunology (Orlando, Fla.), 2008, Volume: 127, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Autoimmunity; CD4-Positive T-Lymphocytes; Cell Line, Tumor; Dacarbazine; Humans; Immunotherapy; Interleukin-2; Male; Melanoma; Middle Aged; Temozolomide; Vitiligo

2008
Immunotherapy of malignant melanoma.
    Journal of the American Academy of Dermatology, 1982, Volume: 6, Issue:4 Pt 1

    Topics: Antigens, Neoplasm; BCG Vaccine; Cholera Vaccines; Clinical Trials as Topic; Dacarbazine; Dinitrochlorobenzene; Double-Blind Method; Humans; Immunotherapy; Interferons; Levamisole; Melanoma; Random Allocation; Skin Neoplasms; Skin Tests; Transfer Factor

1982
Current status and future prospects for adjuvant therapy of melanoma.
    The Australian and New Zealand journal of surgery, 1984, Volume: 54, Issue:4

    Topics: Antigens, Neoplasm; Antigens, Viral, Tumor; Antineoplastic Combined Chemotherapy Protocols; Bacterial Vaccines; Combined Modality Therapy; Dacarbazine; Humans; Immunotherapy; Interferons; Interleukin-2; Melanoma; Skin Neoplasms; T-Lymphocytes, Regulatory

1984
The systemic chemotherapy of hepatic metastases.
    Seminars in oncology, 1983, Volume: 10, Issue:2

    Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Colonic Neoplasms; Dacarbazine; Drug Therapy, Combination; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Melanoma; Pancreatic Neoplasms; Rectal Neoplasms; Semustine; Stomach Neoplasms

1983
Malignant melanoma of the genitourinary tract.
    The Journal of urology, 1984, Volume: 132, Issue:5

    Topics: Adrenal Gland Neoplasms; Adult; Aged; BCG Vaccine; Carmustine; Combined Modality Therapy; Dacarbazine; Female; Humans; Kidney Neoplasms; Kidney Transplantation; Male; Melanoma; Middle Aged; Penile Neoplasms; Prostatic Neoplasms; Radiotherapy Dosage; Testicular Neoplasms; Ureteral Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Urogenital Neoplasms

1984
[Chemotherapy of malignant melanoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chemotherapy, Adjuvant; Cisplatin; Dacarbazine; Humans; Immunotherapy, Adoptive; Melanoma; Neoplasm Metastasis; Nimustine; Peplomycin; Vincristine

1995
Combination of chemotherapy with interleukin-2 and interferon-alfa for the treatment of advanced melanoma.
    Seminars in oncology, 1994, Volume: 21, Issue:6 Suppl 14

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Humans; Interferon-alpha; Interleukin-2; Melanoma; Vinblastine

1994
Role of recombinant interleukin-2 in combination with interferon-alfa and chemotherapy in the treatment of advanced melanoma.
    Seminars in oncology, 1993, Volume: 20, Issue:6 Suppl 9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Dacarbazine; Humans; Interferon Type I; Interleukin-2; Melanoma; Recombinant Proteins

1993
Tamoxifen: is it useful in the treatment of patients with metastatic melanoma?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Drug Synergism; Humans; Melanoma; Tamoxifen; Treatment Outcome

1994
Systemic treatments for advanced cutaneous melanoma.
    Oncology (Williston Park, N.Y.), 1995, Volume: 9, Issue:11

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine; Humans; Immunotherapy, Active; Interferon-alpha; Interleukin-2; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Remission Induction; Skin Neoplasms; Survival Rate; Temozolomide

1995
Xenograft model systems for human melanoma.
    Molecular medicine today, 1996, Volume: 2, Issue:9

    Topics: Animals; Cell Transplantation; Dacarbazine; Humans; Immunohistochemistry; Melanoma; Mice; Mice, SCID; Neoplasm Metastasis; Neoplasms, Experimental; Tumor Cells, Cultured

1996
Medical treatment of metastatic melanoma.
    The Surgical clinics of North America, 1996, Volume: 76, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytokines; Dacarbazine; Humans; Melanoma; Skin Neoplasms; Survival Analysis; Treatment Outcome

1996
[Treatment of malignant melanoma: recent advances and perspectives].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Melanoma; Nimustine; Skin Neoplasms; Tamoxifen; Vincristine

1997
Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy.
    Seminars in oncology, 1997, Volume: 24, Issue:1 Suppl 4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Dacarbazine; Humans; Interferon-alpha; Interleukin-2; Melanoma; Neoplasm Metastasis; Skin Neoplasms; Vincristine

1997
Recombinant interleukin-2-based treatments for advanced melanoma: the experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.
    The cancer journal from Scientific American, 1997, Volume: 3 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Dacarbazine; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Melanoma; Recombinant Proteins; Survival Rate

1997
The use of interferon-alpha in the treatment of cutaneous melanoma: a review.
    Melanoma research, 1998, Volume: 8, Issue:2

    Topics: Dacarbazine; Humans; Immunotherapy; Interferon-alpha; Interferon-gamma; Interleukin-2; Melanoma; Randomized Controlled Trials as Topic; Skin Neoplasms

1998
Current treatment options for malignant melanoma.
    Drugs, 1998, Volume: 55, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cancer Vaccines; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Genetic Therapy; Humans; Interleukin-2; Melanoma; Neoplasm Metastasis

1998
The Dartmouth Regimen: gone or going strong?
    Cancer investigation, 1998, Volume: 16, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Clinical Trials as Topic; Dacarbazine; Humans; Melanoma; Tamoxifen

1998
Acute tumor lysis syndrome associated with concurrent biochemotherapy of metastatic melanoma: a case report and review of the literature.
    Cancer, 1999, Mar-01, Volume: 85, Issue:5

    Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Calcium; Cisplatin; Creatinine; Dacarbazine; Fatal Outcome; Humans; Interferon-alpha; Interleukin-2; L-Lactate Dehydrogenase; Male; Melanoma; Middle Aged; Phosphorus; Skin Neoplasms; Tumor Lysis Syndrome; Uric Acid; Vinblastine

1999
Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma.
    The oncologist, 2000, Volume: 5, Issue:2

    Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Biological Availability; Brain Neoplasms; Dacarbazine; Humans; Melanoma; Skin Neoplasms; Temozolomide

2000
Temozolomide and treatment of malignant glioma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:7

    Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Incidence; Melanoma; Temozolomide

2000
Systemic chemotherapy.
    Clinics in plastic surgery, 2000, Volume: 27, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Immunotherapy; Melanoma; Neoadjuvant Therapy; Palliative Care; Remission Induction; Skin Neoplasms; Survival Rate

2000
[Surgical and adjuvant drug therapy in head and neck cutaneous melanoma].
    Laryngo- rhino- otologie, 2000, Volume: 79, Issue:7

    Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Head and Neck Neoplasms; Humans; Interferons; Lymph Node Excision; Melanoma; Sentinel Lymph Node Biopsy; Skin Neoplasms; Tumor Cells, Cultured

2000
Melanoma erysipeloides: successful treatment by chemoimmunotherapy.
    The British journal of dermatology, 2000, Volume: 143, Issue:4

    Topics: Adult; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Female; Humans; Immunotherapy; Melanoma; Skin Neoplasms

2000
Management of malignant melanoma.
    Annales chirurgiae et gynaecologiae, 2000, Volume: 89, Issue:3

    Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Case-Control Studies; Dacarbazine; Diagnosis, Differential; Female; Follow-Up Studies; Humans; Life Expectancy; Lymph Node Excision; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications, Neoplastic; Prognosis; Risk Factors; Skin; Skin Neoplasms; Sunscreening Agents; Survival Analysis; Time Factors

2000
Biochemotherapy for melanoma.
    Current oncology reports, 2000, Volume: 2, Issue:4

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Humans; Immunotherapy; Interferons; Interleukin-2; Melanoma; Mice; Tamoxifen

2000
New approaches in the treatment of metastatic melanoma: thalidomide and temozolomide.
    Oncology (Williston Park, N.Y.), 2000, Volume: 14, Issue:12 Suppl 1

    Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Temozolomide; Thalidomide

2000
Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials.
    Melanoma research, 2001, Volume: 11, Issue:1

    Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Databases, Factual; Humans; Immunotherapy; Interferons; Melanoma; Odds Ratio; Skin Neoplasms; Time Factors

2001
[Adjuvant therapy of malignant melanoma].
    Praxis, 2001, Feb-22, Volume: 90, Issue:8

    Topics: BCG Vaccine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Humans; Interferon alpha-2; Interferon-alpha; Melanoma; Neoplasm Staging; Recombinant Proteins; Skin Neoplasms

2001
[Treatment of metastasized malignant melanoma].
    Praxis, 2001, Mar-08, Volume: 90, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Dacarbazine; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Killer Cells, Lymphokine-Activated; Melanoma; Skin Neoplasms; Survival Rate

2001
[Dacarbazine].
    Annales de dermatologie et de venereologie, 2001, Volume: 128, Issue:4

    Topics: Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Interactions; France; Humans; Melanoma; Reproduction

2001
Melanoma-associated retinopathy: does autoimmunity prolong survival?
    Clinical & experimental ophthalmology, 2001, Volume: 29, Issue:4

    Topics: Adult; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Autoimmunity; Dacarbazine; Female; Humans; Immunosuppression Therapy; Interneurons; Lomustine; Melanoma; Membrane Proteins; Paraneoplastic Syndromes; Proteins; Retina; Retinal Diseases; Skin Neoplasms; Survival Rate

2001
Adjuvant therapy of malignant melanoma: is there a choice?
    Critical reviews in oncology/hematology, 2001, Volume: 40, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Follow-Up Studies; Humans; Interferons; Lymphatic Metastasis; Melanoma; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Staging; Premedication; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Vindesine

2001
Primary malignant melanoma of the pharynx.
    The Journal of laryngology and otology, 2001, Volume: 115, Issue:11

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Combined Modality Therapy; Dacarbazine; Female; Humans; Immunotherapy, Active; Interferon-alpha; Interleukin-2; Lung Neoplasms; Magnetic Resonance Imaging; Melanoma; Pharyngeal Neoplasms

2001
[Possibilities of immunotherapy in malignant melanoma].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 1978, Volume: 29, Issue:12

    Topics: Antigen-Antibody Reactions; BCG Vaccine; Dacarbazine; Humans; Immunization; Immunotherapy; Melanoma

1978
[Chemotherapy of malignant melanomas].
    Haematology and blood transfusion, 1978, Volume: 21

    Topics: Adjuvants, Immunologic; Antineoplastic Agents; BCG Vaccine; Dacarbazine; Drug Therapy, Combination; Female; Humans; Immunotherapy; Lymphatic Metastasis; Male; Melanoma; Mycobacterium bovis; Neoplasm Metastasis; Nitrosourea Compounds; Prognosis; Vincristine

1978
[Pharmacology of DTIC (author's transl)].
    Wiener klinische Wochenschrift, 1978, Dec-22, Volume: 90, Issue:24

    Topics: Animals; Chemical Phenomena; Chemistry; Dacarbazine; Hodgkin Disease; Humans; Melanoma; Sarcoma; Soft Tissue Neoplasms; Triazenes

1978
[Dacarbacine (DTIC) in the therapy of a malignant disease. A review (author's transl)].
    Wiener klinische Wochenschrift, 1978, Dec-22, Volume: 90, Issue:24

    Topics: Antineoplastic Agents; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Gastrointestinal Neoplasms; Hodgkin Disease; Humans; Melanoma; Sarcoma; Soft Tissue Neoplasms; Triazenes

1978
[DTIC in malignant melanoma: a perspective (author's transl)].
    Wiener klinische Wochenschrift, 1978, Dec-22, Volume: 90, Issue:24

    Topics: Animals; Antineoplastic Agents; Dacarbazine; Drug Evaluation; Drug Evaluation, Preclinical; Drug Therapy, Combination; Humans; Immunotherapy; Melanoma; Mice; Triazenes

1978
The role of immunotherapy in the management of patients with malignant melanoma.
    World journal of surgery, 1979, Jul-30, Volume: 3, Issue:3

    Topics: Bacterial Vaccines; BCG Vaccine; Corynebacterium; Dacarbazine; Dinitrochlorobenzene; Drug Therapy, Combination; Humans; Immunotherapy; Melanoma; Skin Neoplasms

1979
Chemotherapy of malignant melanoma.
    World journal of surgery, 1979, Jul-30, Volume: 3, Issue:3

    Topics: Antineoplastic Agents; BCG Vaccine; Dacarbazine; Drug Therapy, Combination; Humans; Lomustine; Melanoma; Nitrosourea Compounds; Skin Neoplasms

1979
Combined modality therapy of malignant melanoma.
    World journal of surgery, 1979, Jul-30, Volume: 3, Issue:3

    Topics: Antineoplastic Agents; BCG Vaccine; Dacarbazine; Drug Therapy, Combination; Humans; Melanoma; Skin Neoplasms

1979
DTIC (NSC-45388) in malignant melanoma: a perspective.
    Cancer treatment reports, 1976, Volume: 60, Issue:2

    Topics: Animals; Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Humans; Lomustine; Melanoma; Mice; Neoplasm Metastasis; Nitrosourea Compounds; Remission, Spontaneous; Triazenes

1976
[Treatment of disseminated malignant melanoma. Results are promising, but toxicity is high].
    Pathologie-biologie, 1992, Volume: 40, Issue:9 Pt 2

    Topics: Antibodies, Monoclonal; Bone Marrow Transplantation; Cisplatin; Combined Modality Therapy; Dacarbazine; Drug Therapy, Combination; Humans; Interferon-alpha; Melanoma; Nitrosourea Compounds

1992
[Contribution of a new nitrosourea compound: fotemustine].
    Pathologie-biologie, 1992, Volume: 40, Issue:9 Pt 2

    Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dacarbazine; Drug Therapy, Combination; Humans; Liver Neoplasms; Lung Neoplasms; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds

1992
Combined treatment of metastatic melanoma with interferons and cytotoxic drugs.
    Seminars in oncology, 1992, Volume: 19, Issue:2 Suppl 4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Dacarbazine; Humans; Interferons; Melanoma; Vinblastine; Vindesine

1992
[Treatment of metastatic melanoma with interleukin-2].
    Annales de dermatologie et de venereologie, 1992, Volume: 119, Issue:1

    Topics: Cisplatin; Cyclophosphamide; Dacarbazine; Drug Therapy, Combination; Humans; Immunotherapy, Adoptive; Interferons; Interleukin-2; Killer Cells, Lymphokine-Activated; Lymphocytes, Tumor-Infiltrating; Melanoma

1992
Fotemustine: an overview of its clinical activity in disseminated malignant melanoma.
    Melanoma research, 1992, Volume: 2, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Lung Neoplasms; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Recombinant Proteins; Remission Induction; Vindesine

1992
Chemotherapy for advanced malignant melanoma.
    International journal of clinical & laboratory research, 1992, Volume: 21, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Drug Evaluation; Humans; Immunologic Factors; Incidence; Interferon-alpha; Melanoma; Pilot Projects; Skin Neoplasms; Tamoxifen; Transplantation, Autologous

1992
Role of interferons in the therapy of melanoma.
    The Journal of investigative dermatology, 1990, Volume: 95, Issue:6 Suppl

    Topics: Clinical Trials as Topic; Dacarbazine; Dose-Response Relationship, Drug; Drug Evaluation; Drug Therapy, Combination; Humans; Interferon alpha-2; Interferon-alpha; Interferon-gamma; Interferons; Melanoma; Recombinant Proteins

1990
Clinical evaluation of interferons in malignant melanoma.
    The Journal of investigative dermatology, 1990, Volume: 95, Issue:6 Suppl

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dacarbazine; Dose-Response Relationship, Drug; Forecasting; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Melanoma; Recombinant Proteins

1990
[Brain metastases of malignant melanomas].
    Bulletin du cancer, 1991, Volume: 78, Issue:4

    Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Dacarbazine; Humans; Interleukin-2; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Semustine

1991
[Malignant melanoma of the vulva and vagina (a report of 4 cases and review of the literature)].
    Akusherstvo i ginekologiia, 1990, Volume: 29, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Dacarbazine; Female; Humans; Hysterectomy; Lymph Node Excision; Melanoma; Middle Aged; Postoperative Care; Vaginal Neoplasms; Vulva; Vulvar Neoplasms

1990
Interleukin-2. The experience of the Rotterdam Cancer Institute; Daniel den Hoed Kliniek.
    Biotherapy (Dordrecht, Netherlands), 1990, Volume: 2, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Evaluation; Humans; Immunotherapy; Interferon Type I; Interleukin-2; Kidney Neoplasms; Killer Cells, Lymphokine-Activated; Melanoma; Meta-Analysis as Topic; Recombinant Proteins

1990
Therapy for cutaneous melanoma: an update.
    Journal of the American Academy of Dermatology, 1990, Volume: 22, Issue:2 Pt 1

    Topics: Adult; Biopsy; Chemotherapy, Cancer, Regional Perfusion; Combined Modality Therapy; Dacarbazine; Female; Humans; Immunotherapy; Lymph Node Excision; Melanoma; Neoplasm Staging; Pregnancy; Prognosis; Skin Neoplasms

1990
[Diagnosis and prognosis of malignant melanoma].
    Deutsche medizinische Wochenschrift (1946), 1985, Nov-15, Volume: 110, Issue:46

    Topics: Alkaline Phosphatase; Dacarbazine; Female; Humans; L-Lactate Dehydrogenase; Lymphatic Metastasis; Male; Melanoma; Neoplasm Metastasis; Neoplasm Staging; Palliative Care; Palpation; Prognosis; Radionuclide Imaging; Skin; Skin Neoplasms

1985
[Chemotherapy of malignant melanoma].
    Annales de dermatologie et de venereologie, 1988, Volume: 115, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Interferons; Interleukin-2; Lomustine; Melanoma; Prognosis; Skin Neoplasms; Tamoxifen

1988
[An autopsy case of neurocutaneous melanosis associated with intracerebral malignant melanoma].
    No to shinkei = Brain and nerve, 1987, Volume: 39, Issue:8

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Humans; Male; Melanoma; Nevus, Pigmented; Nimustine; Nitrosourea Compounds; Skin Neoplasms; Vincristine

1987
Systemic therapy of malignant melanoma.
    The Medical clinics of North America, 1986, Volume: 70, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Dacarbazine; Humans; Immunotherapy; Melanoma; Neoplasm Staging; Skin Neoplasms

1986

Trials

416 trial(s) available for dacarbazine and Melanoma

ArticleYear
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.
    The New England journal of medicine, 2021, 09-23, Volume: 385, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cytokine Release Syndrome; Dacarbazine; Exanthema; Female; Humans; Ipilimumab; Male; Melanoma; Middle Aged; Recombinant Fusion Proteins; Survival Analysis; Uveal Neoplasms

2021
Theragnostic significance of tumor-infiltrating lymphocytes and Ki67 in BRAFV600-mutant metastatic melanoma (BRIM-3 trial).
    Current problems in cancer, 2022, Volume: 46, Issue:3

    Topics: Dacarbazine; Humans; Ki-67 Antigen; Lymphocytes, Tumor-Infiltrating; Melanoma; Neoplasms, Second Primary; Prognosis; Retrospective Studies; Vemurafenib

2022
A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients.
    Cancer immunology, immunotherapy : CII, 2019, Volume: 68, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Recombinant Fusion Proteins; Skin Neoplasms; Survival Analysis; Young Adult

2019
Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials.
    European journal of cancer (Oxford, England : 1990), 2020, Volume: 125

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dacarbazine; Disease Progression; Female; Follow-Up Studies; Humans; Imidazoles; Male; Melanoma; Middle Aged; Oximes; Patient Selection; Progression-Free Survival; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Time Factors; Young Adult

2020
A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma.
    Cancer immunology, immunotherapy : CII, 2017, Volume: 66, Issue:10

    Topics: Adult; Aged; Antineoplastic Agents, Immunological; Dacarbazine; Female; Humans; Ipilimumab; Male; Melanoma; Middle Aged; Skin Neoplasms; Temozolomide

2017
Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2017, Oct-01, Volume: 28, Issue:10

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Dacarbazine; Enzyme Inhibitors; Female; Humans; Indoles; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Mutation; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Treatment Outcome; Vemurafenib; Young Adult

2017
High frequency of brain metastases after adjuvant therapy for high-risk melanoma.
    Cancer medicine, 2017, Volume: 6, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Humans; Interferon alpha-2; Interferon-alpha; Lymph Nodes; Lymphatic Metastasis; Male; Melanoma; Neoplasm Staging; Recombinant Proteins; Retrospective Studies; Skin Neoplasms; Skin Ulcer; Survival Rate; Vinblastine

2017
Cisplatin, dacarbazine and vinblastine as first line chemotherapy for liver metastatic uveal melanoma in the era of immunotherapy: a single institution phase II study.
    Melanoma research, 2017, Volume: 27, Issue:6

    Topics: Cisplatin; Dacarbazine; Disease-Free Survival; Female; Humans; Immunotherapy; Male; Melanoma; Middle Aged; Uveal Neoplasms; Vinblastine

2017
The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England.
    The European journal of health economics : HEPAC : health economics in prevention and care, 2018, Volume: 19, Issue:8

    Topics: Age Factors; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Health Expenditures; Health Resources; Humans; Imidazoles; Ipilimumab; Kaplan-Meier Estimate; Male; Markov Chains; Melanoma; Middle Aged; Models, Economic; Nivolumab; Oximes; Proto-Oncogene Proteins B-raf; Quality-Adjusted Life Years; Sex Factors; Skin Neoplasms; Vemurafenib

2018
Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018, 04-20, Volume: 36, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Dacarbazine; Double-Blind Method; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Placebos; Progression-Free Survival; Uveal Neoplasms

2018
Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial.
    JAMA oncology, 2019, 02-01, Volume: 5, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Dacarbazine; Disease Progression; Double-Blind Method; Female; Humans; Male; Melanoma; Middle Aged; Nivolumab; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Time Factors; Treatment Outcome; Young Adult

2019
A prospective trial of adjuvant therapy for high-risk uveal melanoma: assessing 5-year survival outcomes.
    The British journal of ophthalmology, 2020, Volume: 104, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Prospective Studies; Survival Rate; Uveal Neoplasms; Young Adult

2020
Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma.
    Journal of translational medicine, 2013, Feb-13, Volume: 11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Interferon alpha-2; Interferon-alpha; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Recombinant Proteins; Survival Analysis

2013
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation.
    Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Drug Synergism; Female; Humans; Indoles; Male; Melanoma; Middle Aged; Poly(ADP-ribose) Polymerase Inhibitors; Skin Neoplasms; Survival Rate; Temozolomide; Treatment Outcome; Young Adult

2013
A phase II, randomized, double-blind, placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma.
    Molecular therapy : the journal of the American Society of Gene Therapy, 2013, Volume: 21, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dacarbazine; Disease-Free Survival; Double-Blind Method; Endostatins; Female; Humans; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Young Adult

2013
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
    The Lancet. Oncology, 2013, Volume: 14, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Brazil; Dacarbazine; Disease-Free Survival; DNA Mutational Analysis; Double-Blind Method; Drug Administration Schedule; Europe; Female; Genetic Predisposition to Disease; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Melanoma; Middle Aged; Mutation; Neoplasms, Unknown Primary; Phenotype; Proportional Hazards Models; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Time Factors; Treatment Outcome; United States

2013
Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma.
    British journal of cancer, 2013, Jul-09, Volume: 109, Issue:1

    Topics: Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Dacarbazine; Disease Progression; Disease-Free Survival; Double-Blind Method; Humans; Ipilimumab; Melanoma; Neoplasm Staging; Survival Analysis

2013
Phase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Aug-15, Volume: 19, Issue:16

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Dacarbazine; Female; Genotype; Humans; Interferon-alpha; Male; Melanoma; Middle Aged; Mucous Membrane; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Temozolomide; Treatment Outcome; Young Adult

2013
Phase I-II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma.
    British journal of cancer, 2013, Sep-17, Volume: 109, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Depsipeptides; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Peptides, Cyclic; Treatment Outcome; Young Adult

2013
Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Health Status; Humans; MAP Kinase Kinase Kinases; Melanoma; Middle Aged; Mutation; Paclitaxel; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Quality of Life; Surveys and Questionnaires

2014
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.
    The Lancet. Oncology, 2014, Volume: 15, Issue:3

    Topics: Adult; Aged; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Indoles; Male; Melanoma; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sulfonamides; Vemurafenib

2014
Dacarbazine with or without oblimersen (a Bcl-2 antisense oligonucleotide) in chemotherapy-naive patients with advanced melanoma and low-normal serum lactate dehydrogenase: 'The AGENDA trial'.
    Melanoma research, 2014, Volume: 24, Issue:3

    Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Gene Expression Regulation, Neoplastic; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Oligonucleotides, Antisense; Prospective Studies; Proto-Oncogene Proteins c-bcl-2; Skin Neoplasms; Thionucleotides; Time Factors; Tomography, X-Ray Computed; Treatment Outcome

2014
Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-α in patients with metastatic melanoma.
    Melanoma research, 2014, Volume: 24, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Skin Neoplasms; Temozolomide; Young Adult

2014
Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:7

    Topics: Antineoplastic Agents; Dacarbazine; Humans; Imidazoles; Melanoma; Neoplasm Metastasis; Oximes; Quality of Life

2014
A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma.
    European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Ramucirumab; Skin Neoplasms; Survival Analysis; Young Adult

2014
Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.
    JAMA, 2014, Jun-18, Volume: 311, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Dacarbazine; Disease Progression; Female; Humans; Male; Melanoma; Middle Aged; Survival Analysis; Temozolomide; Treatment Outcome; Uveal Neoplasms

2014
Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma.
    Autophagy, 2014, Volume: 10, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Hydroxychloroquine; Male; Melanoma; Middle Aged; Neoplasm Staging; Neoplasms; Temozolomide; Treatment Outcome

2014
Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib.
    American journal of ophthalmology, 2014, Volume: 158, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Conjunctivitis; Dacarbazine; Dry Eye Syndromes; Eye Diseases; Female; Humans; Indoles; Male; Melanoma; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Retrospective Studies; Skin Neoplasms; Sulfonamides; Uveitis; Vemurafenib; Young Adult

2014
Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).
    Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:4

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Dacarbazine; Decitabine; DNA Modification Methylases; Dose-Response Relationship, Drug; Drug Monitoring; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epigenomics; Eye Neoplasms; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Panobinostat; Skin Neoplasms; Temozolomide; Treatment Outcome

2014
Quality of life after isolated limb infusion for in-transit melanoma of the extremity.
    Annals of surgical oncology, 2015, Volume: 22, Issue:5

    Topics: Aged; Antineoplastic Agents, Alkylating; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Extremities; Female; Follow-Up Studies; Humans; Infusions, Intra-Arterial; Male; Maximum Tolerated Dose; Melanoma; Neoplasm Staging; Prognosis; Quality of Life; Temozolomide

2015
A multicenter phase I dose escalation trial to evaluate safety and tolerability of intra-arterial temozolomide for patients with advanced extremity melanoma using normothermic isolated limb infusion.
    Annals of surgical oncology, 2015, Volume: 22, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Cohort Studies; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Extremities; Female; Follow-Up Studies; Humans; Infusions, Intra-Arterial; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Staging; Prognosis; Promoter Regions, Genetic; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Skin Neoplasms; Temozolomide; Tissue Distribution; Tumor Suppressor Proteins

2015
Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Ch
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Nov-20, Volume: 32, Issue:33

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cisplatin; Dacarbazine; Female; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukin-2; Male; Melanoma; Middle Aged; Recombinant Proteins; Vinblastine

2014
Liver resection in multimodal concepts improves survival of metastatic melanoma: a single-centre case-matched control study.
    Anticancer research, 2014, Volume: 34, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cisplatin; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Hepatectomy; Humans; Immunotherapy; Interferons; Interleukin-2; Liver Neoplasms; Male; Melanoma; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Skin Neoplasms; Survival Rate

2014
Efficacy and side effects of radiation therapy in comparison with radiation therapy and temozolomide in the treatment of measurable canine malignant melanoma.
    Veterinary and comparative oncology, 2016, Volume: 14, Issue:4

    Topics: Animals; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Dog Diseases; Dogs; Melanoma; Radiotherapy; Temozolomide

2016
Nivolumab in previously untreated melanoma without BRAF mutation.
    The New England journal of medicine, 2015, Jan-22, Volume: 372, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Dacarbazine; Disease-Free Survival; Double-Blind Method; Female; Humans; Male; Melanoma; Middle Aged; Nivolumab; Programmed Cell Death 1 Receptor; Proto-Oncogene Proteins B-raf; Survival Rate; Young Adult

2015
Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine.
    Cancer research and treatment, 2015, Volume: 47, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dacarbazine; Docetaxel; Female; Humans; Male; Melanoma; Middle Aged; Patient Compliance; Taxoids; Young Adult

2015
Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Apr-01, Volume: 33, Issue:10

    Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Diarrhea; Drug Administration Schedule; Exanthema; Female; Humans; Ipilimumab; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Pruritus; Survival Analysis; Survival Rate; Time Factors; Treatment Outcome; Vitiligo

2015
Dacarbazine in combination with bevacizumab for the treatment of unresectable/metastatic melanoma: a phase II study.
    Melanoma research, 2015, Volume: 25, Issue:3

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Dacarbazine; Drug Monitoring; Female; Humans; Infusions, Intravenous; Intention to Treat Analysis; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Skin; Skin Neoplasms; Survival Analysis; Tumor Burden

2015
Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma.
    Journal of translational medicine, 2015, May-02, Volume: 13

    Topics: Adult; Aged; Antigens, Neoplasm; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; Dendritic Cells; Drug Therapy; Female; Gene Expression Profiling; gp100 Melanoma Antigen; Humans; Immunotherapy; Injections, Intralesional; Interferon-alpha; Leukocytes, Mononuclear; Male; Melanoma; Membrane Proteins; Microscopy, Confocal; Middle Aged; Monocytes; Monophenol Monooxygenase; Vitiligo

2015
Adjusting for the Confounding Effects of Treatment Switching-The BREAK-3 Trial: Dabrafenib Versus Dacarbazine.
    The oncologist, 2015, Volume: 20, Issue:7

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Dacarbazine; Disease-Free Survival; Female; Humans; Imidazoles; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Mutation; Oximes; Proto-Oncogene Proteins B-raf; Treatment Outcome

2015
Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT).
    BMC cancer, 2015, Jun-10, Volume: 15

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Dacarbazine; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Uveal Neoplasms

2015
Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; Dacarbazine; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Poly(ADP-ribose) Polymerase Inhibitors; Prognosis; Survival Rate; Temozolomide; Young Adult

2015
Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma.
    Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:5

    Topics: Adult; Aged; Alanine Transaminase; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; CTLA-4 Antigen; Dacarbazine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Eruptions; Endocrine System Diseases; Female; Humans; Immunosuppressive Agents; Ipilimumab; Japan; Kaplan-Meier Estimate; Maintenance Chemotherapy; Male; Melanoma; Middle Aged; Neoplasm Proteins; Remission Induction; Treatment Outcome

2015
A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents, Alkylating; Dacarbazine; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Paclitaxel; Skin Neoplasms; Young Adult

2015
Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma.
    Oncotarget, 2015, Dec-15, Volume: 6, Issue:40

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Phenylurea Compounds; Quinolines; Temozolomide; Young Adult

2015
Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy.
    Cancer medicine, 2016, Volume: 5, Issue:5

    Topics: Antineoplastic Agents; Dacarbazine; Disease Progression; Drug Substitution; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Melanoma; Middle Aged; Mutation; Paclitaxel; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Survival Analysis

2016
Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:10

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; CTLA-4 Antigen; Dacarbazine; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Nivolumab; Programmed Cell Death 1 Receptor; Quality of Life; Surveys and Questionnaires

2016
A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma.
    Melanoma research, 2016, Volume: 26, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Taxoids; Temozolomide

2016
Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma.
    European journal of cancer (Oxford, England : 1990), 2016, Volume: 67

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dacarbazine; Disease-Free Survival; Female; Health Status; Humans; Male; Melanoma; Middle Aged; Paclitaxel; Patient Reported Outcome Measures; Quality of Life; Skin Neoplasms; Temozolomide; Young Adult

2016
Effect of the lymphocyte-to-monocyte ratio on the clinical outcome of chemotherapy administration in advanced melanoma patients.
    Melanoma research, 2017, Volume: 27, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents, Alkylating; CD11c Antigen; CD3 Complex; CD4 Antigens; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Lipopolysaccharide Receptors; Lymphocyte Count; Lymphocytes; Male; Melanoma; Middle Aged; Monocytes; Retrospective Studies; Skin Neoplasms; Temozolomide; Time Factors; Treatment Outcome

2017
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.
    The Lancet. Oncology, 2017, Volume: 18, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Dacarbazine; Female; Follow-Up Studies; GTP Phosphohydrolases; Humans; Male; Melanoma; Membrane Proteins; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Survival Rate

2017
Combined treatment with pegylated interferon-alpha-2a and dacarbazine in patients with advanced metastatic melanoma: a phase 2 study.
    Cancer, 2008, Sep-15, Volume: 113, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antiviral Agents; Bone Neoplasms; Dacarbazine; Drug Carriers; Drug Therapy, Combination; Female; Humans; Interferon alpha-2; Interferon-alpha; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Staging; Polyethylene Glycols; Prognosis; Prospective Studies; Recombinant Proteins; Survival Rate

2008
[Hepatic intra-arterial bio-chemotherapy for the treatment of melanoma patients with liver metastasis: a phase II clinical study].
    Ai zheng = Aizheng = Chinese journal of cancer, 2008, Volume: 27, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytokine-Induced Killer Cells; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Granulocyte-Macrophage Colony-Stimulating Factor; Hepatic Artery; Humans; Immunotherapy, Adoptive; Infusions, Intra-Arterial; Interleukin-2; Liver Neoplasms; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Recombinant Proteins; Remission Induction; Survival Rate; Thrombocytopenia; Young Adult

2008
A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma.
    Cancer, 2008, Oct-01, Volume: 113, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedule; Female; Humans; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Skin Neoplasms; Temozolomide

2008
Adjuvant fermented wheat germ extract (Avemar) nutraceutical improves survival of high-risk skin melanoma patients: a randomized, pilot, phase II clinical study with a 7-year follow-up.
    Cancer biotherapy & radiopharmaceuticals, 2008, Volume: 23, Issue:4

    Topics: Adolescent; Adult; Aged; Chemotherapy, Adjuvant; Dacarbazine; Dietary Supplements; Drug Therapy, Combination; Female; Fermentation; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Pilot Projects; Plant Extracts; Skin Neoplasms; Treatment Outcome; Triticum

2008
Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study.
    Cancer, 2008, Oct-15, Volume: 113, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Temozolomide; Thalidomide

2008
Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordin
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-10, Volume: 26, Issue:35

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Disease-Free Survival; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Time Factors; Treatment Outcome; United States; Vincristine; Young Adult

2008
Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma.
    Cancer chemotherapy and pharmacology, 2009, Volume: 64, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Cohort Studies; Dacarbazine; Docetaxel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Staging; Neutropenia; Pulmonary Embolism; Skin Neoplasms; Taxoids; Temozolomide; Treatment Outcome

2009
Treatment of metastatic malignant melanoma with a combination of 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (NSC-45388), cyclophosphamide (NSC-26271), and vincristine (NSC-67574).
    Cancer chemotherapy reports, 1972, Volume: 56, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Cyclophosphamide; Dacarbazine; Drug Administration Schedule; Female; Granulocytes; Humans; Male; Melanoma; Middle Aged; Remission Induction; Treatment Outcome; Vincristine

1972
Clinical evaluation of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxam-ide (NSC-45388), melphalan (NSC-8806), and hydroxyurea (NSC-32065) in the treatment of disseminated malignant melanoma.
    Cancer chemotherapy reports, 1972, Volume: 56, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Dacarbazine; Female; Humans; Hydroxyurea; Leukocytes; Male; Melanoma; Melphalan; Middle Aged; Remission Induction; Treatment Outcome

1972
Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse.
    Melanoma research, 2009, Volume: 19, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Interferon alpha-2; Interferon-alpha; L-Lactate Dehydrogenase; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Staging; Nerve Growth Factors; Prospective Studies; Recombinant Proteins; Recurrence; S100 Calcium Binding Protein beta Subunit; S100 Proteins; Skin Neoplasms; Vindesine

2009
A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma.
    British journal of cancer, 2009, Jan-13, Volume: 100, Issue:1

    Topics: Adult; Aged; Dacarbazine; Enzyme Inhibitors; Female; Histone Deacetylase Inhibitors; Humans; Interferon-alpha; Male; Melanoma; Middle Aged; Valproic Acid

2009
A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma.
    British journal of cancer, 2009, Apr-21, Volume: 100, Issue:8

    Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Child; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Patient Selection; Purines; Skin Neoplasms; Temozolomide; Thrombocytopenia

2009
O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib.
    British journal of cancer, 2009, Apr-21, Volume: 100, Issue:8

    Topics: Antineoplastic Agents; Biopsy; Dacarbazine; Disease Progression; DNA Damage; DNA Repair; DNA Replication; DNA, Neoplasm; Humans; Kinetics; Melanoma; O(6)-Methylguanine-DNA Methyltransferase; Purines; Temozolomide

2009
Malignant melanoma therapy by chemotherapy and autoimmunity induced by cytokine.
    Cancer biotherapy & radiopharmaceuticals, 2009, Volume: 24, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Autoimmunity; Combined Modality Therapy; Dacarbazine; Drug Interactions; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunotherapy; Interleukin-2; Male; Melanoma; Middle Aged; T-Lymphocytes

2009
LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951).
    European journal of cancer (Oxford, England : 1990), 2009, Volume: 45, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dacarbazine; Follow-Up Studies; Humans; L-Lactate Dehydrogenase; Liver Neoplasms; Melanoma; Prognosis; Skin Neoplasms; Survival Analysis; Thionucleotides; Treatment Outcome

2009
A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence.
    Melanoma research, 2009, Volume: 19, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Dacarbazine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Recombinant Proteins; Survival Rate; Treatment Outcome; Vinblastine; Young Adult

2009
A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma.
    Cancer investigation, 2009, Volume: 27, Issue:7

    Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Chemical and Drug Induced Liver Injury; Dacarbazine; DNA Mismatch Repair; Drug Administration Schedule; Female; Humans; Indoles; Infusions, Intravenous; Male; Melanoma; Middle Aged; Neoplasm Proteins; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Temozolomide

2009
Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
    Chemotherapy, 2009, Volume: 55, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Skin Neoplasms; Thalidomide

2009
Phase I/II study of a cisplatin-taxol-dacarbazine regimen in metastatic melanoma.
    American journal of clinical oncology, 2009, Volume: 32, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Skin Neoplasms; Survival Analysis; Treatment Outcome

2009
Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma.
    Cancer, 2009, Sep-01, Volume: 115, Issue:17

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytokines; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Oligodeoxyribonucleotides; Skin Neoplasms; Survival Analysis; Treatment Outcome

2009
Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:3

    Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Dacarbazine; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Palliative Care; Prospective Studies; Remission Induction; Salvage Therapy; Survival Rate; Temozolomide; Treatment Outcome

2010
Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Dec-20, Volume: 27, Issue:36

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Remission Induction; Skin Neoplasms; Survival Analysis; Vinblastine; Young Adult

2009
Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508.
    Cancer, 2010, Jan-15, Volume: 116, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Skin Neoplasms; Temozolomide; Thalidomide

2010
A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Jan-01, Volume: 16, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemokines; Dacarbazine; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Skin Neoplasms; Temozolomide; Treatment Outcome

2010
Temozolomide and cisplatin combination in naive patients with metastatic cutaneous melanoma: results of a phase II multicenter trial.
    Melanoma research, 2010, Volume: 20, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Temozolomide

2010
Phase II trial of neoadjuvant temozolomide in resectable melanoma patients.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Humans; Male; Melanoma; Middle Aged; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins

2010
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma.
    Investigational new drugs, 2011, Volume: 29, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Demography; Female; Humans; Ipilimumab; Kaplan-Meier Estimate; Lymphocyte Subsets; Male; Melanoma; Middle Aged; Neoplasm Staging; Treatment Outcome

2011
A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma.
    Cancer, 2010, Mar-15, Volume: 116, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Female; Humans; Integrin alphaVbeta3; Male; Melanoma; Middle Aged; Skin Neoplasms

2010
Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Apr-01, Volume: 28, Issue:10

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Interferon-alpha; Male; Melanoma; Middle Aged; Thymalfasin; Thymosin

2010
A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy.
    Molecular cancer, 2010, Mar-30, Volume: 9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bosentan; Dacarbazine; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Neoplasm Staging; Skin Neoplasms; Sulfonamides

2010
A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon-alpha2a as first line treatment in metastatic melanoma.
    Melanoma research, 2010, Volume: 20, Issue:4

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Dacarbazine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Matrix Metalloproteinase 9; Melanoma; Middle Aged; Patient Compliance; Prognosis; Recombinant Proteins; Survival Rate; Vascular Endothelial Growth Factor A

2010
A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma.
    Cancer, 2010, Aug-01, Volume: 116, Issue:15

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Hexanones; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Metastasis; Skin Neoplasms

2010
Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel

2011
Phase I safety study of lenalidomide and dacarbazine in patients with metastatic melanoma previously untreated with systemic chemotherapy.
    Melanoma research, 2010, Volume: 20, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Lenalidomide; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Survival Rate; Thalidomide

2010
Phase I dose finding study of carboplatin, paclitaxel, and temozolomide in advanced solid tumors.
    Melanoma research, 2011, Volume: 21, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Dacarbazine; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Paclitaxel; Skin Neoplasms; Small Cell Lung Carcinoma; Temozolomide

2011
A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours.
    British journal of cancer, 2011, Mar-01, Volume: 104, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasms; Neutropenia; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Thrombocytopenia

2011
First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Temozolomide

2012
Telomerase peptide vaccination combined with temozolomide: a clinical trial in stage IV melanoma patients.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Jul-01, Volume: 17, Issue:13

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cancer Vaccines; Cytokines; Dacarbazine; Humans; Immunologic Memory; Melanoma; Middle Aged; Neoplasm Staging; Survival Analysis; T-Lymphocytes; Telomerase; Temozolomide; Treatment Outcome; Vaccines, Subunit; Young Adult

2011
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032).
    European journal of cancer (Oxford, England : 1990), 2011, Volume: 47, Issue:10

    Topics: Aged; Area Under Curve; Dacarbazine; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Neoplasm Staging; Remission Induction; Safety; Skin Neoplasms; Temozolomide; Time Factors

2011
Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens.
    British journal of cancer, 2011, Jun-07, Volume: 104, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Temozolomide

2011
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
    The New England journal of medicine, 2011, Jun-30, Volume: 364, Issue:26

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dacarbazine; Disease-Free Survival; Female; Humans; Indoles; Intention to Treat Analysis; Male; Melanoma; Middle Aged; Mutation; Proto-Oncogene Proteins B-raf; Sulfonamides; Survival Analysis; Vemurafenib; Young Adult

2011
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
    The New England journal of medicine, 2011, Jun-30, Volume: 364, Issue:26

    Topics: Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Double-Blind Method; Female; Humans; Ipilimumab; Kaplan-Meier Estimate; Liver Function Tests; Male; Melanoma; Middle Aged; Proportional Hazards Models

2011
Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies.
    British journal of cancer, 2011, Jul-26, Volume: 105, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Skin Neoplasms; Sorafenib

2011
A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma.
    British journal of cancer, 2011, Jul-26, Volume: 105, Issue:3

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Female; Humans; Integrin alphaV; Male; Melanoma; Middle Aged; Skin Neoplasms; Uveitis

2011
Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours.
    British journal of cancer, 2011, Sep-06, Volume: 105, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Neoplasms; O(6)-Methylguanine-DNA Methyltransferase; Purines

2011
Health-related quality of life among patients with metastatic melanoma: results from an international phase 2 multicenter study.
    Melanoma research, 2012, Volume: 22, Issue:1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Pain; Pain Measurement; Psychometrics; Quality of Life; Surveys and Questionnaires

2012
A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Dec-15, Volume: 17, Issue:24

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Fever; Humans; Male; Melanoma; Metabolic Clearance Rate; Middle Aged; Neoplasm Metastasis; Recombinant Fusion Proteins; Survival Analysis; Survival Rate; Treatment Outcome

2011
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Jan-15, Volume: 18, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Dacarbazine; Disease-Free Survival; DNA Mutational Analysis; Drug Substitution; Female; Humans; Kaplan-Meier Estimate; Male; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Melanoma; Middle Aged; Mutation; Neoplasm Staging; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Temozolomide; Treatment Outcome; Young Adult

2012
Prospective evaluation of supportive care with or without CVD chemotherapy as a second-line treatment in advanced melanoma by patient's choice: a multicentre Dermatologic Cooperative Oncology Group trial.
    Melanoma research, 2011, Volume: 21, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Choice Behavior; Cooperative Behavior; Cyclophosphamide; Dacarbazine; Dermatology; Disease Progression; Female; Humans; Interdisciplinary Communication; Male; Medical Oncology; Melanoma; Middle Aged; Palliative Care; Patient Preference; Skin Neoplasms; Societies, Medical; Vincristine

2011
Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma.
    British journal of cancer, 2012, Jan-03, Volume: 106, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dasatinib; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Pyrimidines; src-Family Kinases; Survival Analysis; Thiazoles; Treatment Outcome

2012
Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects.
    Oncotarget, 2011, Volume: 2, Issue:12

    Topics: Adult; Aged; Antimony Sodium Gluconate; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Colorectal Neoplasms; Dacarbazine; Drug Therapy, Combination; Enzyme Inhibitors; Female; Gastrointestinal Stromal Tumors; Humans; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Phosphoric Monoester Hydrolases; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Recombinant Proteins; Sarcoma; Vinblastine

2011
Veliparib plus temozolomide in metastatic melanoma trends toward increased PFS but results are not statistically significant.
    Oncology (Williston Park, N.Y.), 2011, Nov-15, Volume: 25, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Dacarbazine; Disease-Free Survival; Double-Blind Method; Humans; Melanoma; Neoplasm Staging; Temozolomide

2011
Phase II trial of temozolomide for leptomeningeal metastases in patients with solid tumors.
    Journal of neuro-oncology, 2012, Volume: 109, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Dacarbazine; Female; Follow-Up Studies; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Melanoma; Meningeal Neoplasms; Middle Aged; Neoplasm Staging; Prognosis; Prospective Studies; Survival Rate; Temozolomide

2012
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.
    Lancet (London, England), 2012, Jul-28, Volume: 380, Issue:9839

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Disease-Free Survival; Female; Humans; Imidazoles; Male; Melanoma; Middle Aged; Mutation; Oximes; Proto-Oncogene Proteins B-raf; Treatment Outcome; Young Adult

2012
A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group study, N0775.
    Cancer, 2013, Feb-01, Volume: 119, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Paclitaxel; Skin Neoplasms; Survival Analysis; Temozolomide; Treatment Outcome; Young Adult

2013
Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial.
    Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:1

    Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Dacarbazine; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Oligonucleotides, Antisense; Paclitaxel; Skin Neoplasms; Temozolomide; Thionucleotides; Treatment Outcome

2013
Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Dacarbazine; Decitabine; Disease-Free Survival; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Skin Neoplasms; Temozolomide

2013
The association of blood angioregulatory microRNA levels with circulating endothelial cells and angiogenic proteins in patients receiving dacarbazine and interferon.
    Journal of translational medicine, 2012, Dec-05, Volume: 10

    Topics: Angiogenic Proteins; Cell Movement; Dacarbazine; Endothelial Cells; Humans; Interferon alpha-2; Interferon-alpha; Melanoma; MicroRNAs; Neovascularization, Pathologic; Recombinant Proteins; Uveal Neoplasms

2012
Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcoma.
    Investigational new drugs, 2013, Volume: 31, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Medication Adherence; Melanoma; Middle Aged; Pyrazines; Radiography; Sarcoma; Treatment Outcome; Young Adult

2013
Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675.
    American journal of clinical oncology, 2014, Volume: 37, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Everolimus; Female; Humans; Induction Chemotherapy; Male; Melanoma; Middle Aged; Sirolimus; Skin Neoplasms; Temozolomide; TOR Serine-Threonine Kinases; Treatment Outcome; Vascular Endothelial Growth Factor A

2014
[Long-term results of adjuvant chemotherapy after therapeutic lymph node dissection in patients with cutaneous malignant melanoma].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2002, Volume: 53, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Humans; Interferon-alpha; Lymph Node Excision; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Staging; Skin Neoplasms; Survival Rate

2002
Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Drug Eruptions; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Hyperthyroidism; Immunologic Factors; Interleukin-2; Life Tables; Melanoma; Neoplasm Metastasis; Prospective Studies; Remission Induction; Survival Analysis; Tamoxifen; Thrombocytopenia; Treatment Outcome; Vinblastine

2002
A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Pilot Projects; Recombinant Proteins; Temozolomide; Treatment Outcome; Vinblastine

2002
Chemoimmunohormonal therapy with carmustine, dacarbazine, cisplatin, tamoxifen, and interferon for metastatic melanoma: a prospective phase II study.
    American journal of clinical oncology, 2002, Volume: 25, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Prospective Studies; Recombinant Proteins; Remission Induction; Survival Analysis; Tamoxifen

2002
Docetaxel in combination with dacarbazine in patients with advanced melanoma.
    Oncology, 2002, Volume: 63, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Docetaxel; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction; Skin Neoplasms; Survival Analysis; Taxoids

2002
Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma.
    Cancer, 2002, Dec-01, Volume: 95, Issue:11

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Disease-Free Survival; Female; Humans; Injections, Intravenous; Interferon-alpha; Lomustine; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Treatment Outcome; Uveal Neoplasms; Vincristine

2002
Phase I/II study of sequential chemoimmunotherapy (SCIT) for metastatic melanoma: outpatient treatment with dacarbazine, granulocyte-macrophage colony-stimulating factor, low-dose interleukin-2, and interferon-alpha.
    Cancer immunology, immunotherapy : CII, 2002, Volume: 51, Issue:11-12

    Topics: Adult; Aged; Dacarbazine; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; T-Lymphocytes

2002
Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study.
    Cancer, 2003, Jan-01, Volume: 97, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Staging; Neutropenia; Recombinant Proteins; Skin Neoplasms; Temozolomide; Thrombocytopenia; Treatment Outcome

2003
Temozolomide and cisplatin in the treatment of leptomeningeal metastatic involvement from melanoma: a case report.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2002, Volume: 23, Issue:5

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Humans; Magnetic Resonance Imaging; Male; Melanoma; Meningeal Neoplasms; Spinal Cord Neoplasms; Temozolomide; Treatment Outcome

2002
Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen, or vindesine plus tamoxifen: a prospective randomized study.
    Melanoma research, 2003, Volume: 13, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Skin Neoplasms; Survival Rate; Tamoxifen; Treatment Outcome; Vindesine

2003
Low molecular weight heparin treatment for malignant melanoma: a pilot clinical trial.
    Thrombosis and haemostasis, 2003, Volume: 89, Issue:2

    Topics: Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Dacarbazine; Enoxaparin; Feasibility Studies; Glycosaminoglycans; Humans; Melanoma; Neoplasm Staging; Pilot Projects; Radiotherapy, Adjuvant; Remission Induction; Survival Analysis; Tamoxifen; Treatment Outcome

2003
Low-dose continuous chemotherapy for metastatic melanoma: a phase II trial.
    Melanoma research, 2003, Volume: 13, Issue:2

    Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chlorambucil; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Injections, Subcutaneous; Lomustine; Male; Melanoma; Methotrexate; Middle Aged; Neoplasm Metastasis; Prognosis; Tamoxifen; Time Factors; Treatment Outcome; Vinblastine

2003
Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma.
    European journal of cancer (Oxford, England : 1990), 2003, Volume: 39, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Disease-Free Survival; Feasibility Studies; Female; Humans; Interferon alpha-2; Interferon-alpha; Lomustine; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Prospective Studies; Recombinant Proteins; Treatment Outcome; Uveal Neoplasms; Vincristine

2003
Biochemotherapy for metastatic melanoma with limited central nervous system involvement.
    Oncology, 2003, Volume: 64, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cisplatin; Dacarbazine; Disease Progression; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Staging; Radiosurgery; Recombinant Proteins; Survival Analysis; Treatment Outcome; Vinblastine

2003
Phase I-II study on isolation antiblastic fotemustine perfusion after dacarbazine chemosensitization for advanced melanoma of the extremities.
    Melanoma research, 2003, Volume: 13, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Extremities; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Treatment Outcome

2003
Phase II evaluation of temozolomide in metastatic choroidal melanoma.
    Melanoma research, 2003, Volume: 13, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Choroid Neoplasms; Dacarbazine; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Prospective Studies; Temozolomide; Treatment Outcome

2003
Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Jul-01, Volume: 21, Issue:13

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Skin Neoplasms; Survival; Temozolomide; Thalidomide

2003
Quality of life evaluation in a randomised trial of chemotherapy versus bio-chemotherapy in advanced melanoma patients.
    European journal of cancer (Oxford, England : 1990), 2003, Volume: 39, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Multivariate Analysis; Prognosis; Quality of Life; Recombinant Proteins; Skin Neoplasms

2003
On the effect of biochemotherapy in metastatic malignant melanoma: an immunopathological evaluation.
    Melanoma research, 2003, Volume: 13, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; CD4 Lymphocyte Count; Cisplatin; Dacarbazine; Female; Humans; Immunotherapy; Interferon alpha-2; Interferon-alpha; Lymphocytes, Tumor-Infiltrating; Male; Melanoma; Middle Aged; Recombinant Proteins; Remission Induction; Skin Neoplasms; Treatment Outcome

2003
[Chemotherapy in combination with laser coagulation or interstitial hyperthermia--effective combined therapy for disseminated skin melanoma].
    Voprosy onkologii, 2003, Volume: 49, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Cisplatin; Dacarbazine; Extracellular Space; Female; Humans; Hyperthermia, Induced; Laser Coagulation; Male; Melanoma; Middle Aged; Skin Neoplasms; Survival Analysis; Tamoxifen; Treatment Outcome

2003
Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Sep-01, Volume: 21, Issue:17

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Male; Melanoma; Middle Aged; Survival Analysis; Temozolomide; Thalidomide; Treatment Outcome

2003
A phase I (tumour site-specific) study of carboplatin and temozolomide in patients with advanced melanoma.
    British journal of cancer, 2003, Nov-17, Volume: 89, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Dacarbazine; Drug Interactions; Female; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Skin Neoplasms; Temozolomide; Thrombocytopenia

2003
Health-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine.
    Cancer investigation, 2003, Volume: 21, Issue:6

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Cognition; Dacarbazine; Emotions; Female; Health Status; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Quality of Life; Skin Neoplasms; Sleep; Survival Analysis; Temozolomide

2003
Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Mar-15, Volume: 22, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Europe; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Quality of Life; Skin Neoplasms; Statistics, Nonparametric; Survival Analysis

2004
Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Onco
    Cancer, 2004, Apr-15, Volume: 100, Issue:8

    Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Agents, Alkylating; BCG Vaccine; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease Progression; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Survival Analysis; Treatment Outcome

2004
Temozolomide as prophylaxis for melanoma brain metastases.
    Melanoma research, 2004, Volume: 14, Issue:1

    Topics: Adult; Aged; Antibiotic Prophylaxis; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Temozolomide

2004
Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jun-01, Volume: 22, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Survival Rate; Temozolomide; United States

2004
[Chemoimmunotherapy with dacarbazine and aranose combined with interferon-alpha in disseminated cutaneous melanoma].
    Voprosy onkologii, 2004, Volume: 50, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Glycosides; Humans; Immunologic Factors; Interferon-alpha; Male; Melanoma; Methylnitrosourea; Middle Aged; Skin Neoplasms; Treatment Outcome

2004
Temozolomide and interferon alpha 2b in metastatic melanoma stage IV.
    The British journal of dermatology, 2004, Volume: 151, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Interferon alpha-2; Interferon-alpha; Liver Neoplasms; Lung Neoplasms; Male; Melanoma; Middle Aged; Proportional Hazards Models; Recombinant Proteins; Remission Induction; Skin Neoplasms; Survival Rate; Temozolomide

2004
The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma.
    Melanoma research, 2004, Volume: 14, Issue:4

    Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Temozolomide; Time Factors

2004
Temozolomide and interferon-alpha in metastatic melanoma: a phase II study of the Italian Melanoma Intergroup.
    Melanoma research, 2004, Volume: 14, Issue:4

    Topics: Adult; Aged; Dacarbazine; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Interferon-alpha; Italy; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Survival Rate; Temozolomide; Treatment Outcome

2004
Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study.
    Journal of neuro-oncology, 2005, Volume: 71, Issue:1

    Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Cisplatin; Dacarbazine; Female; Humans; Leukopenia; Lung Neoplasms; Male; Melanoma; Middle Aged; Nausea; Stomach Neoplasms; Temozolomide; Treatment Outcome

2005
Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations.
    British journal of cancer, 2005, Mar-28, Volume: 92, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Paclitaxel; Temozolomide

2005
Cyclosporine A, alpha-lnterferon and interleukin-2 following chemotherapy with BCNU, DTIC, cisplatin, and tamoxifen: a phase II study in advanced melanoma.
    Cancer investigation, 2005, Volume: 23, Issue:1

    Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cyclosporine; Dacarbazine; Female; Humans; Immunosuppressive Agents; Interferon-alpha; Interleukin-2; Male; Melanoma; Skin Neoplasms; Tamoxifen; Treatment Outcome

2005
Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Temozolomide

2005
Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study.
    Cancer, 2005, Jun-15, Volume: 103, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Skin Neoplasms; Survival Rate; Temozolomide; Thalidomide; Treatment Outcome

2005
Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, May-01, Volume: 11, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Comet Assay; Dacarbazine; DNA Damage; DNA Methylation; DNA Repair; DNA, Neoplasm; Female; Headache; Humans; Lymphocytes; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neutropenia; O(6)-Methylguanine-DNA Methyltransferase; Poly(ADP-ribose) Polymerases; Temozolomide; Thrombocytopenia; Time Factors; Treatment Outcome

2005
Combined chemoimmunotherapy of metastatic melanoma: a single institution experience.
    Melanoma research, 2005, Volume: 15, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dacarbazine; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Nausea; Neutropenia; Recombinant Proteins; Skin Neoplasms; Survival Analysis; Thrombocytopenia; Vinblastine; Vomiting

2005
Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-alpha in patients with advanced melanoma.
    Melanoma research, 2005, Volume: 15, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Female; Humans; Interferon Type I; Interferon-alpha; Lomustine; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Skin Neoplasms; Survival Analysis; Treatment Outcome; Vincristine

2005
A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF.
    Cancer investigation, 2005, Volume: 23, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Eye Neoplasms; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-2; Melanoma; Middle Aged; Neoplasm Metastasis; Reproducibility of Results; Skin Neoplasms; Survival Analysis; Temozolomide

2005
Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases.
    Journal of neuro-oncology, 2006, Volume: 76, Issue:1

    Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Stereotaxic Techniques; Survival Analysis; Temozolomide; Treatment Outcome

2006
Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Sep-20, Volume: 23, Issue:27

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cisplatin; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Europe; Female; Follow-Up Studies; Humans; Immunohistochemistry; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Probability; Proportional Hazards Models; Recombinant Proteins; Reference Values; Skin Neoplasms; Survival Rate; Treatment Outcome

2005
A low rate of central nervous system progression in a phase II trial of outpatient chemobiologic therapy with cisplatin, temozolomide, interleukin-2, and interferon alfa 2-B for metastatic malignant melanoma.
    American journal of clinical oncology, 2005, Volume: 28, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease Progression; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Recombinant Proteins; Temozolomide

2005
Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-alpha2b, and recombinant interleukin-2 for the treatment of metastatic melanoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-10, Volume: 23, Issue:35

    Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Staging; Recombinant Proteins; Survival Analysis; Temozolomide; Treatment Outcome

2005
Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-10, Volume: 23, Issue:35

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Dacarbazine; Female; Humans; Interferon-alpha; Male; Melanoma; Middle Aged; Prognosis; Prospective Studies; Statistics, Nonparametric; Survival Rate; Temozolomide; Treatment Outcome

2005
Decline in angiogenic factors, such as interleukin-8, indicates response to chemotherapy of metastatic melanoma.
    Melanoma research, 2005, Volume: 15, Issue:6

    Topics: Adult; Aged; Angiogenic Proteins; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Fibroblast Growth Factor 2; Humans; Interferon-alpha; Interleukin-2; Interleukin-8; Male; Melanoma; Middle Aged; Neoplasm Staging; Platelet-Derived Growth Factor; Prospective Studies; Vascular Cell Adhesion Molecule-1; Vascular Endothelial Growth Factor A; Vindesine

2005
Temozolomide in combination with cisplatin in patients with metastatic melanoma: a phase II trial.
    Melanoma research, 2005, Volume: 15, Issue:6

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Skin Neoplasms; Temozolomide

2005
Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-20, Volume: 23, Issue:36

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; DNA Methylation; DNA, Neoplasm; Drug Administration Schedule; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Odds Ratio; Predictive Value of Tests; Prognosis; Recombinant Proteins; Skin Neoplasms; Survival Analysis; Tamoxifen; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins; Vinblastine

2005
Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:4

    Topics: Cancer Vaccines; Dacarbazine; Dendritic Cells; Humans; Melanoma; Neoplasm Metastasis; Peptides

2006
A biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, temozolomide (Temodal), interferon-alfa and interleukin-2 for metastatic melanoma: a phase II study.
    Melanoma research, 2006, Volume: 16, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Recombinant Proteins; Skin Neoplasms; Survival Rate; Temozolomide; Treatment Outcome; Vinblastine

2006
Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Vinblastine

2006
Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma.
    Cancer, 2006, Jun-01, Volume: 106, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Eye Neoplasms; Female; Follow-Up Studies; Humans; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Mouth Neoplasms; Polyethylene Glycols; Recombinant Proteins; Remission Induction; Skin Neoplasms; Survival Rate; Temozolomide

2006
A prospective single arm phase II study of dacarbazine and treosulfan as first-line therapy in metastatic uveal melanoma.
    Melanoma research, 2006, Volume: 16, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Prospective Studies; Thrombocytopenia; Uveal Neoplasms

2006
A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma.
    Journal of cancer research and clinical oncology, 2006, Volume: 132, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Skin Neoplasms; Survival Rate; Temozolomide; Thalidomide; Treatment Outcome

2006
Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha: A controlled, randomised multicentre trial.
    Acta oncologica (Stockholm, Sweden), 2006, Volume: 45, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Female; Humans; Interferon-alpha; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Skin Neoplasms; Survival Rate

2006
Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jul-01, Volume: 24, Issue:19

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Humans; Interferon-alpha; Interleukin-2; Lymph Node Excision; Male; Melanoma; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Skin Neoplasms; Survival Analysis; Vinblastine

2006
Basal level and behaviour of cytokines in a randomized outpatient trial comparing chemotherapy and biochemotherapy in metastatic melanoma.
    Melanoma research, 2006, Volume: 16, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytokines; Dacarbazine; Female; Humans; Immunologic Factors; Interleukin-10; Interleukin-12; Interleukin-2; Interleukin-6; Interleukin-8; Male; Melanoma; Middle Aged; Receptors, Interleukin-6; Skin Neoplasms; Survival Analysis; Survival Rate; Vinblastine

2006
Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma.
    Melanoma research, 2006, Volume: 16, Issue:4

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Immunotherapy; Injections, Subcutaneous; Interleukin-2; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Staging; Skin Neoplasms; Survival Rate; Temozolomide

2006
Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma.
    Melanoma research, 2006, Volume: 16, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Staging; Recombinant Proteins; Skin Neoplasms; Survival Rate; Temozolomide

2006
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-10, Volume: 24, Issue:29

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; L-Lactate Dehydrogenase; Male; Melanoma; Middle Aged; Oligonucleotides, Antisense; Proto-Oncogene Proteins c-bcl-2; Skin Neoplasms; Survival Analysis; Thionucleotides; Treatment Outcome

2006
Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:12

    Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dacarbazine; Female; Humans; Immunohistochemistry; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Pyrazoles; Skin Neoplasms; Sulfonamides; Survival Analysis; Temozolomide

2006
Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102).
    Cancer, 2006, Oct-15, Volume: 107, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Humans; Melanoma; Middle Aged; Pulmonary Embolism; Skin Neoplasms; Survival Rate; Temozolomide; Thalidomide; Treatment Failure; Venous Thrombosis; Withholding Treatment

2006
Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:10

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Survival Analysis; Temozolomide; Treatment Outcome

2006
Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Researc
    European journal of cancer (Oxford, England : 1990), 2006, Volume: 42, Issue:17

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dacarbazine; Female; Humans; Immunotherapy; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Patient Compliance; Recombinant Proteins; Skin Neoplasms

2006
A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma.
    British journal of cancer, 2007, Jan-15, Volume: 96, Issue:1

    Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lomustine; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neutropenia; Temozolomide; Thrombocytopenia; Treatment Failure

2007
Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Jun-20, Volume: 25, Issue:18

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Enzyme Inhibitors; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; O(6)-Methylguanine-DNA Methyltransferase; Purines; Skin Neoplasms; Temozolomide; Treatment Outcome

2007
Phase II study of temozolomide and concomitant whole-brain radiotherapy in patients with brain metastases from solid tumors.
    Onkologie, 2007, Volume: 30, Issue:7

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Female; Humans; Lung Neoplasms; Male; Melanoma; Middle Aged; Mouth Neoplasms; Neoplasms, Unknown Primary; Palliative Care; Rectal Neoplasms; Research Design; Temozolomide; Treatment Outcome

2007
Results of a multicenter randomized study to evaluate the safety and efficacy of combined immunotherapy with interleukin-2, interferon-{alpha}2b and histamine dihydrochloride versus dacarbazine in patients with stage IV melanoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Histamine; Humans; Immunotherapy; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Multivariate Analysis; Neoplasm Staging; Recombinant Proteins

2007
Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Sep-01, Volume: 25, Issue:25

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease Progression; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Recombinant Proteins; Skin Neoplasms; Treatment Outcome; Vinblastine

2007
Temozolomide in combination with fotemustine in patients with metastatic melanoma.
    Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Nitrosourea Compounds; Organophosphorus Compounds; Temozolomide

2008
Multicenter phase II study of chemoimmunotherapy in the treatment of metastatic melanoma.
    Anti-cancer drugs, 2008, Volume: 19, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dacarbazine; Dexamethasone; Diarrhea; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Therapy; Female; Humans; Immunotherapy; Interferon alpha-2; Interferon-alpha; Interleukin-2; Isotretinoin; Magnesium Sulfate; Male; Melanoma; Middle Aged; Neutropenia; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Treatment Outcome; Vinblastine

2008
Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Neoplasm Staging; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Skin Neoplasms; Temozolomide; Treatment Outcome

2008
Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:6

    Topics: Adolescent; Adult; Antineoplastic Agents; Child; Child, Preschool; Dacarbazine; Female; Humans; Infant; Infant, Newborn; Interferon alpha-2; Interferon-alpha; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Prospective Studies; Quality of Life; Recombinant Proteins; Skin Neoplasms; Survival Analysis

2008
Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Feb-20, Volume: 26, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Cancer Vaccines; Dacarbazine; Female; Heat-Shock Proteins; Humans; Interleukin-2; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Neoplasm Staging; Odds Ratio; Skin Neoplasms; Temozolomide; Treatment Outcome

2008
Influence of therapy on the antioxidant status in patients with melanoma.
    Journal of clinical pharmacy and therapeutics, 2008, Volume: 33, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Catalase; Dacarbazine; Female; Humans; Lipid Peroxidation; Lomustine; Male; Malondialdehyde; Melanoma; Middle Aged; Oxidative Stress; Superoxide Dismutase

2008
Temozolomide associated with PEG-interferon in patients with metastatic melanoma: a multicenter prospective phase I/II study.
    Melanoma research, 2008, Volume: 18, Issue:2

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Skin Neoplasms; Temozolomide

2008
Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases.
    Melanoma research, 2008, Volume: 18, Issue:2

    Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Brain Neoplasms; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Oxides; Skin Neoplasms; Temozolomide

2008
Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanoma.
    Molecular therapy : the journal of the American Society of Gene Therapy, 2008, Volume: 16, Issue:5

    Topics: Adenoviridae; Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Dacarbazine; Female; Gene Transfer Techniques; Genetic Therapy; Genetic Vectors; Humans; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis

2008
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, May-01, Volume: 26, Issue:13

    Topics: Administration, Oral; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Dacarbazine; Disease-Free Survival; Double-Blind Method; Female; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Time Factors; Treatment Outcome; United States

2008
Phase II study of extended-dose temozolomide in patients with melanoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, May-10, Volume: 26, Issue:14

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Base Sequence; CD3 Complex; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Molecular Sequence Data; Promoter Regions, Genetic; Survival Rate; Temozolomide; Tumor Suppressor Proteins

2008
Immunotherapy of malignant melanoma.
    Journal of the American Academy of Dermatology, 1982, Volume: 6, Issue:4 Pt 1

    Topics: Antigens, Neoplasm; BCG Vaccine; Cholera Vaccines; Clinical Trials as Topic; Dacarbazine; Dinitrochlorobenzene; Double-Blind Method; Humans; Immunotherapy; Interferons; Levamisole; Melanoma; Random Allocation; Skin Neoplasms; Skin Tests; Transfer Factor

1982
Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1984, Volume: 2, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Clinical Trials as Topic; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Mouth Diseases; Neutropenia; Random Allocation; Sepsis; Skin Neoplasms; Thrombocytopenia; Vinblastine

1984
[Chemotherapy in advanced malignant melanoma. Results of a controlled trial comparing a combination of dacarbazine (DTIC) and detorubicin with dacarbazine alone].
    La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris, 1982, Dec-16, Volume: 58, Issue:46

    Topics: Adult; Aged; Clinical Trials as Topic; Dacarbazine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Middle Aged; Time Factors

1982
Randomized controlled trial of adjuvant chemoimmunotherapy with DTIC and BCG after complete excision of primary melanoma with a poor prognosis or melanoma metastases.
    Canadian Medical Association journal, 1983, Apr-15, Volume: 128, Issue:8

    Topics: Antineoplastic Agents; BCG Vaccine; Clinical Trials as Topic; Dacarbazine; Humans; Melanoma; Neoplasm Metastasis; Neoplasm Recurrence, Local; Postoperative Care; Prognosis; Random Allocation; Skin Neoplasms

1983
The systemic chemotherapy of hepatic metastases.
    Seminars in oncology, 1983, Volume: 10, Issue:2

    Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Colonic Neoplasms; Dacarbazine; Drug Therapy, Combination; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Melanoma; Pancreatic Neoplasms; Rectal Neoplasms; Semustine; Stomach Neoplasms

1983
Combination chemotherapy plus levamisole in the treatment of disseminated malignant melanoma. A Southwest Oncology Group study.
    Cancer, 1984, Feb-15, Volume: 53, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Dacarbazine; Dactinomycin; Humans; Hydroxyurea; Levamisole; Melanoma; Random Allocation; Skin Neoplasms

1984
Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A).
    Cancer, 1984, Mar-15, Volume: 53, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Dacarbazine; Female; Humans; Hydroxyurea; Lomustine; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Sex Factors; Skin Neoplasms; Soft Tissue Neoplasms; Time Factors; Vincristine

1984
Ineffectiveness of adjuvant chemotherapy using DTIC and cyclophosphamide in patients with resectable metastatic melanoma.
    Surgery, 1984, Volume: 95, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Female; Humans; Immunotherapy; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Prognosis; Propionibacterium acnes; Prospective Studies; Random Allocation; Skin Neoplasms

1984
Controlled study with imidazole carboxamide (DTIC), DTIC + bacillus Calmette-Guérin (BCG), and DTIC + corynebacterium parvum in advanced malignant melanoma. W.H.O. Collaborating Centres for Evaluation of Methods of Diagnosis and Treatment of Melanoma.
    Tumori, 1984, Feb-29, Volume: 70, Issue:1

    Topics: Bacterial Vaccines; BCG Vaccine; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Female; Fever; Humans; Leukopenia; Male; Melanoma; Middle Aged; Nausea; Propionibacterium acnes; Sex Factors; Time Factors

1984
Controlled study of DTIC versus DTIC plus epirubicin in metastatic malignant melanoma.
    Investigational new drugs, 1984, Volume: 2, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dacarbazine; Doxorubicin; Epirubicin; Female; Heart; Humans; Male; Melanoma; Middle Aged

1984
Clinical trial of chlorozotocin, DTIC, and dactinomycin in metastatic malignant melanoma.
    Cancer treatment reports, 1982, Volume: 66, Issue:2

    Topics: Adolescent; Adult; Bone Marrow; Clinical Trials as Topic; Dacarbazine; Dactinomycin; Digestive System; Drug Therapy, Combination; Female; Humans; Kidney; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Streptozocin

1982
Predictability of response to clinical thermochemotherapy by the clonogenic assay.
    Cancer, 1983, Oct-15, Volume: 52, Issue:8

    Topics: Cells, Cultured; Colony-Forming Units Assay; Combined Modality Therapy; Dacarbazine; Drug Evaluation; Hot Temperature; Humans; Liver Neoplasms; Melanoma; Skin Neoplasms; Tumor Stem Cell Assay

1983
A trial of imidazole carboxamide and corynebacterium parvum in disseminated melanoma: clinical and immunologic results.
    Cancer, 1980, Aug-01, Volume: 46, Issue:3

    Topics: Bacterial Vaccines; Clinical Trials as Topic; Dacarbazine; Female; Humans; Immunotherapy; Injections, Intramuscular; Male; Melanoma; Middle Aged; Nausea; Neoplasm Metastasis; Pancytopenia; Prognosis; Propionibacterium acnes; Skin Neoplasms; Vomiting

1980
[Comparison of the efficacy of imidazole-carboxamide and of a combination of nitrosomethylurea, vincristine and dactinomycin in disseminated melanoma].
    Voprosy onkologii, 1981, Volume: 27, Issue:4

    Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Dacarbazine; Dactinomycin; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Methylnitrosourea; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Skin Neoplasms; Time Factors; Vincristine

1981
DTIC and combination therapy for melanoma: III. DTIC (NSC 45388) Surgical Adjuvant Study COG PROTOCOL 7040.
    Cancer, 1981, Jun-01, Volume: 47, Issue:11

    Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Dacarbazine; Female; Follow-Up Studies; Humans; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Postoperative Care; Prospective Studies; Random Allocation; Skin Neoplasms

1981
Chemoimmunotherapy for melanoma with DTIC, ACNU, VCR and OK432: evaluation of new combinations for survival rates, side effects and cellular immunity.
    The Journal of dermatology, 1981, Volume: 8, Issue:4

    Topics: Biological Products; Clinical Trials as Topic; Dacarbazine; Drug Therapy, Combination; Female; Humans; Immunity, Cellular; Immunotherapy; Male; Melanoma; Nimustine; Nitrosourea Compounds; Picibanil; Vincristine

1981
Trial 6: randomized study of prolonged chemotherapy, immunotherapy, and chemoimmunotherapy as an adjuvant to surgery for stage I and II melanoma: a progress report.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1982, Volume: 80

    Topics: Clinical Trials as Topic; Dacarbazine; Female; Follow-Up Studies; Humans; Immunotherapy; Male; Melanoma; Mycobacterium bovis

1982
Clinical trials of chemotherapy and chemoimmunotherapy in primary malignant melanoma.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1982, Volume: 80

    Topics: Clinical Trials as Topic; Dacarbazine; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immunotherapy; Male; Melanoma; Methotrexate; Procarbazine; Streptonigrin; Vinblastine

1982
Current status of melanoma chemotherapy and immunotherapy.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1982, Volume: 80

    Topics: Clinical Trials as Topic; Dacarbazine; Follow-Up Studies; Humans; Immunotherapy; Levamisole; Melanoma; Microscopy, Electron; Mycobacterium bovis; Neoplasm Staging

1982
A randomized comparison of cyclophosphamide, DTIC with or without piperazinedione in metastatic malignant melanoma.
    Cancer, 1982, Apr-01, Volume: 49, Issue:7

    Topics: Antibiotics, Antineoplastic; Clinical Trials as Topic; Cyclophosphamide; Dacarbazine; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Piperazines; Random Allocation; Skin Neoplasms

1982
Adjuvant chemoimmunotherapy stage I/II malignant melanoma.
    Journal of surgical oncology, 1982, Volume: 19, Issue:3

    Topics: Adolescent; Adult; Aged; BCG Vaccine; Clinical Trials as Topic; Dacarbazine; Female; Humans; Lymph Node Excision; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Prospective Studies; Random Allocation; Semustine; Skin Neoplasms

1982
Actinomycin-D plus 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamine (DTIC) with or without intravenous Corynebacterium parvum in metastatic malignant melanoma.
    Cancer, 1982, Jun-01, Volume: 49, Issue:11

    Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Dacarbazine; Dactinomycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immunotherapy; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Propionibacterium acnes

1982
Combination chemotherapy plus BCG in the treatment of disseminated malignant melanoma: a Southwest Oncology Group Study.
    Medical and pediatric oncology, 1982, Volume: 10, Issue:3

    Topics: Adult; Age Factors; Antineoplastic Agents; BCG Vaccine; Clinical Trials as Topic; Dacarbazine; Drug Administration Schedule; Drug Therapy, Combination; Humans; Leukocyte Count; Melanoma; Middle Aged; Prognosis; Random Allocation; Skin Neoplasms; Skin Tests

1982
A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma.
    The New England journal of medicine, 1982, Oct-07, Volume: 307, Issue:15

    Topics: BCG Vaccine; Clinical Trials as Topic; Dacarbazine; Female; Humans; Lymphatic Metastasis; Male; Melanoma; Postoperative Care; Prognosis; Prospective Studies; Random Allocation; Skin Neoplasms

1982
Phase II trial of recombinant interferon-alpha with BCNU, cisplatin, DTIC and tamoxifen in advanced malignant melanoma.
    Melanoma research, 1995, Volume: 5, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Female; Humans; Interferon Type I; Male; Melanoma; Middle Aged; Recombinant Proteins; Skin Neoplasms; Tamoxifen

1995
Dacarbazine and interferon-alpha 2a in advanced malignant melanoma: high response rate and prolongation of response duration occur in different patient subpopulations.
    Melanoma research, 1995, Volume: 5, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Female; Humans; Immunotherapy; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Neoplasm Staging; Prospective Studies; Recombinant Proteins

1995
Addition of dacarbazine or cisplatin to interferon-alpha/interleukin-2 in metastatic melanoma: toxicity and immunological effects.
    Melanoma research, 1995, Volume: 5, Issue:4

    Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cytokines; Dacarbazine; Humans; Immunotherapy; Interferon Type I; Interleukin-2; Melanoma; Pilot Projects; Recombinant Proteins

1995
Treatment of patients with metastatic melanoma with a one day regimen of dacarbazine, vincristine, bleomycin and lomustine plus interferon-alpha.
    European journal of cancer (Oxford, England : 1990), 1994, Volume: 30A, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Female; Humans; Interferon-alpha; Lomustine; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Skin Neoplasms; Treatment Outcome; Vincristine

1994
Dacarbazine (DTIC)-based chemotherapy or chemoimmunotherapy of patients with disseminated malignant melanoma.
    British journal of cancer, 1994, Volume: 70, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Dacarbazine; Dactinomycin; Female; Granulocyte Colony-Stimulating Factor; Humans; Immunotherapy; Interferon-alpha; Male; Melanoma; Middle Aged; Treatment Outcome; Vinblastine

1994
Intermittent interferon and polychemotherapy in metastatic melanoma.
    Journal of cancer research and clinical oncology, 1995, Volume: 121, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Drug Administration Schedule; Evaluation Studies as Topic; Female; Humans; Interferon-alpha; Lomustine; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Vincristine

1995
Results of a prospective randomized trial using DTIC and interferon as adjuvant therapy for stage I malignant melanoma.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 1995, Volume: 21, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Interferons; Male; Melanoma; Middle Aged; Neoplasm Staging; Prospective Studies; Skin Neoplasms; Treatment Outcome

1995
Interleukin-2-based immunotherapy and chemoimmunotherapy in metastatic melanoma.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1995, Volume: 139

    Topics: Cisplatin; Combined Modality Therapy; Dacarbazine; Humans; Immunologic Factors; Interferon-alpha; Interleukin-2; Melanoma; Neoplasm Metastasis; Pilot Projects; Remission Induction; Salvage Therapy; Skin Neoplasms; Treatment Outcome

1995
Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen.
    European journal of cancer (Oxford, England : 1990), 1995, Volume: 31A, Issue:6

    Topics: Administration, Cutaneous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Infusions, Intravenous; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Skin Neoplasms; Tamoxifen; Treatment Outcome

1995
Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Dacarbazine; Female; Humans; Leukopenia; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Remission Induction; Survival Rate; Temozolomide; Thrombocytopenia; United Kingdom

1995
Biochemotherapy with thymosin alpha 1, interleukin-2 and dacarbazine in patients with metastatic melanoma: clinical and immunological effects.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1994, Volume: 5, Issue:8

    Topics: Adult; Aged; CD4 Antigens; CD8 Antigens; Combined Modality Therapy; Dacarbazine; Female; Humans; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Remission Induction; Skin Neoplasms; Thymalfasin; Thymosin

1994
A multicenter phase II clinical trial using dacarbazine and continuous infusion interleukin-2 for metastatic melanoma. Clinical data and immunomonitoring.
    Cancer, 1995, Feb-15, Volume: 75, Issue:4

    Topics: Adult; Aged; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Interleukin-2; Male; Melanoma; Middle Aged; Prognosis; Regression Analysis; Remission Induction; Skin Neoplasms; Survival Analysis; Treatment Outcome

1995
A phase II study of the sequential administration of dacarbazine and fotemustine in the treatment of cerebral metastases from malignant melanoma.
    European journal of cancer (Oxford, England : 1990), 1994, Volume: 30A, Issue:14

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Drug Administration Schedule; Female; Humans; Leukopenia; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Thrombocytopenia; Treatment Outcome

1994
Mechanism of the anti-tumour effect of biochemotherapy in melanoma: preliminary results.
    Melanoma research, 1994, Volume: 4, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cross-Linking Reagents; Dacarbazine; DNA Damage; DNA, Neoplasm; Drug Synergism; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Interleukin-2; Killer Cells, Lymphokine-Activated; Killer Cells, Natural; Macrophage Activation; Melanoma; Models, Biological; Recombinant Proteins; Vinblastine

1994
[Prevention and treatment of regional lymphatic metastasis of cutaneous melanoma].
    Klinicheskaia khirurgiia, 1993, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Humans; Injections, Intralymphatic; Lymph Node Excision; Lymphatic Metastasis; Melanoma; Methotrexate; Neoplasm Staging; Preoperative Care; Prospidium; Skin Neoplasms; Survival Rate

1993
A phase II study of high-dose hydroxyurea and dacarbazine (DTIC) in the treatment of metastatic malignant melanoma.
    European journal of cancer (Oxford, England : 1990), 1994, Volume: 30A, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Dacarbazine; Female; Gastrointestinal Neoplasms; Humans; Hydroxyurea; Liver Neoplasms; Lung Neoplasms; Male; Melanoma; Middle Aged; Sarcoma, Clear Cell; Treatment Outcome

1994
Combination of chemotherapy with interleukin-2 and interferon-alfa for the treatment of advanced melanoma.
    Seminars in oncology, 1994, Volume: 21, Issue:6 Suppl 14

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Humans; Interferon-alpha; Interleukin-2; Melanoma; Vinblastine

1994
Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:8

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Interleukin-2; Male; Melanoma; Middle Aged; Remission Induction; Tamoxifen

1994
Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide.
    British journal of cancer, 1994, Volume: 69, Issue:3

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Dacarbazine; Female; Humans; Kinetics; Leukocytes, Mononuclear; Male; Melanoma; Methyltransferases; Middle Aged; Neoplasm Metastasis; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Time Factors

1994
Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Recombinant Proteins; Skin Neoplasms; Survival Analysis; Treatment Outcome

1994
A phase II study of combined administration of dacarbazine and carboplatin with home therapy of recombinant interleukin-2 and interferon-alpha 2a in patients with advanced malignant melanoma.
    Cancer immunology, immunotherapy : CII, 1994, Volume: 38, Issue:6

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dacarbazine; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Prospective Studies; Recombinant Proteins; Survival Rate

1994
Chemohormone therapy of metastatic melanoma with megestrol acetate plus dacarbazine, carmustine, and cisplatin.
    Cancer, 1994, Jan-01, Volume: 73, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Cachexia; Carmustine; Cisplatin; Dacarbazine; Drug Administration Schedule; Drug Tolerance; Female; Humans; Male; Megestrol; Megestrol Acetate; Melanoma; Middle Aged; Remission Induction; Survival Rate; Time Factors

1994
Adjuvant chemotherapy with dacarbazine, vindesine, and cisplatin in pathological stage II malignant melanoma.
    American journal of clinical oncology, 1994, Volume: 17, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cisplatin; Dacarbazine; Female; Humans; Life Tables; Male; Melanoma; Middle Aged; Neoplasm Staging; Survival Analysis; Vindesine

1994
Evaluation of cisplatin and DTIC in inoperable stage III and IV melanoma. A Southwest Oncology Group study.
    American journal of clinical oncology, 1993, Volume: 16, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Survival Analysis

1993
Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma.
    European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A, Issue:12

    Topics: Adult; Aged; Dacarbazine; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Predictive Value of Tests; Prognosis; Prospective Studies; Quality of Life; Recombinant Proteins

1993
Preclinical, phase I and pharmacokinetic studies with the dimethyl phenyltriazene CB10-277.
    British journal of cancer, 1993, Volume: 67, Issue:2

    Topics: Adult; Aged; Animals; Antineoplastic Agents; Dacarbazine; Disease Models, Animal; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Melanoma; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Neoplasms; Species Specificity; Transplantation, Heterologous; Triazenes

1993
Phase II study of vindesine and dacarbazine with or without non-specific stimulation of the immune system in patients with metastatic melanoma.
    European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A, Issue:5

    Topics: Adolescent; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Dacarbazine; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Prognosis; Vindesine

1993
A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma.
    Cancer, 1993, Jun-01, Volume: 71, Issue:11

    Topics: Adolescent; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Interleukin-2; Male; Melanoma; Middle Aged; Remission Induction

1993
Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma.
    British journal of cancer, 1993, Volume: 67, Issue:6

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Neutropenia; Nitrosourea Compounds; Organophosphorus Compounds; Respiratory Distress Syndrome; Thrombocytopenia

1993
Recombinant interferon alpha-2a in combination with dacarbazine in the treatment of metastatic malignant melanoma: analysis of long-term responding patients.
    Cancer immunology, immunotherapy : CII, 1993, Volume: 37, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chi-Square Distribution; Dacarbazine; Drug Synergism; Female; Humans; Injections, Intravenous; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Prospective Studies; Recombinant Proteins; Skin Neoplasms; Survival Analysis

1993
Therapy for metastatic melanoma: effective combination of dacarbazine, carmustine, cisplatin and tamoxifen.
    Melanoma research, 1993, Volume: 3, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Cisplatin; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Soft Tissue Neoplasms; Tamoxifen

1993
Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial.
    Melanoma research, 1993, Volume: 3, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Prospective Studies; Recombinant Proteins

1993
Phase II trial of piritrexim and DTIC using an alternating dose schedule in metastatic melanoma.
    American journal of clinical oncology, 1995, Volume: 18, Issue:6

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Liver Neoplasms; Lung Neoplasms; Male; Melanoma; Middle Aged; Pyrimidines; Remission Induction

1995
Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-up.
    Melanoma research, 1995, Volume: 5, Issue:5

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Follow-Up Studies; Humans; Male; Melanoma; Middle Aged; Sex Characteristics; Survival Rate; Tamoxifen

1995
Experience with interferon alpha 2b combined with dacarbazine in the treatment of metastatic malignant melanoma.
    Medical oncology (Northwood, London, England), 1995, Volume: 12, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Injections, Intravenous; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Prospective Studies; Recombinant Proteins; Remission Induction; Treatment Outcome

1995
Correlation of DNA ploidy and S-phase fraction with chemotherapeutic response and survival in a randomized study of disseminated malignant melanoma.
    International journal of cancer, 1996, Jan-03, Volume: 65, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; DNA, Neoplasm; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Ploidies; Regression Analysis; S Phase; Survival Analysis; Vindesine

1996
Fotemustine, dacarbazine, vindesine combination chemotherapy in advanced malignant melanoma: a phase II study of 43 patients.
    Melanoma research, 1995, Volume: 5, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Remission Induction; Risk; Salvage Therapy; Survival Rate; Treatment Outcome; Vindesine

1995
The addition of tamoxifen to dacarbazine and cisplatin in metastatic malignant melanoma. A phase II trial of the Southwest Oncology Group, (SWOG-8921).
    American journal of clinical oncology, 1996, Volume: 19, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Administration Schedule; Estrogen Antagonists; Female; Follow-Up Studies; Humans; Male; Melanoma; Middle Aged; Remission Induction; Sex Factors; Tamoxifen

1996
The use of DAV (DTIC, ACNU and VCR) and natural interferon-beta combination therapy in malignant melanoma.
    Acta dermato-venereologica, 1995, Volume: 75, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Hutchinson's Melanotic Freckle; Interferon-beta; Melanoma; Nimustine; Skin Neoplasms; Survival Rate; Vincristine

1995
Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Disease-Free Survival; Double-Blind Method; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Survival Rate; Tamoxifen

1996
[Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Medizinische Klinik (Munich, Germany : 1983), 1996, Apr-12, Volume: 91 Suppl 3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Recombinant Proteins; Skin Neoplasms; Tamoxifen

1996
[Chemohormonal therapy for malignant melanomas].
    Nihon Jibiinkoka Gakkai kaiho, 1996, Volume: 99, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dacarbazine; Estrogen Antagonists; Female; Head and Neck Neoplasms; Humans; Male; Melanoma; Middle Aged; Tamoxifen

1996
[Protocol for optimal therapy of malignant melanoma in the metastatic stage by the Dermatologic Oncology Working Group].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 1996, Volume: 47, Issue:1

    Topics: Combined Modality Therapy; Dacarbazine; Humans; Interferon-alpha; Interleukin-2; Melanoma; Neoplasm Staging; Prospective Studies; Recombinant Proteins; Skin Neoplasms

1996
DTIC vs. IFN-alpha plus DTIC in the treatment of patients with metastatic malignant melanoma.
    Neoplasma, 1996, Volume: 43, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Interferon-alpha; Male; Melanoma; Middle Aged; Skin Neoplasms

1996
Complete responses and survival after polychemotherapy plus interferon-alpha for patients with metastatic melanoma.
    Melanoma research, 1996, Volume: 6, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Dacarbazine; Female; Humans; Immunotherapy; Interferon alpha-2; Interferon-alpha; Lomustine; Male; Melanoma; Middle Aged; Nimustine; Recombinant Proteins; Treatment Outcome; Vincristine

1996
A phase II study of dacarbazine, cisplatin, interferon-alpha and high-dose interleukin-2 in 'poor-risk' metastatic melanoma.
    European journal of cancer (Oxford, England : 1990), 1996, Volume: 32A, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Combined Modality Therapy; Dacarbazine; Humans; Interferon-alpha; Interleukin-2; Melanoma; Middle Aged; Receptors, Interleukin-2; Remission Induction; Survival Analysis; Tumor Necrosis Factor-alpha

1996
Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1996, Volume: 7, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cisplatin; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Female; Humans; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Skin Neoplasms; Survival Rate; Treatment Outcome; Vinblastine

1996
Combination chemotherapy (dacarbazine, carmustine, cisplastin, and tamoxifen) in advanced melanoma.
    Singapore medical journal, 1996, Volume: 37, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Prognosis; Singapore; Skin Neoplasms; Survival Rate; Tamoxifen

1996
Dose comparison of tropisetron (Navoban) 5 mg and 10 mg orally in the prophylaxis of dacarbazine-induced nausea and emesis.
    Seminars in oncology, 1994, Volume: 21, Issue:5 Suppl 9

    Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Agents; Dacarbazine; Double-Blind Method; Drug Administration Schedule; Female; Humans; Indoles; Male; Melanoma; Middle Aged; Nausea; Quality of Life; Serotonin Antagonists; Tropisetron; Vomiting

1994
Outpatient chemoimmunotherapy for the treatment of metastatic melanoma.
    Seminars in oncology, 1997, Volume: 24, Issue:1 Suppl 4

    Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Skin Neoplasms; Tamoxifen; Treatment Outcome

1997
A phase II study of interferon-alpha 2b with dacarbazine, carmustine, cisplatin and tamoxifen in metastatic melanoma.
    Melanoma research, 1997, Volume: 7, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Confidence Intervals; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Humans; Interferon alpha-2; Interferon-alpha; Melanoma; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Tamoxifen

1997
Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study.
    British journal of cancer, 1997, Volume: 76, Issue:2

    Topics: Abdominal Neoplasms; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; Dacarbazine; Female; Humans; Immunotherapy; Interferon-alpha; Lomustine; Male; Melanoma; Middle Aged; Neoplasm Staging; Skin Neoplasms; Treatment Outcome; Vincristine

1997
BOLD+interferon in the treatment of metastatic uveal melanoma: first report of active systemic therapy.
    Journal of experimental & clinical cancer research : CR, 1997, Volume: 16, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Female; Humans; Interferon alpha-2; Interferon-alpha; Lomustine; Lung Diseases; Male; Melanoma; Middle Aged; Recombinant Proteins; Uveal Neoplasms; Vincristine

1997
Fotemustine and dacarbazine plus recombinant interferon alpha 2a in thetreatment of advanced melanoma.
    European journal of cancer (Oxford, England : 1990), 1997, Volume: 33, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Recombinant Proteins; Survival Rate

1997
Isolated limb perfusion with fotemustine after chemosensitization with dacarbazine in melanoma.
    Melanoma research, 1997, Volume: 7, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arm; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Female; Humans; Leg; Male; Melanoma; Middle Aged; Neoplasm Staging; Nitrosourea Compounds; Organophosphorus Compounds; Pilot Projects; Skin Neoplasms

1997
Development and results of biochemotherapy in metastatic melanoma: the University of Texas M.D. Anderson Cancer Center experience.
    The cancer journal from Scientific American, 1997, Volume: 3 Suppl 1

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dacarbazine; Drug Therapy, Combination; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Melanoma; Middle Aged; Recombinant Proteins; Survival Rate; Treatment Outcome; Vinblastine

1997
Recombinant interleukin-2-based treatments for advanced melanoma: the experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.
    The cancer journal from Scientific American, 1997, Volume: 3 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Dacarbazine; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Melanoma; Recombinant Proteins; Survival Rate

1997
Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma.
    The cancer journal from Scientific American, 1997, Volume: 3 Suppl 1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Female; Humans; Immunotherapy; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Interleukin-2; L-Lactate Dehydrogenase; Male; Melanoma; Middle Aged; Prognosis; Recombinant Proteins; Survival Rate; Tamoxifen; Treatment Outcome

1997
Topical dinitrochlorobenzene combined with systemic dacarbazine in the treatment of recurrent melanoma.
    Melanoma research, 1997, Volume: 7, Issue:6

    Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Dinitrochlorobenzene; Female; Humans; Immunotherapy; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Skin Neoplasms

1997
Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Tamoxifen

1998
[Treatment of lung metastases from malignant melanoma with IL-2 inhalation therapy].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 1997, Volume: 48, Issue:12

    Topics: Administration, Inhalation; Adult; Aged; Combined Modality Therapy; Dacarbazine; Female; Humans; Interleukin-12; Lung Neoplasms; Male; Melanoma; Middle Aged; Skin Neoplasms

1997
Interferon-alpha and chemohormonal therapy for patients with advanced melanoma: final results of a phase I-II study of the Cancer Biotherapy Research Group and the Mid-Atlantic Oncology Program.
    Cancer, 1998, May-01, Volume: 82, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Female; Humans; Interferon alpha-2; Interferon-alpha; Liver Neoplasms; Lung Neoplasms; Male; Melanoma; Middle Aged; Recombinant Proteins; Tamoxifen

1998
Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.
    British journal of cancer, 1998, Volume: 77, Issue:8

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Disease-Free Survival; Female; Flow Cytometry; Humans; Interferon-alpha; Interleukin-2; Killer Cells, Natural; Lymphocyte Activation; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; T-Lymphocytes; Tamoxifen; Treatment Outcome

1998
Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group st
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Recombinant Proteins; Survival Rate; Tamoxifen; Treatment Failure

1998
DNA damage in peripheral blood mononuclear cells correlates with response to biochemotherapy in melanoma.
    Melanoma research, 1998, Volume: 8, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dacarbazine; Disease Progression; DNA Damage; Glutathione Transferase; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Leukocytes, Mononuclear; Melanoma; Neoplasm Staging; Polymerase Chain Reaction; Recombinant Proteins; Skin Neoplasms; Vinblastine

1998
Nitric oxide and neopterin levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapy.
    Melanoma research, 1998, Volume: 8, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dacarbazine; Female; Humans; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Staging; Neopterin; Nitric Oxide; Skin Neoplasms; Vinblastine

1998
Combined treatment with dacarbazine, cisplatin, fotemustine and tamoxifen in metastatic malignant melanoma.
    Melanoma research, 1998, Volume: 8, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine; Humans; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Survival Rate; Tamoxifen

1998
Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration.
    Cancer chemotherapy and pharmacology, 1998, Volume: 42, Issue:6

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Dacarbazine; Female; Glioma; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Temozolomide

1998
Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a.
    British journal of cancer, 1998, Volume: 78, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Prognosis; Risk; Survival Analysis; Tamoxifen; Treatment Outcome

1998
Changes in immunological parameters after combination adjuvant therapy with intravenous DTIC, ACNU, and VCR, and local injection of IFN-beta (DAV + IFN-beta therapy) into malignant melanoma.
    The Journal of dermatology, 1998, Volume: 25, Issue:9

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; CD4-CD8 Ratio; Chemotherapy, Adjuvant; Dacarbazine; Female; Flow Cytometry; Humans; Injections, Intralesional; Injections, Intravenous; Interferon-beta; Killer Cells, Natural; Leukocyte Count; Male; Melanoma; Middle Aged; Nimustine; Skin Neoplasms; Statistics, Nonparametric; T-Lymphocytes; Treatment Outcome; Vincristine

1998
Carmustine and streptozocin in refractory melanoma: an attempt at modulation of O-alkylguanine-DNA-alkyltransferase.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1996, Volume: 2, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Dacarbazine; Female; Glutathione; Humans; Male; Melanoma; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Streptozocin

1996
O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma.
    British journal of cancer, 1998, Volume: 78, Issue:9

    Topics: Adult; Antineoplastic Agents, Alkylating; Biopsy; Dacarbazine; Female; Humans; Leukocytes, Mononuclear; Lymphatic Metastasis; Male; Melanoma; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Predictive Value of Tests; Prospective Studies; Temozolomide

1998
Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A randomised phase III trial.
    European journal of cancer (Oxford, England : 1990), 1998, Volume: 34, Issue:9

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Melanoma; Middle Aged; Nausea; Prospective Studies; Regression Analysis; Skin Neoplasms; Survival Analysis; Treatment Outcome; Vindesine; Vomiting

1998
Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases.
    Melanoma research, 1998, Volume: 8, Issue:6

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Melanoma, Amelanotic; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Recombinant Proteins; Skin Neoplasms; Time Factors; Treatment Outcome; Vinblastine

1998
Long-term outcome of treatment with dacarbazine, cisplatin, interferon-alpha and intravenous high dose interleukin-2 in poor risk melanoma patients.
    Melanoma research, 1998, Volume: 8, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine; Humans; Interferon-alpha; Interleukin-2; L-Lactate Dehydrogenase; Melanoma; Middle Aged; Neoplasm Metastasis; Prognosis; Risk; Skin Neoplasms; Survival Rate; Time Factors; Treatment Outcome

1998
Induction of tyrosinase-reactive T cells by treatment with dacarbazine, cisplatin, interferon-alpha +/- interleukin-2 in patients with metastatic melanoma.
    International journal of cancer, 1999, Jan-05, Volume: 80, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dacarbazine; Epitopes; HLA-A Antigens; HLA-B Antigens; HLA-B44 Antigen; Humans; Interferon-alpha; Interferon-gamma; Interleukin-2; Melanoma; Monophenol Monooxygenase; Neoplasm Staging; Peptide Fragments; T-Lymphocytes

1999
Sustained complete remission after chemobiohormonal therapy for metastatic melanoma.
    American journal of clinical oncology, 1999, Volume: 22, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Interferon-alpha; Lung Neoplasms; Male; Melanoma; Middle Aged; Prospective Studies; Remission Induction; Skin Neoplasms; Tamoxifen

1999
Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dacarbazine; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Prospective Studies; Recombinant Proteins; Remission Induction; Tamoxifen

1999
Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Female; Humans; Immunotherapy, Active; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Pilot Projects; Recombinant Proteins; Treatment Outcome

1999
A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma.
    Cancer, 1999, May-01, Volume: 85, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dacarbazine; Disease Progression; Female; Humans; Male; Melanoma; Middle Aged; Survival Rate; Tamoxifen; Treatment Outcome

1999
Phase II trial of biochemotherapy with interferon alpha, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a Southwest Oncology Group trial.
    Journal of cancer research and clinical oncology, 1999, Volume: 125, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Administration Schedule; Female; Humans; Interferon-alpha; Male; Melanoma; Middle Aged; Southwestern United States; Tamoxifen; Treatment Outcome

1999
Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Glioma; Humans; Lymphocytes; Male; Melanoma; Middle Aged; Nitrosourea Compounds; O(6)-Methylguanine-DNA Methyltransferase; Organophosphorus Compounds; Temozolomide

1999
Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Disease-Free Survival; Eye Neoplasms; Female; Humans; Male; Melanoma; Middle Aged; Prospective Studies; Skin Neoplasms; Survival Rate; Tamoxifen; Treatment Outcome

1999
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Skin Neoplasms; Survival Analysis; Tamoxifen; Treatment Outcome

1999
Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies.
    British journal of cancer, 1999, Volume: 81, Issue:6

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Biological Availability; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Eating; Female; Glioma; Humans; Male; Melanoma; Middle Aged; Neoplasms; Skin Neoplasms; Temozolomide; Treatment Outcome

1999
Pilot study of intra-arterial cisplatin and intravenous vinblastine and dacarbazine in patients with melanoma in-transit metastases.
    Melanoma research, 1999, Volume: 9, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease-Free Survival; Female; Humans; Infusions, Intra-Arterial; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm, Residual; Pilot Projects; Skin Neoplasms; Survival Rate; Treatment Outcome; Vinblastine

1999
Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma).
    Melanoma research, 1999, Volume: 9, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease-Free Survival; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Recombinant Proteins; Survival Rate; Tamoxifen; Treatment Outcome; Vindesine

1999
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biological Availability; Consumer Product Safety; Dacarbazine; Disease-Free Survival; Female; Humans; Male; Melanoma; Neoplasm Metastasis; Quality of Life; Regression Analysis; Survival Rate

2000
GM-CSF can cause T cell activation; results of sequential chemo-immunotherapy.
    European journal of cancer (Oxford, England : 1990), 1999, Volume: 35 Suppl 3

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunophenotyping; Lymphocyte Activation; Male; Melanoma; Middle Aged; T-Lymphocyte Subsets

1999
Results of a phase II trial with cystemustine at 90 mg/m(2) as a first- or second-line treatment in advanced malignant melanoma: a trial of the EORTC Clinical Studies Group.
    Melanoma research, 1999, Volume: 9, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Dacarbazine; Female; Humans; Immunotherapy; Male; Melanoma; Middle Aged; Neoplasm Staging; Nitrosourea Compounds; Treatment Outcome

1999
Rationale for intergroup trial E-3695 comparing concurrent biochemotherapy with cisplatin, vinblastine, and DTIC alone in patients with metastatic melanoma.
    The cancer journal from Scientific American, 2000, Volume: 6 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Humans; Interferon-alpha; Interleukin-2; Melanoma; Vinblastine

2000
A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma.
    British journal of cancer, 2000, Volume: 82, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Humans; Interferon-alpha; Male; Melanoma; Middle Aged; Skin Neoplasms; Survival Analysis; Tamoxifen; Treatment Outcome

2000
Post hoc economic analysis of temozolomide versus dacarbazine in the treatment of advanced metastatic melanoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:7

    Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Cost-Benefit Analysis; Dacarbazine; Female; Health Care Costs; Humans; Infusions, Intravenous; Male; Melanoma; Quality-Adjusted Life Years; Skin Neoplasms; Temozolomide

2000
A phase II study of biochemotherapy for the treatment of metastatic malignant melanoma.
    Melanoma research, 2000, Volume: 10, Issue:2

    Topics: Abdominal Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Colorado; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Humans; Hypotension; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Interleukin-2; Life Tables; Liver Neoplasms; Lung Neoplasms; Male; Melanoma; Middle Aged; Neutropenia; Recombinant Proteins; Remission Induction; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome; Vinblastine

2000
Combined treatment with thymosin-alpha1 and low dose interferon-alpha after dacarbazine in advanced melanoma.
    Melanoma research, 2000, Volume: 10, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Female; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Killer Cells, Natural; Lymphopenia; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Safety; Survival Analysis; Thymalfasin; Thymosin; Treatment Outcome

2000
Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine.
    British journal of cancer, 2000, Volume: 82, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Survival Analysis; Tamoxifen

2000
A sequential four-drug chemotherapy and biotherapy with interferon alpha and GM-CSF--an innovative protocol for the treatment of metastatic melanoma.
    Cancer biotherapy & radiopharmaceuticals, 1998, Volume: 13, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cells, Cultured; Cisplatin; Dacarbazine; Dendritic Cells; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interferon alpha-2; Interferon-alpha; Macrophages; Male; Melanoma; Middle Aged; Recombinant Proteins; Survival Analysis; Time Factors

1998
A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cisplatin; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Pilot Projects; Recombinant Proteins; Recurrence; Time Factors; Treatment Outcome; Vinblastine

2000
Combined chemotherapy with or without interferon alpha N1 (IFN) for advanced malignant melanoma--a randomized pilot phase III study.
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27 Suppl 2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Administration Schedule; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Pilot Projects; Recombinant Proteins; Skin Neoplasms

2000
Unexpected cytokines in serum of malignant melanoma patients during sequential biochemotherapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytokines; Dacarbazine; Enzyme-Linked Immunosorbent Assay; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-10; Interleukin-2; Interleukin-6; Interleukins; Macrophage Activation; Macrophages; Melanoma; Neopterin; Nitrites; Radioimmunoassay; Random Allocation; Receptors, Interleukin-2; Recombinant Proteins; Time Factors; Tumor Necrosis Factor-alpha; Vincristine

2000
O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study.
    International journal of cancer, 2000, Nov-01, Volume: 88, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Administration Schedule; Female; Guanine; Humans; Male; Melanoma; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide

2000
GM-CSF with biochemotherapy (cisplatin, DTIC, tamoxifen, IL-2 and interferon-alpha): a phase I trial in melanoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:9

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Dacarbazine; Dose-Response Relationship, Drug; Drug Evaluation; Feasibility Studies; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Skin Neoplasms; Survival Analysis; Tamoxifen; Treatment Outcome

2000
Chemosensitisation of malignant melanoma by BCL2 antisense therapy.
    Lancet (London, England), 2000, Nov-18, Volume: 356, Issue:9243

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; DNA, Antisense; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fever; Follow-Up Studies; Hematologic Diseases; Humans; Male; Melanoma; Middle Aged; Proto-Oncogene Mas; Proto-Oncogene Proteins c-bcl-2; Skin; Skin Neoplasms; Survival Analysis; Treatment Outcome

2000
Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
    Cancer, 2000, Dec-15, Volume: 89, Issue:12

    Topics: Adult; Aged; Anemia; Antigens, CD; Antigens, Neoplasm; Antigens, Surface; Antineoplastic Combined Chemotherapy Protocols; CD146 Antigen; Cisplatin; Dacarbazine; Female; Fever; Follow-Up Studies; Humans; Interferon-alpha; Male; MART-1 Antigen; Melanoma; Melanoma-Specific Antigens; Membrane Glycoproteins; Middle Aged; Monophenol Monooxygenase; Nausea; Neoplasm Proteins; Neural Cell Adhesion Molecules; Neutropenia; Nitrosourea Compounds; Organophosphorus Compounds; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vomiting

2000
Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11.
    Cancer biotherapy & radiopharmaceuticals, 2000, Volume: 15, Issue:5

    Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Recombinant Proteins; Skin Neoplasms; Survival Rate; Tamoxifen

2000
Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials.
    Melanoma research, 2001, Volume: 11, Issue:1

    Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Databases, Factual; Humans; Immunotherapy; Interferons; Melanoma; Odds Ratio; Skin Neoplasms; Time Factors

2001
Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
    British journal of cancer, 2001, Apr-20, Volume: 84, Issue:8

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chills; Dacarbazine; Female; Fever; Follow-Up Studies; Hematologic Diseases; Humans; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Nausea; Remission Induction; Survival Analysis; Treatment Outcome; Vomiting

2001
Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Jul-01, Volume: 19, Issue:13

    Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease-Free Survival; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Recombinant Proteins; Survival Rate

2001
Granulocyte-macrophage colony-stimulating factor alone or with dacarbazine in metastatic melanoma: a randomized phase II trial.
    British journal of cancer, 2001, Nov-16, Volume: 85, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Male; Melanoma; Middle Aged; Survival Analysis; Treatment Outcome

2001
Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jan-15, Volume: 20, Issue:2

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Docetaxel; Female; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Neutropenia; Paclitaxel; Skin Neoplasms; Taxoids; Temozolomide; Thrombocytopenia

2002
High expression levels of collagenase-1 and stromelysin-1 correlate with shorter disease-free survival in human metastatic melanoma.
    International journal of cancer, 2002, Feb-01, Volume: 97, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cell Division; Collagenases; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Enzyme Induction; Female; Humans; Immunologic Factors; Immunotherapy; Interferon-alpha; Interleukin-2; Lomustine; Male; Matrix Metalloproteinase 3; Melanins; Melanocytes; Melanoma; Middle Aged; Neoplasm Proteins; Neoplastic Stem Cells; Prognosis; Radiotherapy, Adjuvant; Vincristine

2002
Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2001, Volume: 13, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Interferon-alpha; Male; Melanoma; Middle Aged; Pilot Projects; Prospective Studies; Quality of Life; Skin Neoplasms; Survival Rate

2001
Comparison of the efficacy of two different dosage dacarbazine-based regimens and two regimens without dacarbazine in metastatic melanoma: a single-centre randomized four-arm study.
    Melanoma research, 2002, Volume: 12, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Male; Melanoma; Middle Aged; Procarbazine; Skin Neoplasms; Time Factors; Treatment Outcome; Vincristine

2002
Deliberate hypoxic pelvic and limb chemoperfusion in the treatment of recurrent melanoma.
    American journal of surgery, 2002, Volume: 183, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Dacarbazine; Disease Progression; Disease-Free Survival; Epirubicin; Female; Hemodynamics; Humans; Hypoxia; Leg; Male; Melanoma; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Palliative Care; Pelvis; Skin Neoplasms; Treatment Outcome

2002
Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM).
    British journal of cancer, 2002, Jan-21, Volume: 86, Issue:2

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Prospective Studies; Skin Neoplasms; Tamoxifen; Treatment Outcome

2002
Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Mar-15, Volume: 20, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Italy; Male; Melanoma; Middle Aged; Outpatients; Proportional Hazards Models; Prospective Studies; Quality of Life; Recombinant Proteins; Skin Neoplasms; Surveys and Questionnaires; Treatment Outcome

2002
A phase II study of neoadjuvant biochemotherapy for stage III melanoma.
    Cancer, 2002, Jan-15, Volume: 94, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease Progression; Female; Granulocyte Colony-Stimulating Factor; Humans; Interferon-alpha; Interleukin-2; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pilot Projects; Skin Neoplasms; Survival Rate; Treatment Outcome; Vinblastine

2002
Vinblastin-carboplatin for metastatic cutaneous melanoma as first-line chemotherapy and in dacarbazine failures: a single-center study.
    Medical oncology (Northwood, London, England), 2001, Volume: 18, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dacarbazine; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Male; Melanoma; Middle Aged; Neutropenia; Salvage Therapy; Skin Neoplasms; Thrombocytopenia; Treatment Outcome; Vinblastine

2001
Effect of temozolomide on central nervous system relapse in patients with advanced melanoma.
    Melanoma research, 2002, Volume: 12, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Studies; Dacarbazine; Female; Humans; Lung Neoplasms; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Retrospective Studies; Soft Tissue Neoplasms; Survival Rate; Temozolomide; Treatment Outcome

2002
Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group.
    Journal of cancer research and clinical oncology, 2002, Volume: 128, Issue:4

    Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Dose Fractionation, Radiation; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Temozolomide; Treatment Outcome

2002
[Use of local magnitothermia in the treatment of patients with primary-confined skin melanoma].
    Likars'ka sprava, 2002, Issue:1

    Topics: Adjuvants, Immunologic; Adolescent; Adult; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Electromagnetic Fields; Female; Hot Temperature; Humans; Injections; Interferon Type I; Interferon-alpha; Lymphatic System; Male; Melanoma; Middle Aged; Recombinant Proteins; Skin Neoplasms; Survival Rate

2002
Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Apr-15, Volume: 20, Issue:8

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Recombinant Proteins; Survival Analysis; Vinblastine

2002
Phase II trial of Paclitaxel and Dacarbazine with filgrastim administration in advanced malignant melanoma.
    Cancer investigation, 2002, Volume: 20, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Nervous System Diseases; Paclitaxel; Skin Neoplasms; Treatment Outcome

2002
Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jun-01, Volume: 20, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Male; Melanoma; Middle Aged; Survival Rate; Temozolomide; Thalidomide

2002
[Treatment of metastatic malignant melanoma (author's transl)].
    Wiener klinische Wochenschrift, 1978, Dec-22, Volume: 90, Issue:24

    Topics: Adult; Aged; Bleomycin; Dacarbazine; Doxorubicin; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Triazenes; Vincristine

1978
Use of combination chemotherapy with CCNU, bleomycin, and vincristine in the treatment of metastatic melanoma in patients resistant to DTIC therapy.
    Cancer treatment reports, 1979, Volume: 63, Issue:1

    Topics: Adult; Aged; Bleomycin; Clinical Trials as Topic; Dacarbazine; Drug Resistance; Drug Therapy, Combination; Female; Humans; Lomustine; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Vincristine

1979
Chemoimmunotherapy in disseminated melanoma and colorectal carcinoma.
    The Australian and New Zealand journal of surgery, 1978, Volume: 48, Issue:3

    Topics: Bacterial Vaccines; Colonic Neoplasms; Corynebacterium; Dacarbazine; Female; Fluorouracil; Humans; Immunotherapy; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Rectal Neoplasms; Triazenes

1978
Combination chemotherapy for disseminated malignant melanoma with DTIC, vincristine, and methyl-CCNU.
    Cancer treatment reports, 1977, Volume: 61, Issue:5

    Topics: Adult; Aged; Clinical Trials as Topic; Dacarbazine; Drug Therapy, Combination; Female; Humans; Leukocyte Count; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Semustine; Triazenes; Vincristine

1977
Results with methyl-CCNU and DTIC in metastatic melanoma.
    Cancer, 1977, Volume: 40, Issue:3

    Topics: Brain Neoplasms; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Dacarbazine; Drug Therapy, Combination; Female; Humans; Liver Neoplasms; Male; Melanoma; Neoplasm Metastasis; Nitrosourea Compounds; Prognosis; Remission, Spontaneous; Semustine; Thrombocytopenia; Time Factors; Triazenes

1977
Combination chemotherapy in metastatic malignant melanoma: a randomized study of three DTIC-containing combination.
    Cancer, 1978, Volume: 41, Issue:2

    Topics: Adult; Antineoplastic Agents; Clinical Trials as Topic; Cyclophosphamide; Dacarbazine; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Procarbazine; Remission, Spontaneous; Time Factors; Triazenes; Vinblastine

1978
Malignant melanoma (stage IIIB): a pilot study of adjuvant chemo-immunotherapy.
    Cancer treatment reports, 1978, Volume: 62, Issue:4

    Topics: Adult; Aged; Antigens, Neoplasm; BCG Vaccine; Carmustine; Clinical Trials as Topic; Dacarbazine; Female; Humans; Hydroxyurea; Male; Melanoma; Middle Aged; Pilot Projects

1978
Chemoimmunotherapy for disseminated malignant melanoma: a prospective randomized study.
    Cancer treatment reports, 1978, Volume: 62, Issue:7

    Topics: BCG Vaccine; Clinical Trials as Topic; Dacarbazine; Dactinomycin; Evaluation Studies as Topic; Humans; Immunotherapy; Melanoma; Mycobacterium bovis; Neoplasm Metastasis; Prospective Studies; Triazenes

1978
Phase I--II study of intermittent bolus administration of DTIC and actinomycin D in metastatic malignant melanoma.
    Cancer treatment reports, 1978, Volume: 62, Issue:8

    Topics: Adult; Aged; Clinical Trials as Topic; Dacarbazine; Dactinomycin; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Injections, Intravenous; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Triazenes

1978
[Chemotherapy of malignant melanoma. Results of a controlled clinical trial comparing vincristine + dacarbazin (DTIC) with and without duborimycin (author's transl)].
    Bulletin du cancer, 1978, Volume: 65, Issue:2

    Topics: Antibiotics, Antineoplastic; Clinical Trials as Topic; Dacarbazine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Triazenes; Vincristine

1978
[Treatment of malignant melanoma with DTIC--therapeutic effects determined by 5-S-cysteinyldopa changes in the urine (proceedings)].
    Lakartidningen, 1978, Dec-06, Volume: 75, Issue:49

    Topics: Clinical Trials as Topic; Cysteinyldopa; Dacarbazine; Dihydroxyphenylalanine; Drug Evaluation; Humans; Melanoma; Skin Neoplasms; Triazenes

1978
Combined DTIC and cis-dichlorodiammineplatinum(II) therapy for patients with disseminated melanoma: a Northern California Oncology Group study.
    Cancer treatment reports, 1979, Volume: 63, Issue:3

    Topics: Adolescent; Adult; Aged; Child; Cisplatin; Clinical Trials as Topic; Dacarbazine; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Triazenes

1979
Cyclophosphamide plus 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC) with or without Corynebacterium parvum in metastatic malignant melanoma.
    Cancer, 1979, Volume: 44, Issue:3

    Topics: Bone Marrow; Clinical Trials as Topic; Cyclophosphamide; Dacarbazine; Drug Therapy, Combination; Humans; Immunotherapy; Melanoma; Middle Aged; Propionibacterium acnes

1979
Randomized trial of adjuvant therapy for "high risk" primary malignant melanoma.
    Surgery, 1978, Volume: 83, Issue:6

    Topics: Adult; Aged; BCG Vaccine; Dacarbazine; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Risk; Skin Neoplasms; Triazenes

1978
[Chemotherapy of disseminated malignant melanoma].
    La Nouvelle presse medicale, 1978, Sep-16, Volume: 7, Issue:30

    Topics: Dacarbazine; Daunorubicin; Drug Therapy, Combination; Humans; Melanoma; Remission, Spontaneous; Triazenes; Vincristine

1978
Results of a randomized study comparing DTIC with TIC mustard in malignant melanoma.
    Cancer, 1976, Volume: 37, Issue:4

    Topics: Clinical Trials as Topic; Dacarbazine; Drug Evaluation; Female; Humans; Imidazoles; Male; Melanoma; Nitrogen Mustard Compounds; Prospective Studies; Triazenes

1976
DTIC (NSC-45388) in malignant melanoma: a perspective.
    Cancer treatment reports, 1976, Volume: 60, Issue:2

    Topics: Animals; Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Humans; Lomustine; Melanoma; Mice; Neoplasm Metastasis; Nitrosourea Compounds; Remission, Spontaneous; Triazenes

1976
Phase I evaluation of DTIC (NSC-45388) and other studies in malignant melanoma in the Central Oncology Group.
    Cancer treatment reports, 1976, Volume: 60, Issue:2

    Topics: Carmustine; Clinical Trials as Topic; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Leukopenia; Lomustine; Male; Melanoma; Middle Aged; Nausea; Sex Factors; Thrombocytopenia; Triazenes; Vincristine; Vomiting

1976
DTIC (NSC-45388) studies in the southwest oncology group.
    Cancer treatment reports, 1976, Volume: 60, Issue:2

    Topics: Carmustine; Chlorpromazine; Clinical Trials as Topic; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Hodgkin Disease; Humans; Leukopenia; Lymphoma; Melanoma; Nausea; Neoplasm Metastasis; Remission, Spontaneous; Thrombocytopenia; Triazenes; Vincristine; Vomiting

1976
Eastern Cooperative Oncology Group studies with DTIC (NSC-45388).
    Cancer treatment reports, 1976, Volume: 60, Issue:2

    Topics: Adult; Aged; Carmustine; Clinical Trials as Topic; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Lomustine; Male; Melanoma; Middle Aged; Sex Factors; Skin Neoplasms; Triazenes

1976
Combination chemotherapy with DTIC (NSC-45388) in advanced malignant melanoma, soft tissue sarcomas, and Hodgkin's disease.
    Cancer treatment reports, 1976, Volume: 60, Issue:2

    Topics: Antineoplastic Agents; Clinical Trials as Topic; Dacarbazine; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; Female; Hodgkin Disease; Humans; Male; Melanoma; Sarcoma; Skin Neoplasms; Soft Tissue Neoplasms; Triazenes

1976
Clinical comparison of adriamycin and a combination of methyl-CCNU and imidazole carboxamide in disseminated malignant melanoma.
    Clinical pharmacology and therapeutics, 1976, Volume: 19, Issue:6

    Topics: Adult; Aged; Clinical Trials as Topic; Dacarbazine; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Melanins; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Semustine; Triazenes

1976
Cyclophosphamide, vincristine and procarbazine in the treatment of malignant melanoma.
    Cancer, 1976, Volume: 38, Issue:5

    Topics: Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Dacarbazine; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Middle Aged; Procarbazine; Prospective Studies; Semustine; Vincristine

1976
Randomized prospective trial of DTIC (NSC-45388) alone versus BCNU (NSC-409962) plus vincristine (NSC-67574) in the treatment of metastatic malignant melanoma.
    Cancer treatment reports, 1976, Volume: 60, Issue:5

    Topics: Carmustine; Clinical Trials as Topic; Dacarbazine; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Neoplasm Metastasis; Pennsylvania; Prospective Studies; Triazenes; Vincristine

1976
Clinical trial of combination chemotherapy and specific active immunotherapy in disseminated melanoma.
    British journal of cancer, 1976, Volume: 34, Issue:2

    Topics: Antigens, Neoplasm; BCG Vaccine; Dacarbazine; Drug Therapy, Combination; Female; Humans; Immunotherapy; Male; Melanoma; Piperazines; Prognosis; Razoxane; Triazenes

1976
DTIC (nsc-45388) and combination therapy for melanoma. I. Studies with DTIC, BCNU (NSC-409962), CCNU (NSC-79037), vincristine (NSC-67574), and hydroxyurea (NSC-32065).
    Cancer treatment reports, 1976, Volume: 60, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carmustine; Dacarbazine; Drug Therapy, Combination; Humans; Hydroxyurea; Lomustine; Melanoma; Middle Aged; Triazenes; United States; Vincristine

1976
Comparative evaluation of three combination regimens for advanced malignant melanoma: results of an international cooperative study.
    Cancer treatment reports, 1976, Volume: 60, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carmustine; Central Nervous System Diseases; Dacarbazine; Dactinomycin; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Remission, Spontaneous; Vincristine

1976
Combination chemotherapy in disseminated melanoma and other solid tumors in adults.
    Oncology, 1975, Volume: 31, Issue:1

    Topics: Clinical Trials as Topic; Dacarbazine; Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; Humans; Lomustine; Melanoma; Neoplasms; Nitrosourea Compounds; Triazenes

1975
Fotemustine--an advance in the treatment of metastatic malignant melanoma.
    Melanoma research, 1992, Volume: 2, Issue:5-6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms

1992
Phase II study of interferon alfa-2a and dacarbazine in advanced melanoma. Biological Response Modifiers in Melanoma (BREMIM) Italian Cooperative Group.
    European journal of cancer (Oxford, England : 1990), 1992, Volume: 28A, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Evaluation; Female; Follow-Up Studies; Humans; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Recombinant Proteins; Time Factors

1992
Our experience with interferon alpha: metastatic malignant melanoma.
    Molecular biotherapy, 1992, Volume: 4, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Female; Humans; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged

1992
Chemo-immunotherapy in patients with metastatic melanoma using sequential treatment with dacarbazine and recombinant human interleukin-2: evaluation of hematologic and immunologic parameters and correlation with clinical response.
    Immunology letters, 1992, Volume: 33, Issue:2

    Topics: Adolescent; Adult; Cytokines; Dacarbazine; Drug Administration Schedule; Female; Humans; Immunophenotyping; Immunotherapy; Infusions, Intravenous; Interleukin-2; Killer Cells, Lymphokine-Activated; Killer Cells, Natural; Leukocyte Count; Leukocytes; Lymphocyte Subsets; Male; Melanoma; Middle Aged; Recombinant Proteins

1992
Fotemustine: an overview of its clinical activity in disseminated malignant melanoma.
    Melanoma research, 1992, Volume: 2, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Lung Neoplasms; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Recombinant Proteins; Remission Induction; Vindesine

1992
In vivo depletion of O6-alkylguanine-DNA-alkyltransferase in lymphocytes and melanoma of patients treated with CB 10-277, a new DTIC analogue.
    Cancer chemotherapy and pharmacology, 1992, Volume: 31, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Female; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Lymphocytes; Male; Melanoma; Methyltransferases; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Skin Neoplasms; Triazenes

1992
Fotemustine and DTIC combination in patients with disseminated malignant melanoma.
    American journal of clinical oncology, 1992, Volume: 15, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Prospective Studies; Remission Induction

1992
Antiemetic activity of two different high doses and schedules of metoclopramide in dacarbazine-treated cancer patients.
    American journal of clinical oncology, 1992, Volume: 15, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dexamethasone; Diphenhydramine; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Melanoma; Methylprednisolone; Metoclopramide; Middle Aged; Nausea; Sarcoma; Vomiting

1992
A phase II study of metastatic melanoma treated with a combination of interferon alfa 2b, dacarbazine and nimustine.
    European journal of cancer (Oxford, England : 1990), 1992, Volume: 28, Issue:2-3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Drug Evaluation; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Nimustine; Recombinant Proteins

1992
A phase II study of sequential recombinant interleukin-2 followed by dacarbazine in metastatic melanoma.
    European journal of cancer (Oxford, England : 1990), 1992, Volume: 28, Issue:2-3

    Topics: Adult; Combined Modality Therapy; Dacarbazine; Drug Evaluation; Female; Humans; Interleukin-2; Male; Melanoma; Middle Aged; Recombinant Proteins

1992
Chemotherapy for advanced malignant melanoma.
    International journal of clinical & laboratory research, 1992, Volume: 21, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Drug Evaluation; Humans; Immunologic Factors; Incidence; Interferon-alpha; Melanoma; Pilot Projects; Skin Neoplasms; Tamoxifen; Transplantation, Autologous

1992
Dacarbazine and outpatient interleukin-2 in treatment of metastatic malignant melanoma: phase II Southwest Oncology Group trial.
    Journal of the National Cancer Institute, 1992, Jun-03, Volume: 84, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Evaluation; Female; Humans; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Staging; Outpatients; Sex Characteristics

1992
Sequential chemoimmunotherapy in the treatment of metastatic melanoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992, Volume: 10, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Drug Evaluation; Female; Humans; Immunotherapy; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Recombinant Proteins; Survival Analysis; Treatment Outcome

1992
Intrathecal dacarbazine treatment of leptomeningeal malignant melanoma.
    Journal of the National Cancer Institute, 1992, Aug-05, Volume: 84, Issue:15

    Topics: Adult; Arachnoid; Dacarbazine; Female; Humans; Injections, Spinal; Male; Melanoma; Meningeal Neoplasms; Middle Aged; Pia Mater

1992
Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen.
    The New England journal of medicine, 1992, Aug-20, Volume: 327, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Dacarbazine; Female; Humans; Male; Melanoma; Menopause; Middle Aged; Neoplasm Metastasis; Prospective Studies; Sex Factors; Survival Rate; Tamoxifen

1992
Disseminated melanoma--is there a new standard therapy?
    The New England journal of medicine, 1992, Aug-20, Volume: 327, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Melanoma; Neoplasm Metastasis; Tamoxifen

1992
High-dose cisplatin with dacarbazine and tamoxifen in the treatment of metastatic melanoma.
    Cancer, 1992, Aug-15, Volume: 70, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Male; Melanoma; Tamoxifen

1992
[Results of a randomized polychemotherapy study in malignant melanoma].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 1990, Volume: 41, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Dacarbazine; Follow-Up Studies; Humans; Lomustine; Lymphatic Metastasis; Melanoma; Middle Aged; Neoplasm Staging; Prospective Studies; Randomized Controlled Trials as Topic; Skin Neoplasms; Vincristine

1990
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
    British journal of cancer, 1992, Volume: 65, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacarbazine; Drug Administration Schedule; Drug Evaluation; Female; Glioma; Humans; Kidney Neoplasms; Male; Melanoma; Middle Aged; Neoplasms; Stomach Neoplasms; Temozolomide

1992
The skin: an immunoreactive target organ during interleukin-2 administration?
    Dermatologica, 1991, Volume: 183, Issue:2

    Topics: Biopsy; Combined Modality Therapy; Cytokines; Dacarbazine; Dermatitis; Humans; Immunohistochemistry; Immunoradiometric Assay; Interferon-gamma; Interleukin-2; Melanoma; Skin Neoplasms; T-Lymphocyte Subsets; Tumor Necrosis Factor-alpha

1991
Adjuvant treatment in stage I and II malignant melanoma: a randomized trial between chemoimmunotherapy and immunotherapy.
    Dermatologica, 1991, Volume: 183, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Humans; Hydroxyurea; Male; Melanoma; Middle Aged; Skin Neoplasms; Vincristine

1991
A phase II trial of high-dose cisplatin and dacarbazine. Lack of efficacy of high-dose, cisplatin-based therapy for metastatic melanoma.
    Cancer, 1991, Sep-15, Volume: 68, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Administration Schedule; Drug Evaluation; Female; Hematologic Diseases; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Remission Induction; Skin Neoplasms; Survival Rate

1991
High-dose cisplatin with dacarbazine and tamoxifen in the treatment of metastatic melanoma.
    Cancer, 1991, Sep-15, Volume: 68, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Cisplatin; Dacarbazine; Drug Evaluation; Female; Hematologic Diseases; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Remission Induction; Skin Neoplasms; Tamoxifen

1991
Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma: a multicenter phase II study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1991, Volume: 9, Issue:9

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Catheterization, Central Venous; Dacarbazine; Drug Administration Schedule; Drug Evaluation; Female; Humans; Interleukin-2; Male; Melanoma; Recombinant Proteins

1991
Association between chemotherapy response and rate of disease progression in disseminated melanoma.
    British journal of cancer, 1991, Volume: 63, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Lomustine; Male; Melanoma; Middle Aged; Prognosis; Time Factors

1991
High-dose cisplatin plus dacarbazine in the treatment of metastatic melanoma.
    Cancer, 1991, Mar-15, Volume: 67, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Evaluation; Female; Hematologic Diseases; Humans; Kidney Diseases; Male; Melanoma; Middle Aged; Nervous System Diseases; Remission Induction; Survival Rate

1991
Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1991, Volume: 9, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Interferon alpha-2; Interferon-alpha; Life Tables; Male; Melanoma; Middle Aged; Nervous System Diseases; Recombinant Proteins; Survival Rate

1991
[Treatment of metastatic melanoma with dacarbazine recombinant interferon alfa 2A combination: results of multicentric study].
    Bulletin du cancer, 1990, Volume: 77, Issue:12

    Topics: Adolescent; Adult; Aged; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Recombinant Proteins

1990
Interferon alpha-2a and dacarbazine in melanoma.
    Journal of the National Cancer Institute, 1990, Jun-20, Volume: 82, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dacarbazine; Humans; Interferon alpha-2; Interferon Type I; Interferon-alpha; Melanoma; Random Allocation; Recombinant Proteins

1990
Recombinant interleukin-2 and adoptive immunotherapy alternated with dacarbazine therapy in melanoma: a National Biotherapy Study Group trial.
    Journal of the National Cancer Institute, 1990, Aug-15, Volume: 82, Issue:16

    Topics: Adult; Aged; Combined Modality Therapy; Dacarbazine; Female; Humans; Immunization, Passive; Interleukin-2; Killer Cells, Lymphokine-Activated; Male; Melanoma; Middle Aged; Multicenter Studies as Topic; Recombinant Proteins

1990
Phase II study of interferon alpha-2a and dacarbazine in advanced melanoma.
    American journal of clinical oncology, 1990, Volume: 13, Issue:5

    Topics: Adolescent; Adult; Aged; Combined Modality Therapy; Dacarbazine; Drug Evaluation; Female; Humans; Interferon alpha-2; Interferon-alpha; Italy; Male; Melanoma; Middle Aged; Recombinant Proteins; Remission Induction; Skin Neoplasms; Survival Rate

1990
Combination chemotherapy of dacarbazine and fotemustine in disseminated malignant melanoma. Experience of the French Study Group.
    Cancer chemotherapy and pharmacology, 1990, Volume: 27, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds

1990
High-dose cisplatin and dacarbazine in the treatment of metastatic melanoma.
    Journal of the National Cancer Institute, 1990, Dec-19, Volume: 82, Issue:24

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Remission Induction; Sex Factors

1990
[Current results with surgery and adjuvant chemotherapy in malignant melanoma].
    Archiv fur Geschwulstforschung, 1986, Volume: 56, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Bleomycin; Cisplatin; Clinical Trials as Topic; Dacarbazine; Humans; Melanoma; Random Allocation; Vinblastine

1986
Dacarbazine versus dacarbazine-vindesine in disseminated malignant melanoma: a randomized phase II study.
    Medical oncology and tumor pharmacotherapy, 1989, Volume: 6, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Evaluation; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Prospective Studies; Randomized Controlled Trials as Topic; Remission Induction; Vindesine

1989
Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma. A multicentre phase II study.
    European journal of cancer & clinical oncology, 1989, Volume: 25 Suppl 3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Drug Evaluation; Female; Humans; Interleukin-2; Male; Melanoma; Middle Aged; Multicenter Studies as Topic; Recombinant Proteins

1989
Sequential dacarbazine chemotherapy followed by recombinant interleukin-2 in metastatic melanoma. A pilot multicentre phase I-II study.
    European journal of cancer & clinical oncology, 1989, Volume: 25 Suppl 3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Drug Evaluation; Female; Humans; Interleukin-2; Male; Melanoma; Middle Aged; Multicenter Studies as Topic; Pilot Projects; Recombinant Proteins

1989
The significance of conversion of skin reactivity to efficacy of bacillus Calmette-Guérin (BCG) vaccinations given immediately after radical surgery in stage II melanoma patients.
    Cancer immunology, immunotherapy : CII, 1989, Volume: 28, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Prospective Studies; Random Allocation; Risk Factors; Skin Tests

1989
[Results of the treatment of advances melanoma of the skin with high daily doses of dacarbazine].
    Przeglad lekarski, 1988, Volume: 45, Issue:6

    Topics: Adult; Aged; Clinical Trials as Topic; Dacarbazine; Female; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Neoplasm Staging; Remission Induction; Skin Neoplasms; Time Factors

1988
Phase II study of AMSA alone and in combination with DTIC in patients with metastatic melanoma.
    Investigational new drugs, 1988, Volume: 6, Issue:1

    Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Evaluation; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis

1988
Randomized study of Corynebacterium parvum adjuvant therapy following surgery for (stage II) malignant melanoma.
    The British journal of surgery, 1986, Volume: 73, Issue:2

    Topics: Adjuvants, Immunologic; Adult; Aged; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Dactinomycin; Female; Humans; Male; Melanoma; Middle Aged; Postoperative Period; Propionibacterium acnes; Prospective Studies; Random Allocation; Skin Neoplasms

1986
[Combination chemotherapy of disseminated skin melanoma with nitrosomethylurea].
    Archiv fur Geschwulstforschung, 1986, Volume: 56, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dacarbazine; Dactinomycin; Drug Administration Schedule; Humans; Lomustine; Melanoma; Methylnitrosourea; Prognosis; Skin Neoplasms; Vincristine

1986
Lack of benefit of adjunctive chemotherapy in stage I malignant melanoma: a Southwest Oncology Group Study.
    Cancer treatment reports, 1987, Volume: 71, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Dacarbazine; Female; Humans; Hydroxyurea; Male; Melanoma; Middle Aged; Neoplasm Staging; Prognosis

1987
Cytotoxic chemotherapy of disseminated cutaneous malignant melanoma--a prospective and randomized clinical trial of procarbazine, vindesine and lomustine versus procarbazine, DTIC and lomustine.
    European journal of cancer & clinical oncology, 1986, Volume: 22, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Evaluation; Female; Humans; Lomustine; Male; Melanoma; Middle Aged; Procarbazine; Prospective Studies; Random Allocation; Skin Neoplasms; Vindesine

1986
Adjuvant treatment of malignant melanoma with DTIC + estracyt or BCG.
    Journal of surgical oncology, 1987, Volume: 36, Issue:4

    Topics: Administration, Oral; Adult; Aged; BCG Vaccine; Combined Modality Therapy; Dacarbazine; Estramustine; Female; Humans; Injections, Intravenous; Male; Melanoma; Middle Aged; Nitrogen Mustard Compounds; Prospective Studies; Random Allocation

1987
[Adjuvant chemotherapy in addition to radical surgical treatment of regional lymph node metastases in malignant melanoma].
    Deutsche medizinische Wochenschrift (1946), 1986, May-09, Volume: 111, Issue:19

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Dacarbazine; Humans; Hydroxyurea; Inguinal Canal; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Melanoma; Neoplasm Staging; Prognosis

1986
Corynebacterium parvum followed by chemotherapy (actinomycin D and DTIC) compared with chemotherapy alone for metastatic malignant melanoma.
    European journal of cancer & clinical oncology, 1986, Volume: 22, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dactinomycin; Humans; Melanoma; Neoplasm Metastasis; Propionibacterium acnes; Prospective Studies; Random Allocation

1986
A randomized trial of adjuvant chemotherapy and immunotherapy in Stage I and Stage II cutaneous melanoma. An interim report.
    Cancer, 1985, Feb-15, Volume: 55, Issue:4

    Topics: Adult; Aged; BCG Vaccine; Combined Modality Therapy; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Random Allocation; Skin Neoplasms

1985
Adjuvant chemotherapy of malignant melanoma. A pilot study.
    American journal of clinical oncology, 1985, Volume: 8, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Female; Humans; Lomustine; Male; Melanoma; Middle Aged; Pilot Projects; Random Allocation; Skin Neoplasms; Vincristine

1985

Other Studies

821 other study(ies) available for dacarbazine and Melanoma

ArticleYear
Synthesis and antitumor activity of halogen-substituted 4-(3,3-dimethyl-1-triazeno)quinolines.
    Journal of medicinal chemistry, 1978, Volume: 21, Issue:3

    Topics: Animals; Antineoplastic Agents; Chemical Phenomena; Chemistry; In Vitro Techniques; Leukemia L1210; Melanins; Melanoma; Mice; Neoplasms, Experimental; Quinolines; Triazenes

1978
Synthesis and evaluation of 1-(arylsulfonyl)-2-[(methoxycarbonyl)sulfenyl]-1-methylhydrazines++ + as antineoplastic agents.
    Journal of medicinal chemistry, 1986, Volume: 29, Issue:9

    Topics: Animals; Chemical Phenomena; Chemistry; Drug Evaluation; Leukemia L1210; Melanoma; Methylhydrazines; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; Structure-Activity Relationship

1986
1-Aryl-3,3-dimethyltriazenes: potential central nervous system active analogues of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC).
    Journal of medicinal chemistry, 1984, Volume: 27, Issue:12

    Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Dacarbazine; Drug Evaluation, Preclinical; Ependymoma; Leukemia L1210; Melanoma; Mice; Mice, Inbred Strains; Structure-Activity Relationship

1984
Synthesis and antiproliferative activity of thiazolidine analogs for melanoma.
    Bioorganic & medicinal chemistry letters, 2007, Aug-01, Volume: 17, Issue:15

    Topics: Cell Line, Tumor; Cell Proliferation; Humans; Melanoma; Thiazolidines

2007
Synthesis and antiproliferative activity of imidazole and imidazoline analogs for melanoma.
    Bioorganic & medicinal chemistry letters, 2008, Jun-01, Volume: 18, Issue:11

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Imidazoles; Imidazolines; Melanoma; Structure-Activity Relationship; Thiazolidines

2008
Synthesis of new 2-galactosylthiazolidine-4-carboxylic acid amides. Antitumor evaluation against melanoma and breast cancer cells.
    European journal of medicinal chemistry, 2012, Volume: 53

    Topics: Antineoplastic Agents; Breast Neoplasms; Carboxylic Acids; Cell Line, Tumor; Cell Survival; Chemistry Techniques, Synthetic; Dose-Response Relationship, Drug; Humans; Melanoma

2012
Preclinical Evaluation of LVR01 Attenuated Salmonella as Neoadjuvant Intralesional Therapy in Combination with Chemotherapy for Melanoma Treatment.
    The Journal of investigative dermatology, 2022, Volume: 142, Issue:5

    Topics: Animals; Dacarbazine; Humans; Melanoma; Mice; Neoadjuvant Therapy; Salmonella typhimurium; Skin Neoplasms; Tumor Microenvironment

2022
Cost-Effectiveness of the Dabrafenib Schedule in Combination With Trametinib Compared With Other Targeted Therapies, Immunotherapy, and Dacarbazine for the Treatment of Unresectable or Metastatic Melanoma With BRAFV600 Mutation in Colombia.
    Value in health regional issues, 2021, Volume: 26

    Topics: Colombia; Cost-Benefit Analysis; Dacarbazine; Humans; Imidazoles; Immunotherapy; Melanoma; Mutation; Oximes; Pyridones; Pyrimidinones

2021
Ubiquitination and degradation of MGMT by TRIM72 increases the sensitivity of uveal melanoma cells to Dacarbazine treatment.
    Cancer biomarkers : section A of Disease markers, 2022, Volume: 34, Issue:2

    Topics: Adult; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Humans; Melanoma; Tripartite Motif Proteins; Tumor Suppressor Proteins; Ubiquitination; Uveal Neoplasms

2022
Caffeine improves the cytotoxic effect of dacarbazine on B16F10 murine melanoma cells.
    Bioorganic chemistry, 2022, Volume: 120

    Topics: Animals; Antineoplastic Agents; Apoptosis; Caffeine; Cell Line, Tumor; Dacarbazine; Melanoma; Mice

2022
Green synthesis of PEG-coated MIL-100(Fe) for controlled release of dacarbazine and its anticancer potential against human melanoma cells.
    International journal of pharmaceutics, 2022, Apr-25, Volume: 618

    Topics: Dacarbazine; Delayed-Action Preparations; Humans; Melanoma; Metal-Organic Frameworks; Polyethylene Glycols

2022
Sonodynamic Therapy Using Dacarbazine-Loaded AuSiO
    Ultrasound in medicine & biology, 2022, Volume: 48, Issue:6

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dacarbazine; Melanoma; Mice; Nanoparticles

2022
Combined Therapy with Dacarbazine and Hyperthermia Induces Cytotoxicity in A375 and MNT-1 Melanoma Cells.
    International journal of molecular sciences, 2022, Mar-25, Volume: 23, Issue:7

    Topics: Cell Line, Tumor; Cell Survival; Dacarbazine; Humans; Hyperthermia, Induced; Melanoma; Reactive Oxygen Species

2022
Proteomics analysis: inhibiting the expression of P62 protein by chloroquine combined with dacarbazine can reduce the malignant progression of uveal melanoma.
    BMC cancer, 2022, Apr-14, Volume: 22, Issue:1

    Topics: Animals; Cell Line, Tumor; Chloroquine; Dacarbazine; Humans; Melanoma; Mice; Mice, Nude; Proteomics; Tumor Microenvironment; Uveal Neoplasms

2022
Successful treatment with dacarbazine against a parathyroid hormone-related protein-producing melanoma causing hypercalcemia after immune checkpoint inhibitor failure.
    The Journal of dermatology, 2022, Volume: 49, Issue:8

    Topics: Aged; Dacarbazine; Female; Humans; Hypercalcemia; Hypoxia; Immune Checkpoint Inhibitors; Melanoma; Parathyroid Hormone-Related Protein; Pleural Effusion; Proto-Oncogene Proteins B-raf

2022
Extra Virgin Olive Oil Secoiridoids Modulate the Metabolic Activity of Dacarbazine Pre-Treated and Treatment-Naive Melanoma Cells.
    Molecules (Basel, Switzerland), 2022, May-21, Volume: 27, Issue:10

    Topics: Dacarbazine; Humans; Iridoids; Melanoma; Olive Oil; Plant Oils

2022
A novel endoplasmic reticulum stress-related lncRNA prognostic risk model for cutaneous melanoma.
    Journal of cancer research and clinical oncology, 2022, Volume: 148, Issue:12

    Topics: Cisplatin; Dacarbazine; Endoplasmic Reticulum Stress; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Melanoma, Cutaneous Malignant; Paclitaxel; Prognosis; RNA, Long Noncoding; RNA, Messenger; Skin Neoplasms; Tumor Microenvironment

2022
Dacarbazine in the management of metastatic melanoma in the era of immune checkpoint therapy: a valid option or obsolete?
    Melanoma research, 2022, 10-01, Volume: 32, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Immune Checkpoint Inhibitors; Male; Melanoma; Neoplasms, Second Primary; Retrospective Studies; Skin Neoplasms; Tumor Microenvironment

2022
Focal adhesion alterations in G0-positive melanoma cells.
    Cancer medicine, 2023, Volume: 12, Issue:6

    Topics: Cell Cycle; Cell Division; Cell Line, Tumor; Dacarbazine; Humans; Melanoma

2023
Bilberry Anthocyanins (
    Nutrition and cancer, 2023, Volume: 75, Issue:3

    Topics: Animals; Anthocyanins; Apoptosis; Dacarbazine; Melanoma; Mice; Mice, Inbred C57BL; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Vaccinium myrtillus

2023
Bottom-Up Strategy to Forecast the Drug Location and Release Kinetics in Antitumoral Electrospun Drug Delivery Systems.
    International journal of molecular sciences, 2023, Jan-12, Volume: 24, Issue:2

    Topics: Anti-Inflammatory Agents; Dacarbazine; Drug Delivery Systems; Drug Liberation; Excipients; Humans; Melanoma; Nanofibers; Pharmaceutical Preparations

2023
Morusinol extracted from Morus alba induces cell cycle arrest and apoptosis via inhibition of DNA damage response in melanoma by CHK1 degradation through the ubiquitin-proteasome pathway.
    Phytomedicine : international journal of phytotherapy and phytopharmacology, 2023, Volume: 114

    Topics: Animals; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Damage; Flavonoids; Humans; Melanoma; Mice; Proteasome Endopeptidase Complex; Ubiquitins

2023
Protocatechuic aldehyde acts synergistically with dacarbazine to augment DNA double-strand breaks and promote apoptosis in cutaneous melanoma cells.
    BMC complementary medicine and therapies, 2023, Apr-06, Volume: 23, Issue:1

    Topics: Apoptosis; Dacarbazine; DNA; Humans; Melanoma; O(6)-Methylguanine-DNA Methyltransferase; Skin Neoplasms

2023
B7H6 silencing increases chemosensitivity to dacarbazine and suppresses cell survival and migration in cutaneous melanoma.
    Melanoma research, 2023, 06-01, Volume: 33, Issue:3

    Topics: Apoptosis; Caspase 3; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dacarbazine; Humans; Melanoma; Melanoma, Cutaneous Malignant; RNA, Messenger; RNA, Small Interfering; Skin Neoplasms

2023
Metastatic Melanoma: A Preclinical Model Standardization and Development of a Chitosan-Coated Nanoemulsion Containing Temozolomide to Treat Brain Metastasis.
    Cellular and molecular neurobiology, 2023, Volume: 43, Issue:6

    Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Chitosan; Dacarbazine; Humans; Melanoma; Mice; Temozolomide

2023
A step forward on the in vitro and in vivo assessment of a novel nanomedicine against melanoma.
    International journal of pharmaceutics, 2023, Jun-10, Volume: 640

    Topics: Animals; Apoptosis; Cell Line, Tumor; Dacarbazine; Humans; Melanoma; Mice; Nanomedicine; Skin Neoplasms

2023
Quality by design-based development and optimization of fourth-generation ternary solid dispersion of standardized Piper longum extract for melanoma therapy.
    Drug delivery and translational research, 2023, Volume: 13, Issue:12

    Topics: Animals; Biological Availability; Calorimetry, Differential Scanning; Dacarbazine; Melanoma; Mice; Mice, Inbred C57BL; Solubility; Spectroscopy, Fourier Transform Infrared; X-Ray Diffraction

2023
miR 204-5p inhibits apoptosis in dacarbazine-treated melanoma cells.
    Oncology research, 2021, Volume: 29, Issue:6

    Topics: Apoptosis; Dacarbazine; Humans; Ki-67 Antigen; Melanoma; MicroRNAs

2021
Preparation of chitosan nanoparticles for simultaneous drug delivery of dacarbazine and enoxaparin in melanoma.
    Carbohydrate polymers, 2023, Sep-15, Volume: 316

    Topics: Chitosan; Dacarbazine; Drug Delivery Systems; Enoxaparin; Humans; Melanoma; Nanoparticles

2023
Histone Deacetylases (HDAC) Inhibitor-Valproic Acid Sensitizes Human Melanoma Cells to Dacarbazine and PARP Inhibitor.
    Genes, 2023, 06-20, Volume: 14, Issue:6

    Topics: Alkylating Agents; Antineoplastic Agents; Dacarbazine; DNA; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Melanoma; Poly(ADP-ribose) Polymerase Inhibitors; Valproic Acid

2023
Analysis of cost-effectiveness of chemotherapeutic agents and new therapies for the management of unresectable and metastatic melanoma.
    European journal of dermatology : EJD, 2023, Apr-01, Volume: 33, Issue:2

    Topics: Cost-Benefit Analysis; Cost-Effectiveness Analysis; Dacarbazine; Female; Humans; Male; Melanoma; Neoplasms, Second Primary; Retrospective Studies

2023
Chromatographic method for dacarbazine quantification in skin permeation experiments.
    Journal of pharmaceutical and biomedical analysis, 2023, Sep-20, Volume: 234

    Topics: Chromatography, High Pressure Liquid; Dacarbazine; Humans; Melanoma; Skin; Skin Absorption

2023
Measuring Melanoma Nanomechanical Properties in Relation to Metastatic Ability and Anti-Cancer Drug Treatment Using Scanning Ion Conductance Microscopy.
    Cells, 2023, 10-04, Volume: 12, Issue:19

    Topics: Actins; Antineoplastic Agents; Cisplatin; Dacarbazine; Humans; Melanoma; Microscopy, Atomic Force; Paclitaxel

2023
Silencing of Dicer enhances dacarbazine resistance in melanoma cells by inhibiting ADSL expression.
    Aging, 2023, 11-15, Volume: 15, Issue:22

    Topics: Adenylosuccinate Lyase; Dacarbazine; Humans; Melanoma

2023
MIM1 induces COLO829 melanoma cell death through mitochondrial membrane breakdown, GSH depletion, and DNA damage.
    Fundamental & clinical pharmacology, 2020, Volume: 34, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Cell Death; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Damage; DNA Fragmentation; Glutathione; Humans; Melanoma; Mitochondrial Membranes; Myeloid Cell Leukemia Sequence 1 Protein; Skin Neoplasms

2020
Multivariate network meta-analysis of survival function parameters.
    Research synthesis methods, 2020, Volume: 11, Issue:3

    Topics: Dacarbazine; Data Interpretation, Statistical; Humans; Likelihood Functions; Melanoma; Multivariate Analysis; Network Meta-Analysis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Research Design; Software; Survival Analysis; Time Factors; Treatment Outcome

2020
Lysophosphatidic acid receptor-2 (LPA
    Molecular and cellular biochemistry, 2020, Volume: 469, Issue:1-2

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cisplatin; Dacarbazine; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Humans; Lysophospholipids; Melanoma; Pertussis Toxin; Receptors, Lysophosphatidic Acid; Signal Transduction

2020
The effects of metformin on the hippo pathway in the proliferation of melanoma cancer cells: a preclinical study.
    Archives of physiology and biochemistry, 2022, Volume: 128, Issue:5

    Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Cell Proliferation; Dacarbazine; Hippo Signaling Pathway; Humans; Melanoma; Metformin; Signal Transduction; Trans-Activators; YAP-Signaling Proteins

2022
Advanced malignant melanoma successfully treated with dacarbazine following anti-PD-1/CTLA-4 treatment.
    International journal of dermatology, 2020, Volume: 59, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CTLA-4 Antigen; Dacarbazine; Female; Humans; Immunotherapy; Melanoma; Skin Neoplasms

2020
Rechallenge of programmed cell death 1 inhibitor after an interval with dacarbazine treatment may be effective for advanced malignant melanoma.
    The Journal of dermatology, 2020, Volume: 47, Issue:8

    Topics: Apoptosis; Dacarbazine; Humans; Melanoma; Nivolumab; Skin Neoplasms

2020
Cold Atmospheric Plasma Is a Potent Tool to Improve Chemotherapy in Melanoma In Vitro and In Vivo.
    Biomolecules, 2020, 07-08, Volume: 10, Issue:7

    Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Combined Modality Therapy; Dacarbazine; Drug Therapy; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Lipid Peroxidation; Melanoma; Mice; Nitric Oxide; Plasma Gases; Xenograft Model Antitumor Assays

2020
Desensitization of metastatic melanoma cells to therapeutic treatment through repeated exposure to dacarbazine.
    Journal of photochemistry and photobiology. B, Biology, 2020, Volume: 211

    Topics: Anthracenes; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation; Humans; Melanoma; Neoplasm Proteins; Perylene; Photochemotherapy; Photosensitizing Agents

2020
In Vitro Anticancer Effects of All-trans Retinoic Acid in Combination with Dacarbazine against CD117+ Melanoma Cells.
    Drug research, 2020, Volume: 70, Issue:12

    Topics: Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Drug Synergism; G1 Phase; Humans; Melanoma; Melanoma, Cutaneous Malignant; Proto-Oncogene Proteins c-kit; Resting Phase, Cell Cycle; Skin Neoplasms; Tretinoin

2020
BRAF L597K mutation: an opportunity to treat.
    Dermatology online journal, 2021, Jan-15, Volume: 27, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Azetidines; Back; Dacarbazine; Humans; Imidazoles; Male; Melanoma; Middle Aged; Mutation; Oximes; Piperidines; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Skin Neoplasms; Vemurafenib

2021
Dual Encapsulated Dacarbazine and Zinc Phthalocyanine Polymeric Nanoparticle for Photodynamic Therapy of Melanoma.
    Pharmaceutical research, 2021, Volume: 38, Issue:2

    Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Carriers; Drug Compounding; Endothelial Cells; Humans; Isoindoles; Male; Melanoma; Mice; Nanoparticles; Organometallic Compounds; Photochemotherapy; Photosensitizing Agents; Polyesters; Polyvinyl Alcohol; Skin Neoplasms; Tissue Distribution; Zinc Compounds

2021
Melatonin and Metformin Failed to Modify the Effect of Dacarbazine in Melanoma.
    The oncologist, 2021, Volume: 26, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Melanoma; Melatonin; Metformin; Quality of Life

2021
CD47-mediated DTIC-loaded chitosan oligosaccharide-grafted nGO for synergistic chemo-photothermal therapy against malignant melanoma.
    Materials science & engineering. C, Materials for biological applications, 2021, Volume: 123

    Topics: CD47 Antigen; Cell Line, Tumor; Chitosan; Dacarbazine; Doxorubicin; Humans; Melanoma; Nanoparticles; Oligosaccharides; Phototherapy; Photothermal Therapy; Skin Neoplasms

2021
Nicotinamide N-methyltransferase gene silencing enhances chemosensitivity of melanoma cell lines.
    Pigment cell & melanoma research, 2021, Volume: 34, Issue:6

    Topics: Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Gene Silencing; Humans; Melanoma; Neoplasm Proteins; Nicotinamide N-Methyltransferase

2021
Impact of prior treatment with immune checkpoint inhibitors on dacarbazine efficacy in metastatic melanoma.
    British journal of cancer, 2021, Volume: 125, Issue:7

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Dacarbazine; Disease-Free Survival; Female; Humans; Immune Checkpoint Inhibitors; Male; Melanoma; Middle Aged; Retrospective Studies; Treatment Outcome

2021
Examining the In Vitro Efficacy of the IAP Antagonist Birinapant as a Single Agent or in Combination With Dacarbazine to Induce Melanoma Cell Death.
    Oncology research, 2017, Nov-02, Volume: 25, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell Line, Tumor; Dacarbazine; Dipeptides; Humans; Indoles; Melanoma; Mutation; Skin Neoplasms

2017
Acral lentiginous melanoma versus other melanoma: A single-center analysis in Japan.
    The Journal of dermatology, 2017, Volume: 44, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Child; Child, Preschool; Dacarbazine; Dermatologic Surgical Procedures; Disease-Free Survival; Female; Follow-Up Studies; Humans; Immunotherapy; Japan; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Prognosis; Retrospective Studies; Sentinel Lymph Node Biopsy; Skin; Treatment Outcome; Young Adult

2017
Dacarbazine inhibits proliferation of melanoma FEMX-1 cells by up-regulating expression of miRNA-200.
    European review for medical and pharmacological sciences, 2017, Volume: 21, Issue:6

    Topics: Apoptosis Regulatory Proteins; Cell Line, Tumor; Dacarbazine; Humans; Melanoma; MicroRNAs

2017
Combined activity of temozolomide and the mTOR inhibitor temsirolimus in metastatic melanoma involves DKK1.
    Experimental dermatology, 2017, Volume: 26, Issue:7

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Early Growth Response Protein 1; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Transfer Techniques; Humans; Indoles; Intercellular Signaling Peptides and Proteins; Lentivirus; Melanoma; Membrane Proteins; Oligonucleotide Array Sequence Analysis; Signal Transduction; Sirolimus; Skin; Skin Neoplasms; Sulfonamides; Temozolomide; TOR Serine-Threonine Kinases; Vemurafenib

2017
Immunoregulatory protein B7-H3 promotes growth and decreases sensitivity to therapy in metastatic melanoma cells.
    Pigment cell & melanoma research, 2017, Volume: 30, Issue:5

    Topics: B7 Antigens; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Everolimus; Gene Knockdown Techniques; Glycolysis; Humans; Indoles; Melanoma; Molecular Targeted Therapy; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Sulfonamides; Vemurafenib

2017
Dacarbazine-Loaded Hollow Mesoporous Silica Nanoparticles Grafted with Folic Acid for Enhancing Antimetastatic Melanoma Response.
    ACS applied materials & interfaces, 2017, Jul-05, Volume: 9, Issue:26

    Topics: Dacarbazine; Folic Acid; Humans; Melanoma; Nanoparticles; Porosity; Silicon Dioxide

2017
Sensitization of melanoma cells to temozolomide by overexpression of microRNA 203 through direct targeting of glutaminase-mediated glutamine metabolism.
    Clinical and experimental dermatology, 2017, Volume: 42, Issue:6

    Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Down-Regulation; Drug Resistance, Neoplasm; Glutaminase; Glutamine; Humans; Melanoma; MicroRNAs; Temozolomide

2017
A Network Meta-Analysis of Short and Long-Term Efficacy of Targeted Therapy With Single or Double-Drug Regimens in the Treatment of Stage III/IV Malignant Melanoma Based on 16 Randomized Controlled Trials.
    Journal of cellular biochemistry, 2018, Volume: 119, Issue:1

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Dacarbazine; Humans; Imidazoles; Indoles; Ipilimumab; Melanoma; Molecular Targeted Therapy; Neoplasm Staging; Network Meta-Analysis; Nivolumab; Odds Ratio; Oximes; Piperidines; Pyridones; Pyrimidinones; Randomized Controlled Trials as Topic; Sulfonamides; Survival Analysis; Treatment Outcome; Vemurafenib

2018
Effect of Lonidamine on Systemic Therapy of DB-1 Human Melanoma Xenografts with Temozolomide.
    Anticancer research, 2017, Volume: 37, Issue:7

    Topics: Animals; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Heterografts; Humans; Indazoles; Melanoma; Mice; Mice, Nude; Temozolomide; Transplantation, Heterologous

2017
TCTP as a therapeutic target in melanoma treatment.
    British journal of cancer, 2017, Aug-22, Volume: 117, Issue:5

    Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dacarbazine; Female; Gene Expression; Gene Silencing; Humans; Melanoma; Melanoma, Experimental; Mice; Mice, Inbred C57BL; RNA, Messenger; RNA, Small Interfering; Sertraline; Skin Neoplasms; Transfection; Tumor Protein, Translationally-Controlled 1; Tumor Stem Cell Assay; Tumor Suppressor Protein p53

2017
Cytotoxic antimelanoma drugs suppress the activation of M2 macrophages.
    Experimental dermatology, 2018, Volume: 27, Issue:1

    Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Agents; B7-H1 Antigen; Dacarbazine; Female; Japan; Lectins, C-Type; Leukocytes, Mononuclear; Macrophages; Mannose Receptor; Mannose-Binding Lectins; Melanoma; Melanoma, Cutaneous Malignant; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Monocytes; Nimustine; Receptors, Cell Surface; RNA, Messenger; Skin Neoplasms; Vincristine

2018
Microradiopharmaceutical for Metastatic Melanoma.
    Pharmaceutical research, 2017, Volume: 34, Issue:12

    Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Delivery Systems; Female; Melanoma; Mice, Inbred BALB C; Mice, Nude; Radium; Technetium; Tissue Distribution

2017
MicroRNA-195 acts as an anti-proliferative miRNA in human melanoma cells by targeting Prohibitin 1.
    BMC cancer, 2017, Nov-10, Volume: 17, Issue:1

    Topics: Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Dacarbazine; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Indoles; Male; Melanoma; MicroRNAs; Prohibitins; Repressor Proteins; Sulfonamides; Temozolomide; Transfection; Vemurafenib

2017
Dacarbazine nanoparticle topical delivery system for the treatment of melanoma.
    Scientific reports, 2017, 11-28, Volume: 7, Issue:1

    Topics: Administration, Topical; Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Carriers; Drug Delivery Systems; Drug Liberation; Hydrogen-Ion Concentration; Melanoma; Melanoma, Experimental; Mice; Nanoparticles; Particle Size; Permeability; Viscosity

2017
CXCR1/2 Chemokine Network Regulates Melanoma Resistance to Chemotherapies Mediated by NF-κB.
    Current molecular medicine, 2017, Volume: 17, Issue:6

    Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Melanoma; NF-kappa B; Receptors, Interleukin-8A; Receptors, Interleukin-8B; Signal Transduction; Tumor Cells, Cultured

2017
Effect of dacarbazine on CD44 in live melanoma cells as measured by atomic force microscopy-based nanoscopy.
    International journal of nanomedicine, 2017, Volume: 12

    Topics: Actins; Animals; Cell Line, Tumor; Cell Survival; Dacarbazine; Hyaluronan Receptors; Kinetics; Melanoma; Mice; Microscopy, Atomic Force; Quantum Dots; Single Molecule Imaging; Tubulin

2017
Inflammatory Cytokine Pattern Is Sex-Dependent in Mouse Cutaneous Melanoma Experimental Model.
    Journal of immunology research, 2017, Volume: 2017

    Topics: Animals; Antineoplastic Agents, Alkylating; Carcinogenesis; Cytokines; Dacarbazine; Disease Models, Animal; Disease Progression; Female; Humans; Inflammation Mediators; Male; Melanoma; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Sex; Skin Neoplasms

2017
Effects of nivolumab in peritoneal carcinamatosis of malign melanoma in mouse model.
    Acta cirurgica brasileira, 2017, Volume: 32, Issue:12

    Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Dacarbazine; Disease Models, Animal; Drug Evaluation, Preclinical; Hyperthermia, Induced; Male; Melanoma; Mice; Neoplasm Grading; Nivolumab; Peritoneal Neoplasms; Peritoneum; Random Allocation; Regression Analysis

2017
Solid Lipid Nanoparticles Carrying Temozolomide for Melanoma Treatment. Preliminary In Vitro and In Vivo Studies.
    International journal of molecular sciences, 2018, Jan-24, Volume: 19, Issue:2

    Topics: Animals; Biomarkers; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Drug Stability; Female; Humans; Immunohistochemistry; Melanoma; Melanoma, Experimental; Mice; Molecular Structure; Nanoparticles; Neoplastic Stem Cells; Temozolomide

2018
Senescence-associated secretory factors induced by cisplatin in melanoma cells promote non-senescent melanoma cell growth through activation of the ERK1/2-RSK1 pathway.
    Cell death & disease, 2018, 02-15, Volume: 9, Issue:3

    Topics: A549 Cells; Animals; Antineoplastic Agents; Cell Proliferation; Cellular Senescence; Cisplatin; Cyclin-Dependent Kinase Inhibitor p21; Dacarbazine; Drug Resistance, Neoplasm; HeLa Cells; Humans; Interleukin-1alpha; Melanoma; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Ribosomal Protein S6 Kinases, 90-kDa; Secretory Pathway; Signal Transduction; Skin Neoplasms; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2018
Magnetic core mesoporous silica nanoparticles doped with dacarbazine and labelled with 99mTc for early and differential detection of metastatic melanoma by single photon emission computed tomography.
    Artificial cells, nanomedicine, and biotechnology, 2018, Volume: 46, Issue:sup1

    Topics: Animals; Cell Line, Tumor; Cell Transformation, Neoplastic; Dacarbazine; Diagnosis, Differential; Early Detection of Cancer; Humans; Isotope Labeling; Magnets; Melanoma; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasm Metastasis; Porosity; Silicon Dioxide; Technetium; Tomography, Emission-Computed, Single-Photon

2018
Targeting LMW-PTP to sensitize melanoma cancer cells toward chemo- and radiotherapy.
    Cancer medicine, 2018, Volume: 7, Issue:5

    Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy; Flavonoids; Fluorouracil; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Melanoma; Molecular Targeted Therapy; Protein Tyrosine Phosphatases; Proto-Oncogene Proteins; Radiation Tolerance; Radiotherapy; Up-Regulation

2018
Nodal induced by hypoxia exposure contributes to dacarbazine resistance and the maintenance of stemness in melanoma cancer stem‑like cells.
    Oncology reports, 2018, Volume: 39, Issue:6

    Topics: Apoptosis; Cell Hypoxia; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glycolysis; Humans; Melanoma; Neoplastic Stem Cells; Nodal Protein; Reactive Oxygen Species; Signal Transduction

2018
Inhibition of endoplasmic reticulum stress-induced autophagy sensitizes melanoma cells to temozolomide treatment.
    Oncology reports, 2018, Volume: 40, Issue:1

    Topics: Animals; Apoptosis; Autophagy; Caspase 7; Cell Line, Tumor; Dacarbazine; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; Melanoma; Mice; Proto-Oncogene Proteins B-raf; Temozolomide; Xenograft Model Antitumor Assays

2018
Functionalized nanoliposomes loaded with anti survivin and anti angiogenic agents to enhance the activity of chemotherapy against melanoma by 4-pronged action.
    Medical hypotheses, 2018, Volume: 116

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Cell Proliferation; Dacarbazine; Female; Fibroblast Growth Factor 2; Humans; Hyaluronan Receptors; Inhibitor of Apoptosis Proteins; Liposomes; Male; Melanoma; Models, Theoretical; Nanoparticles; Neovascularization, Pathologic; Skin Neoplasms; Survivin; Vascular Endothelial Growth Factor A

2018
Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy.
    Expert opinion on biological therapy, 2018, Volume: 18, Issue:sup1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Checkpoints; Clinical Trials, Phase II as Topic; CTLA-4 Antigen; Dacarbazine; Drug Synergism; Female; Follow-Up Studies; Humans; Ipilimumab; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Skin Neoplasms; Survival Analysis; Thymalfasin; Time Factors; Young Adult

2018
Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
    JAMA oncology, 2018, 10-01, Volume: 4, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Dacarbazine; Female; Humans; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Mutation; Neoplasm Metastasis; Piperidines; Prognosis; Proto-Oncogene Proteins B-raf; Randomized Controlled Trials as Topic; Retrospective Studies; Skin Neoplasms; Treatment Outcome; Vemurafenib

2018
Long-term Survival of Stage IV Melanoma Patients Treated with BOLD Combination Chemotherapy and Intermediate-dose Subcutaneous Interferon-alpha.
    Anticancer research, 2018, Volume: 38, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Drug Administration Schedule; Female; Humans; Injections, Subcutaneous; Interferon-alpha; Lomustine; Male; Melanoma; Middle Aged; Neoplasm Staging; Survival Analysis; Treatment Outcome; Vincristine; Young Adult

2018
Case of malignant melanoma responding to dacarbazine following nivolumab.
    Dermatologic therapy, 2019, Volume: 32, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Melanoma; Nivolumab; Treatment Outcome

2019
Post-treatment de-phosphorylation of p53 correlates with dasatinib responsiveness in malignant melanoma.
    BMC cell biology, 2018, 12-27, Volume: 19, Issue:1

    Topics: Cell Cycle Checkpoints; Cell Death; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Dasatinib; Drug Resistance, Neoplasm; Drug Synergism; Humans; Melanoma; Phosphoproteins; Phosphorylation; Tumor Suppressor Protein p53

2018
Synthesis and characterization of a novel biocompatible pseudo-hexagonal NaCa-layered double metal hydroxides for smart pH-responsive drug release of dacarbazine and enhanced anticancer activity in malignant melanoma.
    Materials science & engineering. C, Materials for biological applications, 2019, Volume: 97

    Topics: Antineoplastic Agents, Alkylating; Biocompatible Materials; Calcium; Cell Line, Tumor; Dacarbazine; Delayed-Action Preparations; Drug Delivery Systems; Drug Liberation; Drug Screening Assays, Antitumor; Half-Life; Humans; Hydrogen-Ion Concentration; Hydroxides; MCF-7 Cells; Melanoma; Sodium

2019
Antiproliferative and apoptotic effects of caffeic acid on SK-Mel-28 human melanoma cancer cells.
    Molecular biology reports, 2019, Volume: 46, Issue:2

    Topics: Adult; Antineoplastic Agents; Apoptosis; Caffeic Acids; Caspases; Cell Cycle; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Female; Healthy Volunteers; Humans; Male; Melanoma; Melanoma, Cutaneous Malignant; Skin Neoplasms

2019
Bixin, an apocarotenoid isolated from Bixa orellana L., sensitizes human melanoma cells to dacarbazine-induced apoptosis through ROS-mediated cytotoxicity.
    Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 2019, Volume: 125

    Topics: Antineoplastic Agents; Apoptosis; Bixaceae; Carotenoids; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; G2 Phase Cell Cycle Checkpoints; Humans; Melanoma; Oxidative Stress; Plant Extracts; Reactive Oxygen Species; Seeds; Skin Neoplasms; Vemurafenib

2019
Survival Extrapolation in Cancer Immunotherapy: A Validation-Based Case Study.
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2019, Volume: 22, Issue:3

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Case-Control Studies; Clinical Trials, Phase III as Topic; Dacarbazine; Double-Blind Method; Humans; Immunotherapy; Ipilimumab; Melanoma; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Survival Rate

2019
p38 MAPK activation through B7-H3-mediated DUSP10 repression promotes chemoresistance.
    Scientific reports, 2019, 04-09, Volume: 9, Issue:1

    Topics: Animals; Antineoplastic Agents; B7 Antigens; Cell Line, Tumor; Cisplatin; Dacarbazine; Drug Resistance, Neoplasm; Dual-Specificity Phosphatases; Humans; Melanoma; Mice; Mitogen-Activated Protein Kinase Phosphatases; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Signal Transduction

2019
Vitamin D and its low calcemic analogs modulate the anticancer properties of cisplatin and dacarbazine in the human melanoma A375 cell line.
    International journal of oncology, 2019, Volume: 54, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cisplatin; Dacarbazine; Drug Resistance, Neoplasm; Drug Synergism; G1 Phase Cell Cycle Checkpoints; Humans; Inhibitory Concentration 50; Melanoma; Reactive Oxygen Species; Skin Neoplasms; Vitamin D

2019
Custo-utilidade de terapias-alvo comparadas à dacarbazina para o tratamento de primeira linha do melanoma avançado não-cirúrgico e metastático no Sistema Único de Saúde do Brazil.
    Value in health regional issues, 2019, Volume: 20

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Brazil; Cost-Benefit Analysis; Dacarbazine; Drug Costs; Health Care Costs; Humans; Imidazoles; Melanoma; Oximes; Piperidines; Pyridones; Pyrimidinones; Vemurafenib

2019
Target therapy versus dacarbazine in first-line treatment of advanced non-surgical and metastatic melanoma: budget impact analysis from the perspective of the Brazilian National Health System, 2018-2020.
    Epidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil, 2019, 06-27, Volume: 28, Issue:2

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brazil; Budgets; Dacarbazine; Female; Humans; Male; Melanoma; Molecular Targeted Therapy; National Health Programs; Skin Neoplasms

2019
Modulation of chemoresistance by lysophosphatidic acid (LPA) signaling through LPA
    Biochemical and biophysical research communications, 2019, 09-17, Volume: 517, Issue:2

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Survival; Cisplatin; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Lysophospholipids; Melanoma; Receptors, Lysophosphatidic Acid; Signal Transduction

2019
Similar efficacy for phase I trials in comparison with DTIC for advanced malignant melanoma: an analysis of melanoma outcomes in CTEP-sponsored phase I trials 1995-2011.
    Melanoma research, 2013, Volume: 23, Issue:2

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Dacarbazine; Female; Humans; Immunotherapy; Male; Melanoma; Middle Aged; Retrospective Studies; Skin Neoplasms

2013
Prognostic factors for overall survival after radiosurgery for brain metastases from melanoma.
    American journal of clinical oncology, 2014, Volume: 37, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Dacarbazine; Female; Humans; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Male; Melanoma; Middle Aged; Multivariate Analysis; Prognosis; Proportional Hazards Models; Radiosurgery; Radiotherapy; Retrospective Studies; Skin Neoplasms; Temozolomide; Young Adult

2014
A dual-regulated oncolytic adenovirus expressing interleukin-24 sensitizes melanoma cells to temozolomide via the induction of apoptosis.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2013, Volume: 34, Issue:2

    Topics: Adenoviridae; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Cell Cycle; Cell Proliferation; Combined Modality Therapy; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Genetic Therapy; Genetic Vectors; Humans; Immunoenzyme Techniques; Interleukins; Ki-67 Antigen; Melanoma; Oncolytic Virotherapy; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Tumor Suppressor Proteins

2013
Vulvar and vaginal melanoma: case series and review of current management options including neoadjuvant chemotherapy.
    Gynecologic oncology, 2013, Volume: 129, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Dacarbazine; Female; Humans; Lymphatic Metastasis; Melanoma; Neoadjuvant Therapy; Paclitaxel; Survival Rate; Temozolomide; Treatment Outcome; Vaginal Neoplasms; Vulvar Neoplasms

2013
Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma.
    Clinical & experimental metastasis, 2013, Volume: 30, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Disease-Free Survival; Female; GTP Phosphohydrolases; Humans; Male; Melanoma; Membrane Proteins; Middle Aged; Neoplasm Metastasis; Prognosis; Proto-Oncogene Proteins B-raf; RNA, Messenger

2013
Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients.
    Journal of translational medicine, 2013, May-31, Volume: 11

    Topics: Adult; Aged; Cancer Vaccines; CTLA-4 Antigen; Dacarbazine; Dendritic Cells; Female; Forkhead Transcription Factors; Hemocyanins; Humans; Interleukin-2; Interleukin-2 Receptor alpha Subunit; Male; Melanoma; Middle Aged; T-Lymphocytes, Regulatory; Temozolomide; Treatment Outcome

2013
Regulation of gap junctions in melanoma and their impact on Melan-A/MART-1-specific CD8⁺ T lymphocyte emergence.
    Journal of molecular medicine (Berlin, Germany), 2013, Volume: 91, Issue:10

    Topics: Antineoplastic Agents, Alkylating; Apoptosis; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Connexin 43; Cytotoxicity, Immunologic; Dacarbazine; Gap Junctions; Gene Expression; Humans; Hypoxia; Immunological Synapses; Interferon-gamma; MART-1 Antigen; Melanoma; Oxidative Stress; Protein Transport; T-Lymphocytes, Cytotoxic

2013
Melanoma of unknown primary origin presenting as a rapidly enlarging adrenal mass.
    BMJ case reports, 2013, Jun-19, Volume: 2013

    Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Diagnosis, Differential; Female; Humans; Melanoma; Neoplasm Metastasis; Neoplasms, Unknown Primary; Radiosurgery; Temozolomide; Tomography, X-Ray Computed

2013
Parthenolide enhances dacarbazine activity against melanoma cells.
    Anti-cancer drugs, 2013, Volume: 24, Issue:8

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Dose-Response Relationship, Drug; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Humans; Interleukin-8; Melanoma; NF-kappa B; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Sesquiterpenes; Skin Neoplasms; Vascular Endothelial Growth Factor A

2013
Has targeted therapy for melanoma made chemotherapy obsolete?
    The Lancet. Oncology, 2013, Volume: 14, Issue:8

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma; Mutation; Neoplasms, Unknown Primary; Proto-Oncogene Proteins B-raf; Skin Neoplasms

2013
Selumetinib increases the efficacy of first-line dacarbazine.
    Cancer discovery, 2013, Volume: 3, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Dacarbazine; Disease-Free Survival; Humans; Melanoma; Mutation; Proto-Oncogene Proteins B-raf; Skin Neoplasms

2013
Selumetinib shows promise in metastatic uveal melanoma.
    Cancer discovery, 2013, Volume: 3, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Clinical Trials, Phase II as Topic; Dacarbazine; Disease-Free Survival; Eye Neoplasms; Humans; Melanoma; Neoplasm Metastasis; Temozolomide; Uveal Neoplasms

2013
Epigenetic regulation of REG1A and chemosensitivity of cutaneous melanoma.
    Epigenetics, 2013, Volume: 8, Issue:10

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Dacarbazine; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression; Humans; Lithostathine; Lymphatic Metastasis; Male; Melanoma; Prognosis; Promoter Regions, Genetic; Skin Neoplasms

2013
Systems analysis of apoptosis protein expression allows the case-specific prediction of cell death responsiveness of melanoma cells.
    Cell death and differentiation, 2013, Volume: 20, Issue:11

    Topics: Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Dacarbazine; Humans; Melanoma; Models, Biological; Neoplasm Proteins

2013
Contribution of ATM and ATR to the resistance of glioblastoma and malignant melanoma cells to the methylating anticancer drug temozolomide.
    Molecular cancer therapeutics, 2013, Volume: 12, Issue:11

    Topics: Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Cell Line, Tumor; Checkpoint Kinase 1; Dacarbazine; DNA Breaks, Double-Stranded; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Glioblastoma; Guanine; Humans; Melanoma; Methylnitronitrosoguanidine; Phosphorylation; Protein Kinases; Signal Transduction; Temozolomide; Tumor Suppressor Proteins

2013
The human melanoma side population displays molecular and functional characteristics of enriched chemoresistance and tumorigenesis.
    PloS one, 2013, Volume: 8, Issue:10

    Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Dacarbazine; Disease Progression; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Jumonji Domain-Containing Histone Demethylases; Male; Melanoma; Mice; Mice, SCID; Neoplasm Proteins; Neoplasm Staging; Neoplasm Transplantation; Neoplastic Stem Cells; Nuclear Proteins; Repressor Proteins; Side-Population Cells; Skin Neoplasms; Tumor Burden

2013
Therapy-related myelodysplastic syndrome after alkylating agents and platinum-based therapy for malignant melanoma.
    The Journal of dermatology, 2014, Volume: 41, Issue:2

    Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Humans; Male; Melanoma; Myelodysplastic Syndromes; Nimustine; Skin Neoplasms

2014
Targeted delivery of CYP2E1 recombinant adenovirus to malignant melanoma by bone marrow-derived mesenchymal stem cells as vehicles.
    Anti-cancer drugs, 2014, Volume: 25, Issue:3

    Topics: Adenoviridae; Adolescent; Adult; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Bone Marrow; Cell Line, Tumor; Cell Movement; Cytochrome P-450 CYP2E1; Dacarbazine; Female; Gene Transfer Techniques; Humans; Male; Melanoma; Mesenchymal Stem Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Young Adult

2014
Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Jul-01, Volume: 32, Issue:19

    Topics: Administration, Oral; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Dacarbazine; Drug Administration Schedule; Fluorodeoxyglucose F18; Humans; Immunosuppressive Agents; Ipilimumab; Kidney Transplantation; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Mycophenolic Acid; Platinum Compounds; Positron-Emission Tomography; Prednisone; Radiopharmaceuticals; Skin Neoplasms; Tacrolimus; Temozolomide; Tomography, X-Ray Computed; Treatment Outcome

2014
[Management of patients with metastatic cutaneous melanoma: French national guidelines. French National Cancer Institute].
    Annales de dermatologie et de venereologie, 2014, Volume: 141, Issue:2

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Management; France; Humans; Indoles; Ipilimumab; Liver Neoplasms; Lung Neoplasms; Melanoma; Molecular Targeted Therapy; Neoplasm Staging; Nitrosourea Compounds; Oncogenes; Organophosphorus Compounds; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Temozolomide; Vemurafenib

2014
Comment on Jiang G. et al.: efficacy and safety between temozolomide alone and temozolomide-based double therapy for malignant melanoma: a meta-analysis.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014, Volume: 35, Issue:6

    Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Melanoma

2014
FDG-PET/CT assessment of differential chemotherapy effects upon skeletal muscle metabolism in patients with melanoma.
    Annals of nuclear medicine, 2014, Volume: 28, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Middle Aged; Multimodal Imaging; Muscle, Skeletal; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Temozolomide; Tomography, X-Ray Computed; Whole Body Imaging

2014
BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy.
    PloS one, 2014, Volume: 9, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Follow-Up Studies; Humans; Male; Melanoma; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Survival Rate; Temozolomide

2014
Insulin induces drug resistance in melanoma through activation of the PI3K/Akt pathway.
    Drug design, development and therapy, 2014, Volume: 8

    Topics: Animals; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Humans; Indoles; Insulin; Melanoma; Mice; Mutation; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Signal Transduction; Sulfonamides

2014
Treatment patterns and outcomes among patients with metastatic melanoma treated in community practice.
    International journal of dermatology, 2014, Volume: 53, Issue:11

    Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Community Health Services; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Platinum Compounds; Practice Patterns, Physicians'; Retrospective Studies; Skin Neoplasms; Survival Rate; Temozolomide; Treatment Outcome

2014
Targeting N-cadherin increases vascular permeability and differentially activates AKT in melanoma.
    Annals of surgery, 2015, Volume: 261, Issue:2

    Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Cadherins; Capillary Permeability; Cell Line, Tumor; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Melanoma; Melphalan; Neoplasm Transplantation; Oligopeptides; Peptides, Cyclic; Phosphatidylinositol 3-Kinases; Protein Array Analysis; Proto-Oncogene Proteins c-akt; Rats; Rats, Nude; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Skin Neoplasms; Temozolomide

2015
[Late gastric metastasis from cutaneous melanoma].
    Gastroenterologia y hepatologia, 2014, Volume: 37, Issue:10

    Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Leg; Lung Neoplasms; Melanoma; Middle Aged; Palliative Care; Skin Neoplasms; Stomach Neoplasms; Time Factors

2014
Proteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance.
    British journal of cancer, 2014, May-13, Volume: 110, Issue:10

    Topics: Adult; Aged; Antineoplastic Agents; Cystatin B; Dacarbazine; Drug Resistance, Neoplasm; Factor XIII; Female; Gene Expression Profiling; Humans; Lymphatic Metastasis; Male; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; Myo-Inositol-1-Phosphate Synthase; Neoplasm Proteins; Prospective Studies; Proteomics; S100 Proteins; Skin Neoplasms; Tandem Mass Spectrometry; Temozolomide; Young Adult

2014
Melanoma: you can have your cake and eat it!
    Nature reviews. Clinical oncology, 2014, Volume: 11, Issue:6

    Topics: Antineoplastic Agents; Dacarbazine; Humans; Imidazoles; Melanoma; Neoplasm Metastasis; Oximes; Quality of Life

2014
[Metastatic malignant melanoma of the oesophagus: case report].
    Magyar sebeszet, 2014, Volume: 67, Issue:3

    Topics: Antineoplastic Agents, Alkylating; Biopsy; Dacarbazine; Esophageal Neoplasms; Esophagectomy; Female; Humans; Melanoma; Middle Aged; Neoplasm Staging; Polyps; Skin Neoplasms; Treatment Outcome

2014
Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells.
    Molecular cancer, 2014, Jun-19, Volume: 13

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA; DNA Methylation; Enzyme Inhibitors; GTP Phosphohydrolases; Humans; Melanoma; Membrane Proteins; Mutation; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Temozolomide

2014
Histone deacetylase inhibitor-temozolomide co-treatment inhibits melanoma growth through suppression of Chemokine (C-C motif) ligand 2-driven signals.
    Oncotarget, 2014, Jun-30, Volume: 5, Issue:12

    Topics: Animals; Apoptosis; Cell Survival; Chemokines; Dacarbazine; Disease Models, Animal; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Melanoma; Mice; Mice, Transgenic; Temozolomide; Tumor Microenvironment

2014
Enhanced antitumor efficacy of a novel oncolytic adenovirus combined with temozolomide in the treatment of melanoma in vivo.
    Journal of cancer research and clinical oncology, 2015, Volume: 141, Issue:1

    Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Cell Proliferation; Combined Modality Therapy; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Flow Cytometry; Genetic Therapy; Humans; Immunoenzyme Techniques; Interleukins; Ki-67 Antigen; Male; Melanoma; Mice; Mice, Inbred BALB C; Mice, Nude; Oncolytic Virotherapy; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays

2015
Prospective study of the evolution of blood lymphoid immune parameters during dacarbazine chemotherapy in metastatic and locally advanced melanoma patients.
    PloS one, 2014, Volume: 9, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; CD4-Positive T-Lymphocytes; Cell Line, Tumor; Cell Survival; Dacarbazine; Female; Flow Cytometry; Gene Expression; Humans; Killer Cells, Natural; Leukocyte Count; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Prognosis; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Skin Neoplasms; T-Lymphocytes, Regulatory; Transcription Factors; Treatment Outcome

2014
Uveal melanoma therapy on the horizon?
    Cancer discovery, 2014, Volume: 4, Issue:9

    Topics: Antineoplastic Agents, Alkylating; Benzimidazoles; Dacarbazine; Female; Humans; Male; Melanoma; Uveal Neoplasms

2014
Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient.
    Melanoma research, 2014, Volume: 24, Issue:5

    Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biopsy; Cell Proliferation; Dacarbazine; Female; Humans; Incidence; Indoles; Ipilimumab; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Melanoma; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Treatment Outcome; Vemurafenib

2014
Conjonctival melanoma metastatic to the breast: a case report.
    BMC research notes, 2014, Sep-09, Volume: 7

    Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Conjunctival Neoplasms; Dacarbazine; Drug Administration Schedule; Fatal Outcome; Female; Humans; Immunohistochemistry; Melanoma; Nasopharyngeal Neoplasms; Oropharyngeal Neoplasms; Palliative Care; Time Factors; Treatment Outcome

2014
Adenovirus-mediated FKHRL1/TM sensitizes melanoma cells to apoptosis induced by temozolomide.
    Human gene therapy. Clinical development, 2014, Volume: 25, Issue:3

    Topics: Adenoviridae; Animals; Apoptosis; Cell Line, Tumor; Cell Survival; Dacarbazine; Forkhead Box Protein O3; Forkhead Transcription Factors; Genetic Therapy; Humans; Male; Melanoma; Mice; Mice, Inbred BALB C; Temozolomide; Transcription Factors; Xenograft Model Antitumor Assays

2014
The receptor for advanced glycation end products influences the expression of its S100 protein ligands in melanoma tumors.
    The international journal of biochemistry & cell biology, 2014, Volume: 57

    Topics: Animals; Antibodies, Monoclonal; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Female; Humans; Ligands; Melanoma; Mice; Mice, SCID; Random Allocation; Receptor for Advanced Glycation End Products; Receptors, Immunologic; S100 Proteins; Xenograft Model Antitumor Assays

2014
MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma.
    International journal of cancer, 2015, Jun-15, Volume: 136, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Dacarbazine; Disease-Free Survival; DNA Methylation; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Male; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Outcome Assessment, Health Care; Prognosis; Promoter Regions, Genetic; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; Skin Neoplasms; Temozolomide

2015
Release the hounds! Activating the T-cell response to cancer.
    The New England journal of medicine, 2015, Jan-22, Volume: 372, Issue:4

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Dacarbazine; Female; Hodgkin Disease; Humans; Immunotherapy; Male; Melanoma; Nivolumab; Programmed Cell Death 1 Receptor

2015
Skin cancer. Golden age of melanoma therapy.
    Nature reviews. Clinical oncology, 2015, Volume: 12, Issue:1

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Cell Transformation, Neoplastic; Dacarbazine; Female; Humans; Male; Melanoma; Programmed Cell Death 1 Receptor; Proto-Oncogene Proteins B-raf

2015
A novel temozolomide analog, NEO212, with enhanced activity against MGMT-positive melanoma in vitro and in vivo.
    Cancer letters, 2015, Mar-28, Volume: 358, Issue:2

    Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Survival; Dacarbazine; Disease Models, Animal; DNA Damage; DNA Methylation; Dose-Response Relationship, Drug; Humans; Inhibitory Concentration 50; Melanoma; Mice; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays

2015
Late-onset paraplegia after complete response to two cycles of ipilimumab for metastatic melanoma.
    Oncology research and treatment, 2014, Volume: 37, Issue:12

    Topics: Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Colitis; Dacarbazine; Fluorodeoxyglucose F18; Humans; Ipilimumab; Magnetic Resonance Imaging; Male; Melanoma; Middle Aged; Multimodal Imaging; Myelitis; Paraplegia; Positron-Emission Tomography; Radiopharmaceuticals; Skin Neoplasms; Temozolomide; Tomography, X-Ray Computed

2014
B-Raf inhibitor vemurafenib in combination with temozolomide and fotemustine in the killing response of malignant melanoma cells.
    Oncotarget, 2014, Dec-30, Volume: 5, Issue:24

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dacarbazine; Drug Synergism; Humans; Indoles; Melanoma; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds; Proto-Oncogene Proteins B-raf; Sulfonamides; Temozolomide; Vemurafenib

2014
Predictive biomarkers to chemotherapy in patients with advanced melanoma receiving the combination of cisplatin--vinblastine--temozolomide (PVT) as first-line treatment: a study of the Hellenic Cooperative Oncology Group (HECOG).
    Anticancer research, 2015, Volume: 35, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Dacarbazine; Humans; Melanoma; Middle Aged; Temozolomide; Vinblastine

2015
Exploiting cannabinoid-induced cytotoxic autophagy to drive melanoma cell death.
    The Journal of investigative dermatology, 2015, Volume: 135, Issue:6

    Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Cannabidiol; Cannabinoids; Cannabinol; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Dronabinol; Drug Combinations; Humans; Male; Melanoma; Membrane Proteins; Mice; Mice, Nude; Microscopy, Confocal; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms; Plant Extracts; Proto-Oncogene Proteins B-raf; ras Proteins; Skin Neoplasms; Temozolomide

2015
Curcumin analog DM-1 in monotherapy or combinatory treatment with dacarbazine as a strategy to inhibit in vivo melanoma progression.
    PloS one, 2015, Volume: 10, Issue:3

    Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Proliferation; Curcumin; Dacarbazine; Disease Progression; Drug Therapy, Combination; Male; Melanoma; Mice; Skin Neoplasms

2015
Targeting nodal in conjunction with dacarbazine induces synergistic anticancer effects in metastatic melanoma.
    Molecular cancer research : MCR, 2015, Volume: 13, Issue:4

    Topics: Antibiotics, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Molecular Targeted Therapy; Neoplasm Metastasis; Nodal Protein; Skin Neoplasms

2015
Long term survival with the combination of interferon and chemotherapy in metastatic melanoma.
    Journal of the Egyptian National Cancer Institute, 2015, Volume: 27, Issue:3

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Fatal Outcome; Female; Humans; Indoles; Interferon alpha-2; Interferon-alpha; Ipilimumab; Melanoma; Middle Aged; Recombinant Proteins; Skin Neoplasms; Sulfonamides; Vemurafenib

2015
MGMT Expression Predicts PARP-Mediated Resistance to Temozolomide.
    Molecular cancer therapeutics, 2015, Volume: 14, Issue:5

    Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Mice; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Temozolomide; Tumor Suppressor Proteins

2015
c-Myc modulation: a key role in melanoma drug response.
    Cancer biology & therapy, 2015, Volume: 16, Issue:9

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Dacarbazine; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gene Expression; Humans; Hydrogen Peroxide; Melanoma; Paclitaxel; Protein Phosphatase 2; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-myc; Skin Neoplasms; Temozolomide

2015
Comparative healthcare costs in patients with metastatic melanoma in the USA.
    Melanoma research, 2015, Volume: 25, Issue:4

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Dacarbazine; Female; Health Care Costs; Humans; Immunotherapy; Indoles; Ipilimumab; Male; Managed Care Programs; Melanoma; Middle Aged; Molecular Targeted Therapy; Paclitaxel; Retrospective Studies; Skin Neoplasms; Sulfonamides; Temozolomide; United States; Vemurafenib

2015
Swinging for the Fences: Long-Term Survival With Ipilimumab in Metastatic Melanoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Jun-10, Volume: 33, Issue:17

    Topics: Adrenal Insufficiency; Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine; Hormone Replacement Therapy; Humans; Hypopituitarism; Hypothyroidism; Interferon-alpha; Interleukin-2; Ipilimumab; Lung Neoplasms; Lymphatic Metastasis; Male; Melanoma; Neoplasm Staging; Parietal Lobe; Radiosurgery; Sentinel Lymph Node Biopsy; Shoulder; Skin Neoplasms; Treatment Outcome; Vinblastine

2015
Treatment patterns in advanced melanoma: findings from a survey of European oncologists.
    European journal of cancer care, 2015, Volume: 24, Issue:6

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Cancer Care Facilities; Dacarbazine; Europe; France; Germany; Hospitals, Community; Hospitals, University; Humans; Indoles; Ipilimumab; Italy; Medical Oncology; Melanoma; Practice Patterns, Physicians'; Spain; Sulfonamides; Surveys and Questionnaires; United Kingdom; Vemurafenib

2015
Efficacy and safety of bio-chemotherapy with dacarbazine plus interleukin-2 in patients with unresectable malignant melanoma.
    Asia-Pacific journal of clinical oncology, 2015, Volume: 11, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Dacarbazine; Female; Humans; Interferon-alpha; Male; Melanoma; Middle Aged; Remission Induction; Retrospective Studies; Safety; Survival Rate; Treatment Outcome; Young Adult

2015
[A Case of Advanced Malignant Melanoma of the Esophagus with Distant Metastases].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:8

    Topics: Aged; Antineoplastic Agents, Alkylating; Bone Neoplasms; Brain Neoplasms; Dacarbazine; Esophageal Neoplasms; Fatal Outcome; Female; Humans; Lymphatic Metastasis; Melanoma; Positron-Emission Tomography; Tomography, X-Ray Computed

2015
Is chemotherapy still an option in the treatment of melanoma?
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:11

    Topics: Albumins; Dacarbazine; Female; Humans; Male; Melanoma; Paclitaxel; Skin Neoplasms

2015
IGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomide.
    Oncotarget, 2015, Nov-24, Volume: 6, Issue:37

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Breaks, Double-Stranded; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; G1 Phase Cell Cycle Checkpoints; Humans; Imidazoles; Melanoma; Mice, Inbred BALB C; Mice, Nude; Mutation; Proto-Oncogene Proteins B-raf; Pyrazines; Receptor, IGF Type 1; Survival Analysis; Temozolomide; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2015
A case series of anal melanoma including the results of treatment with imatinib in selected patients.
    Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2016, Volume: 18, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Antineoplastic Agents; Anus Neoplasms; Dacarbazine; Digestive System Surgical Procedures; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Mutation; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Retrospective Studies; Sorafenib; Survival Rate

2016
Infrared spectra of primary melanomas can predict response to chemotherapy: The example of dacarbazine.
    Biochimica et biophysica acta, 2016, Volume: 1862, Issue:2

    Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Melanoma; Models, Biological; Principal Component Analysis; Prognosis; ROC Curve; Spectroscopy, Fourier Transform Infrared

2016
Bacterial Sepsis Increases Survival in Metastatic Melanoma: Chlamydophila Pneumoniae Induces Macrophage Polarization and Tumor Regression.
    The Journal of investigative dermatology, 2016, Volume: 136, Issue:4

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chlamydophila Infections; Chlamydophila pneumoniae; Dacarbazine; Humans; Lomustine; Lung Neoplasms; Macrophage Activation; Macrophages; Melanoma; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Neoplasms; Sepsis; Skin Neoplasms; Treatment Outcome; Vincristine

2016
Predicting analysis times in randomized clinical trials with cancer immunotherapy.
    BMC medical research methodology, 2016, Feb-01, Volume: 16

    Topics: Algorithms; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Dacarbazine; Humans; Immunotherapy; Ipilimumab; Kaplan-Meier Estimate; Melanoma; Models, Theoretical; Neoplasms; Outcome Assessment, Health Care; Prognosis; Randomized Controlled Trials as Topic; Reproducibility of Results; Research Design; Retrospective Studies; Time Factors

2016
Phase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma.
    The oncologist, 2016, Volume: 21, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Perfusion Imaging; Temozolomide; Tomography, X-Ray Computed; Treatment Outcome; Uveal Neoplasms; Vascular Endothelial Growth Factor A

2016
DNA methylation and histone acetylation regulate the expression of MGMT and chemosensitivity to temozolomide in malignant melanoma cell lines.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:8

    Topics: Acetylation; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Chromatin Immunoprecipitation; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Histones; Humans; Melanoma; Reverse Transcriptase Polymerase Chain Reaction; Skin Neoplasms; Temozolomide; Tumor Suppressor Proteins

2016
Cell Cycle Phase-Specific Drug Resistance as an Escape Mechanism of Melanoma Cells.
    The Journal of investigative dermatology, 2016, Volume: 136, Issue:7

    Topics: Alkylating Agents; Apoptosis; Bortezomib; Cell Cycle Checkpoints; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Dacarbazine; Drug Resistance, Neoplasm; G1 Phase; G2 Phase; Humans; MAP Kinase Signaling System; Melanoma; Mitogen-Activated Protein Kinases; Phosphorylation; Skin Neoplasms; Temozolomide

2016
Case of hypophysitis caused by nivolumab.
    The Journal of dermatology, 2017, Volume: 44, Issue:1

    Topics: Adrenal Insufficiency; Adrenocorticotropic Hormone; Anorexia; Antibodies, Monoclonal; Antineoplastic Agents; Conjunctiva; Dacarbazine; Hormone Replacement Therapy; Humans; Hydrocortisone; Hypophysitis; Hypothyroidism; Lung Diseases, Interstitial; Magnetic Resonance Imaging; Male; Melanoma; Middle Aged; Myalgia; Nausea; Nivolumab; Programmed Cell Death 1 Receptor; Withholding Treatment

2017
NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells.
    Oncotarget, 2016, Jul-26, Volume: 7, Issue:30

    Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Buthionine Sulfoximine; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Female; Glioma; Glutathione; Humans; Melanoma; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Mice, Nude; NF-E2-Related Factor 2; Temozolomide; Xenograft Model Antitumor Assays

2016
DR5 mAb-conjugated, DTIC-loaded immuno-nanoparticles effectively and specifically kill malignant melanoma cells in vivo.
    Oncotarget, 2016, Aug-30, Volume: 7, Issue:35

    Topics: Alanine Transaminase; Animals; Antibodies, Monoclonal; Apoptosis; Cell Line, Tumor; Creatinine; Dacarbazine; Drug Delivery Systems; Humans; Immunotherapy; Leukocytes; Male; Melanoma; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasm Transplantation; Receptors, TNF-Related Apoptosis-Inducing Ligand; Skin Neoplasms

2016
In-vitro and in-vivo inhibition of melanoma growth and metastasis by the drug combination of celecoxib and dacarbazine.
    Melanoma research, 2016, Volume: 26, Issue:6

    Topics: Animals; Celecoxib; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Dacarbazine; Disease Models, Animal; Female; Humans; Melanoma; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Skin Neoplasms

2016
PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas.
    Oncotarget, 2016, 11-15, Volume: 7, Issue:46

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; DNA Breaks, Double-Stranded; DNA Ligase ATP; DNA Repair; Drug Synergism; Histones; Humans; Melanocytes; Melanoma; Mice; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Synthetic Lethal Mutations; Xenograft Model Antitumor Assays

2016
Oral mucosal melanoma treated with carbon ion radiotherapy: a case report.
    Journal of medical case reports, 2016, Oct-18, Volume: 10, Issue:1

    Topics: Aged; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Dacarbazine; Heavy Ion Radiotherapy; Humans; Male; Melanoma; Mouth Mucosa; Mouth Neoplasms; Mucous Membrane; Neoplasm Recurrence, Local; Nimustine; Radiation Injuries; Radiotherapy Dosage; Treatment Outcome; Vincristine

2016
Tumor-targeting Salmonella typhimurium A1-R combined with temozolomide regresses malignant melanoma with a BRAF-V600E mutation in a patient-derived orthotopic xenograft (PDOX) model.
    Oncotarget, 2016, Dec-27, Volume: 7, Issue:52

    Topics: Aged; Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Melanoma; Mice; Mice, Nude; Mutation; Proto-Oncogene Proteins B-raf; Salmonella typhimurium; Temozolomide; Xenograft Model Antitumor Assays

2016
Evaluating the cytotoxic effects of the water extracts of four anticancer herbs against human malignant melanoma cells.
    Drug design, development and therapy, 2016, Volume: 10

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Cell Line, Tumor; Chromatography, High Pressure Liquid; Dacarbazine; Dose-Response Relationship, Drug; Drug Synergism; Hedyotis; Humans; Lobelia; Melanoma; Phytotherapy; Plant Extracts; Plants, Medicinal; Reactive Oxygen Species; Scutellaria; Skin Neoplasms; Solanum nigrum; Solvents; Tandem Mass Spectrometry; Temozolomide; Water

2016
A combination of photodynamic therapy and chemotherapy displays a differential cytotoxic effect on human metastatic melanoma cells.
    Journal of photochemistry and photobiology. B, Biology, 2017, Volume: 166

    Topics: Anthracenes; Antineoplastic Agents; Cell Line, Tumor; Dacarbazine; Humans; Melanoma; Neoplasm Metastasis; Perylene; Photochemotherapy; Skin Neoplasms

2017
Umbelliferone Decreases Intracellular pH and Sensitizes Melanoma Cell Line A375 to Dacarbazin. Comparison with Acetazolamide.
    Current molecular pharmacology, 2018, Volume: 11, Issue:2

    Topics: Acetazolamide; Apoptosis; Carbonic Anhydrase Inhibitors; Carbonic Anhydrase IX; Cell Line, Tumor; Dacarbazine; Humans; Hydrogen-Ion Concentration; Intracellular Space; Melanoma; Umbelliferones

2018
Oncolytic adenovirus expressing interleukin-18 improves antitumor activity of dacarbazine for malignant melanoma.
    Drug design, development and therapy, 2016, Volume: 10

    Topics: Adenoviridae; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Drug Therapy, Combination; Humans; Interleukin-18; Lung Neoplasms; Melanoma; Mice; Mice, Nude; Oncolytic Virotherapy; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2016
Autophagy inhibitors chloroquine and LY294002 enhance temozolomide cytotoxicity on cutaneous melanoma cell lines in vitro.
    Anti-cancer drugs, 2017, Volume: 28, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Chloroquine; Chromones; Dacarbazine; Drug Synergism; Humans; Melanoma; Morpholines; Skin Neoplasms; Temozolomide

2017
Formulation of temozolomide-loaded nanoparticles and their targeting potential to melanoma cells.
    Oncology reports, 2017, Volume: 37, Issue:2

    Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Dendrimers; Drug Delivery Systems; Fluorescein-5-isothiocyanate; Humans; Magnetic Resonance Spectroscopy; Melanoma; Microscopy, Electron, Transmission; Nanoparticles; Peptides; Spectroscopy, Fourier Transform Infrared; Temozolomide

2017
Patterns of use of systemic therapies among patients with metastatic melanoma: a retrospective claims database analysis in the United States.
    The Journal of dermatological treatment, 2017, Volume: 28, Issue:6

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Dacarbazine; Databases, Factual; Female; Humans; Indoles; Insurance Claim Review; Ipilimumab; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Skin Neoplasms; Sulfonamides; Temozolomide; United States; Vemurafenib; Young Adult

2017
An unusual pituitary stalk lesion: What is the place of surgery?
    Neuro-Chirurgie, 2016, Volume: 62, Issue:6

    Topics: Adult; Antineoplastic Agents; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Diabetes Insipidus; Endoscopy; Fatal Outcome; Female; Hemianopsia; Humans; Hypopituitarism; Indoles; Melanoma; Pituitary Neoplasms; Sulfonamides; Temozolomide; Tomography, X-Ray Computed; Vemurafenib

2016
Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Apr-10, Volume: 35, Issue:11

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Cycle Checkpoints; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Dacarbazine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Health Care Costs; Humans; Ipilimumab; Markov Chains; Melanoma; Models, Economic; Nivolumab; Paclitaxel; Proto-Oncogene Proteins B-raf; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Survival Rate

2017
Two cases of melanomas paradoxically metastasizing to the intestinal tract during nivolumab therapy.
    The Journal of dermatology, 2017, Volume: 44, Issue:8

    Topics: Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; C-Reactive Protein; Colonic Neoplasms; Colonoscopy; Dacarbazine; Endoscopy, Gastrointestinal; Fatal Outcome; Female; Humans; Ileocecal Valve; Intussusception; Lung Neoplasms; Lymphatic Metastasis; Male; Melanoma; Nivolumab; Occult Blood; Skin; Skin Neoplasms; Tomography, X-Ray Computed

2017
[Adjuvant chemotherapy as a component of complex treatment for skin melanoma].
    Voprosy onkologii, 2008, Volume: 54, Issue:2

    Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Dacarbazine; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Humans; Lymph Node Excision; Male; Melanoma; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Radiotherapy, Adjuvant; Skin Neoplasms; Survival Analysis; Treatment Outcome; Vincristine

2008
[In vitro drug sensitivity profiling in melanoma].
    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2008, Volume: 6, Issue:7

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Humans; In Vitro Techniques; Melanoma; Randomized Controlled Trials as Topic; Skin Neoplasms; Survival Rate; Tumor Stem Cell Assay

2008
Biochemotherapy in patients with advanced head and neck mucosal melanoma.
    Head & neck, 2008, Volume: 30, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Therapy, Combination; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Immunologic Factors; Injections, Intravenous; Interferon-alpha; Interleukin-2; Male; Medical Records; Melanoma; Middle Aged; Mucous Membrane; Neoplasm Staging; Retrospective Studies; Skin Neoplasms; Survival Analysis; Treatment Outcome; Vinblastine

2008
PARP inhibitors and cancer therapy - early results and potential applications.
    The British journal of radiology, 2008, Volume: 81 Spec No 1

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Breast Neoplasms; Dacarbazine; Enzyme Inhibitors; Female; Humans; Melanoma; Mice; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide

2008
Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines.
    Journal of translational medicine, 2008, Sep-29, Volume: 6

    Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Dasatinib; Drug Screening Assays, Antitumor; Drug Synergism; Focal Adhesion Protein-Tyrosine Kinases; Humans; Melanoma; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins pp60(c-src); Pyridines; Pyrimidines; Receptor, EphA2; Sorafenib; Temozolomide; Thiazoles

2008
Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib.
    Nature clinical practice. Oncology, 2008, Volume: 5, Issue:12

    Topics: Aged; Antineoplastic Agents; Anus Neoplasms; Benzenesulfonates; Dacarbazine; Humans; Male; Melanoma; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Pyridines; Sorafenib; Temozolomide; Treatment Outcome

2008
Melanocytoma in the orbital apex.
    Journal of neuro-oncology, 2009, Volume: 92, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Diagnosis, Differential; Humans; Immunohistochemistry; Interferon-beta; Male; Melanocytes; Melanoma; Meningeal Neoplasms; Middle Aged; Neurosurgical Procedures; Nimustine; Orbital Neoplasms; Tomography, X-Ray Computed; Vincristine

2009
Differential effects of imatinib mesylate against uveal melanoma in vitro and in vivo.
    Melanoma research, 2008, Volume: 18, Issue:6

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Humans; Imatinib Mesylate; Melanoma; Mice; Piperazines; Pyrimidines; Temozolomide; Uveal Neoplasms; Xenograft Model Antitumor Assays

2008
[Combined treatment with dacarbazine, nimustine, cisplatin, and tamoxifen plus interferon-beta in a patient with advanced anorectal malignant melanoma].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2008, Volume: 105, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Cisplatin; Dacarbazine; Humans; Interferon-beta; Liver Neoplasms; Male; Melanoma; Neoplasm Staging; Nimustine; Rectal Neoplasms; Tamoxifen; Treatment Outcome

2008
Concurrent chemobiotherapy with cisplatin, dacarbazine, decrescendo interleukin-2 and interferon alpha2b in patients with metastatic melanoma.
    Oncology reports, 2008, Volume: 20, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease-Free Survival; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Skin Neoplasms; Treatment Outcome

2008
Intra-axial brainstem malignant melanoma mimicking cavernous angioma--case report.
    Neurologia medico-chirurgica, 2008, Volume: 48, Issue:11

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cranial Nerve Diseases; Craniotomy; Dacarbazine; Diagnosis, Differential; Female; Hemangioma, Cavernous, Central Nervous System; Humans; Intracranial Hemorrhages; Magnetic Resonance Imaging; Melanoma; Nimustine; Radiotherapy, Adjuvant; Reoperation; Tamoxifen

2008
Long-term progression-free survival in metastatic uveal melanoma after chemoimmunotherapy and consolidation thermoablation.
    Acta oncologica (Stockholm, Sweden), 2009, Volume: 48, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Catheter Ablation; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Humans; Immunotherapy; Interferon Type I; Liver Neoplasms; Lomustine; Magnetic Resonance Imaging; Male; Melanoma; Middle Aged; Prognosis; Recombinant Proteins; Treatment Outcome; Uveal Neoplasms; Vincristine

2009
Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells.
    Molecular cancer therapeutics, 2008, Volume: 7, Issue:12

    Topics: Antineoplastic Agents, Alkylating; Cell Death; Cell Line, Tumor; Dacarbazine; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Interleukins; Melanoma; O(6)-Methylguanine-DNA Methyltransferase; Skin Neoplasms; Temozolomide; Tumor Suppressor Protein p53

2008
Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide.
    The Journal of investigative dermatology, 2009, Volume: 129, Issue:6

    Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cisplatin; Dacarbazine; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Melanoma; Neoplasm Invasiveness; Phosphatidylinositol 3-Kinases; Protein Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Temozolomide; TOR Serine-Threonine Kinases

2009
Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53.
    British journal of cancer, 2009, Jan-27, Volume: 100, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspases; Collagen Type XI; Dacarbazine; DNA Breaks, Double-Stranded; DNA Mismatch Repair; DNA Modification Methylases; DNA Repair Enzymes; Enzyme Activation; Everolimus; Humans; Melanoma; Necrosis; Phosphorylation; Sirolimus; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Tumor Suppressor Proteins

2009
Genomic and molecular profiling predicts response to temozolomide in melanoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Jan-15, Volume: 15, Issue:2

    Topics: Antineoplastic Agents, Alkylating; Area Under Curve; Cell Line, Tumor; Dacarbazine; DNA Methylation; Drug Screening Assays, Antitumor; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genomics; Humans; Inhibitory Concentration 50; Melanoma; Microsatellite Repeats; Neoplasm Metastasis; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide

2009
Impressive regression of visceral and cerebral melanoma metastases under combination treatment including dacarbacine, radiotherapy and celecoxib.
    International journal of dermatology, 2009, Volume: 48, Issue:2

    Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Celecoxib; Combined Modality Therapy; Cyclooxygenase Inhibitors; Dacarbazine; Female; Humans; Melanoma; Pyrazoles; Skin Neoplasms; Sulfonamides; Tongue Neoplasms

2009
Modulation of the efficacy of temozolomide and dacarbazine melanoma treatment by DNA-repair factors in vivo and in vitro.
    International journal of clinical pharmacology and therapeutics, 2009, Volume: 47, Issue:1

    Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Clinical Trials as Topic; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lymphocytes; Melanoma; Methylation; MutL Protein Homolog 1; MutS Homolog 2 Protein; Nuclear Proteins; Prodrugs; Promoter Regions, Genetic; RNA, Messenger; Temozolomide; Tumor Suppressor Proteins

2009
Primary malignant melanoma of the vagina.
    Archives of gynecology and obstetrics, 2009, Volume: 280, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Humans; Interferon-alpha; Lymphatic Metastasis; Melanoma; Middle Aged; Temozolomide; Vaginal Neoplasms

2009
The sodium pump alpha1 sub-unit: a disease progression-related target for metastatic melanoma treatment.
    Journal of cellular and molecular medicine, 2009, Volume: 13, Issue:9B

    Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cardenolides; Cell Line, Tumor; Dacarbazine; Disease Progression; Female; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Mice; Mice, Nude; Microscopy, Video; Neoplasm Metastasis; Neoplasm Transplantation; Sodium-Potassium-Exchanging ATPase; Temozolomide

2009
Homogeneous MGMT immunoreactivity correlates with an unmethylated MGMT promoter status in brain metastases of various solid tumors.
    PloS one, 2009, Volume: 4, Issue:3

    Topics: Alkylating Agents; Brain Neoplasms; Breast Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Immunohistochemistry; Kidney Neoplasms; Lung Neoplasms; Melanoma; Polymerase Chain Reaction; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins

2009
Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy.
    Molecular cancer therapeutics, 2009, Volume: 8, Issue:3

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Dacarbazine; Drug Delivery Systems; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Melanoma; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Biological; Niacinamide; Phenylurea Compounds; Pyridines; Quinoxalines; Skin Neoplasms; Sorafenib; Substrate Specificity; Temozolomide; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2009
Radioimmunotherapy of experimental human metastatic melanoma with melanin-binding antibodies and in combination with dacarbazine.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Apr-01, Volume: 15, Issue:7

    Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Female; Humans; Melanins; Melanoma; Mice; Mice, Nude; Neoplasm Metastasis; Organometallic Compounds; Positron-Emission Tomography; Radioimmunotherapy; Skin Neoplasms

2009
Effects of fotemustine or dacarbasine on a melanoma cell line pretreated with therapeutic proton irradiation.
    Journal of experimental & clinical cancer research : CR, 2009, Apr-09, Volume: 28

    Topics: Cell Line, Tumor; Cell Survival; Dacarbazine; Humans; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Protons

2009
Evidence of gamma-tocotrienol as an apoptosis-inducing, invasion-suppressing, and chemotherapy drug-sensitizing agent in human melanoma cells.
    Nutrition and cancer, 2009, Volume: 61, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Cadherins; Cell Line, Tumor; Cell Proliferation; Chromans; Dacarbazine; Docetaxel; Humans; JNK Mitogen-Activated Protein Kinases; Melanoma; Neoplasm Invasiveness; Signal Transduction; Taxoids; Vitamin E

2009
Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma.
    Melanoma research, 2009, Volume: 19, Issue:3

    Topics: Aniline Compounds; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cisplatin; Dacarbazine; Dasatinib; Drug Synergism; Enzyme Activation; Humans; Inhibitory Concentration 50; Melanoma; Nitriles; Paclitaxel; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Skin Neoplasms; src-Family Kinases; Temozolomide; Thiazoles

2009
Antifolate activity of pyrimethamine enhances temozolomide-induced cytotoxicity in melanoma cells.
    Molecular cancer research : MCR, 2009, Volume: 7, Issue:5

    Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; DNA Damage; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Folic Acid Antagonists; Glioma; Humans; Melanoma; Molecular Structure; Poly(ADP-ribose) Polymerases; Pyrimethamine; Temozolomide

2009
Nodular malignant melanoma and multiple cutaneous neoplasms under immunosuppression with azathioprine.
    Melanoma research, 2009, Volume: 19, Issue:4

    Topics: Aged; Antineoplastic Agents, Alkylating; Azathioprine; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Dacarbazine; Drug Therapy, Combination; Early Detection of Cancer; Humans; Immunosuppressive Agents; Kidney Transplantation; Lymphatic Metastasis; Male; Melanoma; Neoplasms, Multiple Primary; Skin Neoplasms; Splenic Neoplasms; Temozolomide

2009
Effective treatment of advanced human melanoma metastasis in immunodeficient mice using combination metronomic chemotherapy regimens.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Aug-01, Volume: 15, Issue:15

    Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Cyclophosphamide; Dacarbazine; Female; Humans; Lung Neoplasms; Melanoma; Mice; Mice, SCID; Skin Neoplasms; Vinblastine; Xenograft Model Antitumor Assays

2009
Rapid response to therapy of neurocutaneous melanosis with leptomeningeal melanoma.
    Pediatric blood & cancer, 2010, Volume: 54, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Child, Preschool; Cyclophosphamide; Dacarbazine; Female; Humans; Melanoma; Melanosis; Meningeal Neoplasms; Neurocutaneous Syndromes; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Temozolomide; Treatment Outcome

2010
Dacarbazine induced acute myeloid leukemia in melanoma.
    Melanoma research, 2009, Volume: 19, Issue:5

    Topics: Dacarbazine; Humans; Leukemia, Myeloid, Acute; Male; Melanoma; Skin Neoplasms

2009
Effect of DNA repair host factors on temozolomide or dacarbazine melanoma treatment in Caucasians.
    Pharmacogenetics and genomics, 2009, Volume: 19, Issue:10

    Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; DNA Repair; DNA, Neoplasm; Female; Humans; Male; Melanoma; Middle Aged; MutL Protein Homolog 1; MutS Homolog 2 Protein; Nuclear Proteins; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Tumor Cells, Cultured; White People

2009
Celastrol synergistically enhances temozolomide cytotoxicity in melanoma cells.
    Molecular cancer research : MCR, 2009, Volume: 7, Issue:12

    Topics: Cell Death; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Dacarbazine; Drug Screening Assays, Antitumor; Drug Synergism; Gene Knockdown Techniques; Humans; I-kappa B Proteins; Inhibitory Concentration 50; Melanoma; Mitogen-Activated Protein Kinases; NF-kappa B; NF-KappaB Inhibitor alpha; Pentacyclic Triterpenes; Phosphorylation; Proteasome Endopeptidase Complex; Protein Transport; RNA, Small Interfering; Temozolomide; Triterpenes; Tumor Necrosis Factor-alpha; Ubiquitinated Proteins

2009
Combination of dacarbazine and dimethylfumarate efficiently reduces melanoma lymph node metastasis.
    The Journal of investigative dermatology, 2010, Volume: 130, Issue:4

    Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Movement; Chemokine CXCL11; Chemokine CXCL2; Dacarbazine; Dermatologic Agents; Dimethyl Fumarate; Drug Therapy, Combination; Fumarates; Humans; Lymphatic Metastasis; Lymphatic Vessels; Melanoma; Mice; Mice, SCID; RNA, Messenger; Sentinel Lymph Node Biopsy; Skin Neoplasms; Xenograft Model Antitumor Assays

2010
The clinical efficacy of combination of docetaxel and temozolomide in previously treated patients with stage IV melanoma.
    Melanoma research, 2010, Volume: 20, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Docetaxel; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Retrospective Studies; Skin Neoplasms; Taxoids; Temozolomide; Treatment Outcome

2010
The influence of surgical procedure and the effect of chemotherapy on nodal and distant metastases of human malignant melanomas that have been grafted into nude mice.
    International journal of oral and maxillofacial surgery, 2010, Volume: 39, Issue:1

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Chemotherapy, Adjuvant; Cisplatin; Dacarbazine; Disease Models, Animal; Female; Humans; Injections, Intraperitoneal; Lung Neoplasms; Lymphatic Metastasis; Melanoma; Mice; Mice, Inbred BALB C; Mice, Inbred Strains; Mice, Nude; Mouth Neoplasms; Neoadjuvant Therapy; Neoplasm Seeding; Neoplasm Transplantation; Punctures; Subcutaneous Tissue

2010
The cyclin-dependent kinase inhibitor PHA-848125 suppresses the in vitro growth of human melanomas sensitive or resistant to temozolomide, and shows synergistic effects in combination with this triazene compound.
    Pharmacological research, 2010, Volume: 61, Issue:5

    Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Coloring Agents; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinases; Dacarbazine; DNA Mutational Analysis; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Genes, p53; Humans; Melanoma; O(6)-Methylguanine-DNA Methyltransferase; Pyrazoles; Quinazolines; Temozolomide; Tetrazolium Salts; Thiazoles

2010
Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole brain radiation therapy?
    American journal of clinical oncology, 2010, Volume: 33, Issue:6

    Topics: Administration, Oral; Aged; Antineoplastic Agents; Brain Neoplasms; Cohort Studies; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Radiotherapy Dosage; Retrospective Studies; Risk Assessment; Skin Neoplasms; Survival Analysis; Temozolomide; Treatment Outcome

2010
[Treatment of metastatic malignant melanoma localized to an extremity].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2010, Jan-14, Volume: 130, Issue:1

    Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Infusions, Intra-Arterial; Lower Extremity; Male; Melanoma; Middle Aged; Prognosis; Radiotherapy, Adjuvant; Registries; Remission Induction; Retrospective Studies; Skin Neoplasms; Survival Rate; Treatment Outcome; Upper Extremity

2010
Interleukin-29 binds to melanoma cells inducing Jak-STAT signal transduction and apoptosis.
    Molecular cancer therapeutics, 2010, Volume: 9, Issue:2

    Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Dacarbazine; Gene Expression Regulation, Neoplastic; Humans; Interferons; Interleukins; Janus Kinase 1; Melanoma; Oligonucleotide Array Sequence Analysis; Phosphorylation; Pyrazines; Signal Transduction; Skin Neoplasms; STAT Transcription Factors; Temozolomide

2010
Congenital pigment synthesizing melanoma of the scalp.
    Journal of the American Academy of Dermatology, 2010, Volume: 62, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Humans; Infant; Interferon-alpha; Interleukin-2; Lymphatic Metastasis; Melanins; Melanoma; Skin Neoplasms; Vinblastine

2010
Inhibition of poly(ADP-ribose) polymerase enhances the effect of chemotherapy in an animal model of regional therapy for the treatment of advanced extremity malignant melanoma.
    Annals of surgical oncology, 2010, Volume: 17, Issue:8

    Topics: Alkylating Agents; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Extremities; Humans; In Vitro Techniques; Indoles; Melanoma; Poly(ADP-ribose) Polymerase Inhibitors; Rats; Rats, Nude; Severity of Illness Index; Temozolomide; Treatment Outcome

2010
Enhanced anti-tumor activity by the combination of a conditionally replicating adenovirus mediated interleukin-24 and dacarbazine against melanoma cells via induction of apoptosis.
    Cancer letters, 2010, Aug-28, Volume: 294, Issue:2

    Topics: Adenoviridae; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Dacarbazine; Down-Regulation; Genetic Therapy; Humans; Interleukins; Melanoma; Microscopy, Fluorescence; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Oncolytic Virotherapy; Proto-Oncogene Proteins c-bcl-2; Transduction, Genetic; Up-Regulation

2010
Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Apr-15, Volume: 16, Issue:8

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dacarbazine; Female; Gene Expression Profiling; Humans; In Situ Hybridization, Fluorescence; Male; Melanoma; Mice; Mice, SCID; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Oligonucleotide Array Sequence Analysis; Organophosphorus Compounds; Polymorphism, Single Nucleotide; Temozolomide; Tumor Cells, Cultured; Uveal Neoplasms; Xenograft Model Antitumor Assays

2010
Gene expression signatures as a guide to treatment strategies for in-transit metastatic melanoma.
    Molecular cancer therapeutics, 2010, Volume: 9, Issue:4

    Topics: Aged; Aged, 80 and over; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Intracellular Space; Male; Melanoma; Melphalan; Middle Aged; Neoplasm Metastasis; Regression Analysis; Signal Transduction; Temozolomide; Transcription, Genetic

2010
Anti-melanoma activity of the 9.2.27PE immunotoxin in dacarbazine resistant cells.
    Journal of immunotherapy (Hagerstown, Md. : 1997), 2010, Volume: 33, Issue:3

    Topics: Antineoplastic Agents, Alkylating; Bacterial Toxins; Caspases; Cell Line, Tumor; Cell Survival; Dacarbazine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Activation; Gene Expression Regulation, Neoplastic; Humans; Immunotoxins; Melanoma; Membrane Potential, Mitochondrial; Oligonucleotide Array Sequence Analysis; Poly(ADP-ribose) Polymerases; Protein Biosynthesis; Reverse Transcriptase Polymerase Chain Reaction

2010
Multimodality management of a locally advanced primary oesophageal melanoma with radical surgery and adjuvant chemoimmunoradiotherapy.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2010, Volume: 12, Issue:4

    Topics: Adenocarcinoma, Follicular; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Esophageal Neoplasms; Esophagectomy; Female; Humans; Hypertension; Immunotherapy; Interferons; Melanoma; Middle Aged; Neoplasms, Second Primary; Radiotherapy, Adjuvant; Thyroid Neoplasms

2010
Generalized melanosis and melanuria in a patient with metastatic melanoma.
    Clinical and experimental dermatology, 2010, Volume: 35, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Diphosphonates; Humans; Imidazoles; Male; Melanins; Melanoma; Melanosis; Middle Aged; Positron-Emission Tomography; Skin Neoplasms; Zoledronic Acid

2010
Alterations in the p53 pathway and p16INK4a expression predict overall survival in metastatic melanoma patients treated with dacarbazine.
    The Journal of investigative dermatology, 2010, Volume: 130, Issue:10

    Topics: Animals; Antineoplastic Agents, Alkylating; Cyclin-Dependent Kinase Inhibitor p16; Dacarbazine; Humans; Melanoma; Predictive Value of Tests; Skin Neoplasms; Tumor Suppressor Protein p53

2010
Long-term survival in patients with metastatic melanoma treated with DTIC or temozolomide.
    The oncologist, 2010, Volume: 15, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Remission Induction; Skin Neoplasms; Survival Analysis; Survivors; Temozolomide; Treatment Outcome; Young Adult

2010
Quercetin abrogates chemoresistance in melanoma cells by modulating deltaNp73.
    BMC cancer, 2010, Jun-11, Volume: 10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cell Line, Tumor; Dacarbazine; DNA Damage; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Melanins; Melanoma; Mutation; Nuclear Proteins; Phosphorylation; Poly(ADP-ribose) Polymerases; Protein Serine-Threonine Kinases; Protein Transport; Quercetin; RNA Interference; Temozolomide; Time Factors; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins

2010
MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC.
    European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Eye Neoplasms; Female; Humans; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Skin Neoplasms; Tumor Suppressor Proteins

2010
Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy.
    Molecular cancer therapeutics, 2010, Volume: 9, Issue:7

    Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Blotting, Western; Butadienes; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Melanoma; Melphalan; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Nitriles; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-bcl-2; Pyridines; Rats; Rats, Nude; Sorafenib; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays

2010
Complete remission of metastatic malignant melanoma after surgery in association with development of systemic vitiligo.
    The Journal of dermatology, 2010, Volume: 37, Issue:8

    Topics: Antineoplastic Agents; Dacarbazine; Disease-Free Survival; Humans; Interferon-beta; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Nimustine; Osteomyelitis; Skin Neoplasms; Vincristine; Vitiligo

2010
Melanoma metastatic to multiple visceral organs: further considerations.
    Oncology (Williston Park, N.Y.), 2010, Volume: 24, Issue:7

    Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Dose Fractionation, Radiation; Humans; Melanoma; Neoplasm Metastasis; Nose Neoplasms; Palliative Care; Prognosis

2010
Nijmegen breakage syndrome protein (NBN) causes resistance to methylating anticancer drugs such as temozolomide.
    Molecular pharmacology, 2010, Volume: 78, Issue:5

    Topics: Antineoplastic Agents, Alkylating; Apoptosis; Caspase 7; Cell Cycle Proteins; Cell Line, Transformed; Cell Line, Tumor; Dacarbazine; DNA Methylation; Drug Resistance, Neoplasm; Fibroblasts; Guanine; Homozygote; Humans; Melanoma; Methylnitronitrosoguanidine; Mutagens; Mutation; Necrosis; Nijmegen Breakage Syndrome; Nuclear Proteins; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Temozolomide; Uveal Neoplasms

2010
MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome.
    British journal of cancer, 2010, Sep-07, Volume: 103, Issue:6

    Topics: Antineoplastic Agents; Base Sequence; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Primers; DNA Repair Enzymes; Female; Humans; Immunohistochemistry; Male; Melanoma; Middle Aged; Promoter Regions, Genetic; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins

2010
Dacarbazine treatment before peptide vaccination enlarges T-cell repertoire diversity of melan-a-specific, tumor-reactive CTL in melanoma patients.
    Cancer research, 2010, Sep-15, Volume: 70, Issue:18

    Topics: Antibody Affinity; Antigens, Neoplasm; Cancer Vaccines; CD8-Positive T-Lymphocytes; Combined Modality Therapy; Dacarbazine; Epitopes, T-Lymphocyte; Humans; K562 Cells; MART-1 Antigen; Melanoma; Neoplasm Proteins; Receptors, Antigen, T-Cell; T-Lymphocytes, Cytotoxic; Vaccines, Subunit

2010
Enhancing melanoma treatment with resveratrol.
    The Journal of surgical research, 2012, Volume: 172, Issue:1

    Topics: Animals; Antineoplastic Agents; Cell Line; Cell Line, Tumor; Chemotherapy, Adjuvant; Dacarbazine; Disease Models, Animal; Drug Therapy, Combination; Humans; In Vitro Techniques; Melanoma; Melphalan; Mice; Mice, Nude; Mice, SCID; Resveratrol; Skin Neoplasms; Stilbenes; Temozolomide; Treatment Outcome; Xenograft Model Antitumor Assays

2012
Positron emission tomography/computed tomography: use for initial staging of malignant melanoma.
    International journal of dermatology, 2010, Volume: 49, Issue:9

    Topics: Aged; Antineoplastic Agents, Alkylating; Axilla; Dacarbazine; Fatal Outcome; Humans; Liver Neoplasms; Male; Melanoma; Neoplasm Staging; Positron-Emission Tomography; Skin Neoplasms; Temozolomide; Tomography, X-Ray Computed

2010
Malignant melanoma of the breast: N-isopropyl-p-(123) I-iodoamphetamine single photon emission computed tomography ((123) I-IMP SPECT) is useful for the detection of metastasis.
    The Journal of dermatology, 2010, Volume: 37, Issue:9

    Topics: Adrenal Gland Neoplasms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Cisplatin; Dacarbazine; Fatal Outcome; Female; Humans; Interferon-beta; Iofetamine; Liver Neoplasms; Lung Neoplasms; MART-1 Antigen; Mastectomy, Modified Radical; Melanoma; Middle Aged; Neoplasm Staging; Nimustine; Nipples; Radiopharmaceuticals; S100 Proteins; Skin Neoplasms; Tamoxifen; Tomography, Emission-Computed, Single-Photon; Vincristine

2010
Unsuccessful high dose IL-2 therapy followed immediately by near continuous low dose temozolomide can result in rapid durable complete and near-complete remissions in metastatic melanoma.
    Cancer biology & therapy, 2010, Dec-01, Volume: 10, Issue:11

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Interleukin-2; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Remission Induction; Skin Neoplasms; Temozolomide; Treatment Outcome

2010
siRNA knockdown of ribonucleotide reductase inhibits melanoma cell line proliferation alone or synergistically with temozolomide.
    The Journal of investigative dermatology, 2011, Volume: 131, Issue:2

    Topics: Antineoplastic Agents, Alkylating; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dacarbazine; G1 Phase; Gene Silencing; Humans; Melanoma; Ribonucleoside Diphosphate Reductase; RNA, Small Interfering; S Phase; Skin Neoplasms; Temozolomide

2011
[A case report of anorectal malignant melanoma showing a complete response after DTIC/ACNU/VCR therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Combined Modality Therapy; Dacarbazine; Humans; Liver Neoplasms; Male; Melanoma; Middle Aged; Nimustine; Remission Induction; Tomography, X-Ray Computed; Vincristine

2010
Primary malignant melanoma of the esophagus: a study of clinical features, pathology, management and prognosis.
    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2011, Volume: 24, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Male; Melanoma; Middle Aged; Nimustine; Prognosis; Retrospective Studies; Treatment Outcome; Vincristine

2011
Down-regulation of O6-methylguanine-DNA methyl transferase enhances the effect of temozolomide in melanoma cells.
    Medical hypotheses, 2011, Volume: 76, Issue:1

    Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Down-Regulation; Humans; Melanoma; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide

2011
Silencing HSF1 by short hairpin RNA decreases cell proliferation and enhances sensitivity to hyperthermia in human melanoma cell lines.
    Journal of dermatological science, 2010, Volume: 60, Issue:3

    Topics: Adenoviridae; Antineoplastic Agents, Alkylating; Apoptosis; Base Sequence; Cell Line; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Dacarbazine; DNA-Binding Proteins; Drug Resistance, Neoplasm; G1 Phase; Gene Silencing; Heat Shock Transcription Factors; Heat-Shock Response; Humans; Hyperthermia, Induced; Keratinocytes; Melanoma; RNA, Small Interfering; Transcription Factors

2010
High activity of sequential low dose chemo-modulating Temozolomide in combination with Fotemustine in metastatic melanoma. A feasibility study.
    Journal of translational medicine, 2010, Nov-10, Volume: 8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dose-Response Relationship, Drug; Feasibility Studies; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Temozolomide

2010
Neck dissection and post-operative chemotherapy with dimethyl triazeno imidazole carboxamide and cisplatin protocol are useful for oral mucosal melanoma.
    BMC cancer, 2010, Nov-11, Volume: 10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Mouth Mucosa; Mouth Neoplasms; Neck Dissection; Postoperative Period; Prognosis; Retrospective Studies

2010
Placenta growth factor induces melanoma resistance to temozolomide through a mechanism that involves the activation of the transcription factor NF-κB.
    International journal of oncology, 2011, Volume: 38, Issue:1

    Topics: Dacarbazine; Drug Resistance, Neoplasm; Humans; Melanoma; NF-kappa B; Placenta Growth Factor; Pregnancy Proteins; RNA, Antisense; Temozolomide; Transfection; Vascular Endothelial Growth Factor Receptor-1

2011
Rb-Raf-1 interaction disruptor RRD-251 induces apoptosis in metastatic melanoma cells and synergizes with dacarbazine.
    Molecular cancer therapeutics, 2010, Volume: 9, Issue:12

    Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Humans; Melanoma; Mice; Neoplasm Metastasis; Phosphorylation; Protein Binding; Proto-Oncogene Proteins c-raf; Retinoblastoma Protein; Thiourea; Xenograft Model Antitumor Assays

2010
PTD4-apoptin protein and dacarbazine show a synergistic antitumor effect on B16-F1 melanoma in vitro and in vivo.
    European journal of pharmacology, 2011, Mar-01, Volume: 654, Issue:1

    Topics: Animals; Antineoplastic Agents, Alkylating; Capsid Proteins; Cell Line; Cell Line, Tumor; Dacarbazine; Drug Synergism; Female; Humans; Melanoma; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Recombinant Fusion Proteins

2011
Anti-retinal pigment epithelium antibodies in acute exudative polymorphous vitelliform maculopathy: a new hypothesis about disease pathogenesis.
    Archives of ophthalmology (Chicago, Ill. : 1960), 2011, Volume: 129, Issue:1

    Topics: Acute Disease; Antineoplastic Agents, Alkylating; Autoantibodies; Autoantigens; Blotting, Western; Cells, Cultured; Dacarbazine; Electrophoresis, Gel, Two-Dimensional; Electroretinography; Exudates and Transudates; Fluorescein Angiography; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Mass Spectrometry; Melanoma; Middle Aged; Neoplasms, Unknown Primary; Paraneoplastic Syndromes; Peroxiredoxin III; Peroxiredoxins; Retinal Pigment Epithelium; Temozolomide; Tomography, Optical Coherence; Vitelliform Macular Dystrophy

2011
Therapy-related myelodysplastic syndrome developed by dacarbazine, nimustine hydrochloride and vincristine sulfate (DAV) therapy for patient with malignant melanoma.
    The Journal of dermatology, 2011, Volume: 38, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Fatal Outcome; Female; Foot Diseases; Humans; Melanoma; Middle Aged; Myelodysplastic Syndromes; Nimustine; Retrospective Studies; Vincristine

2011
The glutathione transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) increases temozolomide efficacy against malignant melanoma.
    European journal of cancer (Oxford, England : 1990), 2011, Volume: 47, Issue:8

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Methylation; Drug Synergism; Glutathione Transferase; Humans; Inhibitory Concentration 50; Male; Melanoma; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Oxadiazoles; Temozolomide

2011
Equipoise and the dilemma of randomized clinical trials.
    The New England journal of medicine, 2011, Feb-03, Volume: 364, Issue:5

    Topics: Antineoplastic Agents; Dacarbazine; Ethics, Research; Humans; Indoles; Melanoma; Randomized Controlled Trials as Topic; Sulfonamides; Therapeutic Equipoise; Treatment Outcome; Uncertainty; Vemurafenib

2011
Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, May-15, Volume: 17, Issue:10

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Benzenesulfonates; Cell Count; Clinical Trials, Phase II as Topic; Dacarbazine; Drug Resistance, Neoplasm; Humans; Melanoma; Mice; Mice, Nude; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Skin Neoplasms; Sorafenib; Survival Analysis; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2011
Temozolomide chemoresistance heterogeneity in melanoma with different treatment regimens: DNA damage accumulation contribution.
    Melanoma research, 2011, Volume: 21, Issue:3

    Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Cycle; Cell Line, Tumor; Dacarbazine; DNA Damage; DNA Methylation; DNA Repair; Drug Resistance, Neoplasm; Gene Expression; Humans; Melanoma; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Temozolomide

2011
Dacarbazine-based chemotherapy as first-line treatment in noncutaneous metastatic melanoma: multicenter, retrospective analysis in Asia.
    Melanoma research, 2011, Volume: 21, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Asia; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Young Adult

2011
[Cellular markers based on DNA damage and repair (BER, MMR), expression of MLHI, MSH2, FasR, and cell death of lymphocytes as predictive parameters for clinical response to chemotherapy of melanoma].
    Tsitologiia, 2011, Volume: 53, Issue:1

    Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Death; Cisplatin; Dacarbazine; DNA Breaks, Double-Stranded; DNA Repair; Female; Gene Expression; Humans; Interferon-gamma; Ki-1 Antigen; Lomustine; Lymphocyte Count; Lymphocytes; Male; Melanoma; MutL Protein Homolog 1; MutS Homolog 2 Protein; Nuclear Proteins; Prognosis; Recombinant Proteins; Skin Neoplasms; Treatment Outcome

2011
Intrinsic anticancer drug resistance of malignant melanoma cells is abrogated by IFN-β and valproic acid.
    Cancer research, 2011, Jun-15, Volume: 71, Issue:12

    Topics: Animals; Antineoplastic Agents; Apoptosis; Caspase 8; Cell Line, Tumor; Dacarbazine; DNA Breaks, Double-Stranded; DNA Mismatch Repair; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Female; Humans; Interferon-beta; Male; Melanoma; Mice; Temozolomide; Tumor Suppressor Proteins; Valproic Acid

2011
Targeting inhibitor of apoptosis proteins in combination with dacarbazine or TRAIL in melanoma cells.
    Cancer biology & therapy, 2011, Jul-01, Volume: 12, Issue:1

    Topics: Antineoplastic Agents, Alkylating; Apoptosis; Baculoviral IAP Repeat-Containing 3 Protein; BH3 Interacting Domain Death Agonist Protein; Caspases; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Fragmentation; Drug Resistance, Neoplasm; Humans; Inhibitor of Apoptosis Proteins; Melanoma; Poly(ADP-ribose) Polymerases; RNA, Small Interfering; Survivin; TNF-Related Apoptosis-Inducing Ligand; Tumor Stem Cell Assay; Ubiquitin-Protein Ligases; X-Linked Inhibitor of Apoptosis Protein

2011
NRAS-mutant melanoma: response to chemotherapy.
    Archives of dermatology, 2011, Volume: 147, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Genes, ras; Humans; Male; Melanoma; Mutation; Proto-Oncogene Proteins p21(ras); Skin Neoplasms; Temozolomide

2011
Dacarbazine promotes stromal remodeling and lymphocyte infiltration in cutaneous melanoma lesions.
    The Journal of investigative dermatology, 2011, Volume: 131, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Dacarbazine; Disease Progression; Extracellular Matrix; Female; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Kaplan-Meier Estimate; Lymphocytes; Male; Melanoma; Middle Aged; Osteonectin; Skin Neoplasms; Stromal Cells; Tumor Microenvironment; Young Adult

2011
[Descriptive analysis of cutaneous recurrence patterns in patients with melanoma].
    Actas dermo-sifiliograficas, 2011, Volume: 102, Issue:10

    Topics: Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Female; Humans; Imiquimod; Kaplan-Meier Estimate; Lymph Node Excision; Male; Melanoma; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Multiple Primary; Prognosis; Skin Neoplasms; Skin Ulcer

2011
Melanoma-associated retinopathy: a presenting sign of metastatic disease.
    Journal of the American Academy of Dermatology, 2011, Volume: 65, Issue:1

    Topics: Antineoplastic Agents, Alkylating; Biopsy, Fine-Needle; Dacarbazine; Follow-Up Studies; Humans; Immunohistochemistry; Injections, Intralesional; Male; Melanoma; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Retinal Neoplasms; Risk Assessment; Skin Neoplasms; Temozolomide; Treatment Outcome; Visual Acuity; Visual Fields

2011
Strides in melanoma announced: maximizing value comes next.
    Journal of the National Cancer Institute, 2011, Jul-06, Volume: 103, Issue:13

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dacarbazine; Humans; Indoles; Ipilimumab; Melanoma; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Secondary Prevention; Skin Neoplasms; Sulfonamides; Survival Analysis; Treatment Outcome; Vemurafenib

2011
Acid ceramidase expression modulates the sensitivity of A375 melanoma cells to dacarbazine.
    The Journal of biological chemistry, 2011, Aug-12, Volume: 286, Issue:32

    Topics: Acid Ceramidase; Antineoplastic Agents, Alkylating; Autophagy; Dacarbazine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Neoplasm Metastasis

2011
[News on melanoma from the 2010 Dermatology Days in Paris].
    Annales de dermatologie et de venereologie, 2011, Volume: 138, Issue:5 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Chemotherapy, Adjuvant; Dacarbazine; Dermatology; Evidence-Based Medicine; Humans; Melanoma; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; Radiotherapy, Adjuvant; Skin Neoplasms; Sorafenib; Temozolomide; Treatment Outcome

2011
Leptomeningeal melanomatosis: stabilization of disease due to radiation, temozolomide and intrathecal liposomal cytarabine.
    Acta oncologica (Stockholm, Sweden), 2011, Volume: 50, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Dacarbazine; Humans; Injections, Spinal; Liposomes; Male; Melanoma; Meningeal Neoplasms; Middle Aged; Temozolomide

2011
Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition.
    The Journal of investigative dermatology, 2011, Volume: 131, Issue:10

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Cell Line, Tumor; Dacarbazine; Drug Screening Assays, Antitumor; Genes, Dominant; Humans; Indoles; Melanocytes; Melanoma; Niacinamide; Phenylurea Compounds; Prognosis; Proto-Oncogene Proteins B-raf; Pyridines; Receptors, Fibroblast Growth Factor; Signal Transduction; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib

2011
[Effectiveness of DNA repair and expression of MLH1, MSH2 and FASR in lymphocytes of patients with chemotherapy-responsive, disseminated cutaneous melanoma].
    Voprosy onkologii, 2011, Volume: 57, Issue:2

    Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; DNA Damage; DNA Repair; fas Receptor; Female; Gene Expression Regulation, Neoplastic; Humans; Interferon-gamma; Lomustine; Lymphocytes; Male; Melanoma; Middle Aged; MutL Protein Homolog 1; MutS Homolog 2 Protein; Nuclear Proteins; Predictive Value of Tests; Prognosis; Skin Neoplasms; Treatment Outcome

2011
Interaction of dacarbazine and imexon, in vitro and in vivo, in human A375 melanoma cells.
    Anticancer research, 2011, Volume: 31, Issue:9

    Topics: Animals; Antineoplastic Agents; Area Under Curve; Cell Line, Tumor; Comet Assay; Dacarbazine; Drug Interactions; Drug Screening Assays, Antitumor; Hexanones; Humans; In Vitro Techniques; Male; Melanoma; Mice; Mice, SCID

2011
The combination of BH3-mimetic ABT-737 with the alkylating agent temozolomide induces strong synergistic killing of melanoma cells independent of p53.
    PloS one, 2011, Volume: 6, Issue:8

    Topics: Alkylating Agents; Animals; Apoptosis; Biomimetic Materials; Biphenyl Compounds; Cell Line, Tumor; Dacarbazine; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Mice; Nitrophenols; Piperazines; Protein Structure, Tertiary; Proto-Oncogene Proteins c-bcl-2; Sulfonamides; Temozolomide; Time Factors; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2011
Hypopigmentation in the sites of regressed melanoma metastases after successful dacarbazine therapy.
    International journal of dermatology, 2012, Volume: 51, Issue:9

    Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Forearm; Head and Neck Neoplasms; Humans; Hyperpigmentation; Male; Melanoma; Middle Aged; Scalp; Skin Neoplasms; Torso

2012
Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control.
    Cancer research, 2011, Nov-15, Volume: 71, Issue:22

    Topics: Animals; Cell Movement; Chemokine CCL5; Chemokine CXCL9; Chemokines; Dacarbazine; Humans; Melanoma; Mice; Mice, Inbred C57BL; Skin Neoplasms; T-Lymphocytes; Temozolomide

2011
Anti-DR5 monoclonal antibody-mediated DTIC-loaded nanoparticles combining chemotherapy and immunotherapy for malignant melanoma: target formulation development and in vitro anticancer activity.
    International journal of nanomedicine, 2011, Volume: 6

    Topics: Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Flow Cytometry; Humans; Immunotherapy; Melanoma; Microscopy, Confocal; Nanoconjugates; Receptors, TNF-Related Apoptosis-Inducing Ligand; Skin Neoplasms

2011
Inhibition of coding region determinant binding protein sensitizes melanoma cells to chemotherapeutic agents.
    Pigment cell & melanoma research, 2012, Volume: 25, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dacarbazine; Down-Regulation; Drug Resistance, Neoplasm; Etoposide; Gene Knockdown Techniques; Humans; Melanoma; Microphthalmia-Associated Transcription Factor; Neoplasm Proteins; RNA-Binding Proteins; RNA, Small Interfering; Temozolomide; Vinblastine

2012
Ipilimumab plus dacarbazine in melanoma.
    The New England journal of medicine, 2011, 09-29, Volume: 365, Issue:13

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma

2011
Ipilimumab plus dacarbazine in melanoma.
    The New England journal of medicine, 2011, 09-29, Volume: 365, Issue:13

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma

2011
Ipilimumab plus dacarbazine in melanoma.
    The New England journal of medicine, 2011, 09-29, Volume: 365, Issue:13

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma

2011
Vemurafenib in melanoma with BRAF V600E mutation.
    The New England journal of medicine, 2011, 10-13, Volume: 365, Issue:15

    Topics: Antineoplastic Agents; Dacarbazine; Female; Humans; Indoles; Male; Melanoma; Proto-Oncogene Proteins B-raf; Sulfonamides

2011
Vemurafenib in melanoma with BRAF V600E mutation.
    The New England journal of medicine, 2011, 10-13, Volume: 365, Issue:15

    Topics: Antineoplastic Agents; Dacarbazine; Female; Humans; Indoles; Male; Melanoma; Proto-Oncogene Proteins B-raf; Sulfonamides

2011
Vemurafenib in melanoma with BRAF V600E mutation.
    The New England journal of medicine, 2011, 10-13, Volume: 365, Issue:15

    Topics: Antineoplastic Agents; Dacarbazine; Female; Humans; Indoles; Male; Melanoma; Proto-Oncogene Proteins B-raf; Sulfonamides

2011
[Linear porokeratosis].
    Annales de dermatologie et de venereologie, 2011, Volume: 138, Issue:11

    Topics: Aged; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Female; Foot Diseases; Humans; Immunotherapy, Active; Lasers, Gas; Low-Level Light Therapy; Melanoma; Porokeratosis; Skin Neoplasms; Toes

2011
Signalling and chemosensitivity assays in melanoma: is mutated status a prerequisite for targeted therapy?
    Experimental dermatology, 2011, Volume: 20, Issue:12

    Topics: Adolescent; Antineoplastic Agents; Benzenesulfonates; Butadienes; Cell Survival; Dacarbazine; Drug Therapy, Combination; Extracellular Signal-Regulated MAP Kinases; Fatal Outcome; Female; Genes, ras; Humans; Melanoma; Molecular Targeted Therapy; Mutation; Niacinamide; Nitriles; Nitrosourea Compounds; Organophosphorus Compounds; Phenylurea Compounds; Phosphorylation; Precision Medicine; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-kit; Pyridines; Signal Transduction; Sorafenib; Treatment Outcome

2011
Melanoma of stomach.
    Journal of gastrointestinal cancer, 2012, Volume: 43, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Humans; Lymphatic Metastasis; Melanoma; Middle Aged; Stomach Neoplasms

2012
[The usefulness of neo- and adjuvant therapy in the treatment of cutaneous melanoma].
    Voprosy onkologii, 2011, Volume: 57, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cyclophosphamide; Dacarbazine; Disease Progression; Dose Fractionation, Radiation; Female; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Radiotherapy, Adjuvant; Retrospective Studies; Skin Neoplasms; Surgical Procedures, Operative; Treatment Outcome; Vincristine

2011
Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing.
    Nature genetics, 2011, Dec-25, Volume: 44, Issue:2

    Topics: Antineoplastic Agents; Base Sequence; Cell Line, Tumor; Dacarbazine; Exome; Humans; Loss of Heterozygosity; MAP Kinase Kinase Kinase 5; MAP Kinase Kinase Kinases; Melanoma; Molecular Sequence Data; Mutation; Sequence Analysis, DNA; Sequence Homology, Nucleic Acid; Skin Neoplasms; Temozolomide; Tumor Cells, Cultured

2011
Retrospective study of patients with brain metastases from melanoma receiving concurrent whole-brain radiation and temozolomide.
    Anticancer research, 2011, Volume: 31, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Radiotherapy; Retrospective Studies; Temozolomide; Time Factors

2011
Targeting protein-trafficking pathways alters melanoma treatment sensitivity.
    Proceedings of the National Academy of Sciences of the United States of America, 2012, Jan-10, Volume: 109, Issue:2

    Topics: Amino Acid Sequence; Antineoplastic Agents; Carboplatin; Cell Line, Tumor; Cisplatin; Dacarbazine; DNA Repair; Down-Regulation; Drug Resistance, Neoplasm; Humans; Immunoblotting; Intracellular Signaling Peptides and Proteins; Melanoma; Melanosomes; Microscopy, Electron; Microscopy, Fluorescence; Molecular Sequence Data; Mutation; Protein Transport; Receptor, Melanocortin, Type 1; RNA Interference; Temozolomide; Up-Regulation; Vesicular Transport Proteins

2012
Antiproliferative and apoptosis-inducing effects of lipophilic vitamins on human melanoma A375 cells in vitro.
    Biological & pharmaceutical bulletin, 2012, Volume: 35, Issue:1

    Topics: Annexin A5; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cholecalciferol; Dacarbazine; Drug Resistance, Neoplasm; Humans; Hydrophobic and Hydrophilic Interactions; Inhibitory Concentration 50; Melanoma; Tretinoin; Vitamin K; Vitamins

2012
Regression of metastatic melanoma in a patient by antibody targeting of cancer stem cells.
    Oncotarget, 2012, Volume: 3, Issue:1

    Topics: Aged; Antibodies; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Foot; Humans; Male; Melanoma; Molecular Targeted Therapy; Neoplastic Stem Cells; Remission Induction; Rituximab; Skin Neoplasms; Tumor Burden

2012
Combination of oncolytic adenovirus and dacarbazine attenuates antitumor ability against uveal melanoma cells via cell cycle block.
    Cancer biology & therapy, 2012, Jan-15, Volume: 13, Issue:2

    Topics: Adenoviridae; Antineoplastic Agents, Alkylating; Apoptosis; Cell Cycle; Cell Line, Tumor; Combined Modality Therapy; Cytopathogenic Effect, Viral; Dacarbazine; Drug Synergism; Humans; Melanoma; Oncolytic Virotherapy; Oncolytic Viruses; Time Factors; Uveal Neoplasms; Virus Replication

2012
Immunohistological analysis of in-transit metastasis in a patient with advanced melanoma treated with combination therapy of cytosine guanine dinucleotide oligodeoxynucleotide, dacarbazine and beta-interferon: a case report.
    The Journal of dermatology, 2012, Volume: 39, Issue:12

    Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dinucleoside Phosphates; Fatal Outcome; Female; Humans; Interferon-beta; Lymphatic Metastasis; Melanoma; T-Lymphocytes

2012
Rational incorporation of selenium into temozolomide elicits superior antitumor activity associated with both apoptotic and autophagic cell death.
    PloS one, 2012, Volume: 7, Issue:4

    Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Brain Neoplasms; Calpain; Cell Line, Tumor; Dacarbazine; Glioma; Humans; Male; Melanoma; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Selenium; Skin Neoplasms; Temozolomide; Xenograft Model Antitumor Assays

2012
Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07.
    Oncology reports, 2012, Volume: 28, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Dacarbazine; DNA Methylation; Epigenomics; Female; Humans; Immunohistochemistry; Male; Melanoma; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Predictive Value of Tests; Promoter Regions, Genetic; Temozolomide; Treatment Outcome

2012
Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistance.
    The Journal of investigative dermatology, 2012, Volume: 132, Issue:10

    Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Coloring Agents; Dacarbazine; Drug Resistance, Neoplasm; Female; Humans; In Vitro Techniques; Interleukin-8; Melanoma; Mice; Mice, Nude; Paclitaxel; Side-Population Cells; Skin Neoplasms; Temozolomide; Up-Regulation; Xenograft Model Antitumor Assays

2012
Melanoma chemotherapy leads to the selection of ABCB5-expressing cells.
    PloS one, 2012, Volume: 7, Issue:5

    Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Membrane; Cell Survival; Dacarbazine; Female; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Mice; Mice, Nude; Neoplasm, Residual; Skin Neoplasms; Xenograft Model Antitumor Assays

2012
BRAF inhibition and beyond in advanced melanoma.
    Lancet (London, England), 2012, Jul-28, Volume: 380, Issue:9839

    Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Imidazoles; Male; Melanoma; Oximes

2012
Two cases of malignant melanoma of the toe developed skin ulcers following local injection of natural beta-interferon.
    The Journal of dermatology, 2012, Volume: 39, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Foot Diseases; Humans; Interferon-beta; Melanoma; Nimustine; Skin Neoplasms; Skin Ulcer; Vincristine

2012
Redox-related antimelanoma activity of ATN-224.
    Melanoma research, 2009, Volume: 19, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Disulfiram; Drug Synergism; Enzyme Inhibitors; Glutathione; Humans; Melanins; Melanoma; Molybdenum; Oxidation-Reduction; Oxides; Reactive Oxygen Species; Superoxide Dismutase; Temozolomide

2009
A neoadjuvant biochemotherapy approach to stage III melanoma: analysis of surgical outcomes.
    Immunotherapy, 2012, Volume: 4, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Therapy; Chemotherapy, Adjuvant; Cisplatin; Dacarbazine; Female; Hematologic Diseases; Humans; Interferon-alpha; Interleukin-2; Lymph Node Excision; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Postoperative Complications; Prognosis; Retrospective Studies; Skin Neoplasms; Survival Analysis; Treatment Outcome; Vinblastine; Young Adult

2012
ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets.
    Stem cells (Dayton, Ohio), 2012, Volume: 30, Issue:10

    Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Aldehyde Oxidoreductases; Animals; Apoptosis; Cell Transformation, Neoplastic; Dacarbazine; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Isoenzymes; Melanoma; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Transplantation; Neoplastic Stem Cells; Response Elements; Retinal Dehydrogenase; RNA, Small Interfering; Skin Neoplasms; Temozolomide; Tretinoin

2012
p53R2 is a prognostic factor of melanoma and regulates proliferation and chemosensitivity of melanoma cells.
    Journal of dermatological science, 2012, Volume: 68, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Child; Cisplatin; Cyclin-Dependent Kinase Inhibitor p21; Dacarbazine; Dose-Response Relationship, Drug; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Male; Melanoma; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Nimustine; Prognosis; Ribonucleotide Reductases; RNA Interference; Skin Neoplasms; Transfection; Vincristine; Young Adult

2012
Survival over 6 years in a patient with brain metastases from melanoma treated with temozolomide.
    BMJ case reports, 2012, Sep-24, Volume: 2012

    Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Humans; Melanoma; Middle Aged; Temozolomide; Treatment Outcome

2012
[A silent-growing and fast-killing melanoma in a teenager].
    Annales de pathologie, 2012, Volume: 32, Issue:4

    Topics: Adolescent; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Back Pain; Combined Modality Therapy; Cyclin D1; Dacarbazine; Drug Resistance, Neoplasm; Fatal Outcome; Female; Gene Amplification; Head and Neck Neoplasms; Humans; Immunotherapy; In Situ Hybridization, Fluorescence; Ipilimumab; Lymphatic Metastasis; Melanoma; Nausea; Neoplasm Proteins; Neoplasms, Second Primary; Nevus; Osteolysis; Scalp; Skin Neoplasms; Weight Loss

2012
Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma.
    PloS one, 2012, Volume: 7, Issue:9

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Caspases; Cell Death; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Synergism; Female; Humans; Inhibitor of Apoptosis Proteins; Melanoma; Mice; Proto-Oncogene Proteins c-bcl-2; Receptors, TNF-Related Apoptosis-Inducing Ligand; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays

2012
XIAP downregulation accompanies mebendazole growth inhibition in melanoma xenografts.
    Anti-cancer drugs, 2013, Volume: 24, Issue:2

    Topics: Animals; Apoptosis; Cell Line, Tumor; Dacarbazine; Down-Regulation; Drug Resistance, Neoplasm; Female; Humans; Mebendazole; Melanoma; Mice; Mice, Nude; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Temozolomide; Transplantation, Heterologous; X-Linked Inhibitor of Apoptosis Protein; Xenograft Model Antitumor Assays

2013
Anti-cancer drugs elicit re-expression of UDP-glucuronosyltransferases in melanoma cells.
    PloS one, 2012, Volume: 7, Issue:10

    Topics: Antineoplastic Agents; Cell Line, Tumor; Dacarbazine; Doxorubicin; Drug Resistance, Neoplasm; Epirubicin; Gene Expression Regulation; Gene Knockdown Techniques; Glucuronosyltransferase; Humans; Indoles; Melanocytes; Melanoma; Sulfonamides; Temozolomide; Vemurafenib

2012
Serum soluble MICB (sMICB) correlates with disease progression and survival in melanoma patients.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2013, Volume: 34, Issue:1

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Cisplatin; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Histocompatibility Antigens Class I; Humans; Interferon-alpha; Kaplan-Meier Estimate; Male; Melanoma; Temozolomide; Vincristine

2013
Management options for metastatic melanoma in the era of novel therapies: a primer for the practicing dermatologist: part II: Management of stage IV disease.
    Journal of the American Academy of Dermatology, 2013, Volume: 68, Issue:1

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Humans; Immunologic Factors; Indoles; Interleukin-2; Ipilimumab; Melanoma; Neoplasm Staging; Palliative Care; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Radiosurgery; raf Kinases; Skin Neoplasms; Sulfonamides; Vemurafenib

2013
The curcumin analog DM-1 induces apoptotic cell death in melanoma.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2013, Volume: 34, Issue:2

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Cell Proliferation; Curcumin; Dacarbazine; Flow Cytometry; Free Radicals; Humans; Lipid Peroxidation; Melanoma; Membrane Potential, Mitochondrial; Mice; Tumor Cells, Cultured

2013
Effect of O6-(4-bromothenyl)guanine on different temozolomide schedules in a human melanoma xenograft model.
    International journal of cancer, 2002, Aug-10, Volume: 100, Issue:5

    Topics: Adenosine Triphosphatases; Animals; Cell Division; Dacarbazine; Disease Models, Animal; Guanine; Humans; Male; Melanoma; Mice; Mice, Nude; Neoplasm Transplantation; Temozolomide; Time Factors

2002
Analysis of O(6)-methylguanine-DNA methyltransferase in melanoma tumours in patients treated with dacarbazine-based chemotherapy.
    Melanoma research, 2002, Volume: 12, Issue:4

    Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; DNA Damage; DNA Methylation; DNA Repair; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Humans; Immunoenzyme Techniques; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Proteins; O(6)-Methylguanine-DNA Methyltransferase; Observer Variation; Prodrugs; Vindesine

2002
Clinical results using biochemotherapy as a standard of care in advanced melanoma.
    Melanoma research, 2002, Volume: 12, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cost-Benefit Analysis; Dacarbazine; Drug Costs; Female; Granulocyte Colony-Stimulating Factor; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Interleukin-2; Life Tables; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Failure; Vinblastine

2002
Successful palliation of stenosing anorectal melanoma by intratumoral injections with natural interferon-beta.
    Melanoma research, 2002, Volume: 12, Issue:4

    Topics: Aged; Antineoplastic Agents, Alkylating; Anus Neoplasms; Combined Modality Therapy; Constriction, Pathologic; Dacarbazine; Female; Gastrointestinal Hemorrhage; Humans; Immunologic Factors; Injections, Intralesional; Interferon-beta; Lung Neoplasms; Lymphatic Metastasis; Melanoma; Palliative Care; Quality of Life; Rectal Neoplasms; Rectal Prolapse; Remission Induction

2002
Cisplatin and dacarbazine with or without subcutaneous interleukin-2 and interferon alfa-2b in advanced melanoma outpatients.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Aug-15, Volume: 20, Issue:16

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Humans; Interferon alpha-2; Interferon-alpha; Melanoma; Recombinant Proteins

2002
Chemoimmunotherapy for melanoma with dacarbazine and 2,4-dinitrochlorobenzene elicits a specific T cell-dependent immune response.
    Cancer immunology, immunotherapy : CII, 2002, Volume: 51, Issue:8

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Dinitrochlorobenzene; Immunotherapy; Irritants; Lung Neoplasms; Lymphocytes, Tumor-Infiltrating; Melanoma; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Neoplasm Transplantation; Ribonucleases; RNA, Messenger; T-Lymphocytes; Time Factors; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha

2002
Immunophenotypical markers, ultrastructure and chemosensitivity profile of metastatic melanoma cells.
    Cancer letters, 2002, Dec-05, Volume: 186, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cells, Cultured; Cisplatin; Dacarbazine; Dose-Response Relationship, Drug; Fluorescent Antibody Technique, Indirect; Humans; Immunophenotyping; Inhibitory Concentration 50; Interferon alpha-2; Interferon-alpha; Melanoma; Microscopy, Electron; Neoplasm Metastasis; Paclitaxel; Recombinant Proteins; Temozolomide; Time Factors; Tumor Cells, Cultured; Vindesine

2002
[Temozolomide as therapeutic option for patients with metastatic melanoma and poor prognosis].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2002, Volume: 53, Issue:10

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Prognosis; Retrospective Studies; Skin Neoplasms; Temozolomide; Time Factors

2002
Biochemotherapy of metastatic malignant melanoma. On down-regulation of CD28.
    Cancer immunology, immunotherapy : CII, 2002, Volume: 51, Issue:9

    Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Agents, Alkylating; CD28 Antigens; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cisplatin; Dacarbazine; Down-Regulation; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Recombinant Proteins; Time Factors

2002
Combined liver and pancreas resection with biochemotherapy for metastatic ocular melanoma.
    Journal of hepato-biliary-pancreatic surgery, 2002, Volume: 9, Issue:4

    Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Eye Enucleation; Female; Hepatectomy; Humans; Interferon-alpha; Liver Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Melanoma; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Uveal Neoplasms

2002
[Complete response of cerebral metastasic melanoma after a combined treatment of radiotherapy and temozolomide].
    Medicina clinica, 2002, Nov-30, Volume: 119, Issue:19

    Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Humans; Male; Melanoma; Middle Aged; Remission Induction; Skin Neoplasms; Temozolomide; Temporal Lobe

2002
Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly (adp-ribose) polymerase inhibitor.
    Molecular pharmacology, 2003, Volume: 63, Issue:1

    Topics: Antineoplastic Agents, Alkylating; Carmustine; Cell Division; Dacarbazine; DNA Ligases; Drug Combinations; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Melanoma; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Sulfones; Telomerase; Temozolomide; Transfection; Tumor Cells, Cultured

2003
The effect of O6-alkylguanine-DNA alkyltransferase and mismatch repair activities on the sensitivity of human melanoma cells to temozolomide, 1,3-bis(2-chloroethyl)1-nitrosourea, and cisplatin.
    The Journal of pharmacology and experimental therapeutics, 2003, Volume: 304, Issue:2

    Topics: Alkyl and Aryl Transferases; Base Pair Mismatch; Carmustine; Cisplatin; Clone Cells; Dacarbazine; DNA Ligases; DNA Repair; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Melanoma; Temozolomide; Tumor Cells, Cultured

2003
Effects of interferon-alpha, verapamil and dacarbazine in the treatment of advanced malignant melanoma.
    Melanoma research, 2003, Volume: 13, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Calcium Channel Blockers; Dacarbazine; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Staging; Radionuclide Imaging; Recombinant Proteins; Remission Induction; Skin Neoplasms; Survival Rate; Treatment Outcome; Uveal Neoplasms; Verapamil

2003
Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma.
    British journal of cancer, 2003, Jan-27, Volume: 88, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Disease-Free Survival; Drug Therapy, Combination; Eye Neoplasms; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunotherapy; Interferon alpha-2; Interferon-alpha; Interleukin-2; Lymphocyte Activation; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Staging; Recombinant Proteins; Skin Neoplasms; T-Lymphocyte Subsets; Temozolomide; Treatment Outcome

2003
Topical imiquimod in the treatment of metastatic melanoma to skin.
    Archives of dermatology, 2003, Volume: 139, Issue:3

    Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Dacarbazine; Female; Humans; Imiquimod; Interferon alpha-2; Interferon-alpha; Knee; Leg; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds; Recombinant Proteins; Scalp; Skin Neoplasms; Treatment Outcome

2003
Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model.
    The Journal of investigative dermatology, 2003, Volume: 120, Issue:6

    Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Dacarbazine; Drug Synergism; Drug Therapy, Combination; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Melanoma; Mice; Mice, SCID; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Neoplasm Transplantation; Oligonucleotides, Antisense; Proto-Oncogene Proteins c-bcl-2; Skin Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured

2003
DNA repair enzymes and cytotoxic effects of temozolomide: comparative studies between tumor cells and normal cells of the immune system.
    Journal of chemotherapy (Florence, Italy), 2003, Volume: 15, Issue:2

    Topics: Antineoplastic Agents, Alkylating; Burkitt Lymphoma; Cell Division; Dacarbazine; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Humans; Interleukin-2; Killer Cells, Lymphokine-Activated; Leukemia, Erythroblastic, Acute; Leukocytes, Mononuclear; Lymphocytes; Melanoma; O(6)-Methylguanine-DNA Methyltransferase; Skin Neoplasms; Temozolomide; Tumor Cells, Cultured

2003
Primary jejunal malignant melanoma first noticed because of the presence of parotid lymph node metastasis.
    Journal of the American Academy of Dermatology, 2003, Volume: 49, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Diagnostic Errors; Fatal Outcome; Humans; Jejunal Neoplasms; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Melanoma; Neoplasms, Unknown Primary; Parotid Gland

2003
Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy.
    Molecular cancer therapeutics, 2003, Volume: 2, Issue:8

    Topics: Cell Line, Tumor; Dacarbazine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Interleukin-8; Melanoma; Mitogen-Activated Protein Kinases; NF-kappa B; Transcription Factor AP-1; Transcription, Genetic; Transfection; Up-Regulation; Vascular Endothelial Growth Factor A

2003
Induction of apoptosis and/or necrosis following exposure to antitumour agents in a melanoma cell line, probably through modulation of Bcl-2 family proteins.
    Melanoma research, 2003, Volume: 13, Issue:5

    Topics: Annexin A5; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Caspase 3; Caspases; Cell Death; Cell Line, Tumor; Cell Survival; Cisplatin; Coloring Agents; Dacarbazine; Dactinomycin; Dose-Response Relationship, Drug; Down-Regulation; Enzyme Activation; Flow Cytometry; Fluorescent Dyes; Humans; Melanoma; Necrosis; Proto-Oncogene Proteins c-bcl-2; Time Factors; Trypan Blue; Up-Regulation

2003
Synchronous cancer and metastatic melanoma of the breasts.
    Archives of gynecology and obstetrics, 2004, Volume: 270, Issue:4

    Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Cisplatin; Dacarbazine; Female; Humans; Mammography; Melanoma; Retroperitoneal Neoplasms; Tamoxifen

2004
O6-methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma.
    British journal of cancer, 2003, Oct-20, Volume: 89, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Melanoma; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Polymorphism, Genetic; Skin Neoplasms; Treatment Outcome; Vindesine

2003
Primary malignant melanoma of the oral mucosa.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2003, Volume: 61, Issue:10

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Female; Humans; Liver Neoplasms; Lung Neoplasms; Male; Melanoma; Middle Aged; Mouth Mucosa; Mouth Neoplasms; Neck Dissection; Nimustine; Retrospective Studies; Vincristine

2003
IL-2-mediated augmentation of NK-cell activity and activation antigen expression on NK- and T-cell subsets in patients with metastatic melanoma treated with interferon-alpha and DTIC.
    Clinical & experimental metastasis, 2003, Volume: 20, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Interferon-alpha; Interleukin-2; Killer Cells, Natural; Lymphocyte Activation; Lymphocyte Subsets; Male; Melanoma; Middle Aged; T-Lymphocytes; Tumor Necrosis Factor Receptor Superfamily, Member 7

2003
Temozolomide for melanoma: new toxicities and new opportunities.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Feb-15, Volume: 22, Issue:4

    Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Drug Administration Schedule; Humans; Lymphopenia; Melanoma; Opportunistic Infections; Temozolomide

2004
Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Feb-15, Volume: 22, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; CD4-Positive T-Lymphocytes; Dacarbazine; Drug Administration Schedule; Female; Humans; Lymphopenia; Male; Melanoma; Middle Aged; Multivariate Analysis; Opportunistic Infections; Proportional Hazards Models; Retrospective Studies; Temozolomide

2004
Quality of life, at what cost?
    Cancer investigation, 2003, Volume: 21, Issue:6

    Topics: Antineoplastic Agents, Alkylating; Cost-Benefit Analysis; Dacarbazine; Drug Costs; Humans; Melanoma; Quality of Life; Skin Neoplasms; Temozolomide

2003
Angiomatoid metastatic melanoma.
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2004, Volume: 30, Issue:2 Pt 2

    Topics: Antineoplastic Agents; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interferon-alpha; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Skin Neoplasms; Surgical Procedures, Operative; Treatment Outcome

2004
Diffuse melanosis after chemotherapy-induced tumor lysis syndrome in a patient with metastatic melanoma.
    Journal of cutaneous pathology, 2004, Volume: 31, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Dacarbazine; DNA, Neoplasm; Female; Humans; Interferon-alpha; Interleukin-2; Liver Neoplasms; Lung Neoplasms; Melanoma; Melanosis; Melanosomes; Microscopy, Electron; Polymerase Chain Reaction; Skin; Skin Neoplasms; Tumor Lysis Syndrome; Vinblastine

2004
Metastatic malignant melanoma presenting as a cavernous sinus syndrome.
    Journal of neurology, 2004, Volume: 251, Issue:2

    Topics: Adult; Antineoplastic Agents; Biomarkers, Tumor; Blepharoptosis; Cavernous Sinus Thrombosis; Cranial Nerves; Dacarbazine; Fatal Outcome; Headache; Humans; Lymph Nodes; Magnetic Resonance Imaging; Male; Melanoma; Neoplasm Metastasis; Ophthalmoplegia; Orbital Neoplasms; Risk Factors; Skin Neoplasms; Survival Rate; Temozolomide

2004
Correspondence re: DC Lev et al., Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol Cancer Ther, 2003;2(8):753-63.
    Molecular cancer therapeutics, 2004, Volume: 3, Issue:3

    Topics: Cell Line, Tumor; Dacarbazine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Interleukin-8; Melanoma; Mitogen-Activated Protein Kinases; NF-kappa B; Transcription Factor AP-1; Transcription, Genetic; Transfection; Up-Regulation; Vascular Endothelial Growth Factor A

2004
Treatment of melanoma with 5-fluorouracil or dacarbazine in vitro sensitizes cells to antigen-specific CTL lysis through perforin/granzyme- and Fas-mediated pathways.
    Journal of immunology (Baltimore, Md. : 1950), 2004, Apr-01, Volume: 172, Issue:7

    Topics: Antigens, Neoplasm; Antineoplastic Agents; Cell Line, Tumor; Cytotoxicity, Immunologic; Dacarbazine; Epitopes, T-Lymphocyte; Fas Ligand Protein; fas Receptor; Fluorouracil; Humans; Immune Sera; Ligands; Melanoma; Melanoma-Specific Antigens; Membrane Glycoproteins; Neoplasm Proteins; Peptide Fragments; Perforin; Pore Forming Cytotoxic Proteins; Protein Binding; Serine Endopeptidases; Signal Transduction; T-Lymphocytes, Cytotoxic

2004
[Temozolomide in patients with melanoma brain metastases treated with whole brain irradiation].
    Medicina clinica, 2004, Mar-27, Volume: 122, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Retrospective Studies; Survival Rate; Temozolomide

2004
Dacarbazine but not temozolomide induces phototoxic dermatitis in patients with malignant melanoma.
    Journal of the American Academy of Dermatology, 2004, Volume: 50, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Dermatitis, Phototoxic; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Temozolomide

2004
Chemotherapy for melanoma: the resultant of conflicting vectors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jun-01, Volume: 22, Issue:11

    Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Humans; Melanoma; Mice; Skin Neoplasms

2004
Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jun-01, Volume: 22, Issue:11

    Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Interleukin-8; Melanoma; Mice; Mice, Nude; Skin Neoplasms; Up-Regulation; Vascular Endothelial Growth Factor A

2004
Complete response of multiple melanoma brain metastases after treatment with temozolomide.
    Onkologie, 2004, Volume: 27, Issue:2

    Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Humans; Magnetic Resonance Imaging; Melanoma; Middle Aged; Neoplasms, Multiple Primary; Remission Induction; Skin Neoplasms; Temozolomide; Treatment Outcome

2004
In vitro antitumour activity of resveratrol in human melanoma cells sensitive or resistant to temozolomide.
    Melanoma research, 2004, Volume: 14, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Humans; Inhibitory Concentration 50; Keratinocytes; Melanoma; Necrosis; Poly(ADP-ribose) Polymerases; Resveratrol; S Phase; Stilbenes; Temozolomide; Time Factors

2004
Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma.
    Cancer research, 2004, Jul-15, Volume: 64, Issue:14

    Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Dacarbazine; Drug Synergism; Female; Gene Expression; Humans; Melanoma; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; NF-kappa B; Protease Inhibitors; Pyrazines; Temozolomide

2004
Local control of primary oropharyngeal malignant melanomas with limited tissue excision: a report of three cases.
    European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2005, Volume: 262, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Dacarbazine; Fatal Outcome; Female; Humans; Immunotherapy; Male; Melanoma; Middle Aged; Oropharyngeal Neoplasms; Radiotherapy, Adjuvant; Vincristine

2005
Isolated limb infusion with fotemustine after dacarbazine chemosensitisation for inoperable loco-regional melanoma recurrence.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2004, Volume: 30, Issue:10

    Topics: Aged; Aged, 80 and over; Amputation, Surgical; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Follow-Up Studies; Humans; Limb Salvage; Lower Extremity; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nitrosourea Compounds; Organophosphorus Compounds; Remission Induction; Salvage Therapy; Skin Neoplasms; Treatment Outcome

2004
Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma.
    American journal of surgery, 2004, Volume: 188, Issue:5

    Topics: Analysis of Variance; Animals; Antineoplastic Agents, Alkylating; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Disease Models, Animal; Dose-Response Relationship, Drug; Extremities; Female; Infusions, Parenteral; Melanoma; Melphalan; Probability; Random Allocation; Rats; Rats, Nude; Reference Values; Sensitivity and Specificity; Severity of Illness Index; Skin Neoplasms; Survival Rate; Temozolomide; Transplantation, Heterologous; Treatment Outcome

2004
Breast metastases from cutaneous malignant melanoma.
    Breast (Edinburgh, Scotland), 2004, Volume: 13, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Female; Humans; Melanoma; Middle Aged; Skin Neoplasms; Vincristine

2004
The prognostic role of CD4+ and CD8+ lymphocytes during chemoimmunotherapy in metastatic melanoma.
    Melanoma research, 2004, Volume: 14, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Dacarbazine; Female; Humans; Immunotherapy; Interferon-alpha; Lomustine; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Prognosis; Skin Neoplasms; Survival Rate; T-Lymphocytes, Regulatory; Treatment Outcome; Vinblastine

2004
Biochemotherapy in patients with advanced vulvovaginal mucosal melanoma.
    Melanoma research, 2004, Volume: 14, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Follow-Up Studies; Humans; Interferon-alpha; Interleukin-2; Male; Medical Records; Melanoma; Middle Aged; Mucous Membrane; Retrospective Studies; Skin Neoplasms; Survival Rate; Tamoxifen; Temozolomide; Treatment Outcome; Vaginal Neoplasms; Vinblastine; Vulvar Neoplasms

2004
Serum bcl-2 and survivin levels in melanoma.
    Melanoma research, 2004, Volume: 14, Issue:6

    Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Dacarbazine; Female; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Microtubule-Associated Proteins; Middle Aged; Neoplasm Proteins; Prognosis; Proto-Oncogene Proteins c-bcl-2; Recombinant Proteins; Skin Neoplasms; Survivin

2004
Relevance and necessity of studies on second-line chemotherapy in melanoma.
    Onkologie, 2004, Volume: 27, Issue:6

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Dacarbazine; Doxorubicin; Drug Administration Schedule; Evidence-Based Medicine; Humans; Interleukin-2; Melanoma; Practice Patterns, Physicians'; Treatment Outcome

2004
Chemotherapeutic induced fascial oedema.
    Annals of the rheumatic diseases, 2005, Volume: 64, Issue:1

    Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Drug Eruptions; Edema; Fascia; Female; Humans; Melanoma; Middle Aged; Thigh

2005
Multiple ground-glass opacity in metastasis of malignant melanoma diagnosed by lung biopsy.
    The Annals of thoracic surgery, 2005, Volume: 79, Issue:1

    Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Chemotherapy, Adjuvant; Dacarbazine; Diagnosis, Differential; Female; Humans; Lung Neoplasms; Melanocytes; Melanoma; Middle Aged; Nasal Cavity; Nose Neoplasms; Picibanil; Tegafur; Tomography, X-Ray Computed; Uracil

2005
Prolonged survival after resection of liver metastases from uveal melanoma and intra-arterial chemotherapy.
    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2005, Volume: 243, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Fatal Outcome; Female; Follow-Up Studies; Hepatectomy; Humans; Injections, Intra-Arterial; Liver Neoplasms; Melanoma; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Survival Rate; Time Factors; Uveal Neoplasms

2005
Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Feb-01, Volume: 11, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; DNA Helicases; DNA-Binding Proteins; Endonucleases; Female; Gene Frequency; Genotype; Humans; Interferon-alpha; Interferon-gamma; Interleukin-10; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Staging; Pilot Projects; Polymorphism, Genetic; Survival Analysis; Transcription Factors; Treatment Outcome; Vinblastine; X-ray Repair Cross Complementing Protein 1; Xeroderma Pigmentosum Group D Protein

2005
Cerebral metastases of malignant melanoma: contemporary treatment modalities and survival outcome.
    Neoplasma, 2005, Volume: 52, Issue:2

    Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Humans; Male; Melanoma; Middle Aged; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Skin Neoplasms; Survival Analysis; Temozolomide; Treatment Outcome

2005
[Malignant melanoma of nasal fossae: clinical and therapeutic considerations about three cases].
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2005, Volume: 9, Issue:2

    Topics: Aged; Antineoplastic Agents, Alkylating; Biopsy; Combined Modality Therapy; Dacarbazine; Diagnosis, Differential; Female; Humans; Immunohistochemistry; Male; Melanoma; Middle Aged; Nasal Mucosa; Nasal Septum; Neoplasm Metastasis; Nose Neoplasms; Prognosis; Radiotherapy Dosage; Time Factors; Turbinates

2005
Clusterin regulates drug-resistance in melanoma cells.
    The Journal of investigative dermatology, 2005, Volume: 124, Issue:6

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Clusterin; Dacarbazine; Down-Regulation; Drug Resistance, Neoplasm; Glycoproteins; Humans; Melanocytes; Melanoma; Mice; Mice, SCID; Molecular Chaperones; Neoplasm Transplantation; Oligonucleotides, Antisense; Transplantation, Heterologous

2005
Amelanotic malignant melanoma of the esophagus: report of a patient with recurrence successfully treated with chemoendocrine therapy.
    International journal of clinical oncology, 2005, Volume: 10, Issue:3

    Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Esophageal Neoplasms; Esophagectomy; Humans; Infusions, Intravenous; Interferon-beta; Male; Melanoma; Middle Aged; Nimustine; Survival Analysis; Treatment Outcome; Vincristine

2005
Cardiac metastasis of melanoma.
    Melanoma research, 2005, Volume: 15, Issue:4

    Topics: Adult; Antineoplastic Agents, Alkylating; Choroid Neoplasms; Dacarbazine; Female; Heart Neoplasms; Heart Ventricles; Humans; Magnetic Resonance Imaging; Melanoma; Temozolomide

2005
O(6)-methylguanine DNA-methyltransferase (MGMT) overexpression in melanoma cells induces resistance to nitrosoureas and temozolomide but sensitizes to mitomycin C.
    Toxicology and applied pharmacology, 2006, Mar-01, Volume: 211, Issue:2

    Topics: Antineoplastic Agents; Buthionine Sulfoximine; Cell Line, Tumor; Cell Survival; Dacarbazine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glutathione; Humans; Inhibitory Concentration 50; Melanoma; Mitomycin; Nitrosourea Compounds; O(6)-Methylguanine-DNA Methyltransferase; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Temozolomide; Transfection

2006
[Correlation between functional capability and phenotypic characteristics of peripheral blood lymphocytes in patients with malignant melanoma].
    Glas. Srpska akademija nauka i umetnosti. Odeljenje medicinskih nauka, 2002, Issue:47

    Topics: Adult; Antigens, CD; Antineoplastic Agents; Chemotherapy, Adjuvant; Dacarbazine; Female; Humans; Interferon-alpha; Killer Cells, Natural; Lymphocyte Activation; Lymphocytes; Male; Melanoma; Skin Neoplasms

2002
Thalidomide enhances the anti-tumor activity of standard chemotherapy in a human melanoma xenotransplatation model.
    The Journal of investigative dermatology, 2005, Volume: 125, Issue:2

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Therapy, Combination; Humans; Melanoma; Mice; Mice, SCID; Microcirculation; Skin Neoplasms; Thalidomide; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays

2005
Complete remission of brain metastases in three patients with stage IV melanoma treated with BOLD and G-CSF.
    Japanese journal of clinical oncology, 2005, Volume: 35, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Lomustine; Male; Melanoma; Middle Aged; Neoplasm Staging; Remission Induction; Skin Neoplasms; Treatment Outcome; Vincristine

2005
Biochemotherapy with low doses of subcutaneous interleukin-2 in patients with melanoma: results of a phase II trial.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2005, Volume: 7, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Humans; Immunologic Factors; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Skin Neoplasms; Survival Analysis; Vinblastine

2005
[Spinal and cerebral leptomeningeal seeding from a melanocytoma of the cerebello-pontine angle].
    Wiener medizinische Wochenschrift (1946), 2005, Volume: 155, Issue:15-16

    Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Arachnoid; Cerebellar Diseases; Cerebellar Neoplasms; Cerebellopontine Angle; Combined Modality Therapy; Dacarbazine; Diagnosis, Differential; Disease Progression; Humans; Magnetic Resonance Imaging; Male; Melanocytes; Melanoma; Meningeal Neoplasms; Meninges; Neoplasm Recurrence, Local; Neoplasm Seeding; Pia Mater; Radiotherapy Dosage; Temozolomide; Time Factors

2005
518A2 melanoma cells are protected by G3139 and other antineoplastic agents against the cytotoxic effects of DTIC.
    Oligonucleotides, 2005,Fall, Volume: 15, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cisplatin; Dacarbazine; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Guanine; Humans; Melanoma; Oligonucleotides, Antisense; Thionucleotides

2005
Gastrin exerts pleiotropic effects on human melanoma cell biology.
    Neoplasia (New York, N.Y.), 2005, Volume: 7, Issue:10

    Topics: Actins; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Movement; Cholecystokinin; Cisplatin; Cytoskeleton; Dacarbazine; DNA Primers; DNA, Complementary; Flow Cytometry; Gastrins; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Immunohistochemistry; Melanoma; Mice; Neoplasm Invasiveness; Neoplasm Transplantation; Neovascularization, Pathologic; Oligonucleotide Array Sequence Analysis; Poly(ADP-ribose) Polymerases; Receptor, Cholecystokinin B; Receptors, Cholecystokinin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Time Factors; Wound Healing

2005
A retrospective study of biochemotherapy for metastatic melanoma: the importance of dose intensity.
    Cancer biotherapy & radiopharmaceuticals, 2005, Volume: 20, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Retrospective Studies; Temozolomide; Treatment Outcome; Vinblastine

2005
Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Nov-01, Volume: 23, Issue:31

    Topics: Adolescent; Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Cisplatin; Dacarbazine; Female; Humans; Interferon-alpha; Interleukin-2; Male; MART-1 Antigen; Melanoma; Middle Aged; N-Acetylgalactosaminyltransferases; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Paired Box Transcription Factors; PAX3 Transcription Factor; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors; RNA, Messenger; RNA, Neoplasm; Skin Neoplasms; Survival Rate; Treatment Outcome; Vinblastine

2005
Artesunate in the treatment of metastatic uveal melanoma--first experiences.
    Oncology reports, 2005, Volume: 14, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Artemisia; Artemisinins; Artesunate; Dacarbazine; Fatal Outcome; Female; Humans; Liver Neoplasms; Lung Neoplasms; Male; Melanoma; Sesquiterpenes; Time Factors; Treatment Outcome; Uveal Neoplasms

2005
Topical immunotherapy with diphenylcyclopropenone in combination with DTIC and radiation for cutaneous metastases of melanoma.
    Dermatology (Basel, Switzerland), 2005, Volume: 211, Issue:4

    Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclopropanes; Dacarbazine; Dose Fractionation, Radiation; Follow-Up Studies; Humans; Injections, Intravenous; Male; Melanoma; Radiotherapy, Adjuvant; Skin Neoplasms

2005
Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide.
    European journal of cancer (Oxford, England : 1990), 2005, Volume: 41, Issue:18

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Interactions; Fluorenes; Glycoside Hydrolases; Melanoma; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Skin Neoplasms; Temozolomide

2005
Skin delivery potency and antitumor activities of temozolomide ester prodrugs.
    Cancer letters, 2006, Nov-28, Volume: 244, Issue:1

    Topics: Administration, Cutaneous; Animals; Antineoplastic Agents, Alkylating; Cell Membrane Permeability; Cell Proliferation; Dacarbazine; Drug Delivery Systems; Esterases; Esters; Humans; Liver; Melanoma; Mice; Mice, Inbred BALB C; Mice, Nude; Prodrugs; Rats; Skin; Skin Neoplasms; Swine; Temozolomide; Tumor Cells, Cultured

2006
Clinical analysis of primary malignant melanoma of the cervix.
    Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih, 2005, Volume: 20, Issue:4

    Topics: Adult; Antibodies, Monoclonal; Chemotherapy, Adjuvant; Dacarbazine; Diagnosis, Differential; Female; Follow-Up Studies; Humans; Hysterectomy; Interferon-gamma; Melanoma; Middle Aged; Prognosis; Retrospective Studies; S100 Proteins; Uterine Cervical Neoplasms

2005
Biochemotherapy with temozolomide, cisplatin, vinblastine, subcutaneous interleukin-2 and interferon-alpha in patients with metastatic melanoma.
    Melanoma research, 2006, Volume: 16, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Recombinant Proteins; Skin Neoplasms; Survival Rate; Temozolomide; Treatment Outcome; Vinblastine

2006
[Hypersensitivity to dacarbazine in patients with metastatic malignant melanoma].
    Annales de dermatologie et de venereologie, 2006, Volume: 133, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Anemia, Aplastic; Antineoplastic Agents, Alkylating; Cross-Sectional Studies; Dacarbazine; Drug Hypersensitivity; Female; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Skin Neoplasms; Time Factors

2006
Primary malignant melanoma of the lung: a case report and review of the literature.
    Clinical lung cancer, 2006, Volume: 7, Issue:4

    Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Dacarbazine; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Melanoma; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Temozolomide; Tomography, X-Ray Computed

2006
Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine.
    Molecular cancer therapeutics, 2006, Volume: 5, Issue:3

    Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Deoxyguanosine; Drug Resistance, Neoplasm; Humans; Injections, Intra-Arterial; Melanoma; O(6)-Methylguanine-DNA Methyltransferase; Rats; Rats, Inbred Strains; Skin Neoplasms; Temozolomide; Xenograft Model Antitumor Assays

2006
Acute myocardial infarction induced by cisplatin-based combination chemotherapy for malignant melanoma: a case report.
    Journal of cardiology, 2006, Volume: 47, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Calcinosis; Cisplatin; Coronary Artery Disease; Dacarbazine; Drug Administration Schedule; Female; Humans; Melanoma; Middle Aged; Myocardial Infarction; Nimustine; Skin Neoplasms; Tamoxifen

2006
Whole brain irradiation and temozolomide based chemotherapy in melanoma brain metastases.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2006, Volume: 8, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Cohort Studies; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Drug Administration Schedule; Drug Evaluation; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Life Tables; Male; Melanoma; Middle Aged; Patient Selection; Proportional Hazards Models; Recombinant Proteins; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome; Vinblastine

2006
Targeting the endothelin axis in human melanoma: combination of endothelin receptor antagonism and alkylating agents.
    Experimental biology and medicine (Maywood, N.J.), 2006, Volume: 231, Issue:6

    Topics: Alkylating Agents; Antineoplastic Agents; Apoptosis; Bosentan; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Delivery Systems; Drug Synergism; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Fas Ligand Protein; Genetic Variation; Humans; Melanoma; Membrane Glycoproteins; Oligopeptides; Peptides, Cyclic; Piperidines; Receptor, Endothelin B; RNA, Messenger; Sulfonamides; Tumor Necrosis Factors

2006
Adjuvant therapy of cutaneous melanoma -- current status.
    Acta oncologica (Stockholm, Sweden), 2006, Volume: 45, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Interferon-alpha; Melanoma; Randomized Controlled Trials as Topic; Skin Neoplasms

2006
[Phototoxicity of dacarbazine (Deticene) not reinduced by temozolomide (Temodal)].
    Annales de dermatologie et de venereologie, 2006, Volume: 133, Issue:5 Pt 1

    Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Dermatitis, Phototoxic; Humans; Melanoma; Skin Neoplasms; Temozolomide

2006
Implications of tissue transglutaminase expression in malignant melanoma.
    Molecular cancer therapeutics, 2006, Volume: 5, Issue:6

    Topics: Apoptosis; Cell Adhesion; Cell Line, Tumor; Cell Membrane; Cisplatin; Culture Media, Serum-Free; Dacarbazine; Disease Progression; Drug Resistance, Neoplasm; Fibronectins; GTP-Binding Proteins; Humans; Immunoprecipitation; Integrin beta Chains; Melanoma; Protein Glutamine gamma Glutamyltransferase 2; RNA, Small Interfering; Signal Transduction; Survival Rate; Transglutaminases

2006
The course of melanoma-associated vitiligo: report of a case.
    Melanoma research, 2006, Volume: 16, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Interferon-alpha; Lung Neoplasms; Male; Melanoma; Middle Aged; Prognosis; Skin Neoplasms; Vinblastine; Vitiligo

2006
[Effect of interferon alfa therapy on malignant melanoma of oral mucosa].
    Shanghai kou qiang yi xue = Shanghai journal of stomatology, 2006, Volume: 15, Issue:3

    Topics: Antineoplastic Agents; Dacarbazine; Humans; Interferon alpha-2; Interferon-alpha; Lymphatic Metastasis; Maxilla; Melanoma; Mouth Mucosa; Mouth Neoplasms; Recombinant Proteins; Retrospective Studies; Survival Rate

2006
Overall and progression-free survival in metastatic melanoma: analysis of a single-institution database.
    Cancer control : journal of the Moffitt Cancer Center, 2006, Volume: 13, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Cisplatin; Dacarbazine; Databases, Factual; Disease-Free Survival; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Staging; Recombinant Proteins; Retrospective Studies; Skin Neoplasms; Survival Rate; Treatment Outcome; Vinblastine

2006
A single cycle of treatment with temozolomide, alone or combined with O(6)-benzylguanine, induces strong chemoresistance in melanoma cell clones in vitro: role of O(6)-methylguanine-DNA methyltransferase and the mismatch repair system.
    International journal of oncology, 2006, Volume: 29, Issue:4

    Topics: Antineoplastic Agents; Base Pair Mismatch; Dacarbazine; DNA Methylation; DNA Repair; Drug Resistance, Neoplasm; Enzyme Inhibitors; Guanine; Humans; Melanoma; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Temozolomide; Tumor Cells, Cultured; Up-Regulation

2006
Successful treatment of acute disseminated intravascular coagulation in a patient with metastatic melanoma.
    Onkologie, 2006, Volume: 29, Issue:11

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disseminated Intravascular Coagulation; Humans; Liver Neoplasms; Male; Melanoma; Skin Neoplasms; Treatment Outcome; Vinblastine

2006
Hematoma-like metastases.
    Journal of the American Academy of Dermatology, 2006, Volume: 55, Issue:6

    Topics: Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain; Dacarbazine; Diagnosis, Differential; Fatal Outcome; Hematoma; Hemorrhage; Humans; Liver Neoplasms; Male; Melanoma; Muscle Neoplasms; Paresis; Skin; Skin Neoplasms; Vascular Neoplasms

2006
Combined effect of temozolomide and hyperthermia on human melanoma cell growth and O6-methylguanine-DNA methyltransferase activity.
    International journal of oncology, 2007, Volume: 30, Issue:2

    Topics: Antineoplastic Agents, Alkylating; Base Pair Mismatch; Cancer Vaccines; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Methylation; DNA Repair; Dose-Response Relationship, Drug; Fever; Humans; Inhibitory Concentration 50; Melanoma; O(6)-Methylguanine-DNA Methyltransferase; Skin Neoplasms; Temozolomide

2007
Chemoimmunotherapy for cutaneous melanoma with dacarbazine and epifocal contact sensitizers: results of a nationwide survey of the German Dermatologic Co-operative Oncology Group.
    Journal of cancer research and clinical oncology, 2007, Volume: 133, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dinitrochlorobenzene; Disease-Free Survival; Female; Germany; Humans; Irritants; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Retrospective Studies; Skin Neoplasms; Survival Analysis

2007
Viability of a human melanoma cell after single and combined treatment with fotemustine, dacarbazine, and proton irradiation.
    Annals of the New York Academy of Sciences, 2007, Volume: 1095

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Dacarbazine; Humans; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Proton Therapy

2007
Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines.
    The journal of gene medicine, 2007, Volume: 9, Issue:6

    Topics: Adenoviridae; Antineoplastic Agents; Apoptosis; bcl-X Protein; BH3 Interacting Domain Death Agonist Protein; Caspases; Cell Line, Tumor; Cell Survival; Dacarbazine; Down-Regulation; Drug Synergism; Humans; Hydroxamic Acids; Melanoma; Membrane Potential, Mitochondrial; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Proto-Oncogene Proteins c-bcl-2; TNF-Related Apoptosis-Inducing Ligand; Transduction, Genetic; Vorinostat; X-Linked Inhibitor of Apoptosis Protein

2007
Complex combination biochemotherapy regimen in advanced metastatic melanoma in a non-intensive care unit: toxicity or benefit?
    Japanese journal of clinical oncology, 2007, Volume: 37, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Administration Schedule; Female; Humans; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Retrospective Studies; Skin Neoplasms; Treatment Outcome; Vindesine

2007
Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents.
    Molecular cancer therapeutics, 2007, Volume: 6, Issue:5

    Topics: Animals; Antineoplastic Agents; Base Pair Mismatch; Cell Line, Tumor; Dacarbazine; Female; Gene Expression Regulation, Neoplastic; Glutathione; Humans; Infusions, Intravenous; Melanoma; Melphalan; Neoplasm Transplantation; Rats; Rats, Nude; Skin Neoplasms; Temozolomide

2007
Galectin-1 knockdown increases sensitivity to temozolomide in a B16F10 mouse metastatic melanoma model.
    The Journal of investigative dermatology, 2007, Volume: 127, Issue:10

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Cathepsin B; Cell Line, Tumor; Cisplatin; Dacarbazine; Disease Models, Animal; Female; Galectin 1; Gene Expression Regulation, Neoplastic; HSP72 Heat-Shock Proteins; Melanoma; Mice; Mice, Knockout; RNA, Small Interfering; Skin Neoplasms; Temozolomide; Xenograft Model Antitumor Assays

2007
Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice.
    The Journal of investigative dermatology, 2007, Volume: 127, Issue:10

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Dacarbazine; Drug Therapy, Combination; Humans; Melanoma; Mice; Mice, SCID; Oncogene Protein v-akt; Protein Kinases; PTEN Phosphohydrolase; Sirolimus; Skin Neoplasms; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays

2007
Molecular classification of patients with malignant melanoma for new therapeutic strategies.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Jun-01, Volume: 25, Issue:16

    Topics: Combined Modality Therapy; Dacarbazine; Extracellular Signal-Regulated MAP Kinases; Humans; Melanoma; Oligonucleotides, Antisense; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Skin Neoplasms; Thionucleotides

2007
Radiochemotherapy for brain metastasis: how to define a role for temozolomide.
    Onkologie, 2007, Volume: 30, Issue:7

    Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Cranial Irradiation; Dacarbazine; Humans; Lung Neoplasms; Melanoma; Mouth Neoplasms; Neoplasms, Unknown Primary; Rectal Neoplasms; Research Design; Temozolomide; Treatment Outcome

2007
Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases.
    Cancer, 2007, Sep-15, Volume: 110, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Patient Care Team; Radiosurgery; Recombinant Proteins; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome

2007
Microemulsions as topical delivery vehicles for the anti-melanoma prodrug, temozolomide hexyl ester (TMZA-HE).
    The Journal of pharmacy and pharmacology, 2007, Volume: 59, Issue:6

    Topics: Administration, Cutaneous; Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Detergents; Drug Carriers; Drug Delivery Systems; Emulsions; Esters; In Vitro Techniques; Melanoma; Mice; Mice, Hairless; Myristates; Oleic Acid; Permeability; Pharmaceutical Vehicles; Polyethylene Glycols; Prodrugs; Rats; Skin Absorption; Skin Neoplasms; Solubility; Temozolomide; Vitamin E

2007
Local injection of interferon beta in malignant melanoma of the esophagus as adjuvant of systemic pre- and postoperative DAV chemotherapy: case report with 7 years of long-term survival.
    Gastrointestinal endoscopy, 2007, Volume: 66, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Esophageal Neoplasms; Esophagoscopy; Female; Humans; Injections, Intralesional; Interferon-beta; Melanoma; Middle Aged; Nimustine; Vincristine

2007
Hemorrhagic cystitis in a patient receiving conventional doses of dacarbazine for metastatic malignant melanoma: case report and review of the literature.
    Clinical therapeutics, 2007, Volume: 29, Issue:6

    Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cystitis; Cystoscopy; Dacarbazine; Diagnosis, Differential; Dysuria; Fatal Outcome; Foot; Hematuria; Hemorrhage; Humans; Lung Neoplasms; Male; Melanoma; Middle Aged; Ultrasonography; Urinary Bladder

2007
Microphthalmos associated with Dartmouth combination chemotherapy in pregnancy: a case report.
    The Journal of reproductive medicine, 2007, Volume: 52, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Infant, Newborn; Liver Neoplasms; Male; Melanoma; Microphthalmos; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimester, First; Pregnancy Trimester, Second; Skin Neoplasms; Tamoxifen

2007
Combining adenoviral oncolysis with temozolomide improves cell killing of melanoma cells.
    International journal of cancer, 2007, Dec-15, Volume: 121, Issue:12

    Topics: Adenoviridae; Antineoplastic Agents, Alkylating; Cell Cycle; Cell Line, Tumor; Chemotherapy, Adjuvant; Dacarbazine; G2 Phase; Gene Amplification; Genome, Viral; Humans; Melanoma; Oncolytic Virotherapy; Skin Neoplasms; Temozolomide; Treatment Outcome; Tumor Cells, Cultured

2007
Predictors of distant brain recurrence for patients with newly diagnosed brain metastases treated with stereotactic radiosurgery alone.
    International journal of radiation oncology, biology, physics, 2008, Jan-01, Volume: 70, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Dacarbazine; Female; Humans; Lung Neoplasms; Male; Melanoma; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Radiosurgery; Retrospective Studies; Temozolomide

2008
O6-methylguanine-DNA-methyltransferase promoter demethylation is involved in basic fibroblast growth factor induced resistance against temozolomide in human melanoma cells.
    Molecular cancer therapeutics, 2007, Volume: 6, Issue:10

    Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Base Pair Mismatch; Blotting, Western; Dacarbazine; DNA Methylation; DNA Mismatch Repair; DNA Repair Enzymes; Drug Resistance, Neoplasm; Fibroblast Growth Factor 2; Guanine; Humans; Luciferases; Melanoma; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Skin Neoplasms; Temozolomide; Tumor Cells, Cultured

2007
[A case of liver metastasis from anorectal malignant melanoma on hemodialysis treated by chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:10

    Topics: Antineoplastic Agents, Alkylating; Anus Neoplasms; Dacarbazine; Humans; Kidney Failure, Chronic; Liver Neoplasms; Male; Melanoma; Middle Aged; Renal Dialysis

2007
Genasense: it ain't over till the fat lady sings.
    Oligonucleotides, 2007,Winter, Volume: 17, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Approval; Humans; Melanoma; Oligonucleotides, Antisense; Randomized Controlled Trials as Topic; Skin Neoplasms; Thionucleotides; United States; United States Food and Drug Administration

2007
Evaluation of twenty-one human adenovirus types and one infectivity-enhanced adenovirus for the treatment of malignant melanoma.
    The Journal of investigative dermatology, 2008, Volume: 128, Issue:4

    Topics: Adenoviruses, Human; Animals; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Genetic Vectors; Humans; Melanoma; Membrane Cofactor Protein; Mice; Mice, Nude; Oncolytic Virotherapy; Recoverin; Skin Neoplasms; Viral Fusion Proteins; Viral Proteins; Virus Internalization; Virus Replication; Xenograft Model Antitumor Assays

2008
Temozolomide induces senescence but not apoptosis in human melanoma cells.
    British journal of cancer, 2007, Nov-05, Volume: 97, Issue:9

    Topics: Antineoplastic Agents, Alkylating; Apoptosis; Benzothiazoles; Cell Division; Cellular Senescence; Dacarbazine; G2 Phase; Humans; Lymphoma; Melanoma; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Toluene; Tumor Cells, Cultured; Tumor Suppressor Protein p53

2007
CD69 on CD56+ NK cells and response to chemoimmunotherapy in metastatic melanoma.
    European journal of clinical investigation, 2007, Volume: 37, Issue:11

    Topics: Adult; Aged; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; CD56 Antigen; Dacarbazine; Female; Humans; Immunotherapy; Interferon alpha-2; Interferon Regulatory Factor-1; Interferon-alpha; Killer Cells, Natural; Lectins, C-Type; Male; Melanoma; Middle Aged; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Skin Neoplasms; Tretinoin

2007
Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma.
    Nature clinical practice. Oncology, 2008, Volume: 5, Issue:1

    Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Follow-Up Studies; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Lymphatic Metastasis; Melanoma; Meta-Analysis as Topic; Multicenter Studies as Topic; Neoplasm Staging; Patient Selection; Quality of Life; Randomized Controlled Trials as Topic; Recombinant Proteins; Risk; Skin Neoplasms; Survival Analysis; Treatment Failure

2008
[Dacarbazine: deticene].
    Annales de dermatologie et de venereologie, 2007, Volume: 134, Issue:12

    Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Melanoma; Skin Neoplasms

2007
Temozolomide-induced desquamative skin rash in a patient with metastatic melanoma.
    Pharmacotherapy, 2008, Volume: 28, Issue:3

    Topics: Adult; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Eruptions; Female; Humans; Melanoma; Skin Neoplasms; Temozolomide

2008
Interleukin-2-based biochemotherapy for patients with stage IV melanoma: long-term survivors outside a clinical trial setting.
    Oncology, 2007, Volume: 73, Issue:1-2

    Topics: Academic Medical Centers; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Interferon alpha-2; Interferon-alpha; Interleukin-2; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Neoplasm Staging; Recombinant Proteins; Retrospective Studies; Skin Neoplasms; Treatment Outcome; Vinblastine

2007
The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma.
    Oncology reports, 2008, Volume: 19, Issue:4

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dacarbazine; DNA Mismatch Repair; Drug Synergism; Endothelial Cells; Integrins; Male; Melanoma; Mice; Mice, Inbred C57BL; Snake Venoms; Temozolomide

2008
Topical CpG enhances the response of murine malignant melanoma to dacarbazine.
    The Journal of investigative dermatology, 2008, Volume: 128, Issue:9

    Topics: Adjuvants, Immunologic; Administration, Topical; Animals; Antineoplastic Agents, Alkylating; Apoptosis; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Drug Therapy, Combination; Injections, Intraperitoneal; Melanoma; Mice; Mice, Inbred C57BL; Oligodeoxyribonucleotides; Skin Neoplasms; T-Lymphocytes, Cytotoxic; Treatment Outcome

2008
Leser-Trelat sign in metastasized malignant melanoma.
    European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2009, Volume: 266, Issue:2

    Topics: Aged, 80 and over; Biomarkers, Tumor; Dacarbazine; Follow-Up Studies; Humans; Keratosis, Seborrheic; Lymphatic Metastasis; Male; Melanoma; Neoplasm Staging; Palliative Care; Paraneoplastic Syndromes; Risk Assessment; Skin Neoplasms

2009
A rare case of melanoma recurring as subcutaneous metastatic melanoma with overlying ecchymoses.
    Archives of dermatology, 2008, Volume: 144, Issue:4

    Topics: Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Dacarbazine; Ecchymosis; Female; Humans; Lung Neoplasms; Melanoma; Neoplasm Recurrence, Local; Neoplasms, Multiple Primary; Skin; Skin Neoplasms; Temozolomide; Treatment Outcome

2008
Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment.
    Cancer research, 2008, May-15, Volume: 68, Issue:10

    Topics: Animals; Antineoplastic Agents, Alkylating; Cadherins; Dacarbazine; DNA Adducts; Humans; Immunotherapy; Melanoma; Melphalan; Models, Biological; Neoplasm Transplantation; Phenotype; Rats; Rats, Nude; Temozolomide

2008
Treatment and prognosis of malignant melanoma of the oral cavity: preoperative surgical procedure increases risk of distant metastasis.
    Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2008, Volume: 106, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Contraindications; Dacarbazine; Female; Humans; Immunotherapy; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Mouth Neoplasms; Neoplasm Metastasis; Nimustine; Picibanil; Prognosis; Risk Factors; Tooth Extraction; Vincristine

2008
Radiation therapy for brain metastases from malignant melanoma.
    Acta radiologica. Oncology, 1984, Volume: 23, Issue:4

    Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Radiation; Female; Humans; Lomustine; Male; Melanoma; Middle Aged; Prognosis

1984
DTIC (dacarbazine)-induced hepatic damage. Possible pathogenesis and prevention.
    Archives of dermatological research, 1981, Volume: 270, Issue:3

    Topics: Aged; Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; Dacarbazine; Female; gamma-Glutamyltransferase; Humans; Melanoma; Prednisone; Skin Neoplasms

1981
Treatment of malignant melanoma with dacarbazin (DTIC-DOME) with special reference to urinary excretion of 5-S-cysteinyldopa.
    Cancer, 1980, Jan-15, Volume: 45, Issue:2

    Topics: Adult; Aged; Brain Neoplasms; Cysteinyldopa; Dacarbazine; Digestive System; Dihydroxyphenylalanine; Female; Humans; Infusions, Intra-Arterial; Male; Melanoma; Middle Aged; Palliative Care; Remission, Spontaneous

1980
[Adjuvant chemotherapy in malignant melanoma after pretherapeutic sensitivity testing].
    Folia haematologica (Leipzig, Germany : 1928), 1981, Volume: 108, Issue:5

    Topics: BCG Vaccine; Dacarbazine; Drug Therapy, Combination; Humans; Melanoma; Neoplasm Staging; Prognosis

1981
Functional-group modifications of dextran for linkage to a diazonium group. A potential vehicle for tumour targeting of antineoplastic triazenes.
    Carbohydrate research, 1982, Jul-01, Volume: 105, Issue:1

    Topics: Animals; Antineoplastic Agents; Dacarbazine; Dextrans; Diazonium Compounds; Melanoma; Mice; Neoplasms, Experimental; Triazenes

1982
Bleomycin, carmustine, vincristine, and dacarbazine in patients with metastatic malignant melanoma.
    Cancer treatment reports, 1983, Volume: 67, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Dacarbazine; Female; Humans; Male; Melanoma; Neoplasm Metastasis; Vincristine

1983
Management of malignant melanoma: a retrospective analysis of 182 patients.
    Clinical radiology, 1984, Volume: 35, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Female; Humans; Lomustine; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Retrospective Studies; Skin Neoplasms

1984
Phase II trial of vinblastine, bleomycin, and cisplatin (VBP) followed by dacarbazine and mitolactol in metastatic melanoma.
    Cancer treatment reports, 1984, Volume: 68, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Dacarbazine; Drug Administration Schedule; Drug Evaluation; Female; Humans; Male; Melanoma; Middle Aged; Mitolactol; Neoplasm Metastasis; Vinblastine

1984
Modern problems of clinical chemotherapy of malignant tumours.
    Archiv fur Geschwulstforschung, 1980, Volume: 50, Issue:7

    Topics: Antineoplastic Agents; Carcinoma, Small Cell; Carubicin; Dacarbazine; Dactinomycin; Drug Therapy, Combination; Female; Humans; Lomustine; Lung Neoplasms; Male; Melanoma; Methylnitrosourea; Neoplasms; Sarcoma; Skin Neoplasms; Soft Tissue Neoplasms; Vincristine

1980
Changes in T and B lymphocyte subpopulations before, during and after chemotherapy for malignant melanoma.
    International journal of tissue reactions, 1984, Volume: 6, Issue:6

    Topics: Aged; B-Lymphocytes; Dacarbazine; Female; Humans; Leukocyte Count; Lomustine; Lymphocytes; Male; Melanoma; Middle Aged; Neoplasm Metastasis; T-Lymphocytes

1984
[Isolated hyperthermic extremity perfusion with vindesine, dacarbazine and cisplatin in the treatment of malignant melanomas].
    Onkologie, 1984, Volume: 7, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Dacarbazine; Humans; Leg; Lymphatic Metastasis; Melanoma; Neoplasm Staging; Skin Neoplasms; Vinblastine; Vindesine

1984
[Therapeutic evaluation of human malignant melanoma by urinary 5-S-cysteinyldopa dynamics: chemotherapy and surgery].
    Nihon Hifuka Gakkai zasshi. The Japanese journal of dermatology, 1984, Volume: 94, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Cysteinyldopa; Dacarbazine; Dihydroxyphenylalanine; Female; Humans; Immunotherapy; Male; Melanoma; Middle Aged; Nimustine; Nitrosourea Compounds; Prognosis; Vincristine

1984
Adverse photo reaction to decarbazine (DTIC).
    Contact dermatitis, 1981, Volume: 7, Issue:3

    Topics: Adult; Dacarbazine; Drug Eruptions; Female; Humans; Melanoma; Postoperative Complications; Skin Neoplasms

1981
[Control of multiple skin and lung metastasis of malignant melanoma by combined DAV and OK-432 chemoimmunotherapy in association with large-scale administration of indomethacin].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1984, Volume: 11, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Indomethacin; Lung Neoplasms; Male; Melanoma; Nimustine; Nitrosourea Compounds; Pain, Intractable; Picibanil; Skin Neoplasms; Suppositories; Vincristine

1984
Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma.
    Journal of surgical oncology, 1984, Volume: 27, Issue:4

    Topics: Budd-Chiari Syndrome; Dacarbazine; Hepatic Veins; Humans; Male; Melanoma; Middle Aged; Necrosis

1984
Epigenetic effects of the methylating agent 5-(3-methyl-1-triazeno) imidazole-4-carboxamide in human melanoma cells.
    The Australian journal of experimental biology and medical science, 1984, Volume: 62 ( Pt 5)

    Topics: Alkylating Agents; Antineoplastic Agents; Cell Line; Dacarbazine; Deoxycytidine; Deoxyguanosine; Genes; Humans; Melanoma; Theophylline; Thymidine

1984
Studies on drug resistance in a human melanoma xenograft system.
    Cancer treatment reviews, 1984, Volume: 11 Suppl A

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease Models, Animal; DNA; Drug Resistance; Humans; Ifosfamide; Kinetics; Melanoma; Melphalan; Mice; Mice, Nude; Neoplasm Transplantation; Semustine; Transplantation, Heterologous

1984
Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma.
    Cancer treatment reports, 1984, Volume: 68, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Tamoxifen

1984
[Malignant melanoma of the penile fossa navicularis].
    Der Urologe. Ausg. A, 1984, Volume: 23, Issue:5

    Topics: Combined Modality Therapy; Dacarbazine; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Staging; Penile Neoplasms; Penis; Prognosis; Urethra; Urethral Neoplasms

1984
DTIC and CPZ cytotoxicities on established human melanocyte cell lines.
    Medical oncology and tumor pharmacotherapy, 1984, Volume: 1, Issue:3

    Topics: Cell Division; Cell Line; Chlorpromazine; Dacarbazine; Drug Resistance; Humans; Melanocytes; Melanoma

1984
[Case of metastatic malignant melanoma responded to combination chemotherapy with DTIC].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1984, Volume: 11, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedule; Female; Humans; Melanoma; Middle Aged; Neoplasm Metastasis; Nimustine; Nitrosourea Compounds; Picibanil; Vincristine

1984
Thymostimulin therapy in melanoma patients: correlation of immunologic effects with clinical course.
    Clinical immunology and immunopathology, 1983, Volume: 28, Issue:3

    Topics: Adult; Aged; B-Lymphocytes; Dacarbazine; Female; Humans; Leukocyte Count; Lung Neoplasms; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Rosette Formation; Skin Neoplasms; T-Lymphocytes; Thymus Extracts

1983
Intracarotid artery infusion of DTIC for invasive maxillofacial melanoma.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1983, Volume: 86

    Topics: Aged; Carotid Artery, External; Dacarbazine; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Infusions, Intra-Arterial; Male; Melanoma; Middle Aged; Prognosis

1983
Tourniquet infusion with DTIC in therapy-resistant melanoma on the extremities: a pilot study.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1983, Volume: 86

    Topics: Aged; Combined Modality Therapy; Dacarbazine; Female; Humans; Infusions, Intra-Arterial; Leg; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Prognosis; Skin Neoplasms

1983
In vitro activation of dacarbazine (DTIC) for a human tumor cloning system.
    International journal of cell cloning, 1983, Volume: 1, Issue:1

    Topics: Animals; Biotransformation; Cell Line; Clone Cells; Dacarbazine; Drug Evaluation, Preclinical; Humans; Leukemia L1210; Light; Melanoma; Mice; Microsomes, Liver

1983
[Results in the use of immunochemotherapy in patients with cutaneous malignant melanoma].
    Chirurgia italiana, 1983, Volume: 35, Issue:4

    Topics: BCG Vaccine; Combined Modality Therapy; Dacarbazine; Humans; Melanoma; Skin Neoplasms

1983
[Technic of isolated perfusion of the extremities. Experience with 171 cases].
    Langenbecks Archiv fur Chirurgie, 1983, Volume: 359, Issue:2

    Topics: Arm; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Dacarbazine; Drug Therapy, Combination; Extracorporeal Circulation; Humans; Hyperthermia, Induced; Leg; Mechlorethamine; Melanoma; Melphalan; Postoperative Care; Soft Tissue Neoplasms

1983
Regional perfusion with cis-platinum and dacarbazine.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1983, Volume: 86

    Topics: Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Dacarbazine; Extremities; Follow-Up Studies; Humans; Melanoma; Skin Neoplasms

1983
Antimetastatic action and hematological toxicity of p-(3,3-dimethyl-1-triazeno)benzoic acid potassium salt and 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide used as prophylactic adjuvants to surgical tumor removal in mice bearing B16 melanoma.
    Cancer research, 1984, Volume: 44, Issue:1

    Topics: Animals; Antineoplastic Agents; Combined Modality Therapy; Dacarbazine; Melanoma; Mice; Mice, Inbred Strains; Triazenes

1984
Regional isolated perfusion of high risk melanoma of the extremities with imidazole carboxamide.
    Surgery, gynecology & obstetrics, 1984, Volume: 158, Issue:3

    Topics: Arm; Chemotherapy, Cancer, Regional Perfusion; Creatinine; Dacarbazine; Follow-Up Studies; Humans; Leg; Leukocyte Count; Liver Function Tests; Melanoma; Skin Neoplasms

1984
[Malignant melanoma in Japan: unique distribution and effect of DAV chemoimmunotherapy (part II)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1984, Volume: 11, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Child; Dacarbazine; Female; Foot; Hand; Humans; Japan; Male; Melanoma; Middle Aged; Nimustine; Nitrosourea Compounds; Picibanil; Proteoglycans; Skin Neoplasms; Vincristine

1984
Scheduling of combination chemotherapy for a murine melanoma, with the subrenal capsular assay.
    Journal of surgical oncology, 1984, Volume: 26, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedule; Female; Melanoma; Mice; Neoplasm Transplantation; Semustine

1984
[Marked regression of melanoma metastases under combined chemotherapy].
    Zeitschrift fur Hautkrankheiten, 1984, Apr-01, Volume: 59, Issue:7

    Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Dacarbazine; Female; Humans; Hydroxyurea; Lung Neoplasms; Melanoma; Middle Aged; Skin Neoplasms

1984
Triazene metabolism. III. In vitro cytotoxicity towards M21 cells and in vivo antitumour activity of the proposed metabolites of the antitumour 1-aryl-3,3-dimethyltriazenes.
    Canadian journal of physiology and pharmacology, 1984, Volume: 62, Issue:4

    Topics: Animals; Antineoplastic Agents; Biotransformation; Cell Line; Cell Survival; Chemical Phenomena; Chemistry; Dacarbazine; Half-Life; Humans; Leukemia P388; Melanoma; Mice; Triazenes

1984
Cell kinetic studies of the effect of DTIC combined with fluorescent light or UVA irradiation on human melanoma cell line (SEKI, II).
    The Journal of dermatology, 1982, Volume: 9, Issue:4

    Topics: Cell Cycle; Cells, Cultured; Dacarbazine; Fluorescence; Humans; Kinetics; Melanoma; Skin Neoplasms; Ultraviolet Rays

1982
[Dacarbazine (DTIC) therapy and the Budd-Chiari syndrome].
    MMW, Munchener medizinische Wochenschrift, 1980, May-23, Volume: 122, Issue:21

    Topics: Budd-Chiari Syndrome; Dacarbazine; Female; Humans; Melanoma; Middle Aged

1980
Drug activity and therapeutic synergism in cancer treatment.
    Cancer research, 1982, Volume: 42, Issue:8

    Topics: Animals; Antineoplastic Agents; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Female; Fluorouracil; Humans; Hydroxamic Acids; Lung Neoplasms; Male; Melanoma; Mice; Mitomycin; Mitomycins; Neoplasms; Neoplasms, Experimental; Rats; Razoxane; Teniposide

1982
[Correlation of urinary 5-S-cysteinyldopa with repeated remission of melanoma induced by DTIC combination chemotherapy].
    Nihon Hifuka Gakkai zasshi. The Japanese journal of dermatology, 1982, Volume: 92, Issue:10

    Topics: Cysteinyldopa; Dacarbazine; Dihydroxyphenylalanine; Female; Humans; Lymphoma; Melanoma; Middle Aged; Skin Neoplasms

1982
Adjuvant dacarbazine in cutaneous melanoma.
    The New England journal of medicine, 1983, Mar-31, Volume: 308, Issue:13

    Topics: Dacarbazine; Humans; Melanoma; Skin Neoplasms

1983
In vivo drug sensitivity assay of clonogenic human melanoma cells and correlation with treatment outcome.
    Cancer research, 1983, Volume: 43, Issue:7

    Topics: Animals; Biological Assay; Biotransformation; Cell Survival; Clone Cells; Dacarbazine; Drug Evaluation; Drug Tolerance; Humans; Kinetics; Melanoma; Mice; Mitolactol; Nitrosourea Compounds; Semustine; Specimen Handling

1983
Acute liver dystrophy with thrombosis of hepatic veins: a fatal complication of dacarbazine treatment.
    Cancer treatment reports, 1983, Volume: 67, Issue:9

    Topics: Chemical and Drug Induced Liver Injury; Dacarbazine; Female; Hepatic Veins; Humans; Liver Diseases; Male; Melanoma; Middle Aged; Necrosis; Skin Neoplasms; Thrombosis

1983
[New modifications in isolated extremity perfusion ].
    Zeitschrift fur Hautkrankheiten, 1982, Jul-15, Volume: 57, Issue:14

    Topics: Antineoplastic Agents; Arm; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Dacarbazine; Dactinomycin; Drug Therapy, Combination; Hot Temperature; Humans; Leg; Mechlorethamine; Melanoma; Melphalan; Skin Neoplasms

1982
Combination chemotherapy with AMSA on L1210 leukaemia and B16 melanoma.
    European journal of cancer & clinical oncology, 1981, Volume: 17, Issue:9

    Topics: Aminoacridines; Amsacrine; Animals; Antineoplastic Agents; Carmustine; Dacarbazine; Drug Therapy, Combination; Leukemia L1210; Male; Melanoma; Melphalan; Mice; Mice, Inbred Strains; Neoplasms, Experimental

1981
[Malignant melanoma. Clinicopathological analysis of 37 cases (author's transl)].
    Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association, 1982, Volume: 81, Issue:2

    Topics: Adult; Aged; BCG Vaccine; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms

1982
Phase II study of cyclophosphamide, vincristine and D.T.I.C. +/- B.C.G. in the treatment of malignant melanoma.
    Australian and New Zealand journal of medicine, 1982, Volume: 12, Issue:4

    Topics: Adolescent; Adult; Aged; BCG Vaccine; Cyclophosphamide; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Vincristine

1982
[A case of malignant melanoma responded to chemotherapy including DTIC and local injection of OK-432].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1982, Volume: 9, Issue:10

    Topics: Adult; Biological Products; Dacarbazine; Drug Therapy, Combination; Female; Humans; Melanoma; Nimustine; Nitrosourea Compounds; Picibanil; Skin Neoplasms; Vincristine

1982
[A combination chemotherapy of ACNU and DTIC for advanced malignant melanoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1982, Volume: 9, Issue:5

    Topics: Adult; Aged; Dacarbazine; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Middle Aged; Nimustine; Nitrosourea Compounds; Skin Neoplasms

1982
[Cell kinetic studies on human melanoma cell line (SEKI II) under the effect of DTIC with fluorescent light and UVA irradiation (author's transl)].
    Nihon Hifuka Gakkai zasshi. The Japanese journal of dermatology, 1980, Volume: 90, Issue:9

    Topics: Cell Cycle; Cell Line; Dacarbazine; Humans; Light; Melanoma; Neoplasms, Experimental; Photic Stimulation; Skin Neoplasms; Ultraviolet Rays

1980
[Budd-Chiari syndrome during treatment with dacarbazine (DTIC) (author's transl)].
    Deutsche medizinische Wochenschrift (1946), 1980, Feb-15, Volume: 105, Issue:7

    Topics: Budd-Chiari Syndrome; Dacarbazine; Humans; Male; Melanoma; Metoclopramide; Middle Aged; Mycobacterium bovis; Skin Neoplasms; Vomiting

1980
Chemoimmunotherapy for disseminated malignant melanoma with DTIC, ACNU, VCR and OK432. Case presentation of two complete and one partial reponse out of fifteen attempts.
    The Journal of dermatology, 1982, Volume: 9, Issue:1

    Topics: Adjuvants, Immunologic; Adult; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Nimustine; Nitrosourea Compounds; Picibanil; Skin Neoplasms; Vincristine

1982
Thermochemotherapy for melanoma metastases in liver.
    Cancer, 1982, Mar-15, Volume: 49, Issue:6

    Topics: Adult; Aged; Dacarbazine; Female; Hot Temperature; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Melanoma; Middle Aged; Pilot Projects; Retrospective Studies

1982
Pilot studies using melanoma tumor-associated antigens (TAA) in specific-active immunochemotherapy of malignant melanoma.
    Cancer, 1982, Apr-01, Volume: 49, Issue:7

    Topics: Adult; Aged; Antigens, Neoplasm; Chromatography, Affinity; Dacarbazine; Drug Administration Schedule; Female; Humans; Immunity, Cellular; Immunization; Male; Melanoma; Middle Aged; Neoplasm Staging; Pilot Projects; Prognosis; Random Allocation; Recurrence; Skin Neoplasms

1982
Effect of scheduling of combinations of 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide and 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea on the Harding-Passey and Cloudman S91 mouse melanomas.
    Cancer research, 1982, Volume: 42, Issue:3

    Topics: Animals; Cell Line; Dacarbazine; Drug Administration Schedule; Drug Therapy, Combination; Female; Melanoma; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms, Experimental; Nitrosourea Compounds; Semustine; Time Factors

1982
Properties of human melanoma cells resistant to 5-(3',3'-dimethyl-1-triazeno)imidazole-4-carboxamide and other methylating agents.
    Cancer research, 1982, Volume: 42, Issue:4

    Topics: Alkylating Agents; Biotransformation; Cell Line; Dacarbazine; DNA, Neoplasm; Drug Resistance; Humans; Melanoma; Protein Biosynthesis

1982
[Immunological aspects in the treatment of malignant melanoma].
    Minerva medica, 1982, Apr-28, Volume: 73, Issue:18

    Topics: Administration, Topical; BCG Vaccine; Dacarbazine; Humans; Injections, Intralymphatic; Injections, Intravenous; Injections, Jet; Lymphatic Metastasis; Melanoma; Prognosis

1982
[Experience with adjuvant chemoimmunotherapy with DTIC and BCG in malignant melanoma (author's transl)].
    Zeitschrift fur Hautkrankheiten, 1982, Feb-15, Volume: 57, Issue:4

    Topics: BCG Vaccine; Dacarbazine; Drug Therapy, Combination; Humans; Melanoma; Skin Neoplasms

1982
[Budd-Chiari syndrome in DTIC therapy].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 1982, Volume: 33, Issue:1

    Topics: Adult; Budd-Chiari Syndrome; Dacarbazine; Eosinophilia; Female; Humans; Melanoma

1982
[Dacarbazine in malignant melanoma. Rare, severe side-effect: Budd-Chiari-syndrome (author's transl)].
    Zeitschrift fur Hautkrankheiten, 1982, Jul-01, Volume: 57, Issue:13

    Topics: Budd-Chiari Syndrome; Dacarbazine; Humans; Liver; Male; Melanoma; Middle Aged; Skin Neoplasms

1982
Changes in the rosette forming capacity of lymphocytes after surgery or surgery and immunochemotherapy of malignant melanoma in man.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 1982, Volume: 36, Issue:5

    Topics: Adolescent; Adult; Aged; BCG Vaccine; Dacarbazine; Humans; Lymphocytes; Melanoma; Middle Aged; Rosette Formation

1982
[Malignant melanoma in Japan: unique distribution and effect of DAV chemoimmunotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1982, Volume: 9, Issue:11

    Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Therapy, Combination; Female; Humans; Leucine; Male; Melanoma; Middle Aged; Nimustine; Nitrosourea Compounds; Picibanil; Proteoglycans; Skin Neoplasms; Vincristine

1982
Combination chemotherapy with ifosfamide and cis-dichlorodiammineplatinum (II) in advanced malignant melanoma.
    Journal of cancer research and clinical oncology, 1980, Volume: 97, Issue:3

    Topics: Adult; Aged; Cisplatin; Cyclophosphamide; Dacarbazine; Drug Synergism; Drug Therapy, Combination; Female; Humans; Ifosfamide; Male; Melanoma; Middle Aged

1980
Angiographic appearance of recurrent malignant melanoma before and after intra-arterial chemotherapy.
    Radiology, 1982, Volume: 142, Issue:2

    Topics: Angiography; Antineoplastic Agents; Cisplatin; Dacarbazine; Drug Therapy, Combination; Extremities; Humans; Infusions, Intra-Arterial; Melanoma; Neoplasm Recurrence, Local

1982
Dacarbazine (DTIC) in malignant melanoma: reduced toxicity with protection from light.
    Clinical radiology, 1981, Volume: 32, Issue:1

    Topics: Dacarbazine; Darkness; Female; Humans; Male; Melanoma; Neoplasm Recurrence, Local

1981
In vitro sensitivity of human melanoma xenografts to cytotoxic drugs. Correlation with in vivo chemosensitivity.
    International journal of cancer, 1980, Dec-15, Volume: 26, Issue:6

    Topics: Abrin; Animals; Antineoplastic Agents; Dacarbazine; Humans; Lomustine; Melanoma; Mice; Mice, Nude; Neoplasms, Experimental; Procarbazine; Ricin; Vinblastine

1980
[Veno-occlusive syndrome with acute liver dystrophy following decarbazine therapy of malignant melanoma (author's transl)].
    Klinische Wochenschrift, 1981, Mar-02, Volume: 59, Issue:5

    Topics: Aged; Budd-Chiari Syndrome; Chemical and Drug Induced Liver Injury; Dacarbazine; Hepatic Veins; Humans; Liver; Lymphatic Metastasis; Male; Melanoma; Skin Neoplasms

1981
[Malignant melanoma of the esophagus (author's transl)].
    Leber, Magen, Darm, 1981, Volume: 11, Issue:1

    Topics: Adult; BCG Vaccine; Brain Neoplasms; Dacarbazine; Esophageal Neoplasms; Humans; Male; Melanoma; Seizures

1981
[Scintigraphy of liver after combined chemo-/immunotherapy with malignant melanoma (author's transl)].
    Zeitschrift fur Hautkrankheiten, 1981, Feb-01, Volume: 56, Issue:3

    Topics: Adult; BCG Vaccine; Dacarbazine; Female; Humans; Liver; Male; Melanoma; Middle Aged; Radionuclide Imaging; Skin Neoplasms

1981
Dacarbazine-induced photosensitivity reaction.
    Journal of the American Academy of Dermatology, 1981, Volume: 4, Issue:5

    Topics: Aged; Dacarbazine; Female; Humans; Melanoma; Middle Aged; Photosensitivity Disorders; Skin; Skin Neoplasms

1981
[Influence and importance of dacarbazine and BCG in sonography of the liver (author's transl)].
    Rontgen-Blatter; Zeitschrift fur Rontgen-Technik und medizinisch-wissenschaftliche Photographie, 1981, Volume: 34, Issue:8

    Topics: BCG Vaccine; Dacarbazine; Female; Humans; Immunotherapy; Liver Neoplasms; Male; Melanoma; Middle Aged; Radiography

1981
[Effect of DTIC on the level of various blood components in melanoma].
    Nowotwory, 1981, Volume: 31, Issue:1

    Topics: Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Bilirubin; Blood Proteins; Dacarbazine; Female; Hematocrit; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms

1981
Comparison of two soft-agar methods for assaying chemosensitivity of human tumours in vitro: malignant melanomas.
    British journal of cancer, 1981, Volume: 44, Issue:4

    Topics: Abrin; Agar; Animals; Cell Survival; Cells, Cultured; Dacarbazine; Drug Evaluation, Preclinical; Erythrocytes; Humans; Lomustine; Melanoma; Oxygen Consumption; Rats; Vinblastine

1981
Chemoimmunotherapy for metastatic malignant melanoma using vincristine (NSC-67574), DTIC (NSC-45388) and Bacillus Calmette-Guerin.
    European journal of cancer, 1981, Volume: 17, Issue:4

    Topics: Adult; Aged; BCG Vaccine; Dacarbazine; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Vincristine

1981
The usefulness of human tumor cell lines in the study of chemosensitivity. A study of malignant melanomas.
    International journal of cancer, 1981, Oct-15, Volume: 28, Issue:4

    Topics: Animals; Antineoplastic Agents; Cell Division; Cell Line; Dacarbazine; Drug Evaluation, Preclinical; Humans; Lomustine; Melanoma; Mice; Neoplasm Transplantation; Procarbazine; Ricin; Transplantation, Heterologous; Vinblastine

1981
Metastatic tumor to the retina and vitreous cavity from primary melanoma of the skin: treatment with systemic and subconjunctival chemotherapy.
    Ophthalmology, 1981, Volume: 88, Issue:12

    Topics: Adult; Carmustine; Dacarbazine; Eye Neoplasms; Female; Humans; Lomustine; Melanoma; Retina; Skin Neoplasms; Vitreous Body

1981
Response to chemotherapy of human, malignant melanoma xenografts in athymic, nude mice.
    International journal of cancer, 1980, Apr-15, Volume: 25, Issue:4

    Topics: Abrin; Animals; Antineoplastic Agents; Dacarbazine; Humans; Lomustine; Melanoma; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Procarbazine; Ricin; Skin Neoplasms; Time Factors; Transplantation, Heterologous; Vinblastine

1980
Chemoimmunotherapy of disseminated malignant melanoma with DTIC-BCG, transfer factor + melphalan.
    Cancer, 1980, May-15, Volume: 45, Issue:10

    Topics: Adult; Aged; BCG Vaccine; Blood Cell Count; Dacarbazine; Drug Therapy, Combination; Female; Humans; Immunocompetence; Immunotherapy; Male; Melanoma; Melphalan; Middle Aged; Neoplasm Metastasis; Prognosis; Skin Tests; Time Factors; Transfer Factor

1980
Hepatic veno-occlusive disease due to DTIC.
    Cancer, 1980, May-15, Volume: 45, Issue:10

    Topics: Budd-Chiari Syndrome; Chemical and Drug Induced Liver Injury; Dacarbazine; Humans; Liver; Male; Melanoma; Middle Aged; Necrosis

1980
[Phototoxic dermatitis caused by DTIC-treatment].
    Zeitschrift fur Hautkrankheiten, 1980, Jan-15, Volume: 55, Issue:2

    Topics: Dacarbazine; Humans; Melanoma; Photosensitivity Disorders; Skin Neoplasms

1980
[Chemotherapy and malignant melanoma].
    Ceskoslovenska dermatologie, 1980, Volume: 55, Issue:4

    Topics: Dacarbazine; Humans; Melanoma

1980
[Results of immunochemotherapy in malignant melanoma].
    Ceskoslovenska dermatologie, 1980, Volume: 55, Issue:4

    Topics: BCG Vaccine; Dacarbazine; Humans; Levamisole; Melanoma; Transfer Factor

1980
[Use of imidazole carboxamide in melanoblastoma of the eye].
    Voprosy onkologii, 1980, Volume: 26, Issue:8

    Topics: Animals; Dacarbazine; Drug Evaluation; Drug Evaluation, Preclinical; Eye Neoplasms; Female; Humans; Imidazoles; Melanoma; Neoplasm Transplantation; Preoperative Care; Rabbits

1980
Biologic behavior of ocular malignant melanoma and comparison with melanoma of the head and neck.
    American journal of surgery, 1980, Volume: 140, Issue:4

    Topics: Adult; Aged; Dacarbazine; Eye Neoplasms; Female; Head and Neck Neoplasms; Humans; Male; Melanoma; Middle Aged

1980
An inverse relationship between the growth rate of human melanoma xenografts and their response to some cytostatic drugs.
    British journal of cancer, 1980, Volume: 41, Issue:5

    Topics: Animals; Dacarbazine; Humans; Lomustine; Melanoma; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Nitrosourea Compounds; Procarbazine; Transplantation, Heterologous

1980
[Photosensitization with DTIC therapy in metastatic malignant melanoma].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 1980, Volume: 31, Issue:11

    Topics: Aged; Dacarbazine; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Photosensitivity Disorders; Skin Neoplasms

1980
Chemotherapy against human melanoma in the hamster cheek pouch.
    Journal of surgical oncology, 1980, Volume: 15, Issue:4

    Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Cheek; Cricetinae; Cyclophosphamide; Dacarbazine; Doxorubicin; Fluorouracil; Humans; Male; Melanoma; Methotrexate; Middle Aged; Neoplasm Transplantation; Neoplasms, Experimental; Vincristine

1980
Symptoms of occult brain metastases initiated by systemic Dacarbazine (DTIC-DOME) therapy in melanoma patients.
    Clinical oncology, 1980, Volume: 6, Issue:4

    Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Dizziness; Female; Headache; Humans; Male; Melanoma; Middle Aged

1980
[Anorectal malignant melanomas. Apropos of 5 cases. Review of the literature].
    Annales de gastroenterologie et d'hepatologie, 1995, Volume: 31, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Female; Humans; Immunotherapy; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Palliative Care; Prognosis; Radiotherapy Dosage; Radiotherapy, Adjuvant; Rectal Neoplasms; Vindesine

1995
Chemosensitivity testing of human malignant melanoma. A retrospective analysis of clinical response and in vitro drug sensitivity.
    Cancer, 1994, Jan-01, Volume: 73, Issue:1

    Topics: Antineoplastic Agents; Bleomycin; Carboplatin; Carmustine; Cisplatin; Dacarbazine; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance; Drug Screening Assays, Antitumor; Fluorouracil; Forecasting; Humans; In Vitro Techniques; Lymphatic Metastasis; Melanoma; Methotrexate; Nitrosourea Compounds; Organophosphorus Compounds; Pilot Projects; Remission Induction; Retrospective Studies; Skin Neoplasms; Tumor Cells, Cultured; Vindesine

1994
Contribution of radiotherapy to the management of malignant melanoma. A ten year experience at the University of Illinois Hospital in Chicago.
    Neoplasma, 1993, Volume: 40, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Combined Modality Therapy; Dacarbazine; Dose-Response Relationship, Radiation; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Neoplasm Staging; Palliative Care; Survival Analysis; Survival Rate; Treatment Outcome

1993
Decreasing CD4/CD8 ratio during prolonged four-drug chemotherapy plus interferon treatment for metastatic melanoma.
    Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy, 1994, Volume: 15, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; CD4-CD8 Ratio; Dacarbazine; Humans; Interferon-alpha; Leukocyte Count; Lomustine; Melanoma; Middle Aged; Vincristine

1994
Response of subcutaneous and cutaneous metastases of malignant melanoma to combined cytostatic plus interferon therapy.
    The British journal of dermatology, 1995, Volume: 132, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Dacarbazine; Female; Humans; Interferons; Lomustine; Male; Melanoma; Middle Aged; Skin Neoplasms; Vincristine

1995
Statistical survey from 1982 to 1991 of 49 patients with malignant melanocytic tumors.
    The Journal of dermatology, 1995, Volume: 22, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; Dacarbazine; Female; Humans; Interferon-beta; Male; Melanoma; Middle Aged; Nimustine; Prognosis; Skin Neoplasms; Survival Rate; Vincristine

1995
[Combination of dacarbazine, vindesine and interferon alpha in the treatment of metastatic melanoma].
    Annales de dermatologie et de venereologie, 1994, Volume: 121, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Interferon-alpha; Male; Melanoma; Treatment Outcome; Vindesine

1994
Three-drug combination of cisplatin, dacarbazine, and tamoxifen in metastatic malignant melanoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Remission Induction; Tamoxifen

1995
Isolated pelvic perfusion for unresectable cancer using a balloon occlusion technique.
    Archives of surgery (Chicago, Ill. : 1960), 1993, Volume: 128, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Catheterization; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Dacarbazine; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Melanoma; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Palliative Care; Pelvis; Rectal Neoplasms; Remission Induction

1993
[Chemotherapy of malignant melanoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Dacarbazine; Drug Administration Schedule; Female; Humans; Melanoma; Middle Aged; Nimustine; Peplomycin; Skin Neoplasms; Vincristine

1993
Chemoimmunotherapy of melanoma. Is it time for phase III trials?
    Cancer, 1995, Feb-15, Volume: 75, Issue:4

    Topics: Clinical Trials, Phase III as Topic; Combined Modality Therapy; Dacarbazine; Humans; Immunotherapy; Interleukin-2; Melanoma

1995
Modification of the effect of tamoxifen, cis-platin, DTIC, and interferon-alpha 2b on human melanoma cells in culture by a mixture of vitamins.
    Nutrition and cancer, 1994, Volume: 22, Issue:3

    Topics: Ascorbic Acid; beta Carotene; Carotenoids; Cell Division; Cisplatin; Dacarbazine; Drug Screening Assays, Antitumor; Humans; Interferon alpha-2; Interferon-alpha; Isotretinoin; Melanoma; Recombinant Proteins; Tamoxifen; Tocopherols; Tumor Cells, Cultured; Vitamin E; Vitamins

1994
Combination chemotherapy of metastatic melanoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Humans; Melanoma; Neoplasm Metastasis; Tamoxifen

1995
Pilot study of preoperative chemotherapy with cisplatin, vinblastine, and dacarbazine in patients with local-regional recurrence of melanoma.
    Cancer, 1994, Nov-01, Volume: 74, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Remission Induction; Skin Neoplasms; Survival Analysis; Vinblastine

1994
Mouse subrenal capsule assay chemosensitivity and DNA flow cytometry parameters of human melanoma metastases.
    Acta oncologica (Stockholm, Sweden), 1994, Volume: 33, Issue:4

    Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; DNA, Neoplasm; Etoposide; Female; Flow Cytometry; Humans; Male; Melanoma; Mice; Middle Aged; Subrenal Capsule Assay; Vincristine

1994
[Melanoma metastasis in the oropharynx].
    HNO, 1994, Volume: 42, Issue:5

    Topics: Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Humans; Interferon-alpha; Lymph Node Excision; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Nasopharyngeal Neoplasms; Nasopharynx; Skin Neoplasms

1994
Hyperthermic isolation limb perfusion (HILP) in the management of extremity melanoma and sarcoma with particular reference to the dosage, pharmacokinetics, and toxicity of cisplatin.
    Cancer treatment and research, 1993, Volume: 62

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Combined Modality Therapy; Dacarbazine; Dactinomycin; Evaluation Studies as Topic; Extremities; Humans; Hyperthermia, Induced; Incidence; Melanoma; Melphalan; Neoplasm Metastasis; Osteosarcoma; Rhabdomyolysis; Skin Neoplasms; Treatment Outcome

1993
Clinical relevance of ICAM-1 expression in primary lesions and serum of patients with malignant melanoma.
    Cancer research, 1993, Oct-15, Volume: 53, Issue:20

    Topics: Antibodies, Monoclonal; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Cell Adhesion Molecules; Dacarbazine; Humans; Immunoenzyme Techniques; Immunohistochemistry; Intercellular Adhesion Molecule-1; Interferon-beta; Liver Neoplasms; Lymphatic Metastasis; Melanoma; Neoplasm Metastasis; Neoplasm Staging; Skin Neoplasms; Vincristine

1993
Antiphospholipid syndrome associated with immunotherapy for patients with melanoma.
    Cancer, 1994, Mar-15, Volume: 73, Issue:6

    Topics: Adult; Aged; Antibodies, Antinuclear; Antibodies, Antiphospholipid; Antineoplastic Combined Chemotherapy Protocols; Antiphospholipid Syndrome; Autoantibodies; Cardiolipins; Carmustine; Chemotherapy, Adjuvant; Cisplatin; Dacarbazine; Female; Humans; Immunoglobulin G; Immunotherapy; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Recombinant Proteins; Tamoxifen; Thromboembolism

1994
Long term response to chemotherapy in patients with visceral metastatic melanoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1994, Volume: 5, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Interferon-alpha; Lomustine; Male; Melanoma; Middle Aged; Remission Induction; Semustine; Survival Rate

1994
Phenotypic and functional profile of peripheral blood mononuclear cells isolated from melanoma patients undergoing combined immunotherapy and chemotherapy.
    Cancer immunology, immunotherapy : CII, 1993, Volume: 37, Issue:6

    Topics: Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Division; Chemotherapy, Adjuvant; Concanavalin A; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Immunophenotyping; Immunotherapy; Interferon Type I; Interleukin-2; Killer Cells, Lymphokine-Activated; Leukocytes, Mononuclear; Male; Melanoma; Middle Aged; Phytohemagglutinins; Pokeweed Mitogens; Recombinant Proteins

1993
[Combination of fotemustine-dacarbazine and interferon alpha in the treatment of metastatic malignant melanoma].
    Annales de dermatologie et de venereologie, 1993, Volume: 120, Issue:6-7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Interferon-alpha; Karnofsky Performance Status; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Treatment Outcome

1993
The chemohormonal therapy of metastatic melanoma: possible benefit of tamoxifen.
    The West Virginia medical journal, 1993, Volume: 89, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Tamoxifen; Thrombophlebitis

1993
Fotemustine-dacarbazine combinations in the treatment of metastatic melanoma.
    European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Liver Neoplasms; Lung Neoplasms; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds

1993
Brain metastases of metastatic malignant melanoma: response to DTIC and interferon-gamma.
    Journal of neuro-oncology, 1993, Volume: 16, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Female; Humans; Interferon-gamma; Melanoma; Remission Induction

1993
Tamoxifen and chemotherapy for refractory metastatic malignant melanoma.
    The New England journal of medicine, 1993, Jan-14, Volume: 328, Issue:2

    Topics: Adult; Antineoplastic Agents; Cisplatin; Dacarbazine; Female; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Tamoxifen

1993
Long-term complete remissions in patients with disseminated melanoma treated by fotemustine and dacarbazine.
    European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Remission Induction

1993
Dosage and cycle effects of dacarbazine (DTIC) and fotemustine on O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells.
    British journal of cancer, 1993, Volume: 67, Issue:2

    Topics: Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Humans; Leukocytes, Mononuclear; Melanoma; Methyltransferases; Nitrosourea Compounds; O(6)-Methylguanine-DNA Methyltransferase; Organophosphorus Compounds

1993
[Dramatic remission of a multiple metastasized melanoma caused by chemo-immunotherapy].
    Deutsche medizinische Wochenschrift (1946), 1993, Mar-12, Volume: 118, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Dacarbazine; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukins; Liver Neoplasms; Melanoma; Middle Aged; Recombinant Proteins; Remission Induction; Skin Neoplasms; Splenic Neoplasms

1993
Activity and unexpected lung toxicity of the sequential administration of two alkylating agents--dacarbazine and fotemustine--in patients with melanoma.
    European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Lung; Lung Neoplasms; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Respiratory Distress Syndrome

1993
Error in chemotherapy dosages.
    The New England journal of medicine, 1993, May-27, Volume: 328, Issue:21

    Topics: Cisplatin; Dacarbazine; Drug Administration Schedule; Humans; Melanoma

1993
From triazines and triazenes to temozolomide.
    European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A, Issue:7

    Topics: Animals; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Chemistry, Pharmaceutical; Dacarbazine; Humans; Melanoma; Mice; Nitrogen Mustard Compounds; Prodrugs; Temozolomide

1993
Porcine splenic peptides (Polyerga) decrease the number of experimental lung metastases in mice.
    Clinical & experimental metastasis, 1996, Volume: 14, Issue:1

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cell Survival; Dacarbazine; Dose-Response Relationship, Drug; Drug Combinations; Glycopeptides; Lung Neoplasms; Melanoma; Mice; Phenols; Tumor Cells, Cultured

1996
Intracellular Localization and intercellular heterogeneity of the human DNA repair protein O(6)-methylguanine-DNA methyltransferase.
    Cancer chemotherapy and pharmacology, 1996, Volume: 37, Issue:6

    Topics: Animals; Cell Compartmentation; Cell Nucleus; Cytoplasm; Dacarbazine; DNA Repair; Enzyme Inhibitors; Fluorescent Antibody Technique, Indirect; Guanine; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Melanoma; Methyltransferases; Mice; Mice, Nude; Neoplasm Transplantation; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Transplantation, Heterologous

1996
The CD4+/CD8+ ratio as a prognostic factor in patients with metastatic melanoma receiving chemoimmunotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; CD4-CD8 Ratio; Dacarbazine; Female; Humans; Immunotherapy; Interferon-alpha; Lomustine; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Prognosis; Survival Analysis; Vincristine

1996
The effect of tirapazamine (SR-4233) alone or combined with chemotherapeutic agents on xenografted human tumours.
    British journal of cancer, 1996, Volume: 73, Issue:12

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cell Division; Cisplatin; Dacarbazine; Drug Screening Assays, Antitumor; Etoposide; Fluorouracil; Humans; Melanoma; Mice; Mice, Nude; Rectal Neoplasms; Tirapazamine; Transplantation, Heterologous; Triazines

1996
[Acquired myelodysplastic syndromes after treatment of melanoma with fotemustine and dacarbazine].
    Annales de dermatologie et de venereologie, 1995, Volume: 122, Issue:10

    Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Therapy, Combination; Fatal Outcome; Female; Humans; Melanoma; Middle Aged; Myelodysplastic Syndromes; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms

1995
Dacarbazine, vincristine, bleomycin and lomustine plus natural interferon-alpha for metastatic melanoma.
    European journal of cancer (Oxford, England : 1990), 1996, Volume: 32A, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Dacarbazine; Female; Humans; Interferon-alpha; Lomustine; Male; Melanoma; Middle Aged; Pilot Projects; Vincristine

1996
Subcutaneous recombinant interleukin-2 plus chemotherapy with cisplatin and dacarbazine in metastatic melanoma.
    European journal of cancer (Oxford, England : 1990), 1996, Volume: 32A, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Humans; Injections, Subcutaneous; Interleukin-2; Male; Melanoma; Middle Aged; Recombinant Proteins; Remission Induction; Survival Analysis

1996
[A case of adrenal gland metastasis of a cutaneous melanoma treated by excision with 3-year survival].
    Annales d'urologie, 1996, Volume: 30, Issue:1

    Topics: Adrenal Gland Neoplasms; Adult; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Fatal Outcome; Follow-Up Studies; Humans; Male; Melanoma; Skin Neoplasms; Vindesine

1996
Chemosensitivity of human melanoma metastases in mouse subrenal capsule assay--can it predict tumour response to combined cytostatic plus interferon therapy in metastatic melanoma?
    Melanoma research, 1996, Volume: 6, Issue:3

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Confidence Intervals; Dacarbazine; Female; Humans; Interferons; Lomustine; Male; Melanoma; Mice; Mice, Inbred Strains; Neoplasm Metastasis; Sex Characteristics; Subrenal Capsule Assay; Vincristine

1996
Ukrain with chemotherapy in malignant melanoma (case report).
    Drugs under experimental and clinical research, 1996, Volume: 22, Issue:3-5

    Topics: Alkaloids; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Berberine Alkaloids; Dacarbazine; Female; Humans; Lung Neoplasms; Melanoma; Neoplasm Recurrence, Local; Phenanthridines

1996
Pharmacokinetics of dacarbazine in the regional perfusion of extremities with melanoma.
    Journal of surgical oncology, 1996, Volume: 63, Issue:3

    Topics: Antineoplastic Agents; Arm; Dacarbazine; Drug Administration Schedule; Humans; Hyperthermia, Induced; Leg; Melanoma; Models, Biological; Perfusion

1996
Immunohistochemical examination of the expression of O6-methylguanine-DNA methyltransferase in human melanoma metastases.
    European journal of cancer (Oxford, England : 1990), 1997, Volume: 33, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Division; Cell Nucleus; Dacarbazine; Female; Humans; Immunoenzyme Techniques; Lymphatic Metastasis; Male; Melanoma; Methyltransferases; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Skin Neoplasms

1997
Regional isolated perfusion of extremities for melanoma: a 20-year experience with drugs other than L-phenylalanine mustard.
    Plastic and reconstructive surgery, 1997, Volume: 99, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Dacarbazine; Extremities; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Skin Neoplasms; Survival Rate; Thiotepa

1997
The effect of dacarbazine and vincristine sulfate on human melanoma cell lines. In vitro analysis of interaction on DNA synthesis, RNA synthesis and protein synthesis.
    Nihon Ika Daigaku zasshi, 1997, Volume: 64, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cell Line; Dacarbazine; DNA, Neoplasm; Drug Screening Assays, Antitumor; Humans; Melanoma; Neoplasm Proteins; RNA, Neoplasm; Tumor Cells, Cultured; Vincristine

1997
DNA flow cytometry and the outcome of chemoimmunotherapy in metastatic melanoma.
    Melanoma research, 1997, Volume: 7, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Dacarbazine; DNA, Neoplasm; Female; Flow Cytometry; Humans; Immunotherapy; Interferons; Lomustine; Male; Melanoma; Middle Aged; Ploidies; Treatment Outcome; Vincristine

1997
Tourniquet infusion chemotherapy for extremity in-transit lesions in malignant melanoma.
    Annals of surgical oncology, 1997, Volume: 4, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arm; Cisplatin; Combined Modality Therapy; Dacarbazine; Doxorubicin; Female; Follow-Up Studies; Humans; Infusions, Intra-Arterial; Leg; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Prospective Studies; Survival Rate

1997
Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy.
    Cancer research, 1997, Nov-15, Volume: 57, Issue:22

    Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Cysteinyldopa; Dacarbazine; Disease Progression; Female; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Prognosis; Skin Neoplasms

1997
Paralytic ileus associated with a combination of dacarbazine-nimustine hydrochloride-vincristine chemotherapy.
    The Journal of dermatology, 1997, Volume: 24, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Intestinal Pseudo-Obstruction; Melanoma; Nimustine; Skin Neoplasms; Vincristine

1997
Fatal hepatic toxicity of DTIC: a new case.
    Intensive care medicine, 1997, Volume: 23, Issue:10

    Topics: Chemical and Drug Induced Liver Injury; Dacarbazine; Fatal Outcome; Female; Humans; Melanoma; Middle Aged

1997
Immunochemotherapy with recombinant interferon-alpha 2b plus dacarbazine in the treatment of advanced malignant melanoma.
    Melanoma research, 1997, Volume: 7, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Humans; Interferon alpha-2; Interferon-alpha; Lung Neoplasms; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Recombinant Proteins; Skin Neoplasms; Soft Tissue Neoplasms; Survival Rate; Time Factors

1997
bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice.
    Nature medicine, 1998, Volume: 4, Issue:2

    Topics: Actins; Animals; Antineoplastic Agents; Apoptosis; Dacarbazine; Female; Humans; Melanoma; Mice; Mice, SCID; Neoplasm Transplantation; Oligonucleotides, Antisense; Proto-Oncogene Proteins c-bcl-2; Transplantation, Heterologous

1998
[Immunochemotherapy of malignant melanoma. Epifocal administration of dinitrochlorobenzene (DNCB) combined with systemic chemotherapy with dacarbazine (DTIC)].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 1998, Volume: 49, Issue:1

    Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Dacarbazine; Dinitrochlorobenzene; Female; Follow-Up Studies; Humans; Immunotherapy; Infusions, Intravenous; Irritants; Male; Melanoma; Middle Aged; Skin; Skin Neoplasms; Treatment Outcome

1998
Safety and efficacy of isolated perfusion of extremities for recurrent tumor in elderly patients.
    Surgery, 1998, Volume: 123, Issue:3

    Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Dacarbazine; Edema; Extremities; Female; Humans; Male; Melanoma; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Outcome Assessment, Health Care; Perfusion; Recurrence; Skin Neoplasms

1998
Commentary: management of the patient.
    BMJ (Clinical research ed.), 1998, Mar-14, Volume: 316, Issue:7134

    Topics: Antineoplastic Agents; Dacarbazine; Decision Making; Ethics, Medical; Fatal Outcome; Female; Humans; Melanoma; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Spinal Neoplasms

1998
Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease Progression; Female; Humans; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Survival Rate; Vinblastine

1998
Primary malignant melanoma of the vagina: case report.
    European journal of gynaecological oncology, 1998, Volume: 19, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Female; Follow-Up Studies; Humans; Interferon alpha-2; Interferon-alpha; Liver Neoplasms; Lymph Node Excision; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Recombinant Proteins; Vaginal Neoplasms

1998
[Combination of dacarbazine, cisplatin and interferon alpha in the treatment of metastatic melanoma].
    Annales de dermatologie et de venereologie, 1996, Volume: 123, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Therapy, Combination; Female; Humans; Interferon-alpha; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Treatment Outcome

1996
[The role of glutathione and glutathione-S-transferase in neoplasm drug resistance].
    Biulleten' eksperimental'noi biologii i meditsiny, 1998, Volume: 125, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclophosphamide; Dacarbazine; Drug Resistance, Neoplasm; Erythrocytes; Etoposide; Female; Glutathione; Glutathione Transferase; Humans; Male; Melanoma; Ovarian Neoplasms; Propionates; Skin Neoplasms; Testicular Neoplasms

1998
[At the front line of malignant melanoma, great maneuvers: to cut the road to Bcl2 and "attack with chemotherapy"].
    Bulletin du cancer, 1998, Volume: 85, Issue:6

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Melanoma; Mice; Mice, SCID; Neoplasm Proteins; Neoplasm Transplantation; Oligonucleotides, Antisense; Proto-Oncogene Proteins c-bcl-2; Skin Neoplasms; Thionucleotides; Tumor Cells, Cultured

1998
Syndrome of inappropriate secretion of antidiuretic hormone in a patient affected by metastatic melanoma.
    Melanoma research, 1998, Volume: 8, Issue:4

    Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Facial Neoplasms; Fatal Outcome; Frontal Lobe; Humans; Inappropriate ADH Syndrome; Lymphatic Metastasis; Male; Melanoma; Middle Aged

1998
Methyl DNA adducts, DNA repair, and hypoxanthine-guanine phosphoribosyl transferase mutations in peripheral white blood cells from patients with malignant melanoma treated with dacarbazine and hydroxyurea.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1996, Volume: 2, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; DNA Adducts; DNA Repair; Female; Guanine; Humans; Hydroxyurea; Hypoxanthine Phosphoribosyltransferase; Leukocytes; Male; Melanoma; Middle Aged; Mutation; O(6)-Methylguanine-DNA Methyltransferase

1996
Transgenic mice with pigmented intraocular tumors: tissue of origin and treatment.
    Investigative ophthalmology & visual science, 1998, Volume: 39, Issue:13

    Topics: Animals; Antigens, Neoplasm; Antigens, Polyomavirus Transforming; Dacarbazine; Fas Ligand Protein; Female; Immunohistochemistry; In Situ Hybridization; Male; Melanoma; Melanoma-Specific Antigens; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Transgenic; Neoplasm Proteins; Pigment Epithelium of Eye; S100 Proteins; Uveal Neoplasms

1998
The behaviour of blood lymphocyte subsets in patients treated with immunochemotherapy for metastatic melanoma.
    European journal of histochemistry : EJH, 1997, Volume: 41 Suppl 2

    Topics: Antigens, CD; Dacarbazine; Female; Flow Cytometry; HLA-DR Antigens; Humans; Immunophenotyping; Interleukin-2; Lymphocyte Subsets; Male; Melanoma; Middle Aged

1997
Primary malignant melanoma of the esophagus: report of a case successfully treated with pre- and post-operative adjuvant hormone-chemotherapy.
    Japanese journal of clinical oncology, 1998, Volume: 28, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Dacarbazine; Esophageal Neoplasms; Esophagectomy; Humans; Lymph Node Excision; Male; Melanoma; Middle Aged; Nimustine; Tamoxifen

1998
Treatment of metastatic malignant melanoma with dacarbazine plus fotemustine.
    European journal of cancer (Oxford, England : 1990), 1998, Volume: 34, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Treatment Outcome

1998
[Chemotherapy of malignant melanoma].
    Polskie Archiwum Medycyny Wewnetrznej, 1998, Volume: 100, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Dacarbazine; Humans; Immunotherapy; Interleukins; Lomustine; Melanoma; Middle Aged; Palliative Care; Skin Neoplasms; Tamoxifen; Vincristine

1998
Dacarbazine, nimustine hydrochloride, cisplatin and tamoxifen combination chemotherapy for advanced malignant melanoma.
    The Journal of dermatology, 1999, Volume: 26, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Nimustine; Skin Neoplasms; Tamoxifen; Tomography, X-Ray Computed; Treatment Outcome

1999
Comments on: Treatment of metastatic malignant melanoma with dacarbazine plus fotemustine, Seeber, et al., Eur J Cancer 1998, 34, 2129-2131.
    European journal of cancer (Oxford, England : 1990), 1999, Volume: 35, Issue:7

    Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds

1999
Management of cerebral metastases from malignant melanoma: results of a combined, simultaneous treatment with fotemustine and irradiation.
    Journal of neuro-oncology, 1999, Volume: 43, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Female; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Retrospective Studies; Survival Analysis

1999
Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease-Free Survival; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Humans; Interleukin-2; Male; Melanoma; Middle Aged; Pilot Projects; Skin Diseases; Skin Neoplasms; Tamoxifen; Vinblastine

1999
O(6)-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts.
    International journal of cancer, 2000, Jan-15, Volume: 85, Issue:2

    Topics: Adenosine Triphosphatases; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Synergism; Enzyme Inhibitors; Guanine; Male; Melanoma; Mice; Mice, Nude; Neoplasm Transplantation; Temozolomide; Transplantation, Heterologous

2000
SODs are involved in the regulation of ICAM-1 expression in human melanoma and endothelial cells.
    Cellular and molecular biology (Noisy-le-Grand, France), 1999, Volume: 45, Issue:7

    Topics: Cells, Cultured; Cytoplasm; Dacarbazine; Endothelium, Vascular; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Humans; Intercellular Adhesion Molecule-1; Isoenzymes; Melanoma; Metalloporphyrins; Mitochondria; Neoplasm Proteins; Oxidative Stress; Paraquat; Skin Neoplasms; Superoxide Dismutase; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Umbilical Veins

1999
Effect of dacarbazine (DTIC) on cultures from malignant melanoma of the choroid: an immunohistochemical and electron microscopic study.
    Folia medica, 1999, Volume: 41, Issue:3

    Topics: Antigens, Neoplasm; Antineoplastic Agents, Alkylating; Choroid Neoplasms; Dacarbazine; Humans; Immunohistochemistry; Melanoma; Melanoma-Specific Antigens; Microscopy, Electron; Neoplasm Proteins; S100 Proteins; Tumor Cells, Cultured

1999
Evaluation of the alkaline comet assay and urinary 3-methyladenine excretion for monitoring DNA damage in melanoma patients treated with dacarbazine and tamoxifen.
    Cancer chemotherapy and pharmacology, 2000, Volume: 45, Issue:2

    Topics: Adenine; Adult; Aged; Antineoplastic Agents, Alkylating; Comet Assay; Dacarbazine; DNA Damage; Female; Humans; Lymphocytes; Male; Melanoma; Middle Aged; Predictive Value of Tests; Sensitivity and Specificity; Skin Neoplasms

2000
The role of interleukin-2 in the management of stage IV melanoma: the EORTC melanoma cooperative group program.
    The cancer journal from Scientific American, 2000, Volume: 6 Suppl 1

    Topics: Cisplatin; Clinical Trials as Topic; Dacarbazine; Humans; Interferon-alpha; Interleukin-2; Melanoma; Neoplasm Staging; Survival Rate; T-Lymphocytes

2000
Myelodysplastic syndrome following treatment of malignant melanoma with vincristine, ACNU, and dacarbazine.
    The Journal of dermatology, 2000, Volume: 27, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Dacarbazine; Humans; Leukocyte Count; Male; Melanoma; Middle Aged; Myelodysplastic Syndromes; Nimustine; Skin Neoplasms; Vincristine

2000
Temozolomide for advanced, metastatic melanoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:10

    Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Melanoma; Proportional Hazards Models; Quality of Life; Skin Neoplasms; Survival Analysis; Temozolomide

2000
High dose inhalation interleukin-2 therapy for lung metastases in patients with malignant melanoma.
    Cancer, 2000, May-01, Volume: 88, Issue:9

    Topics: Administration, Inhalation; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Confounding Factors, Epidemiologic; Dacarbazine; Disease Progression; Female; Follow-Up Studies; Humans; Interleukin-2; Lung Neoplasms; Male; Melanoma; Recombinant Proteins; Remission Induction; Reproducibility of Results; Safety; Treatment Outcome

2000
Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.
    Journal of experimental & clinical cancer research : CR, 2000, Volume: 19, Issue:1

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Dacarbazine; Humans; Melanoma; Neoplasm Metastasis; Retrospective Studies; Survival Analysis; Tamoxifen; Treatment Outcome

2000
Analysis of G(1)/S checkpoint regulators in metastatic melanoma.
    Genes, chromosomes & cancer, 2000, Volume: 28, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Female; G1 Phase; Gene Expression Regulation, Neoplastic; Humans; Lomustine; Male; Melanoma; Middle Aged; Polymerase Chain Reaction; Polymorphism, Single-Stranded Conformational; S Phase; Survival Analysis; Treatment Outcome; Vincristine

2000
What can we learn from phase II adjuvant trials in melanoma?
    British journal of cancer, 2000, Volume: 83, Issue:1

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Controlled Clinical Trials as Topic; Dacarbazine; Drug Synergism; Humans; Immunologic Factors; Interferons; Interleukin-2; Melanoma; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Research Design; Skin Neoplasms; Tamoxifen; Treatment Outcome; Vinblastine

2000
Cutaneous malignant melanoma in children.
    European journal of pediatrics, 2000, Volume: 159, Issue:8

    Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Chemotherapy, Adjuvant; Child; Child, Preschool; Cisplatin; Dacarbazine; Female; Follow-Up Studies; Humans; Infant; Male; Melanoma; Neoplasm Staging; Prognosis; Risk Factors; Skin Neoplasms; Survival Analysis; Time Factors; Treatment Outcome; Vindesine

2000
Prognostic factors of overall survival in patients with delayed lymph node dissection for cutaneous malignant melanoma.
    Melanoma research, 2000, Volume: 10, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Female; Humans; Interferon-alpha; Lymph Node Excision; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Prognosis; Retrospective Studies; Skin Neoplasms; Survival Rate; Time Factors

2000
Repeatable acute rhabdomyolysis with multiple organ dysfunction because of interferon alpha and dacarbazine treatment in metastatic melanoma.
    The British journal of dermatology, 2001, Volume: 144, Issue:1

    Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Multiple Organ Failure; Recombinant Proteins; Recurrence; Rhabdomyolysis

2001
What's new in the treatment of melanoma?
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2000, Volume: 14, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Humans; Immunotherapy; Melanoma; Skin Neoplasms; Temozolomide

2000
Prognostic factors in therapeutic lymphadenectomy in melanoma.
    Melanoma research, 2001, Volume: 11, Issue:3

    Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Disease-Free Survival; Humans; Lymph Nodes; Melanoma; Prognosis; Time Factors

2001
Cisplatin and carboplatin combination as second-line chemotherapy in dacarbazine-resistant melanoma patients.
    Melanoma research, 2001, Volume: 11, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Cisplatin; Dacarbazine; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Survival Analysis

2001
Necrosis in melanoma metastases with treatment.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease-Free Survival; Follow-Up Studies; Humans; Lymph Node Excision; Male; Melanoma; Middle Aged; Necrosis; Skin Neoplasms; Time Factors; Tomography, X-Ray Computed; Treatment Outcome

2001
Treatment of brain metastases of malignant melanoma with temozolomide.
    The New England journal of medicine, 2001, Aug-23, Volume: 345, Issue:8

    Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Melanoma; Middle Aged; Skin Neoplasms; Temozolomide

2001
Therapeutic implications of the kinetics of immunomodulation during single or combined treatment of melanoma patients with dacarbazine and interferon-alpha.
    Neoplasma, 2001, Volume: 48, Issue:3

    Topics: ADP-ribosyl Cyclase; ADP-ribosyl Cyclase 1; Adult; Antigens, CD; Antigens, Differentiation; Antineoplastic Agents, Alkylating; CD4-CD8 Ratio; Dacarbazine; Drug Administration Schedule; Female; Flow Cytometry; Humans; Immunologic Factors; Interferon-alpha; Killer Cells, Natural; Male; Melanoma; Membrane Glycoproteins; Middle Aged; NAD+ Nucleosidase; Skin Neoplasms; Treatment Outcome

2001
Penetration of dacarbazine and its active metabolite 5-aminoimidazole-4-carboxamide into cutaneous metastases of human malignant melanoma.
    Cancer, 2001, Oct-15, Volume: 92, Issue:8

    Topics: Aged; Aminoimidazole Carboxamide; Antineoplastic Agents, Alkylating; Area Under Curve; Chromatography, High Pressure Liquid; Dacarbazine; Extracellular Space; Female; Humans; Male; Melanoma; Microdialysis; Middle Aged; Skin Neoplasms

2001
Radiation recall dermatitis in a patient treated with dacarbazine.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2001, Volume: 13, Issue:6

    Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glucocorticoids; Humans; Melanoma; Prednisolone; Radiodermatitis; Recurrence; Skin Neoplasms

2001
Primary malignant melanoma of the esophagus treated by esophagectomy and systemic chemotherapy.
    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2001, Volume: 14, Issue:3-4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Combined Modality Therapy; Dacarbazine; Esophageal Neoplasms; Esophagectomy; Esophagoscopy; Follow-Up Studies; Humans; Male; Melanoma; Nimustine; Treatment Outcome; Vincristine

2001
The role of glucocorticoids in the treatment of fulminant hepatitis induced by dacarbazine.
    Anti-cancer drugs, 2002, Volume: 13, Issue:2

    Topics: Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Eye Neoplasms; Glucocorticoids; Humans; Liver Failure; Male; Melanoma; Treatment Outcome

2002
Treatment of metastatic melanoma in the brain with temozolomide and thalidomide.
    The Lancet. Oncology, 2001, Volume: 2, Issue:10

    Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Therapy, Combination; Female; Frontal Lobe; Humans; Melanoma; Remission Induction; Temozolomide; Thalidomide

2001
Is there a standard for the palliative treatment of melanoma?
    Onkologie, 2002, Volume: 25, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Evidence-Based Medicine; Humans; Interferons; Interleukin-2; Melanoma; Palliative Care; Randomized Controlled Trials as Topic; Skin Neoplasms; Treatment Outcome

2002
Biochemotherapy for advanced melanoma: maybe it is real.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, May-15, Volume: 20, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Dacarbazine; Humans; Interleukin-2; Melanoma; Skin Neoplasms; Vincristine

2002
Phase 1-11 study of DTIC and cyclocytidine in disseminated malignant melanoma.
    Cancer treatment reports, 1976, Volume: 60, Issue:9

    Topics: Adult; Aged; Ancitabine; Brain Neoplasms; Cytarabine; Dacarbazine; Drug Therapy, Combination; Humans; Liver Neoplasms; Lung Neoplasms; Melanoma; Middle Aged; Neoplasm Metastasis; Retroperitoneal Neoplasms; Skin Neoplasms; Triazenes

1976
Phase II study of subcutaneously administered 5-azacytidine (NSC-102816) in patients with metastatic malignant melanoma.
    Medical and pediatric oncology, 1978, Volume: 4, Issue:1

    Topics: Azacitidine; Bone Marrow; Dacarbazine; Drug Evaluation; Drug Resistance; Female; Humans; Injections, Subcutaneous; Male; Melanoma; Neoplasm Metastasis; Vomiting

1978
Combination chemotherapy with vinblastine, bleomycin and methotrexate in DTIC-resistant metastatic melanoma.
    Tumori, 1979, Apr-30, Volume: 65, Issue:2

    Topics: Adult; Antineoplastic Agents; Bleomycin; Dacarbazine; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Methotrexate; Middle Aged; Neoplasm Metastasis; Vinblastine

1979
Evaluation of a "nude" mouse-human tumor panel as a predictive secondary screen for cancer chemotherapeutic agents.
    Journal of the National Cancer Institute, 1979, Volume: 63, Issue:5

    Topics: Animals; Antineoplastic Agents; Azacitidine; Carmustine; Dacarbazine; Doxorubicin; Drug Evaluation, Preclinical; Drug Resistance; Female; Humans; Male; Melanoma; Mice; Mice, Inbred C57BL; Mice, Nude; Neoplasms, Experimental

1979
[Dacarbazin -- therapy of metastazising malignant melanoma (author's transl)].
    Zentralblatt fur Chirurgie, 1979, Volume: 104, Issue:15

    Topics: Adult; Dacarbazine; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Palliative Care; Skin Neoplasms

1979
Adjuvant chemotherapy or chemoimmunotherapy in the management of primary malignant melanoma of level III, IV, or V.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1978, Volume: 68

    Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Bacterial Vaccines; BCG Vaccine; Dacarbazine; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Methotrexate; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Procarbazine; Propionibacterium acnes; Streptonigrin; Thiotepa; Vinblastine

1978
Primary malignant melanoma of the esophagus: report of two cases.
    Journal of surgical oncology, 1979, Volume: 12, Issue:1

    Topics: BCG Vaccine; Dacarbazine; Esophageal Neoplasms; Female; Humans; Melanoma; Middle Aged; Radiotherapy, High-Energy; Smoking

1979
Future prospects for immunotherapy.
    Cancer, 1975, Volume: 36, Issue:2

    Topics: Animals; BCG Vaccine; Carcinoma, Hepatocellular; Dacarbazine; Guinea Pigs; Humans; Immunotherapy; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Liver Neoplasms; Melanoma; Methotrexate; Mice; Neoplasms; Neoplasms, Experimental; Sarcoma

1975
Chemotherapy in the treatment of malignant melanomas.
    Transactions of the ophthalmological societies of the United Kingdom, 1977, Volume: 97, Issue:3

    Topics: Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Drug Therapy, Combination; Humans; Injections, Intra-Arterial; Melanoma; Neoplasm Metastasis

1977
The survival of patients with malignant melanoma receiving BCG with or without chemotherapy.
    The Australian and New Zealand journal of surgery, 1979, Volume: 49, Issue:3

    Topics: BCG Vaccine; Dacarbazine; Drug Therapy, Combination; Humans; Hydroxyurea; Immunity, Cellular; Melanoma; Nitrosourea Compounds; Skin Tests; Time Factors; Triazenes

1979
Massive upper gastrointestinal bleeding during chemotherapy for malignant melanoma.
    The American surgeon, 1977, Volume: 43, Issue:11

    Topics: Dacarbazine; Gastrointestinal Hemorrhage; Humans; Intestinal Neoplasms; Jejunum; Male; Melanoma; Middle Aged; Stomach Neoplasms; Triazenes

1977
[T-lymphocytes in the peripheral blood. Study on 113 patients with malignant melanoma].
    Zeitschrift fur Hautkrankheiten, 1978, Feb-01, Volume: 53, Issue:3

    Topics: Adolescent; Adult; Aged; BCG Vaccine; Cell Count; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; T-Lymphocytes

1978
Experimental intraocular penetration of dacarbazine.
    American journal of ophthalmology, 1977, Volume: 84, Issue:3

    Topics: Animals; Chorioretinitis; Choroid; Dacarbazine; Eye; Haplorhini; Macaca mulatta; Male; Melanoma; Rabbits; Retina; Retinal Diseases; Triazenes

1977
Dacarbazine and melphalan. Enhancement by dosage scheduling of the effect in combination treatment on the Harding-Passey melanoma in C3D2F1 mice.
    Archives of surgery (Chicago, Ill. : 1960), 1979, Volume: 114, Issue:2

    Topics: Animals; Dacarbazine; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Female; Melanoma; Melphalan; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Neoplasms, Experimental; Skin Neoplasms; Triazenes

1979
Effects of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide, 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea, and L-phenylalanine mustard on B16, Cloudman S91, and Harding-Passey mouse melanomas.
    Cancer research, 1979, Volume: 39, Issue:3

    Topics: Animals; Cell Count; Dacarbazine; Female; Melanoma; Melphalan; Mice; Mice, Inbred Strains; Neoplasm Transplantation; Neoplasms, Experimental; Nitrosourea Compounds; Semustine; Time Factors; Transplantation, Isogeneic; Triazenes

1979
Feasibility of integration of modalities in melanomas and sarcomas.
    American journal of surgery, 1979, Volume: 137, Issue:3

    Topics: BCG Vaccine; Dacarbazine; Estramustine; Humans; Melanoma; Melphalan; Radiotherapy Dosage; Sarcoma; Skin Neoplasms

1979
[Treatment of advanced malignant melanoma with DTIC].
    Polski tygodnik lekarski (Warsaw, Poland : 1960), 1979, Feb-19, Volume: 34, Issue:8

    Topics: Adult; Aged; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Triazenes

1979
Adjuvant immunotherapy of malignant melanoma.
    Cancer, 1979, Volume: 43, Issue:4

    Topics: BCG Vaccine; Cholera Vaccines; Dacarbazine; Female; Humans; Lymphatic Metastasis; Male; Melanoma; Neoplasm Staging; Neoplasms; Neuraminidase; Vibrio cholerae

1979
Amphotericin B effects in tissue culture cell lines.
    Cancer treatment reports, 1979, Volume: 63, Issue:4

    Topics: Amphotericin B; Animals; Cell Line; Dacarbazine; Drug Interactions; Humans; Leukemia, Experimental; Melanoma; Mice; Mycosis Fungoides; Neoplasms, Experimental

1979
Recurrent orbital and metastatic melanoma in a patient undergoing previous glaucoma surgery.
    American journal of ophthalmology, 1979, Volume: 87, Issue:6

    Topics: Choroid Neoplasms; Dacarbazine; Female; Glaucoma; Humans; Melanoma; Middle Aged; Neoplasm Metastasis; Orbital Neoplasms

1979
A preliminary report of a pilot trial in adjuvant chemotherapy of primary melanoma.
    Tumori, 1979, Apr-30, Volume: 65, Issue:2

    Topics: Antineoplastic Agents; BCG Vaccine; Dacarbazine; Dactinomycin; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Procarbazine; Skin Neoplasms; Vinblastine

1979
Monocytopoiesis in malignant melanoma: untreated, during immunotherapy and chemoimmunotherapy.
    Archives of dermatological research, 1979, May-04, Volume: 264, Issue:3

    Topics: Adult; Aged; BCG Vaccine; Dacarbazine; Female; Hematopoiesis; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Monocytes; Skin Neoplasms

1979
Cytotoxicity studies of human melanoma cells and fibroblasts.
    The Australian journal of experimental biology and medical science, 1979, Volume: 57, Issue:2

    Topics: Animals; Cell Survival; Cells, Cultured; Cytarabine; Dacarbazine; DNA; DNA Repair; DNA, Neoplasm; Fibroblasts; Humans; Melanoma; Melphalan

1979
Chemoimmunotherapy for meningeal melanocytoma of the thoracic spinal cord. Report of a case.
    JAMA, 1979, Nov-30, Volume: 242, Issue:22

    Topics: Aged; Dacarbazine; Dactinomycin; Female; Humans; Immunotherapy; Melanoma; Meningeal Neoplasms; Neoplasm Recurrence, Local; Postoperative Care; Propionibacterium acnes; Spinal Cord Neoplasms

1979
Hepatic failure in a patient treated with dacarbazine (DTIC) for malignant melanoma.
    Journal of cancer research and clinical oncology, 1979, Volume: 95, Issue:3

    Topics: Budd-Chiari Syndrome; Chemical and Drug Induced Liver Injury; Dacarbazine; Drug Hypersensitivity; Eosinophils; Female; Humans; Liver Diseases; Melanoma; Middle Aged; Skin Neoplasms

1979
[BK-mole syndrome].
    Fortschritte der Medizin, 1979, Sep-20, Volume: 97, Issue:35

    Topics: Adult; BCG Vaccine; Child; Dacarbazine; Female; Humans; Male; Melanoma; Nevus, Pigmented

1979
[Chemotherapy of malignant melanoma using DTIC].
    Dermatologische Monatschrift, 1977, Volume: 163, Issue:11

    Topics: Adult; Dacarbazine; Female; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Skin Neoplasms; Triazenes

1977
Lymphocyte function and response to chemo-immunotherapy in patients with metastatic melanoma.
    British journal of cancer, 1977, Volume: 36, Issue:6

    Topics: Adult; Aged; BCG Vaccine; Cytotoxicity, Immunologic; Dacarbazine; Female; Humans; Leukocyte Count; Lymphocytes; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Rosette Formation

1977
Use of methyl-CCNU and procarbazine in advanced malignant melanoma resistant to DTIC therapy.
    Cancer treatment reports, 1977, Volume: 61, Issue:9

    Topics: Dacarbazine; Drug Evaluation; Drug Resistance; Humans; Melanoma; Nitrosourea Compounds; Procarbazine; Semustine

1977
Adjuvant chemotherapy and immunotherapy in high risk patients with melanoma.
    Surgery, gynecology & obstetrics, 1978, Volume: 146, Issue:2

    Topics: Adult; Aged; Aminoimidazole Carboxamide; BCG Vaccine; Dacarbazine; Evaluation Studies as Topic; Female; Follow-Up Studies; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Postoperative Care; Risk; Skin Neoplasms; Triazenes

1978
Phase II study of ICRF-159 versus combination cis-dichlorodiammineplatinum(II) and DTIC in patients with disseminated malignant melanoma.
    Cancer treatment reports, 1978, Volume: 62, Issue:1

    Topics: Cisplatin; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Kidney; Male; Melanoma; Middle Aged; Piperazines; Razoxane; Remission, Spontaneous; Triazenes

1978
Specific active immunotherapy does not prolong survival in surgically treated patients with stage IIB malignant melanoma and may promote early recurrence.
    British journal of cancer, 1978, Volume: 37, Issue:4

    Topics: Adult; Aged; Antigens, Neoplasm; BCG Vaccine; Dacarbazine; Female; Humans; Immunotherapy; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prospective Studies; Time Factors; Vincristine

1978
Failure of lymphocyte microcytotoxicity to distinguish relapsers from non-relapsers in melanoma patients receiving post-surgical adjuvant chemotherapy.
    European journal of cancer, 1978, Volume: 14, Issue:7

    Topics: Adult; Cytotoxicity, Immunologic; Dacarbazine; Female; Humans; Lymphocytes; Male; Melanoma; Middle Aged; Prognosis; Recurrence

1978
[The malignant melanoma: criteria for the prognosis and therapy].
    Schweizerische medizinische Wochenschrift, 1978, Sep-02, Volume: 108, Issue:35

    Topics: Dacarbazine; Female; Humans; Lymph Nodes; Male; Melanoma; Neoplasm Invasiveness; Neoplasm Staging; Patient Care Planning; Prognosis

1978
[DTIC in the therapy of solid tumours (author's transl)].
    Wiener klinische Wochenschrift, 1978, Dec-22, Volume: 90, Issue:24

    Topics: Antineoplastic Agents; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Head and Neck Neoplasms; Humans; Melanoma; Neoplasm Metastasis; Neoplasms; Otorhinolaryngologic Diseases; Sarcoma, Kaposi; Soft Tissue Neoplasms; Thymoma; Thymus Neoplasms; Triazenes

1978
[Combined immuno-chemotherapy of malignant melanoma: epidemiological elements].
    Chirurgie; memoires de l'Academie de chirurgie, 1978, Nov-29, Volume: 104, Issue:10

    Topics: Adolescent; Adult; Aged; Dacarbazine; Female; Follow-Up Studies; Humans; Immunotherapy; Male; Melanoma; Middle Aged; Remission, Spontaneous; Skin Neoplasms

1978
New treatments for malignant melanoma.
    Cancer treatment reports, 1978, Volume: 62, Issue:12

    Topics: Antineoplastic Agents; Dacarbazine; Drug Evaluation; Humans; Melanoma; Nitrosourea Compounds; Research Design

1978
Positive phase II trial of dibromodulcitol in patients with metastatic melanoma refractory to DTIC and a nitrosourea.
    Cancer treatment reports, 1978, Volume: 62, Issue:12

    Topics: Adult; Aged; Bone Marrow; Dacarbazine; Drug Evaluation; Drug Resistance; Female; Humans; Male; Melanoma; Middle Aged; Mitolactol; Neoplasm Metastasis; Nitrosourea Compounds; Remission, Spontaneous; Triazenes

1978
Immunotherapy for recurrent malignant melanoma: efficacy of BCG in prolonging the postoperative disease-free interval and survival.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1978, Volume: 68

    Topics: BCG Vaccine; Dacarbazine; Humans; Melanoma; Neoplasm Recurrence, Local; Postoperative Complications

1978
Results of a nonrandomized trial in malignant melanoma patients (Clark's stages III--V) treated by post-surgical chemoimmunotherapy.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1978, Volume: 68

    Topics: Antineoplastic Agents; BCG Vaccine; Dacarbazine; Drug Therapy, Combination; Humans; Lomustine; Melanoma; Neoplasm Staging; Vincristine

1978
Value of adjuvant therapy with bacille Calmette Guerin (BCG) or dimethl triazeno imidazole carboximide (DTIC) in the control of minimal residual disease in stage II melanoma.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1978, Volume: 68

    Topics: Adult; Aged; BCG Vaccine; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Triazenes

1978
Controlled study for prolonged chemotherapy, immunotherapy, and chemotherapy plus immunotherapy as an adjuvant to surgery in malignant melanoma (Trial 6): preliminary report.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1978, Volume: 68

    Topics: Adult; Aged; BCG Vaccine; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Triazenes

1978
Adjuvant therapy in malignant melanoma: a trial of immunotherapy. chemotherapy, and combined treatment.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1978, Volume: 68

    Topics: Adult; BCG Vaccine; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Triazenes

1978
Chemotherapy of unresectable or recurrent metastatic malignant melanomas: an update.
    The Journal of dermatologic surgery and oncology, 1979, Volume: 5, Issue:2

    Topics: Amphotericin B; BCG Vaccine; Dacarbazine; Drug Combinations; Estradiol Congeners; Female; Hot Temperature; Humans; Melanoma; Methotrexate; Neoplasm Metastasis; Nitrosourea Compounds; Skin Neoplasms

1979
Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.
    Cancer treatment reports, 1976, Volume: 60, Issue:2

    Topics: BCG Vaccine; Blood Cell Count; Dacarbazine; Drug Therapy, Combination; Humans; Immunotherapy; Lomustine; Melanoma; Mycobacterium bovis; Neoplasm Metastasis; Propionibacterium acnes; Remission, Spontaneous; Triazenes; Vincristine

1976
[Melanoma therapy].
    Deutsche medizinische Wochenschrift (1946), 1976, Jun-04, Volume: 101, Issue:23

    Topics: BCG Vaccine; Dacarbazine; Humans; Immunotherapy; Lymph Node Excision; Lymphatic Metastasis; Melanoma; Mycobacterium bovis; Skin Neoplasms

1976
Multimodal surgical adjuvant therapy for a broad spectrum of tumors in humans.?
    Surgery, gynecology & obstetrics, 1976, Volume: 142, Issue:6

    Topics: Adult; Altretamine; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carmustine; Colonic Neoplasms; Cyclophosphamide; Dacarbazine; Doxorubicin; Drug Evaluation; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Lomustine; Lung Neoplasms; Male; Melanoma; Mitolactol; Neoplasms; Osteosarcoma; Pancreatic Neoplasms; Rectal Neoplasms; Vincristine

1976
Combination chemotherapy with bis chloroethyl nitrosourea (BCNU), vincristine and dimethyl triazeno imidazole carboxamide (DTIC) in disseminated malignant melanoma.
    Cancer, 1977, Volume: 39, Issue:1

    Topics: Carmustine; Dacarbazine; Drug Therapy, Combination; Eosinophils; Female; Humans; Leukocyte Count; Lymphocytes; Male; Melanoma; Neoplasm Metastasis; Remission, Spontaneous; Triazenes; Vincristine

1977
Combination chemotherapy of malignant melanoma with imidazole carboxamide, BCNU and vincristine.
    Cancer, 1977, Volume: 39, Issue:1

    Topics: Adult; Aged; Carmustine; Dacarbazine; Drug Therapy, Combination; Female; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Triazenes; Vincristine

1977
Bis chloroethyl nitrosourea, vincristine, dimethyl triazeno imidazole carboxamide and chlorpromazine combination chemotherapy in disseminated malignant melanoma.
    Cancer, 1977, Volume: 39, Issue:1

    Topics: Carmustine; Chlorpromazine; Dacarbazine; Drug Therapy, Combination; Eosinophils; Female; Humans; Leukocyte Count; Lymphocytes; Male; Melanoma; Monocytes; Neoplasm Metastasis; Remission, Spontaneous; Time Factors; Triazenes; Vincristine

1977
Immunochemotherapy of malignant melanoma with chlorambucil-bound antimelanoma globulins: preliminary results in patients with disseminated disease.
    Journal of the National Cancer Institute, 1977, Volume: 58, Issue:4

    Topics: Adolescent; Adult; Aged; Antibodies, Neoplasm; Chlorambucil; Dacarbazine; Female; Humans; Hypersensitivity, Delayed; Immunoglobulins; Immunotherapy; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Skin Neoplasms

1977
Effect of cobalt-60 gamma rays and DTIC (5-(3,3 dimethyl-1-triazeno)-imidazole-r-carboxamide) on human malignant melanomas grown in athymic nude mice.
    The British journal of radiology, 1977, Volume: 50, Issue:593

    Topics: Animals; Cobalt Radioisotopes; Dacarbazine; Dose-Response Relationship, Radiation; Melanoma; Mice; Mice, Nude; Neoplasm Transplantation; Radiotherapy; Transplantation, Heterologous; Triazenes

1977
Effect of chemotherapy and immunotherapy on tumor-specific immunity in melanoma.
    The Journal of clinical investigation, 1977, Volume: 59, Issue:6

    Topics: Adult; Antilymphocyte Serum; BCG Vaccine; Cytotoxicity Tests, Immunologic; Dacarbazine; Drug Therapy, Combination; Female; Humans; Immunity, Cellular; Immunosuppressive Agents; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Skin Neoplasms; Structure-Activity Relationship; Triazenes

1977
Single drug and combination chemotherapy in the treatment. Disseminated malignant melanoma.
    Minnesota medicine, 1977, Volume: 60, Issue:8

    Topics: Antineoplastic Agents; Carmustine; Dacarbazine; Drug Therapy, Combination; Humans; Hydroxyurea; Lomustine; Melanoma; Neoplasm Metastasis; Skin Neoplasms; Vincristine

1977
Tumour regression and survival of patients with disseminated malignant melanoma treated with chemotherapy and specific active immunotherapy.
    European journal of cancer, 1977, Volume: 13, Issue:10

    Topics: Adult; Antigens, Neoplasm; BCG Vaccine; Dacarbazine; Female; Humans; Immunotherapy; Lung Neoplasms; Lymph Nodes; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Prognosis; Skin Neoplasms; Triazenes

1977
Dacarbazine (DTIC) in malignant melanoma.
    Drug and therapeutics bulletin, 1976, May-07, Volume: 14, Issue:10

    Topics: Dacarbazine; Humans; Melanoma; Triazenes

1976
[Modern trends in the therapy of malignant melanoblastoma (author's transl)].
    Casopis lekaru ceskych, 1976, Nov-12, Volume: 115, Issue:45

    Topics: Dacarbazine; Humans; Immunotherapy; Melanoma; Skin Neoplasms

1976
[Results with new cytotoxic agents].
    Harefuah, 1976, Nov-01, Volume: 91, Issue:9

    Topics: Carmustine; Dacarbazine; Gastrointestinal Neoplasms; Humans; Melanoma; Remission, Spontaneous; Triazenes

1976
Combination cytotoxic chemotherapy for metastatic cutaneous malignant melanoma with DTIC, BCNU, and vincristine.
    Cancer treatment reports, 1976, Volume: 60, Issue:9

    Topics: Adult; Aged; Carmustine; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Humans; Melanoma; Middle Aged; Neoplasm Metastasis; Skin Neoplasms; Triazenes; Vincristine

1976
Chemoimmunotherapy of human solid tumors.
    The Medical clinics of North America, 1976, Volume: 60, Issue:3

    Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; BCG Vaccine; Breast Neoplasms; Colonic Neoplasms; Dacarbazine; Drug Therapy, Combination; Humans; Immunization Schedule; Immunotherapy; Lung Neoplasms; Lymphatic Metastasis; Lymphoma; Melanoma; Neoplasms; Neoplasms, Experimental; Osteosarcoma

1976
Immunotherapy of human solid tumors with Bacillus Calmette-Guérin: prolongation of disease-free interval and survival in malignant melanoma, breast, and colorectal cancer.
    Annals of the New York Academy of Sciences, 1976, Volume: 277, Issue:00

    Topics: BCG Vaccine; Breast Neoplasms; Colonic Neoplasms; Dacarbazine; Doxorubicin; Female; Fluorouracil; Humans; Immunotherapy; Melanoma; Neoplasm Metastasis; Rectal Neoplasms; Time Factors

1976
Chemotherapy of a human malignant melanoma transplanted in the nude mouse.
    Cancer research, 1975, Volume: 35, Issue:10

    Topics: Animals; Body Weight; Dacarbazine; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Fluorouracil; Lomustine; Male; Melanoma; Mice; Mice, Nude; Models, Biological; Neoplasm Transplantation; Nitrosourea Compounds; Transplantation, Heterologous; Triazenes

1975
Multimodality therapy in the treatment of regionally inoperable melanomas and sarcomas.
    Surgery, gynecology & obstetrics, 1975, Volume: 141, Issue:3

    Topics: Adult; Aged; BCG Vaccine; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Dactinomycin; Female; Humans; Lymphatic Metastasis; Male; Melanoma; Melphalan; Middle Aged; Sarcoma

1975
Active immunotherapy as an adjunct to chemotherapy in the treatment of disseminated malignant melanoma: a pilot study.
    British journal of cancer, 1975, Volume: 31, Issue:2

    Topics: Adult; Aged; Antigens, Neoplasm; BCG Vaccine; Dacarbazine; Female; Humans; Immunization; Immunotherapy; Male; Melanoma; Middle Aged; Retroperitoneal Neoplasms; Skin Neoplasms; Vincristine

1975
[Dimethyl-triazeno-imidazol-carboxamide (DTIC)--a new cytostatic agent].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 1975, Sep-30, Volume: 95, Issue:27

    Topics: Dacarbazine; Hodgkin Disease; Humans; Melanoma; Sarcoma; Triazenes

1975
Letter: Chemoimmunotherapy of malignant melanoma.
    The New England journal of medicine, 1975, Jan-16, Volume: 292, Issue:3

    Topics: BCG Vaccine; Dacarbazine; Humans; Melanoma; Triazenes

1975
[Treatment of malignant melanomas. Trial of D.T.I.C. by intra-arterial infusion].
    La Nouvelle presse medicale, 1975, May-17, Volume: 4, Issue:20

    Topics: Adult; Aged; Antineoplastic Agents; Dacarbazine; Drug Evaluation; Female; Humans; Injections, Intra-Arterial; Male; Melanoma; Middle Aged; Skin Neoplasms; Triazenes

1975
A clinical trial of procarbazine plus vincristine plus bis-chloroethyl-nitrosourea plus imidazole carboxamide dimethyl triazeno in metastatic malignant melanoma.
    Medical and pediatric oncology, 1975, Volume: 1, Issue:2

    Topics: Adult; Aged; Carmustine; Dacarbazine; Drug Therapy, Combination; Female; Humans; Liver Neoplasms; Lung Neoplasms; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Procarbazine; Remission, Spontaneous; Skin Neoplasms; Triazenes; Vincristine

1975
Evaluation of cell-mediated reactivity and serum blocking factors in melanoma patients on chemotherapy.
    Medical and pediatric oncology, 1975, Volume: 1, Issue:3

    Topics: Adult; Antibodies; Cell Division; Clone Cells; Cytotoxicity Tests, Immunologic; Dacarbazine; Female; Humans; Imidazoles; Immunity, Cellular; Lymphocytes; Male; Melanoma; Middle Aged; Nitrogen Mustard Compounds

1975
Chemotherapy of melanoma.
    Seminars in oncology, 1975, Volume: 2, Issue:2

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carmustine; Cyclophosphamide; Dacarbazine; Dactinomycin; Drug Therapy, Combination; Female; Humans; Hydroxyurea; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Semustine; Skin Neoplasms; Vinca Alkaloids

1975
[Non-surgical treatment of melanoma].
    Lakartidningen, 1976, Feb-11, Volume: 73, Issue:7

    Topics: Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Humans; Immunotherapy; Male; Melanoma; Middle Aged; Skin Neoplasms

1976
Letter: Disseminated intravascular coagulation syndrome with metastatic melanoma: Remission after treatment with 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (DTIC).
    Annals of internal medicine, 1976, Volume: 84, Issue:2

    Topics: Aged; Dacarbazine; Disseminated Intravascular Coagulation; Humans; Male; Melanoma; Neoplasm Metastasis; Triazenes

1976
[Treatment of metastasising melanoma with a combination of cytostatic agents (author's transl)].
    Deutsche medizinische Wochenschrift (1946), 1976, Jun-04, Volume: 101, Issue:23

    Topics: Adult; Bone Neoplasms; Carmustine; Dacarbazine; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Remission, Spontaneous; Skin Neoplasms; Soft Tissue Neoplasms; Triazenes; Vincristine

1976
A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992, Volume: 10, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Drug Administration Schedule; Female; Humans; Interferon-alpha; Lomustine; Male; Melanoma; Middle Aged; Treatment Outcome; Vincristine

1992
Nine years' experience of BELD combination chemotherapy (bleomycin, vindesine, CCNU and DTIC) for metastatic melanoma.
    The British journal of dermatology, 1992, Volume: 127, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Female; Humans; Lomustine; Male; Melanoma; Middle Aged; Neoplasm Staging; Survival Rate; Vindesine

1992
Cerebral metastatic melanoma: correlation between clinical and CT findings.
    Melanoma research, 1992, Volume: 2, Issue:5-6

    Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Tomography, X-Ray Computed

1992
Efficacy of ondansetron against nausea and vomiting caused by dacarbazine-containing chemotherapy.
    Cancer, 1992, Oct-01, Volume: 70, Issue:7

    Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Humans; Imidazoles; Male; Melanoma; Middle Aged; Nausea; Ondansetron; Vinblastine; Vomiting

1992
Malignant melanoma treated with natural interferons alfa and beta and DAV.
    European journal of cancer (Oxford, England : 1990), 1992, Volume: 28A, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Interferon-alpha; Interferon-beta; Male; Melanoma; Middle Aged; Nimustine; Vincristine

1992
Fotemustine plus dacarbazine for malignant melanoma.
    European journal of cancer (Oxford, England : 1990), 1992, Volume: 28A, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Evaluation; Female; Humans; Leukopenia; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Thrombocytopenia

1992
Fotemustine plus dacarbazine in advanced stage III malignant melanoma.
    European journal of cancer (Oxford, England : 1990), 1992, Volume: 28A, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Leukopenia; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Thrombocytopenia

1992
[A case of malignant melanoma of the clitoris].
    Wiadomosci lekarskie (Warsaw, Poland : 1960), 1992, Volume: 45, Issue:3-4

    Topics: Adult; Clitoris; Combined Modality Therapy; Dacarbazine; Female; Humans; Lymph Node Excision; Melanoma; Vulvar Neoplasms

1992
[Enhancement of the effects of anticancer agents on B16 melanoma cells by combination with cepharanthine--II. Antimetabolite, alkylating agent, nitrosourea].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1992, Volume: 19, Issue:13

    Topics: Alkaloids; Antineoplastic Agents; Benzylisoquinolines; Dacarbazine; Drug Synergism; Humans; Hydroxyurea; Melanoma; Nitrosourea Compounds; Tumor Cells, Cultured; Tumor Stem Cell Assay

1992
[Primary intracranial melanoma: a case report].
    No shinkei geka. Neurological surgery, 1992, Volume: 20, Issue:11

    Topics: Adult; Amphetamines; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Dacarbazine; Diagnosis, Differential; Humans; Interferon-beta; Iodine Radioisotopes; Iofetamine; Magnetic Resonance Imaging; Male; Melanoma; Nimustine; Prognosis; Tomography, Emission-Computed, Single-Photon; Vincristine

1992
Modulation of cisplatin resistance in human malignant melanoma cells.
    Cancer research, 1992, Dec-15, Volume: 52, Issue:24

    Topics: Carboplatin; Cisplatin; Dacarbazine; DNA; Drug Resistance; Drug Synergism; Humans; Melanoma; Metallothionein; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Tumor Cells, Cultured

1992
Splenic lymphoma in a patient treated with interleukin-2 and dacarbazine for metastatic melanoma.
    Leukemia & lymphoma, 1992, Volume: 7, Issue:1-2

    Topics: Adult; Dacarbazine; Humans; Interleukin-2; Lymphatic Metastasis; Lymphoma; Male; Melanoma; Skin Neoplasms; Splenic Neoplasms

1992
Metastases to skeletal muscles and interferon treatment.
    Molecular biotherapy, 1992, Volume: 4, Issue:2

    Topics: Aged; Carcinoma, Renal Cell; Combined Modality Therapy; Dacarbazine; Humans; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Male; Melanoma; Middle Aged; Muscular Diseases; Recombinant Proteins

1992
Multifocal neurotoxicity during interleukin-2 therapy for malignant melanoma.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 1992, Volume: 4, Issue:2

    Topics: Adult; Brain; Combined Modality Therapy; Dacarbazine; Female; Humans; Interleukin-2; Lymphatic Metastasis; Magnetic Resonance Imaging; Melanoma; Quadriplegia; Skin Neoplasms; Tomography, X-Ray Computed

1992
Impaired levodopa response in Parkinson's disease during melanoma therapy.
    Clinical neuropharmacology, 1992, Volume: 15, Issue:1

    Topics: Adult; Dacarbazine; Dopamine; Drug Interactions; Humans; Levodopa; Male; Melanins; Melanoma; Parkinson Disease; Skin Neoplasms

1992
Sequential administration of dacarbazine and fotemustine in patients with disseminated malignant melanoma--an effective combination with unexpected toxicity.
    European journal of cancer (Oxford, England : 1990), 1992, Volume: 28, Issue:2-3

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Pneumonia

1992
Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines.
    Cancer immunology, immunotherapy : CII, 1992, Volume: 35, Issue:2

    Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Cytotoxicity, Immunologic; Dacarbazine; Drug Administration Schedule; Female; Fluorouracil; Humans; Immunotherapy, Adoptive; Interferon Type I; Interleukin-2; Killer Cells, Lymphokine-Activated; Lymphocytes, Tumor-Infiltrating; Male; Melanoma; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Recombinant Proteins; T-Lymphocytes; Tumor Cells, Cultured

1992
Determination of N7-methylguanine in DNA of white blood cells from cancer patients treated with dacarbazine.
    Carcinogenesis, 1992, Volume: 13, Issue:7

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; DNA; Enzyme-Linked Immunosorbent Assay; Female; Guanine; Humans; Leukocytes; Male; Melanoma; Middle Aged; Sarcoma

1992
Adjuvant chemotherapy in malignant melanoma using dacarbazine, carmustine, cisplatin, and tamoxifen: a University of South Florida and H. Lee Moffitt Melanoma Center Study.
    Annals of plastic surgery, 1992, Volume: 28, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Cisplatin; Dacarbazine; Female; Florida; Follow-Up Studies; Hospitals, University; Humans; Lymph Node Excision; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Skin Neoplasms; Survival Rate; Tamoxifen

1992
Treatment of stage IV malignant melanoma with dacarbazine, carmustine, cisplatin, and tamoxifen regimens: a University of South Florida and H. Lee Moffitt Melanoma Center Study.
    Annals of plastic surgery, 1992, Volume: 28, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Florida; Follow-Up Studies; Hospitals, University; Humans; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Survival Analysis; Survival Rate; Tamoxifen

1992
Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit.
    British journal of cancer, 1990, Volume: 61, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Dacarbazine; Female; Humans; Lomustine; Male; Melanoma; Melphalan; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Vincristine; Vindesine

1990
[Breast metastases of skin melanoma].
    Il Giornale di chirurgia, 1990, Volume: 11, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Breast; Breast Neoplasms; Dacarbazine; Female; Humans; Interferons; Male; Melanoma; Skin; Skin Neoplasms

1990
New approaches to the chemotherapy of melanoma.
    Oncology (Williston Park, N.Y.), 1991, Volume: 5, Issue:5

    Topics: Alkaloids; Amifostine; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Carmustine; Cisplatin; Cyclophosphamide; Dacarbazine; Daunorubicin; Humans; Lomustine; Melanoma; Nitrosourea Compounds; Paclitaxel; Procarbazine; Tamoxifen; Taurine; Thiotepa; Vincristine; Vindesine

1991
Malignant melanoma: primary presentation in bone marrow and lymph node.
    Medical and pediatric oncology, 1992, Volume: 20, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carmustine; Cisplatin; Dacarbazine; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Tamoxifen

1992
Effective chemotherapy for melanoma after treatment with interleukin-2.
    Cancer, 1992, Jan-15, Volume: 69, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Interleukin-2; Male; Melanoma; Middle Aged; Remission Induction; Tamoxifen

1992
Site-dependent differences in sensitivity of LOX human melanoma tumors in nude rats to dacarbazine and mitozolomide, but not to doxorubicin and cisplatin.
    Cancer research, 1992, Mar-01, Volume: 52, Issue:5

    Topics: Animals; Antineoplastic Agents; Bone Marrow; Bone Neoplasms; Cisplatin; Dacarbazine; Doxorubicin; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; Melanoma; Nitrogen Mustard Compounds; Rats; Rats, Nude; Skin Neoplasms; Transplantation, Heterologous

1992
Dacarbazine (DTIC), human recombinant interferon alpha 2a (Roferon) and 5-fluorouracil for disseminated malignant melanoma.
    British journal of cancer, 1992, Volume: 65, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Drug Administration Schedule; Female; Fluorouracil; Humans; Interferon-alpha; Male; Melanoma; Middle Aged

1992
[Immunophenotype of lymphocytes of patients with malignant melanoma and its dynamics during immunotherapy with interleukin-2].
    Voprosy onkologii, 1991, Volume: 37, Issue:5

    Topics: Antibodies, Monoclonal; B-Lymphocytes; Dacarbazine; Drug Therapy, Combination; Humans; Immunophenotyping; Interleukin-2; Lymphocyte Activation; Lymphocyte Subsets; Lymphocytes; Melanoma; T-Lymphocytes

1991
O6-alkylguanine-DNA alkyltransferase depletion and regeneration in human peripheral lymphocytes following dacarbazine and fotemustine.
    Cancer research, 1991, Jan-15, Volume: 51, Issue:2

    Topics: Adenosine Triphosphatases; Adult; Aged; Antineoplastic Agents; Dacarbazine; Female; Humans; Kinetics; Lymphocytes; Male; Melanoma; Methyltransferases; Middle Aged; Nitrosourea Compounds; O(6)-Methylguanine-DNA Methyltransferase; Organophosphorus Compounds

1991
Interferon plus dacarbazine in advanced malignant melanoma: a phase I-II study.
    European journal of cancer (Oxford, England : 1990), 1991, Volume: 27, Issue:2

    Topics: Combined Modality Therapy; Dacarbazine; Drug Evaluation; Humans; Interferon Type I; Melanoma

1991
Malignant melanoma and renal cell carcinoma: immunological and haematological effects of recombinant human interleukin-2.
    European journal of cancer (Oxford, England : 1990), 1991, Volume: 27, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carcinoma, Renal Cell; Cytotoxicity, Immunologic; Dacarbazine; Female; Humans; Interleukin-2; Kidney Neoplasms; Killer Cells, Lymphokine-Activated; Killer Cells, Natural; Melanoma; Mitosis; Recombinant Proteins

1991
Fotemustine with or without dacarbazine for brain metastases of malignant melanoma.
    European journal of cancer (Oxford, England : 1990), 1991, Volume: 27, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Evaluation; Humans; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds

1991
The prognosis of melanoma patients with metastases to two or more lymph node areas.
    Annals of surgery, 1991, Volume: 214, Issue:2

    Topics: Adolescent; Adult; BCG Vaccine; Combined Modality Therapy; Dacarbazine; Female; Humans; Immunotherapy; Lomustine; Lymph Node Excision; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Invasiveness; Prognosis; Skin Neoplasms; Survival Rate

1991
Treatment of advanced malignant melanoma with recombinant interferon alfa-2a in combination with DTIC: long-term follow-up of two phase II studies.
    British journal of haematology, 1991, Volume: 79 Suppl 1

    Topics: Adolescent; Adult; Aged; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Drug Evaluation; Female; Follow-Up Studies; Humans; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Prognosis; Prospective Studies; Recombinant Proteins

1991
Treatment of metastatic malignant melanoma with 24 hours continuous venous infusion of dacarbazine and cisplatin.
    Journal of surgical oncology, 1991, Volume: 48, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Pilot Projects; Remission Induction; Survival Analysis

1991
Sequential chemoimmunotherapy for metastatic melanoma.
    Seminars in oncology, 1991, Volume: 18, Issue:5 Suppl 7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Carmustine; Cisplatin; Dacarbazine; Drug Administration Schedule; Female; Humans; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Skin Neoplasms; Survival Rate; Tamoxifen; Thrombocytopenia

1991
Practical spontaneous metastasis model for in vivo therapeutic studies using a human melanoma.
    Cancer research, 1991, Jun-01, Volume: 51, Issue:11

    Topics: Animals; Cyclophosphamide; Dacarbazine; Humans; Lung Neoplasms; Melanoma; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Tumor Cells, Cultured

1991
Sequential dacarbazine/cisplatin and interleukin-2 in metastatic melanoma: immunological effects of therapy.
    Journal of immunotherapy : official journal of the Society for Biological Therapy, 1991, Volume: 10, Issue:2

    Topics: Adolescent; Adult; Aged; Cisplatin; Combined Modality Therapy; Dacarbazine; Drug Evaluation; Female; Humans; Immunophenotyping; Immunotherapy; Interleukin-2; Killer Cells, Lymphokine-Activated; Killer Cells, Natural; Leukocyte Count; Lymphocytes; Male; Melanoma; Middle Aged

1991
Phase II study of carboplatin and cytosine arabinoside in patients with disseminated malignant melanoma.
    Journal of cancer research and clinical oncology, 1990, Volume: 116, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Dacarbazine; Drug Evaluation; Female; Humans; Male; Melanoma; Middle Aged; Organoplatinum Compounds

1990
Metastatic malignant melanoma in pregnancy.
    Irish medical journal, 1990, Volume: 83, Issue:3

    Topics: Dacarbazine; Female; Humans; Infant, Newborn; Melanoma; Pregnancy; Pregnancy Complications, Neoplastic; Skin Neoplasms

1990
Alteration of dacarbazine pharmacokinetics after interleukin-2 administration in melanoma patients.
    Cancer chemotherapy and pharmacology, 1990, Volume: 27, Issue:2

    Topics: Chromatography, High Pressure Liquid; Dacarbazine; Drug Interactions; Humans; Injections, Intravenous; Interleukin-2; Melanoma

1990
Dacarbazine (DTIC) and human recombinant interferon alpha 2a (Roferon) in the treatment of disseminated malignant melanoma.
    British journal of cancer, 1990, Volume: 62, Issue:6

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Recombinant Proteins

1990
[Fotemustine in the treatment of metastatic malignant melanoma. Overall analysis of results].
    Pathologie-biologie, 1990, Volume: 38, Issue:8

    Topics: Antineoplastic Agents; Dacarbazine; Drug Synergism; Drug Therapy, Combination; Humans; Melanoma; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms

1990
[The prevention of skin melanoma metastases to the regional lymph nodes].
    Vrachebnoe delo, 1990, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Humans; Injections, Intralymphatic; Lymphatic Metastasis; Melanoma; Methotrexate; Postoperative Care; Prospidium; Remission Induction; Skin Neoplasms

1990
[Study of procreation capacity of men after treatment of their malignant tumors (melanoblastoma, thyroid carcinoma) with ionizing radiation and cytostatic agents].
    Zentralblatt fur Chirurgie, 1990, Volume: 115, Issue:20

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cobalt Radioisotopes; Cyclophosphamide; Dacarbazine; Fertility; Fluorouracil; Humans; Male; Melanoma; Methotrexate; Radiotherapy Dosage; Sperm Count; Sperm Motility; Spermatozoa; Thyroid Neoplasms

1990
[Hepatic veno-occlusive disease caused by Deticene: a cause of acute hypovolemic shock].
    Annales francaises d'anesthesie et de reanimation, 1990, Volume: 9, Issue:6

    Topics: Abdominal Pain; Ascites; Dacarbazine; Female; Hemodynamics; Hepatic Veno-Occlusive Disease; Humans; Hydrocortisone; Melanoma; Middle Aged; Shock; Skin Neoplasms

1990
Sequential treatment of melanoma patients who progressed on interleukin-2 and dacarbazine by alpha-interferon and dacarbazine--a preliminary report.
    Molecular biotherapy, 1990, Volume: 2, Issue:4

    Topics: Adult; Dacarbazine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Immunologic Factors; Interferon Type I; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasms; Recombinant Proteins

1990
Nude rat model for studying metastasis of human tumor cells to bone and bone marrow.
    Journal of the National Cancer Institute, 1990, Mar-07, Volume: 82, Issue:5

    Topics: Age Factors; Animals; Bone Marrow; Bone Neoplasms; Dacarbazine; Disease Models, Animal; Heart Ventricles; Humans; Injections; Melanoma; Microspheres; Neoplasm Transplantation; Paraplegia; Rats; Rats, Nude; Tissue Distribution; Transplantation, Heterologous

1990
In vitro chemosensitivity testing of Fotemustine (S 10036), a new antitumor nitrosourea.
    Cancer chemotherapy and pharmacology, 1990, Volume: 25, Issue:5

    Topics: Antineoplastic Agents; Carmustine; Cell Division; Cisplatin; Dacarbazine; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Lomustine; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Thymidine; Tumor Cells, Cultured

1990
Intraarterial infusion chemotherapy in regionally advanced malignant melanoma.
    Journal of surgical oncology, 1990, Volume: 43, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dacarbazine; Female; Humans; Infusions, Intra-Arterial; Male; Melanoma; Survival Rate

1990
A phase I-II study of dacarbazine in combination with outpatient interleukin-2 in metastatic malignant melanoma.
    Cancer, 1990, Jun-01, Volume: 65, Issue:11

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Evaluation; Female; Humans; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; T-Lymphocytes

1990
Hypothyroidism and goiter in a patient during treatment with interleukin-2.
    Cancer, 1990, Jun-15, Volume: 65, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Goiter; Humans; Hypothyroidism; Interleukin-2; Melanoma; Middle Aged; Recombinant Proteins; Thyroiditis, Autoimmune

1990
Dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A phase I-II trial.
    American journal of clinical oncology, 1990, Volume: 13, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Evaluation; Humans; Melanoma; Neoplasm Metastasis; Remission Induction; Vindesine

1990
Case report: development of Hodgkin's disease in patient receiving long-term administration of dacarbazine and interleukin-2 for metastatic melanoma.
    Journal of the National Cancer Institute, 1990, Aug-15, Volume: 82, Issue:16

    Topics: Combined Modality Therapy; Dacarbazine; Female; Hodgkin Disease; Humans; Interleukin-2; Melanoma; Middle Aged

1990
[Diagnosis and treatment of malignant melanoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1985, Volume: 12, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Dacarbazine; Humans; Lymph Node Excision; Melanoma; Nimustine; Nitrosourea Compounds; Peplomycin; Prognosis; Skin; Skin Neoplasms; Vincristine

1985
Basic studies of cryochemotherapy in a murine tumor system.
    Cryobiology, 1985, Volume: 22, Issue:5

    Topics: Animals; Antineoplastic Agents; Bleomycin; Cell Line; Combined Modality Therapy; Cryosurgery; Dacarbazine; Doxorubicin; Female; Melanoma; Mice; Peplomycin

1985
Angiotensin-induced hypertension and chemotherapy for multiple lesions of malignant melanoma.
    The British journal of dermatology, 1985, Volume: 113, Issue:4

    Topics: Adult; Aged; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blood Flow Velocity; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Peplomycin; Vincristine

1985
Treatment of metastatic malignant melanoma with vinblastine, dacarbazine, and cisplatin: a report from the Cancer and Leukemia Group B.
    Cancer treatment reports, 1986, Volume: 70, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Dacarbazine; Humans; Melanoma; Middle Aged; Vinblastine

1986
[Therapeutic response of interferon-beta in malignant melanoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1986, Volume: 13, Issue:4 Pt 1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Female; Humans; Indomethacin; Infusions, Parenteral; Interferon Type I; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Skin Neoplasms; Vincristine

1986
Phase II study of bleomycin, actinomycin D, DTIC and vindesine in disseminated malignant melanoma.
    European journal of cancer & clinical oncology, 1986, Volume: 22, Issue:7

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Dactinomycin; Drug Evaluation; Female; Humans; Lung Neoplasms; Male; Melanoma; Middle Aged; Vindesine

1986
Expression of the c-src protooncogene in human skin tumors.
    Cancer research, 1987, Jan-01, Volume: 47, Issue:1

    Topics: Adult; Aged; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Nevus; Protein Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins pp60(c-src); RNA, Messenger; Skin Neoplasms

1987
[Primary malignant melanoma of the female urethra: a case report].
    Hinyokika kiyo. Acta urologica Japonica, 1987, Volume: 33, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combined Modality Therapy; Dacarbazine; Female; Humans; Melanoma; Peplomycin; Urethral Neoplasms

1987
[Successful therapy of secondary melanoma of the orbit with DTIC].
    Klinische Monatsblatter fur Augenheilkunde, 1987, Volume: 191, Issue:1

    Topics: Aged; Dacarbazine; Facial Neoplasms; Humans; Male; Melanoma; Orbital Neoplasms; Palliative Care; Skin Neoplasms

1987
Bleomycin, vincristine, lomustine, and DTIC chemotherapy for metastatic melanoma.
    Cancer, 1988, Jun-01, Volume: 61, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Humans; Lomustine; Melanoma; Neoplasm Metastasis; Vincristine

1988
A phase II trial of vinblastine, bleomycin, and cisplatin induction followed by dacarbazine and dibromodulcitol maintenance in the treatment of metastatic melanoma. A follow-up study of twenty-two patients.
    American journal of clinical oncology, 1988, Volume: 11, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Dacarbazine; Drug Evaluation; Female; Follow-Up Studies; Humans; Male; Melanoma; Middle Aged; Mitolactol; Vinblastine

1988
Phase II study of bleomycin, dacarbazine (DTIC) and vindesine in disseminated malignant melanoma.
    Journal of cancer research and clinical oncology, 1989, Volume: 115, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Vindesine

1989
Chemotherapy of disseminated melanoma with bleomycin, vincristine, CCNU, and DTIC (BOLD regimen). The Prudente Foundation Melanoma Study Group.
    Cancer, 1989, May-01, Volume: 63, Issue:9

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Drug Administration Schedule; Female; Humans; Lomustine; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Staging; Skin Neoplasms; Vincristine

1989
Malignant melanoma infiltrating the reticular dermis at level IV.
    The Journal of the Arkansas Medical Society, 1989, Volume: 85, Issue:11

    Topics: Dacarbazine; Female; Humans; Interferons; Melanoma; Middle Aged; Referral and Consultation; Skin Neoplasms; Wrist

1989
Effectiveness and toxicity of "BELD" polychemotherapy in advanced malignant melanoma.
    Tumori, 1989, Jun-30, Volume: 75, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Female; Humans; Lomustine; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Remission Induction; Skin Neoplasms; Vindesine

1989
Relationships among cell survival, O6-alkylguanine-DNA alkyltransferase activity, and reactivation of methylated adenovirus 5 and herpes simplex virus type 1 in human melanoma cell lines.
    Cancer research, 1989, Sep-01, Volume: 49, Issue:17

    Topics: Adenoviruses, Human; Alkylating Agents; Cell Survival; Dacarbazine; DNA Damage; DNA Repair; DNA, Neoplasm; Drug Resistance; Humans; Melanoma; Methylation; Methyltransferases; O(6)-Methylguanine-DNA Methyltransferase; Simplexvirus; Tumor Cells, Cultured

1989
The use of BELD combination chemotherapy (bleomycin, vindesine, CCNU, and DTIC) in advanced malignant melanoma.
    Cancer, 1985, May-01, Volume: 55, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Drug Administration Schedule; Female; Humans; Lomustine; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Pilot Projects; Skin Neoplasms; Vinblastine; Vindesine

1985
Spermidine level as a parameter in the treatment of patients with malignant melanoma.
    European journal of nuclear medicine, 1985, Volume: 10, Issue:5-6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Dactinomycin; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Spermidine; Vinblastine; Vindesine

1985
High-dose, double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma.
    Cancer, 1989, Apr-01, Volume: 63, Issue:7

    Topics: Adult; Aged; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Dacarbazine; Humans; Ifosfamide; Lung Neoplasms; Melanoma; Melphalan; Middle Aged; Neoplasm Metastasis; Skin Neoplasms

1989
Hepatic vascular toxicity of dacarbazine (DTIC): not a rare complication.
    Hepatology (Baltimore, Md.), 1989, Volume: 9, Issue:5

    Topics: Budd-Chiari Syndrome; Dacarbazine; Humans; Melanoma

1989
Tourniquet infusion chemotherapy of the lower extremities--clinical and pharmacokinetic results.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 1989, Volume: 15, Issue:4

    Topics: Adult; Aged; Dacarbazine; Doxorubicin; Female; Humans; Infusions, Intra-Arterial; Leg; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Sarcoma, Kaposi; Skin Neoplasms; Time Factors; Tourniquets

1989
Isolated limb perfusion for stage I melanoma of the extremity: a comparison of melphalan and dacarbazine (DTIC).
    Southern medical journal, 1989, Volume: 82, Issue:8

    Topics: Adult; Chemotherapy, Cancer, Regional Perfusion; Cicatrix; Dacarbazine; Extremities; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Melanoma; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Retrospective Studies

1989
Reduced DNA damage induced in human melanoma cells by dacarbazine in the presence of deoxyribonucleosides.
    Cancer research, 1989, Jun-01, Volume: 49, Issue:11

    Topics: Dacarbazine; Deoxyadenosines; Deoxycytidine; Deoxyguanosine; DNA Damage; DNA, Neoplasm; Humans; Melanoma; Thymidine

1989
Alternating recombinant human interleukin-2 and dacarbazine in advanced melanoma. A multicentric phase II study.
    Cancer treatment reviews, 1989, Volume: 16 Suppl A

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedule; Drug Evaluation; Drug Synergism; Female; Humans; Interleukin-2; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Monitoring, Physiologic; Recombinant Proteins; Remission Induction

1989
Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin.
    British journal of cancer, 1989, Volume: 60, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Skin Neoplasms; Vindesine

1989
A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma.
    Cancer, 1989, Nov-15, Volume: 64, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Prospective Studies; Vincristine

1989
Seven years experience with hyperthermic perfusions in extracorporeal circulation for melanoma of the extremities.
    Journal of surgical oncology, 1989, Volume: 42, Issue:3

    Topics: Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Dacarbazine; Extracorporeal Circulation; Extremities; Female; Humans; Hyperthermia, Induced; Male; Melanoma; Melphalan; Neoplasm Staging; Risk Factors; Time Factors

1989
Summary of recent clinical experience in whole-body hyperthermia combined with chemotherapy.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1988, Volume: 107

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Doxorubicin; Etoposide; Evaluation Studies as Topic; Female; Humans; Hyperthermia, Induced; Lung Neoplasms; Male; Melanoma; Vincristine; Vindesine

1988
The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma.
    Cancer, 1989, Apr-01, Volume: 63, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Hematologic Diseases; Humans; Male; Melanoma; Middle Aged; Pulmonary Embolism; Skin Neoplasms; Tamoxifen; Thrombophlebitis

1989
Peripheral DTIC neurotoxicity: a case report.
    Cancer chemotherapy and pharmacology, 1987, Volume: 19, Issue:1

    Topics: Aged; Dacarbazine; Humans; Lung Neoplasms; Male; Melanoma; Peripheral Nervous System Diseases; Skin Neoplasms

1987
Inhibition of poly(ADP-ribose) synthetase potentiates cell dacarbazine cytotoxicity.
    Biochemical and biophysical research communications, 1987, Feb-13, Volume: 142, Issue:3

    Topics: Antineoplastic Agents; Aphidicolin; Benzamides; Cell Line; Dacarbazine; Diterpenes; DNA; DNA Repair; Drug Synergism; Humans; Melanoma; Poly(ADP-ribose) Polymerase Inhibitors

1987
Suicide enzyme inhibition as a chemotherapeutic strategy for controlling metastases derived from intraocular melanomas.
    Investigative ophthalmology & visual science, 1987, Volume: 28, Issue:11

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Eflornithine; Enzyme Inhibitors; Eye Neoplasms; Female; Injections, Intravenous; Lung Neoplasms; Melanoma; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Time Factors

1987
[Regional intra-arterial chemotherapy].
    Deutsche medizinische Wochenschrift (1946), 1988, Jul-15, Volume: 113, Issue:28-29

    Topics: Cisplatin; Dacarbazine; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Melanoma; Mitomycin; Mitomycins

1988
Alpha-interferons in malignant melanoma.
    British journal of clinical practice. Supplement, 1988, Volume: 62

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cimetidine; Dacarbazine; Humans; Interferon Type I; Melanoma

1988
[Problems and results of treatment of 43 patients with melanomas of the head and neck].
    Fortschritte der Kiefer- und Gesichts-Chirurgie, 1988, Volume: 33

    Topics: Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Skin Neoplasms; Surgical Flaps

1988
Evaluation of cis-platinum and DTIC combination chemotherapy in disseminated melanoma. A Southwest Oncology Group Study.
    American journal of clinical oncology, 1988, Volume: 11, Issue:5

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Administration Schedule; Drug Evaluation; Female; Humans; Male; Melanoma; Middle Aged; Prospective Studies

1988
Predictive chemosensitivity testing in malignant melanoma: reliable methodology--ineffective drugs.
    British journal of cancer, 1988, Volume: 58, Issue:6

    Topics: Dacarbazine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Lomustine; Melanoma; Predictive Value of Tests; Prospective Studies; Retrospective Studies; Vinblastine

1988
Heterogeneity of the response to inducers of differentiation and to cytostatics of tumor cell populations.
    Pathology, research and practice, 1988, Volume: 184, Issue:1

    Topics: Antineoplastic Agents; Cell Differentiation; Cisplatin; Cytarabine; Dacarbazine; Dimethyl Sulfoxide; Dose-Response Relationship, Drug; Doxorubicin; Fluorouracil; Humans; Leukemia, Erythroblastic, Acute; Leukemia, Promyelocytic, Acute; Melanoma; Neoplasms; Tetradecanoylphorbol Acetate; Tretinoin; Tumor Cells, Cultured

1988
[Systemic therapy of metastatic malignant melanoma].
    Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis, 1988, Apr-26, Volume: 77, Issue:17

    Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Immunotherapy; Interferon Type I; Interleukin-2; Killer Cells, Natural; Lomustine; Melanoma; Skin Neoplasms

1988
[Regional intra-arterial chemotherapy with Dacarbazine in isolated liver metastases of a malignant melanoma].
    Deutsche medizinische Wochenschrift (1946), 1988, Jan-08, Volume: 113, Issue:1

    Topics: Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Female; Humans; Liver Neoplasms; Melanoma; Middle Aged; Skin Neoplasms

1988
Fatal hepatic vascular toxicity of DTIC. Is it really a rare event?
    Cancer, 1988, May-15, Volume: 61, Issue:10

    Topics: Aged; Budd-Chiari Syndrome; Combined Modality Therapy; Dacarbazine; Eosinophilia; Fever; Humans; Male; Melanoma; Middle Aged; Necrosis; Skin Neoplasms

1988
[Multiple BCG-induced ulcers after subcutaneous vaccination in the framework of immunochemotherapy in malignant melanoma].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 1988, Volume: 39, Issue:3

    Topics: BCG Vaccine; Combined Modality Therapy; Dacarbazine; Female; Humans; Injections, Subcutaneous; Melanoma; Middle Aged; Skin Neoplasms; Skin Ulcer

1988
Treatment of advanced malignant melanoma with interferon alpha and etretinate.
    European journal of cancer & clinical oncology, 1988, Volume: 24, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Etretinate; Female; Humans; Interferon Type I; Male; Melanoma; Middle Aged; Skin Neoplasms; Vindesine

1988
[Adjuvant chemotherapy of malignant melanoma with DTIC. Lack of effect in stage I. Possible improvement of the prognosis for survival in stage IIb].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 1988, Volume: 39, Issue:4

    Topics: Combined Modality Therapy; Dacarbazine; Humans; Lymphatic Metastasis; Melanoma; Neoplasm Staging; Prognosis; Skin Neoplasms

1988
Combination of cisplatin, vindesine, and dacarbazine in advanced malignant melanoma. A Phase II Study of the EORTC Malignant Melanoma Cooperative Group.
    Cancer, 1988, Sep-15, Volume: 62, Issue:6

    Topics: Actuarial Analysis; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Evaluation; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Vindesine

1988
[Adjuvant chemotherapy of malignant melanoma of the female genital organs].
    Nihon Sanka Fujinka Gakkai zasshi, 1986, Volume: 38, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Female; Humans; Melanoma; Middle Aged; Nimustine; Nitrosourea Compounds; Picibanil; Vaginal Neoplasms; Vincristine; Vulvar Neoplasms

1986
Recombinant interferon alfa-2a in advanced malignant melanoma. A phase I-II study in combination with DTIC.
    International journal of cancer. Supplement = Journal international du cancer. Supplement, 1987, Volume: 1

    Topics: Adolescent; Adult; Aged; Combined Modality Therapy; Dacarbazine; Dose-Response Relationship, Drug; Drug Evaluation; Female; Humans; Interferon Type I; Male; Melanoma; Middle Aged; Prospective Studies; Recombinant Proteins

1987
Adenovirus replication as an in vitro probe for drug sensitivity in human tumors.
    European journal of cancer & clinical oncology, 1986, Volume: 22, Issue:4

    Topics: Adenoviridae; Antigens, Viral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Division; Cell Line; Dacarbazine; Humans; Immunoenzyme Techniques; Melanoma

1986
[DTIC: effect on fibrinolysis and thrombocyte function].
    Onkologie, 1986, Volume: 9, Issue:5

    Topics: Blood Coagulation Tests; Budd-Chiari Syndrome; Dacarbazine; Fibrinolysis; Humans; Melanoma; Platelet Aggregation; Platelet Count; Skin Neoplasms

1986
Hyperthermic antiblastic perfusion with DTIC in stage IIIA-IIIAB melanoma of the extremities.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 1987, Volume: 13, Issue:2

    Topics: Adult; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Extremities; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Male; Melanoma; Middle Aged; Skin Neoplasms

1987
[Late results of the conservative treatment of melanoma of the skin].
    Sovetskaia meditsina, 1986, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dactinomycin; Humans; Melanoma; Skin Neoplasms; Vincristine

1986
Adjuvant chemoimmunotherapy after regional lymphadenectomy for malignant melanoma.
    American journal of clinical oncology, 1987, Volume: 10, Issue:2

    Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carmustine; Combined Modality Therapy; Dacarbazine; Humans; Hydroxyurea; Lymph Node Excision; Lymphatic Metastasis; Melanoma; Neoplasm Recurrence, Local; Postoperative Care; Skin Neoplasms; Time Factors

1987
Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma.
    Cancer treatment reports, 1987, Volume: 71, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Kidney Diseases; Leukopenia; Male; Melanoma; Middle Aged; Nausea; Pulmonary Embolism; Skin Neoplasms; Tamoxifen; Thrombocytopenia; Thromboembolism; Vomiting

1987
W-7, a calmodulin inhibitor, potentiates dacarbazine cytotoxicity in human neoplastic cells.
    International journal of cancer, 1987, May-15, Volume: 39, Issue:5

    Topics: Calmodulin; Cell Division; Cell Line; Cell Survival; Dacarbazine; DNA Repair; DNA Replication; DNA, Neoplasm; Drug Synergism; Humans; Melanoma; Sulfonamides

1987
Acute non-lymphocytic leukemia (ANLL) following treatment with dacarbazine for malignant melanoma.
    American journal of hematology, 1987, Volume: 25, Issue:1

    Topics: Acute Disease; Dacarbazine; Humans; Leukemia; Male; Melanoma; Middle Aged; Muramidase; Scalp; Skin Neoplasms

1987
[Clinical trials of supplementary chemotherapy in cases of malignant melanoma of the skin with unfavorable prognosis after surgical treatment].
    Wiadomosci lekarskie (Warsaw, Poland : 1960), 1987, Feb-15, Volume: 40, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Prognosis; Skin Neoplasms; Vinblastine

1987
Treatment of metastatic malignant melanoma with dacarbazine and cisplatin.
    Cancer treatment reports, 1987, Volume: 71, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Evaluation; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Pilot Projects

1987
Adjuvant and neoadjuvant chemotherapy with dacarbazine in high-risk childhood melanoma.
    Cancer, 1987, Oct-15, Volume: 60, Issue:8

    Topics: Child; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Humans; Infant; Male; Melanoma; Retrospective Studies; Skin Neoplasms

1987
Dacarbazine, vindesine, and cisplatin combination chemotherapy in advanced malignant melanoma: a phase II study.
    Cancer treatment reports, 1987, Volume: 71, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cisplatin; Dacarbazine; Drug Evaluation; Female; Humans; Male; Melanoma; Middle Aged; Nausea; Vindesine; Vomiting

1987
Treatment of metastatic melanoma by 24-hour DTIC infusions and hemibody irradiation.
    Cancer, 1986, Jun-01, Volume: 57, Issue:11

    Topics: Adult; Aged; Combined Modality Therapy; Dacarbazine; Evaluation Studies as Topic; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Radiotherapy Dosage; Skin Neoplasms; Time Factors

1986
[5-year results of a chemo-immunotherapeutic treatment in stage-I and -II malignant melanoma].
    Minerva medica, 1986, Mar-31, Volume: 77, Issue:13

    Topics: Actuarial Analysis; Adult; Aged; BCG Vaccine; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Humans; Lymph Node Excision; Melanoma; Middle Aged; Neoplasm Staging; Postoperative Care; Urinary Bladder Neoplasms

1986
[Phase II study of decarbazine (DTIC) in malignant melanoma. DTIC Research Group].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1986, Volume: 13, Issue:5

    Topics: Adolescent; Adult; Aged; Child; Dacarbazine; Drug Administration Schedule; Drug Evaluation; Female; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Skin Neoplasms

1986
Phase II study: the combination DTIC, BCNU, actinomycin D, and vincristine in disseminated malignant melanoma.
    Medical and pediatric oncology, 1986, Volume: 14, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Dacarbazine; Dactinomycin; Drug Evaluation; Female; Humans; Male; Melanoma; Middle Aged; Vincristine

1986
Combination chemotherapy with dacarbazine and vindesine in the treatment of metastatic malignant melanoma.
    Cancer treatment reports, 1986, Volume: 70, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Skin Neoplasms; Vindesine

1986
Radiation in combination with intra-arterial infusion therapy with dacarbazine for metastatic malignant melanoma localized to a lower extremity.
    Cancer treatment reports, 1986, Volume: 70, Issue:8

    Topics: Aged; Combined Modality Therapy; Dacarbazine; Female; Humans; Leg; Male; Melanoma; Middle Aged; Nausea; Neoplasm Recurrence, Local; Radiography; Skin Neoplasms

1986
[Prognosis-oriented therapy of malignant melanoma. New concepts].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 1986, Volume: 37, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Female; Humans; Immunotherapy; Lymph Node Excision; Lymph Nodes; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Risk; Skin; Skin Neoplasms

1986
Dose-response relationship to dacarbazine demonstrated in a patient with malignant melanoma.
    Cancer treatment reports, 1986, Volume: 70, Issue:10

    Topics: Dacarbazine; Dose-Response Relationship, Drug; Hepatic Artery; Humans; Liver Neoplasms; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local

1986
Combination of fibroblast interferon (HuIFN beta), carboxamide (DTIC), and cimetidine for advanced malignant melanoma.
    Journal of biological response modifiers, 1986, Volume: 5, Issue:5

    Topics: Adult; Cimetidine; Combined Modality Therapy; Dacarbazine; Female; Humans; Immunotherapy; Interferon Type I; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Recombinant Proteins

1986
[Therapy and prognosis of malignant melanoma of the skin].
    Deutsche medizinische Wochenschrift (1946), 1986, Nov-14, Volume: 111, Issue:46

    Topics: Adult; BCG Vaccine; Combined Modality Therapy; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Prognosis; Skin Neoplasms

1986
[Chemotherapy of malignant melanoma].
    Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 1986, Volume: 57, Issue:10

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Chemotherapy, Cancer, Regional Perfusion; Combined Modality Therapy; Dacarbazine; Humans; Melanoma; Neoplasm Metastasis; Prognosis; Skin Neoplasms; Tamoxifen

1986
Allergy-induced hepatic toxicity associated with dacarbazine.
    Cancer treatment reports, 1987, Volume: 71, Issue:2

    Topics: Autopsy; Budd-Chiari Syndrome; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Dacarbazine; Drug Hypersensitivity; Humans; Laparotomy; Liver Diseases; Male; Melanoma; Middle Aged; Skin Diseases

1987
Prognostic factors in advanced metastatic and recurrent melanoma treated with DTIC.
    Tumori, 1987, Feb-28, Volume: 73, Issue:1

    Topics: Dacarbazine; Humans; Melanoma; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prognosis

1987
Sequential treatment with interferon and chemotherapy of metastatic malignant melanoma. Total remission of cutaneous and visceral metastasis, but not of cerebral metastasis.
    Tumori, 1987, Feb-28, Volume: 73, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; Drug Evaluation; Female; Humans; Interferon Type I; Lomustine; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Recombinant Proteins; Skin Neoplasms; Vincristine

1987
Dibromodulcitol (DBD), DTIC, and actinomycin-D in disseminated malignant melanoma. A phase I-II clinical trial.
    American journal of clinical oncology, 1985, Volume: 8, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dactinomycin; Drug Evaluation; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Melanoma; Middle Aged; Mitolactol

1985
Applicability of high-dose chemotherapy with autologous marrow transplantation for malignant melanoma.
    Journal of the American Academy of Dermatology, 1985, Volume: 13, Issue:3

    Topics: Alkylating Agents; Antineoplastic Agents; Bone Marrow Transplantation; Dacarbazine; Humans; Leukemia; Melanoma; Skin Neoplasms

1985
[Adjuvant chemotherapy of intraocular malignant melanoma. Apropos of 20 cases].
    Journal francais d'ophtalmologie, 1985, Volume: 8, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Eye Neoplasms; Female; Humans; Liver Neoplasms; Male; Melanoma; Methotrexate; Middle Aged; Procarbazine; Thiotepa; Vinblastine

1985
Assessment of survival rates with metastatic malignant melanomas.
    Surgery, gynecology & obstetrics, 1986, Volume: 162, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Female; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Skin Neoplasms

1986
Toxicity and complications of vascular isolation and hyperthermic perfusion with imidazole carboxamide (DTIC) in melanoma.
    Cancer, 1986, May-15, Volume: 57, Issue:10

    Topics: Adult; Aged; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Female; Humans; Hyperthermia, Induced; Leukopenia; Liver; Male; Melanoma; Middle Aged; Skin Neoplasms; Technetium Tc 99m Aggregated Albumin

1986
Single-dose dacarbazine and dactinomycin in advanced malignant melanoma.
    Cancer treatment reports, 1985, Volume: 69, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dactinomycin; Female; Humans; Leukocyte Count; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Platelet Count; Urinary Tract Infections

1985
[Budd-Chiari syndrome following dacarbazine therapy of malignant melanoma--an avoidable complication?].
    Zeitschrift fur Hautkrankheiten, 1985, Jun-15, Volume: 60, Issue:12

    Topics: Budd-Chiari Syndrome; Dacarbazine; Female; Humans; Melanoma; Middle Aged; Skin Neoplasms

1985
Simultaneous determination of dacarbazine, its photolytic degradation product, 2-azahypoxanthine, and the metabolite 5-aminoimidazole-4-carboxamide in plasma and urine by high-pressure liquid chromatography.
    Antimicrobial agents and chemotherapy, 1985, Volume: 27, Issue:6

    Topics: Aminoimidazole Carboxamide; Chromatography, High Pressure Liquid; Dacarbazine; Humans; Hypoxanthines; Imidazoles; Kinetics; Melanoma

1985
Arterial infusion of dacarbazine and cisplatin for recurrent regionally confined melanoma.
    Archives of surgery (Chicago, Ill. : 1960), 1985, Volume: 120, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arm; Cisplatin; Dacarbazine; Female; Humans; Infusions, Intra-Arterial; Leg; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Skin Neoplasms; Vulvar Neoplasms

1985
[Therapy of malignant melanoma].
    Deutsche medizinische Wochenschrift (1946), 1985, Nov-15, Volume: 110, Issue:46

    Topics: Combined Modality Therapy; Dacarbazine; Humans; Lymphatic Metastasis; Melanoma; Methods; Neoplasm Metastasis

1985
[Radiotherapy with intra-arterial chemotherapy. Treatment with 5-(3,3 dimethyl-1-triazeno)imidazole-4-carboxamide. Effect in malignant melanoma of the extremities].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 1985, Aug-30, Volume: 105, Issue:24

    Topics: Aged; Combined Modality Therapy; Dacarbazine; Female; Humans; Leg; Male; Melanoma; Middle Aged; Skin Neoplasms

1985